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Call To Order, Welcome, Overview / Announcements, & Introductions  
Call To Order / Welcome 
Nancy Bennett, MD, MS
ACIP Chair
Dr. Bennett called the October 2016 Advisory Committee on Immunization Practices (ACIP)
meeting to order and welcomed those present.
Overview / Announcements
Amanda Cohn, MD
Executive Secretary, ACIP / CDC
Dr. Cohn welcomed everyone to the October 2016 ACIP meeting. She indicated that the 
proceedings of this meeting would be accessible to people not in attendance via the World Wide 
Web, and welcomed those who could not attend the meeting in person.  She then recognized 
several others in the room who were to be present throughout the duration of the meeting to 
assist with various meeting functions:  Ms. Natalie Greene and Dr. Jean Clare Smith.  She
noted that handouts of the presentations were distributed to the ACIP members and were made 
available for others on the tables outside of the auditorium.  Slides presented during this
meeting will be posted on the ACIP website approximately two weeks after the meeting 
concludes after being made visually accessible to all viewers, including the visually disabled.  
The live webcast will be posted within four weeks following the meeting, and the meeting 
minutes will be available on the website within approximately 90 days following this meeting.  
Members of the media interested in conducting interviews with ACIP members were instructed 
to contact Ian Branam, located at the press table, for assistance in arranging interviews.
The next ACIP meeting will be convened at the Centers for Disease Control and Prevention 
(CDC) on Wednesday and Thursday, February 22-23, 2017.  Registration for all meeting 
attendees is required.  The registration deadline for Non-US citizens is February 1, 2017 and for
US citizens registration closes February 13, 2017.  Registration is not required for webcast 
viewing.  As a reminder for non-United States (US) citizens attending ACIP meetings, 
completion of several forms is required for each meeting at the time of registration.  It is
important that these forms are submitted within the required time frame.  Stephanie Thomas, 
the ACIP Committee Management Specialist, will be able to help with any questions about the 
process.
Dr. Cohn introduced and welcomed Dr. Allen Craig who recently joined the National Center for
Immunization and Respiratory Diseases (NCIRD) as the Deputy Director.  Dr. Craig was most 
recently part of CDC’s Global Immunization Division (GID) where he served as the Africa Team
Lead in the Polio Eradication Branch since 2013.  After completing his medical residency, Dr. 
Craig joined the Indian Health Service where he served as the Acting Chief Medical Officer from
1993 to 1995.  In 1995, he joined the Tennessee Department of Health and later became a 
State Epidemiologist before returning to CDC in 2007.  He was an ACIP member for a short 
duration of time before he joined CDC.
11
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Dr. Cohn introduced the following guests attending this ACIP meeting:
 Dr. Lu Ming, EPI Division Director, Ministry of Health (MoH)
 Dr. Feng Zijian, Deputy Director of China CDC
 Dr. Wang Huaqing, National Immunization Program Director, China CDC
 Dr. An Zhijie, Vaccine Evaluation Division Director, China CDC
 Dr. Xu Keming, External Affairs and Communication Division Director, Ministry of Health
 Dr. Xia Wei, National Professional Officer, World Health Organization (WHO) China Office
 Dr. Su Qiru, Epidemiologist, China CDC
 Dr. Lance Rodewald, CDC Medical Officer on Secondment to WHO China
Dr. Cohn reported the following Ex Officio and Liaison Representative substitutions during this
meeting:
Ex Officio Members
 Ms. Kathleen Pittman is representing the US Department of Veterans Affairs (DVA)
 Dr. Gus Birkhead is representing the National Vaccine Program Office (NVPO)
Liaison Representatives
 Dr. Corey Robertson is representing Pharmaceutical Research and Manufacturers of 
America (PhRMA)
 Dr. Bonnie Maldonado is representing the Committee on Infectious Diseases (COID) of the 
American Academy of Pediatrics (AAP)
 Dr. Greg Frank is representing Biotechnology Innovation Organization (BIO)
 Dr. Susan Lett is representing the Association of Immunization Managers (AIM)
Regarding public comments, Dr. Cohn indicated that topics presented during ACIP meetings
include open discussion with time reserved for public comment. She explained that time for
public comment pertaining to topics on the agenda was scheduled following the end of the day’s
sessions, and that time for public comments also would be provided prior to each vote by ACIP
to enable these comments to be considered before a vote.  Registration for public comments is
solicited in advance of meetings.  People who planned to make public comments were 
instructed to visit the registration table at the rear of the auditorium where Ms. Natalie Greene
would record their name and provide information on the process.  People making public
comments were instructed to provide 3 pieces of information:  name, organization if applicable,
and any conflicts of interest (COI). Registration for public comment also was solicited in 
advance of this meeting through the Federal Register. Given time constraints, each comment 
was limited to 3 minutes.  Participants unable to present comments during this meeting were 
invited to submit their comments in writing for inclusion in the meeting minutes.
Recommendations and immunization schedules can be downloaded from the ACIP website. 
ACIP has a policy that every three to five years each recommendation is reviewed, and then 
renewed, revised, or retired. During every meeting, an update is provided on the status of ACIP
recommendations.  There was one ACIP publication since the June 2016 meeting, which is
reflected in the following table:
12
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Applications for ACIP membership are due no later than August 2, 2017 for the 4-year term
beginning July 1, 2018. Detailed instructions for submission of names of potential candidates to 
serve as ACIP members may be found on the ACIP web site:
E-mail: acip@cdc.gov Web homepage:
Nominations:  www.cdc.gov/vaccines/acip/committee/req-nominate.html 
A current CV, at least one recommendation letter from a non-federal government employee, and 
complete contact information are required.  These may be submitted as e-mail attachments to 
Dr. Jean Clare Smith at jsmith2@cdc.gov 
To summarize COI provisions applicable to the ACIP, as noted in the ACIP Policies and 
Procedures manual, members of the ACIP agree to forgo participation in certain activities 
related to vaccines during their tenure on the committee.  For certain other interests that 
potentially enhance a member’s expertise while serving on the committee, CDC has issued 
limited COI waivers.  Members who conduct vaccine clinical trials or serve on data safety 
monitoring boards (DSMBs) may present to the committee on matters related to those vaccines, 
but these members are prohibited from participating in committee votes on issues related to 
those vaccines.  Regarding other vaccines of the concerned company, a member may 
participate in discussions, with the proviso that he/she abstains on all votes related to the 
vaccines of that company.  It is important to note that at the beginning of each meeting, ACIP 
members state any COIs. 
Nancy Bennett, MD, MS 
ACIP Chair 
Dr. Bennett introduced the following new ACIP members, who will serve a 4-year term from July
2016 through June 2020:
 Robert Atmar, MD is Board Certified in Internal Medicine and Infectious Diseases, has
served joint appointments since 2006 as Professor of Medicine and Professor of Molecular
Virology and Microbiology at the Baylor College of Medicine.  He has served since 2007 as
Chief of the Infectious Diseases Service at Ben Taub General Hospital.  In addition to his
13
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strong record of basic and clinical research, Dr. Atmar has contributed generously to the 
administrative, clinical, and educational missions of the college. 
 Paul Hunter, MD is Board Certified in Family Medicine.  He has served since 2009 as
Associate Medical Director of the City of Milwaukee Health Department in Milwaukee, 
Wisconsin, Wisconsin’s largest and most ethnically diverse city, with public health problems
related to disparities within the city’s population.  He also is Associate Professor in the 
Department of Family Medicine and Community Health, School of Medicine and Public
Health, at the University of Wisconsin Madison.  Dr. Hunter has completed many projects
related to population health, health disparities, and immunization initiatives.
 Grace Lee, MD, MPH is Board Certified in Pediatrics and Pediatric Infectious Diseases.  She 
is the Director of the Center for Healthcare Research in Pediatrics (CHeRP) at Harvard 
Medical School where she has been conducting analyses for more than a decade on clinical
and policy issues in immunization and infectious disease.  She also is Associate Professor
of Population Medicine and Pediatrics, Department of Population Medicine, Harvard Medical
School, Boston, Massachusetts.  She served on The Institute of Medicine (IOM) Committee 
on Review of Priorities in the National Vaccine Plan (NVP), and the IOM Board on 
Population Health and Public Health Practice.  Dr. Lee also has participated extensively in 
activities related to immunization safety, including the Vaccine Safety Datalink (VSD)
project.
 Peter Szilagyi, MD, MPH is Board Certified in Pediatrics.  He is Professor and Vice-Chair for
Clinical Research in the Department of Pediatrics, David Geffen School of Medicine
(DGSOM) at the University of California at Los Angeles (UCLA).  He brings extensive 
experience as both an immunization delivery researcher and a primary care clinician.  He 
has carried out a large body of work over more than 25 years dedicated to immunization 
practices and policies.  He also is an expert on children’s health insurance plans.
Before officially beginning the meeting, Dr. Bennett called the roll to determine whether any
ACIP members had COIs.  The following COIs were declared:
 Robert Atmar receives research support from Takeda Vaccines
 Dr. Belongia has a conflict for respiratory syncytial virus (RSV) due to receiving research 
support from Novavax
 Dr. Romero has a conflict for RSV for funding non-related to vaccine trials and therapeutics
 The remainder of the ACIP members declared no conflicts
Dr. Bennett then requested that the liaison and ex officio members introduce themselves.  A list 
of Members, Ex Officio Members, and Liaisons are included in the appendixes at this end of this
document.
14
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Hepatitis Vaccines 
Introduction
José Romero, MD, FAAP, FIDSA, FPIDS
ACIP Hepatitis Work Group Member
Dr. Romero reminded everyone that the ACIP Hepatitis Work Group (WG) Terms of Reference 
are to:
 Update ACIP recommendations for hepatitis B (HepB) vaccine:
 Current ACIP recommendations
• 	 ACIP Routine Recommendation for HepB vaccine (Infants/Children).  MMWR
2005 Dec 23;54(RR-16):1-33. 
• 	 ACIP Routine Recommendation for HepB vaccine (Adult).  MMWR 2006 Dec
8;55(RR-16):1-33.
• 	 Use of HepB vaccine for adults with diabetes mellitus: recommendations of 
the ACIP. MMWR 2011 Dec 23;60(50):1709-11.
 Current CDC Guidelines
• 	 CDC guidance for evaluating health-care personnel for HepB virus (HBV)
protection and for administering postexposure management. MMWR 2013 
Dec 20;62(RR-10):1-19.
• 	 Update: Shortened Interval for Postvaccination Serologic Testing of Infants
Born to HepB-Infected Mothers.  MMWR 2015 Oct 9;64(39):1118-20.
The objectives for this session were to:  1) vote on removing the permissive language for the 
HBV birth dose to be administered after hospital discharge; and 2) vote to approve the revised 
HBV statement.
From February through September 2016, the WG deliberated on HepB vaccine 
recommendation topics and held five teleconference meetings.  The WG and ACIP members
reviewed and commented on a draft of the statement prior to the ACIP’s October 2016 meeting.  
The key updates to the HepB vaccine recommendations include the following:
 Removal of permissive language for delaying birth dose
 Provide examples of chronic liver disease (CLD), including recommending HepB vaccine for
persons with hepatitis C virus (HCV) infection
 Postvaccination serologic testing for infants whose mother’s hepatitis B surface antigen 
(HBsAg) status remains unknown indefinitely
 Testing HBsAg-positive pregnant women for HBV deoxyribonucleic acid (DNA)
 Guidance on the use of maternal antiviral therapy during pregnancy
15

































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
Updated Hepatitis B Vaccine Recommendations
Sarah Schillie, MD, MPH, MBA
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Dr. Schillie discussed Hepatitis B Virus (HBV) background, epidemiology, and prevention; 
existing HepB recommendations; and the revisions deliberated by the WG.  The Hepatitis WG 
has drafted a revised statement for HepB vaccine recommendations.  The revised statement is 
a single document containing guidance for HepB vaccination of infants, children, adolescents, 
and adults; testing of pregnant women for hepatitis B surface antigen (HBsAg), and, if positive, 
HBV DNA; HepB pre-vaccination and post-vaccination serologic testing; and HBV post-
exposure prophylaxis for occupational and non-occupational exposures.  The revised statement 
incorporates previously-published recommendations from ACIP and CDC, and is augmented 
with the American Association for the Study of Liver Diseases (AASLD) recommendation 8A:  
The AASLD suggests antiviral therapy to reduce the risk of perinatal transmission of hepatitis B 
in HBsAg-positive pregnant women with an HBV DNA level >200,000 IU/mL [Terrault et al.  
Hepatology 2015]. 
The single revised statement will update the two existing ACIP HepB statements for infants, 
children and adolescents published in 2005 and for adults published in 2006.  The revised 
statement also will incorporate previous ACIP guidance for HepB vaccination of adults with 
diabetes published in 2011, ensuring HBV protection among healthcare personnel (HCP)
published in 2013, and CDC guidance for shortening the interval for post-vaccination serologic
testing for infants born to HBsAg-positive mothers published in 2015.
HBV is transmitted through percutaneous or mucosal exposure to infectious blood or body
fluids.  The virus is highly infectious and remains viable on environmental surfaces for at least 7 
days.  HBV can be transmitted in the absence of visible blood [Bond et al.  Lancet 1981].  
Approximately 3,000 cases of acute HBV were reported to CDC in 2014, accounting for an 
estimated 19,200 new cases when considering under-ascertainment and underreporting.  It also
is estimated that 952 perinatal HBV infections occur annually.  According to analyses from the 
National Health and Nutrition Examination Survey (NHANES), approximately 850,000 persons
in the US have chronic HBV infection.  Other studies have yielded higher estimates.  Persons
with chronic infection serve as the main reservoir for transmission.  Imported chronic HBV
accounts for approximately 95% of new cases in the US [National Notifiable Diseases
Surveillance System (NNDSS); Ko et al.  JPIDS 2016; Roberts et al.  Hepatology 2016; Mitchell
et al.  PLoS One 2011].
The rate of reported acute HBV infections has declined by 90.6% since recommendations for
HepB vaccine were first issued in 1982.  The rate has been fairly stable from 2010-2014, 
although increases occurred in some populations such as white persons 30 through 39 years of 
age reporting injection drug use in Kentucky, Tennessee, and West Virginia [NNDSS; Harris et 
al.  MMWR 2016].
16
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This graphic depicts the decline of acute HBV since 2000.  Note that the rate is lowest for
persons 19 years of age and younger, which is likely the result of routine vaccination:
Chronic HBV infection develops in approximately 90% of infected infants, 30% of infected 
children less than 5 years of age, and in less than 5% of infected persons 5 years of age and 
older.  The risk of premature death from cirrhosis or liver cancer with chronic HBV infection is
approximately 25% if infected during childhood, and approximately 15% if infected after
childhood [Mast et al. MMWR 2005; Goldstein et al.  Int J Epidemiol 2005].
Perinatal transmission occurs primarily from mucosal exposure to infected blood and other body
fluids during delivery.  Without post-exposure prophylaxis (PEP), perinatal HBV infection 
develops in approximately 90% of infants born to mothers who are HBsAg-positive and hepatitis
B e antigen (HBeAg)-positive, and 5% to 20% of infants born to mothers who are HBsAg­
positive and HBeAg-negative [Nelson et al.  JPIDS 2014; Mast et al.  MMWR 2005].
The WHO recommends all infants receive their first dose of HepB vaccine as soon as possible 
after birth, preferably within 24 hours [WHO Hepatitis B Vaccines Position Paper.  Weekly
Epidemiological Record 2009].  Countries in which a HepB birth dose (HepB-BD) vaccine has
been implemented in the national immunization program are depicted in the following map in 
green, reflecting 49% of countries:
17



















   
 
To identify HBV infected pregnant women, all women should be tested routinely for HBsAg 
during pregnancy during an early prenatal visit.  Testing should occur during every pregnancy, 
even if the woman has been previously vaccinated or tested.  For infants born to HBsAg­
positive mothers, ACIP recommends HepB vaccine and HBIG within 12 hours of birth.  For 
those infants with birthweights <2000 grams, the birth dose is not counted as part of the vaccine 
series.  Infants born to mothers with unknown HBsAg weighing ≥2000 grams should receive 
HepB vaccine within 12 hours of birth.  Infants weighing <2000 grams should receive both HepB 
vaccine and HBIG within 12 hours of birth.  For those infants weighing <2000 grams, the birth 
dose is not counted as part of the vaccine series.  Infants weighing ≥2000 grams who are born 
to HBsAg-negative mothers should receive HepB vaccine before hospital discharge.  For infants 
weighing <2000 grams born to HBsAg-negative mothers, the first dose of HepB vaccine should 
be delayed until 1 month of age or hospital discharge. 
 
The existing recommendations contain permissive language to delay the birth dose.  The 
language states that, “On a case-by-case basis and only in rare circumstances, the first dose 
may be delayed until after hospital discharge for an infant who weighs ≥2,000 grams and whose 
mother is HBsAg-negative.”  A physician’s order to withhold the birth dose should be present, 
along with a copy of the original maternal HBsAg-negative laboratory report.  The birth dose 
should be administered by 2 months of age, and should not be delayed in high risk situations, 
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PEP shortly after birth is efficacious in preventing perinatal HBV transmission.  HepB vaccine 
alone is 75% effective in preventing perinatal HBV transmission, and HepB immune globulin 
(HBIG) alone 71% effective.  The combined efficacy is 94% [Beasley et al.  Lancet 1983; Lee et 
al.  BMJ 2006].
Serologic evidence of vaccine-induced protection is assessed by the level of antibody to 
hepatitis B surface antigen (anti-HBs) measured 1 to 2 months after HepB vaccination.  Anti-
HBs of ≥10mIU/mL corresponds to vaccine-induced protection.  Protection exists for 30 years or
longer among immunocompetent vaccine responders [Leuridan et al.  CID 2011; Bruce et al. 
JID 2016].
The 3-dose vaccine series results in protective anti-HBs in 98% of healthy infants and 90% to 
95% of healthy children and adults aged 40 years and younger.  Lower seroprotection is
associated with prematurity, advanced age, diabetes, obesity, chronic illness, and smoking 
[Schillie et al.  Vaccine 2012; Mast et al.  MMWR 2006].
Anti-HBs after the HepB vaccine series wanes over time.  However, even when levels wane to 
less than <10 mIU/mL, breakthrough HBV infections are uncommon in immunocompetent 
vaccine responders [Middleman et al.  Pediatrics 2014; Leuridan et al.  CID 2011].
In terms of existing HepB recommendations, the national strategy to eliminate HBV
transmission in the US encompasses the following: 1) screen all pregnant women for HBsAg 
and provide prophylaxis consisting of HepB vaccine and HBIG within 12 hours of birth for all
infants born to HBsAg-positive women; 2) universal vaccination of all infants beginning at birth, 
before hospital discharge, as a safety net; 3) routine vaccination of previously unvaccinated 
children and adolescents aged 19 years and less; and 4) vaccination of adults at risk for HBV
infection, including those requesting protection from HBV without acknowledgment of a specific
risk factor [Mast et al.  MMWR 2005; Mast et al.  MMWR 2006].
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The HepB vaccine series is completed at age 6 months for infants born to HBsAg-positive or
unknown mothers, or at age 6 to 18 months for infants born to HBsAg-negative mothers. Post-
vaccination serologic testing consisting of testing for anti-HBs and HBsAg is recommended at 
age 9 to 12 months, or 1 to 2 months after the final dose of the vaccine series if delayed, for
infants born to HBsAg-positive mothers.  Three-dose revaccination followed by repeat post-
vaccination serologic testing is recommended for infants with anti-HBs <10mIU/mL.  HepB
vaccination is recommended for all children and adolescents aged <19 years.  Those not 
previously vaccinated should be vaccinated routinely at any age using an appropriate dose and 
schedule.
Adults recommended for HepB vaccination include those at high risk for infection by sexual
exposure, such as sex partners of HBsAg-positive persons and men who have sex with men 
(MSM); those at risk for infection by percutaneous or mucosal exposure to blood, such as
injection-drug users, health-care and public safety workers, persons with end-stage renal
disease, and adults with diabetes; international travelers to regions with high or intermediate 
HBV endemicity, defined as HBsAg-positive prevalence ≥8% and ≥2%, respectively; persons
with chronic liver disease; persons with HIV infection; and all persons seeking protection from
HBV infection even without acknowledgement of a specific risk factor.  All adults in certain 
settings also are recommended for HepB vaccination, including the following:
 Sexually transmitted disease treatment facilities
 HIV testing and treatment facilities
 Facilities providing drug-abuse treatment and prevention services
 Health-care settings targeting services to injection-drug users
 Correctional facilities
 Health-care settings targeting services to men who have sex with men 
 Chronic-hemodialysis facilities and end-stage renal disease programs
 Institutions and nonresidential day care facilities for developmentally disabled persons
Vaccination of persons who are immune to HBV infection due to past infection or vaccination
does not increase risk for adverse events (AEs).  However, pre-vaccination serologic testing 
might reduce costs by avoiding vaccination of persons who already are immune. Pre­
vaccination serologic testing is recommended for household, needle-sharing, or sex contacts of 
HBsAg-positive persons; persons born in regions of high HBV endemicity; and HIV-positive 
persons.  The existing recommendations also state that pre-vaccination serologic testing might 
be cost-effective for injection drug users, incarcerated persons, MSM, and persons born in 
regions of intermediate HBV endemicity.  The first vaccine dose typically should be 
administered immediately after the collection of blood for serologic testing.
Post-vaccination serologic testing for immunity is not recommended after routine vaccination of 
infants, children, adolescents, and adults.  Post-vaccination serologic testing is recommended 
for infants born to HBsAg-positive mothers, HCP, chronic hemodialysis patients, HIV-infected 
and other immunocompromised persons, and sex partners of HBsAg-positive persons.  Testing 
is recommended 1 to 2 months after the final dose of the vaccine series or at age 9 to 12 
months for infants of HBsAg-positive mothers.  Revaccination is recommended if anti-HBs is 
<10 mIU/mL.
In terms of post-exposure prophylaxis following occupational exposures, unvaccinated HCP
exposed to blood or body fluids from a source patient positive for HBsAg should receive 1 dose 
of HBIG and initiate vaccination.  Those exposed to a source patient negative for HBsAg should 
initiate vaccination.  A previously vaccinated HCP who is a known vaccine responder requires
19




































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
no PEP regardless of source patient status.  Previously vaccinated HCP who are known non-
responders after 3 vaccine doses and exposed to a positive source patient should receive 1 
dose of HBIG and initiate revaccination.  Those exposed to a source patient negative for HBsAg 
should initiate revaccination.  Previously vaccinated HCP who are known non-responders after
6 vaccine doses and exposed to a positive source patient should receive 2 doses of HBIG
separated by 1 month.  Those exposed to a source patient negative for HBsAg require no 
prophylaxis.
With regard to post-exposure recommendations following non-occupational exposures, an 
unvaccinated person exposed to a HBsAg-positive source should receive a HepB vaccine 
series and HBIG.  A previously vaccinated person exposed to a HBsAg-positive source should 
receive a dose of HepB vaccine.  An unvaccinated person exposed to a source with an 
unknown HBsAg status should receive the HepB vaccine series, while a vaccinated person 
exposed to a source with unknown status requires no prophylaxis.
Dr. Schillie then discussed the revisions to the recommendations deliberated upon by the WG.  
The WG deliberated upon and supports guidance for testing HBsAg-positive pregnant women 
for HBV DNA.  DNA testing identifies infants at greatest risk for perinatal HBV infection and 
prioritizes women for referral for antiviral therapy in accordance with AASLD’s suggestion for
maternal antiviral therapy to reduce the risk of perinatal transmission when maternal HBV DNA
is >200,000 IU/mL.
The WG also deliberated upon and supports guidance for post-vaccination serologic testing for
infants whose mother’s HBsAg status remains unknown indefinitely, such as infants
surrendered anonymously shortly after birth.  Note that all 50 states have some form of safe-
haven law to reduce the risk of infant abandonment, and that medical data on these infants is
lacking.
The WG also deliberated on removal of the permissive language for birth dose administration 
after hospital discharge.  The following table reflects the existing and proposed language.  Note 
the proposed revised language on the right, which reflects removal of the permissive paragraph 
from the existing language regarding delaying birth dose administration:
Existing Language
For all medically stable infants weighing 
≥2,000 grams at birth and born to HBsAg­
negative mothers, the first dose of vaccine 
should be administered before hospital
discharge.  Only single-antigen HepB vaccine 
should be used for the birth dose.
On a case-by-case basis and only in rare 
circumstances, the first dose may be delayed 
until after hospital discharge for an infant who 
weighs ≥2,000 grams and whose mother is
HBsAg-negative.
Revised Language (proposed)
For all medically stable infants weighing 
≥2,000 grams at birth and born to HBsAg­
negative mothers, the first dose of vaccine 
should be administered before hospital
discharge.  Only single-antigen HepB vaccine 
should be used for the birth dose.
20
 











































Advisory Committee on Immunization Practices (ACIP)	 Summary Report October 19-20, 2016
Included in the WG’s deliberations was a study demonstrating an increase in HBV infections for
infants born to HBsAg-positive mothers with increasing age at first dose of vaccination.  The 
adjusted odds ratio for an increase in infection was 4.3 (95% CI, 2.2-8.4) [Marion et al.  Am J
Epidemiol 1994].  Birth dose coverage in the US is currently 72.4% and has remained relatively
stable in recent years.  Note that current coverage is below the Healthy People 2020 target of 
85%.
The WG also discussed the safety net provided by birth dose prior to hospital discharge, 
including when infants born to infected mothers are not identified due to errors in maternal
HBsAg testing or transcription or reporting of test results.  Note that the WG did not reach 
consensus on removal of the permissive language.
The WG deliberated upon and supports providing examples of chronic liver disease (CLD) in the 
statement.  The existing guidance recommends HepB vaccination for persons with CLD.  The 
WG supports providing examples of CLD such as cirrhosis, fatty liver disease, alcoholic liver
disease, autoimmune hepatitis, and liver function tests >2 times the upper limit of normal.  
Three-dose HepB vaccine coverage among adults aged ≥19 years with chronic liver conditions
is slightly less than 30% [Williams et al.  MMWR 2016].
CDC supports explicit language for recommending HepB vaccination for persons with HCV
infection.  The increasing incidence of HBV and HCV infections have been noted in young, non-
urban adults who inject drugs in Kentucky, Tennessee, and West Virginia.  Concurrent HepB
virus infection may increase the risk for liver disease progression among HCV-infected persons
[Zibbell et al.  MMWR 2015; Harris et al.  MMWR 2016; Bell et al.  Acta Gastroenterol Belg 
2000.; Oh et al.  BMC Cancer 2012].
For discussion and vote, Dr. Schillie posed the following questions:
 Does ACIP approve removing the permissive language for the HepB vaccine birth dose to 
be administered after hospital discharge?
 Does ACIP approve the revised HepB statement?
Discussion Points
Dr. Belongia requested insight as to why the original language was included regarding the 
permissive birth dose prior to discharge, and an example of what would be a circumstance that 
would have been considered reasonable not to vaccinate prior to hospital discharge.
Dr. Schillie replied that she had no insight as to why the language originally was placed in the 
recommendation.  That was from the 2005 recommendations.  Some of the WG deliberations in 
favor of not removing the permissive language was for mothers who feel that they know that 
they are negative for HBV, and that perhaps those mothers should not be required to have their
infant vaccinated before hospital discharge.  Perhaps they should have the choice to have the 
infant vaccinated later in life.
Dr. Hunter asked whether there were any data that would suggest that removing the birth dose 
permissive recommendation would change the overall completion rate of the 3-dose infant 
series and, if not, whether there were any plans to study this question.
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Dr. Schillie responded that there are studies which are 10 to 15 years old that showed an 
association with receipt of the birth dose and timely completion of the vaccine series.
Speaking on behalf of some mothers she has spoken to about the birth dose, Dr. Even (ACHA)
reported that these mothers have concern about vaccinating a child at birth in terms of their
immune system not being ready for vaccine, and that the infant’s immune system should be 
more mature before beginning vaccination.
While they may have concerns, Dr. Moore said she did not believe there was any scientific
evidence to support that.  She reminded everyone that having a clear recommendation does not 
mandate anything.  People make their own choices all of the time about whether to refuse 
something that is recommended.  It did not seem to her that removal of the permissive language 
would result in a compulsion of parents to immunize who are resistant to that any more than any
other recommendation does.  However, in her experience, clinicians may choose to have a 
patient get their vaccine at the doctor’s office at the 2-week visit.  That may be for convenience 
for the clinicians, and so that the clinician is paid for that visit instead of it being something that 
the hospital takes care of.  Other issues may come into play in terms of pediatric practice.  A
clear recommendation without the permissive language may make it easier to make vaccination 
routine in hospitals prior to discharge.
Regarding the recommendation for infants <2000 grams born to seronegative mothers, Dr. 
Walter pointed out that the language stated “delay dose of HepB vaccine until age 1 month or
hospital discharge.”  He asked what the intent was, especially for a child who is approximately
2000 grams or just under that who may be discharged at 2 to 3 weeks of age.
Dr. Schillie replied that among term infants, vaccine response is normal when it is administered 
early in life.  Vaccine response among low birthweight infants improves quite a bit when 
vaccination is delayed until about 1 month of life.  When low birthweight babies are immunized 
in the first couple of days of life, 60% to 65% might achieve seroprotective antibody levels.  
When vaccination in those infants is delayed starting at 1 month of life, 90% or more achieve 
seroprotective levels.
Dr. Walter asked whether they should be vaccinated at 1 month or at hospital discharge, which 
may be before 1 month.  The language is somewhat confusing.
Dr. Schillie clarified that the language shown on the slide was taken verbatim from the existing 
recommendation, which do not specify a preference. It states either “1 month of life or hospital
discharge.” The WG could certainly entertain a preference.
Regarding testing post-vaccination for infants born to HBsAg-positive mothers, Dr. Kimberlain 
(AAP) noted that one of Dr. Schillie’s slides illustrated that the recommendation is 9 to 12 
months or 1 to 2 months of the final dose of the vaccine series.  Pointing out that it used to be 9 
to 18 months, he asked whether Dr. Schillie could comment on why it changed from 18 to 12 
months.
Dr. Schillie indicated that in 2015, CDC issued a recommendation to shorten that interval from 9 
to 18 months to 9 to 12 months for two reasons.  One, there were new data that showed the 
decline in anti-HBs over time when post-vaccination testing was done at increasing intervals
following vaccination.  Infants were falsely identified as non-responders and were being 
revaccinated unnecessarily due to the decline in anti-HBs over time.  Second, COMVAX® 
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production was discontinued.  With COMVAX®, the last dose was given at age 15 months.  So, 
one reason the interval was extended out to 18 months was to accommodate intervals 

























Dr. Schaffner (NFID) said he was supportive of removing the permissive language regarding the 
HepB birth dose.  He requested a brief discussion of adult immunization, because he was 
disappointed in the WG’s report because he thought an opportunity had been missed.  Part of 
the title of the document is “A Strategy to Interrupt Transmission.”  As was demonstrated, there 
have been flat rats in the adult population for some time.  Indeed, rates are increasing in some 
parts of the country in some age groups.  This is an opportunity to move forward in the strategy 
to interrupt transmission in a more innovative and assertive way.  After the 19th  birthday, in a 
way that differs from all other vaccine recommendations, an adult has to acquire risk before 
being eligible for immunization.  However, individuals do not have to wait to be exposed to 
measles before receiving measles vaccine.  Also, it is known that this risk-based strategy is 
honored most often in the breech rather than the observance.  Therefore, it is a strategy that is 
stuck or even failed.  It has been about 15 years since universal immunization has been 
recommended of everyone up to the 19th  birthday.  He has never understood why, once 
someone turns 19 years of age plus one day, they are no longer eligible.  He suggested taking 
that universal recommendation with that cohort and moving it forward with them.  This is an 
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Dr. Kimberlain (AAP) pointed out that the 2015 STI guidelines do not specifically state this, but 
points to the 2005 Morbidity and Mortality Weekly Report (MMWR), not the 2015 document.  If 
there is a living document with the STI guidelines, he suggested that it might be worth adding 
that in.
Dr. Messonnier asked whether COID has language pertaining to this in the Red Book, and if 
there is an opinion and / or agreement about the permissive language.
Dr. Maldonado (AAP) replied that COID discussed this on a conference call the previous week, 
and was in agreement with the recommendation.  Discussion regarding the 2005 
recommendations pertained to the difficulty among practitioners and hospitals in developing a 
birth dose within their systems and capturing every child.  The idea was to allow some 
permissiveness.  Since that point, most hospitals and practices have been able to make that 
switch.
Dr. Kimberlain (AAP) added that the Red Book currently contains permissive language, but they
are working actively on the 2018 edition and would be delighted to incorporate this in should 
ACIP vote in favor of removing the permissive language.
Dr. Thompson (NVAC) asked what is known about the fraction of births that occur outside of 
what would be captured as hospitals in terms of whether a small part of the population is being 
missed who might be relevant to uptake, and what is being done to improve uptake.
Dr. Schillie replied that while the WG focused primarily on infants born in the hospital, certainly
they are concerned about those born outside the hospital as well.  However, she said she did 
not have data on the proportion of infants born outside of hospitals and their HepB birth dose 
coverage rates.  In terms of what is being done to improve rates of birth dose before discharge, 
educational efforts are underway to try to educate mothers and providers about the importance 
of the birth dose as a safety net.  Birth dose coverage before hospital discharge also is a quality
metric for hospitals that choose to use that measure.
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strategic rather than lethargic.  He urged the colleagues to re-deliberate and do something 
innovative regarding this continuing concern about HepB acutely occurring in adult age groups.
Dr. Schillie thought Dr. Schaffner raised an excellent point.  Certainly, there are areas in which 
HBV is increasing among young adult populations such that immunization of adults 30 through 
39 years of age would help to address the increasing HBV prevalence among those 
populations.
Dr. Wexler (Immunization Action Coalition) pointed out that the permissive language was
developed as restrictive language.  She has been attending ACIP meetings since before 2000, 
and she has been following the HepB birth dose issue since 1991.  She recalled that before the 
thimerosal controversy, there were very high rates of HepB vaccination at birth.  The rate was
approaching 80%, decreased to zero with thimerosal, and then increased only to about 40%
after the 1998 thimerosal fiasco.  In 2002, ACIP recommended the birth dose for every baby.  
Rates began to increase again, but not very quickly.  The purpose of the language in 2005 
being referred to as “permissive” that actually was “restrictive” was to say, “Do not give the birth 
dose later.  Give it at birth, except in rare circumstances and on a case-by-case basis.”  As a 
result of that, the birth dose rate has been increasing gradually and is approximately 72%.  That 
is within 3 days of birth, not before hospital discharge.  Dr. Wexler emphasized that she wanted 
to set the stage for how important it is to give this birth dose in the hospital.  She said she had 
just received an email from a Perinatal HepB Coordinator who has been to every hospital in her
state, and is fighting to get the birth dose implemented.  Private doctors are still delaying the 
dose and giving it in their practices at the 1-week visit.  She is hungry for help about what to do.  
In light of the former restrictive language and perhaps moving toward the language of everybody
giving the vaccine, programmatically it would be very helpful to Perinatal HepB Coordinators for
ACIP to explain what it means to administer the dose before hospital discharge—either before 
12 hours of age or before 24 hours of age.  That would help Perinatal HepB Coordinators and 
everyone else be very clear in what they are trying to implement rather than stating “before 
hospital discharge.”
Dr. Decker (Sanofi Pasteur) added that another factor which played into this that Dr. Wexler did 
not mention, which was an economic / political issue.  At the time, there was the original
recommendation and hospitals adopted it widely.  When the thimerosal issue arose, hospitals
leapt at the opportunity to keep this out of their programs because it was an unfunded mandate.  
When it occurs during the birth process, it was capitated for the mother but nobody was paying 
for the injection to the baby.  Another reason there was the language in 2005 was because it 
was part of political compromise. This is 11 years later and in order to make progress, it is
necessary to move to mandatory language.  He agreed that rather than stating “before 
discharge” they should state “within the first 24 hours of life.”  He emphasized that they must be 
very specific and concrete if they wanted to get it done.
Dr. Fryhofer (AMA / ACP) noted that on page 5 of the handout in terms of adults recommended 
for HepB vaccine, an example was not given for the bullet “persons at risk for infection by
sexual exposure” through having more than one sex partner within the last six months.  This
relates to what Dr. Schaffner was saying.  Even patients in their 50s, 60s, and up may
experience changes in their situations and that may apply to them.  She applauded the WG for
highlighting fatty liver as an indication as an example of CLD, because an increasing number of 
patients with fatty liver are being seen in practices because of the obesity crisis.
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Dr. Hunter asked why the cutoff for the upper limit of normal of liver function tests as a risk was 
twice the upper limit of normal versus three times the upper limit of normal, which is what most 
clinicians use as a decision factor in clinical situations.
Dr. Schillie replied that the number was chosen fairly arbitrarily.  There are some clinical
guidelines that use greater than two times the upper limit of normal in some of the decision 
factors.  Unrelatedly, an algorithm for prenatal testing was issued that received some comments
that the alanine aminotransferase (ALT) cutoff was perhaps too low.  It is important to capture a 
level that is not too high or too low, and the WG is open for feedback on that level.
Dr. Hunter added that for primary care physicians, he was arguing in general to try to make the 
recommendations as uniform as possible for correct implementation.
Dr. O’Leary (PIDS) noted that the 2005 guidelines have fairly extensive guidance for hospitals
on policies to increase the uptake of the birth dose, screening, et cetera, and included
recommending the use of standing orders.  He wondered whether that would be included in the 
new guidelines.  Dr. Schillie replied that it would.
Regarding Dr. Schaffner’s comments, Dr. Ward (Director, Division of Viral Hepatitis) noted that 
the major gap in HepB coverage is among adults.  That is where most cases are being 
observed in states such as Tennessee, which is heavily related to the opioid abuse crisis and 
the injection of those medications or heroin.  There has been an elimination goal, although it is
one that has been proposed without a numerical target, since the infant vaccine was
recommended by ACIP in about 1992.  This elimination target has taken on some renewed 
interest.  The IOM, now known as the National Academy of Medicine (NAM), has convened a 
panel to set elimination targets for HepB and HepC elimination and is framing it as the 
elimination of HepB transmission and disease as a public health threat in the US.  This is
proposed to be coming out from that panel in Spring 2017.  A more ambitious HepB vaccination
policy for the most vulnerable parts of the population, in this case young, middle-aged, and even 
older adults, would be very appropriate.  He suggested that the WG could reconvene to assess
stronger recommendations for adults, while still hopefully having ACIP agree with what already
was before them during this session.
Regarding measurement, Dr. Lee pointed out that it would be helpful to understand whether the 
rate of 72% for the birth dose excludes premature populations.  That is, if 10% actually are 
premature, vaccination rates may be higher.  It also might give them a better sense of where to 
target improvement efforts.  From a systems level perspective, it seemed like they were trying to 
bridge the gaps and that minimizing permissive use would be helpful in that instance.  It also 
might be helpful to assess the impact of alternative vaccination strategies, particularly in terms
of the adult disease burden.  She asked whether the WG would consider that.
Dr. Moore completely supported the idea of having the WG consider an age-based 
recommendation for adults.  As the Program Manager for Tennessee, she reported that they are 
one of the three states that are struggling mightily with this.  Risk-based strategies have not 
helped them.  Reminding everyone that the proposed language specified hospitals and 
excluded children born outside of the hospital setting, she emphasized that the concern was not 
about the setting.  It was about protecting the infant at birth.  She asked whether there would be 
opposition to proposing, especially from a programmatic standpoint, the clear-cut 
communication message that the first dose should be administered within 24 hours of life rather
than before hospital discharge.  That would eliminate the setting of the birth from consideration 
in the protection of the newborn.
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Dr. Hunter indicated that the American Congress of Obstetricians and Gynecologists (ACOG)
website reported that there are about 35,000 births per year outside of the hospital setting, 
which is about 0.9% of births.
Dr. Belongia supported the suggested amendment of the inclusion of “within 24 hours of life”
and elimination of setting, given that it does not matter whether the birth occurs in the hospital.
Dr. Messonnier pointed out that the language “within 24 hours of birth” is consistent with the 
WHO.  In order to facilitate the upcoming Vaccines for Children (VFC) vote, she requested that 
the specific language preferred be utilized in terms of “within 24 hours of birth” or “before 
hospital discharge.”
Dr. Lee asked whether there were any implementation issues of concern with regard to the 
proposed change to “within 24 hours of birth” versus “before hospital discharge.”
Dr. O’Leary (PIDS) said he would argue that the suggested change would make things clearer
for hospitals and clinicians, because there is confusion regarding whether they should wait for
72 hours if it is a Cesarean section (C-section) for example.
Dr. Riley added that from a programmatic standpoint, it would just mean changing standing 
orders.  She did not think this would be problematic.  However, she was not wildly optimistic that 
people who deliver outside of the hospital suddenly will be the ones who get vaccinated.  The 
very people who deliver outside of the hospital generally are not people who are tremendously
excited about organized medicine, and the need to get vaccinated.
Dr. Stephens emphasized the need to keep in mind Dr. Schaffner’s point about universal
vaccination.
Dr. Kempe reiterated the importance of the WG returning to the adult recommendations at a 
later time.
Dr. Szilagyi agreed, stressing that risk-based strategies typically are not effective.
In terms of implementation considerations, Patsy Stinchfield (NAPNAP) underscored that a lot 
of education will be needed for those who do not meet the 24-hour stipulation.  For example, a 
birth center might ask, “We’re at hour 25.  What do we do?”
Christina Hildebrand (A Voice for Choice Advocacy) expressed concern about the 24 hours, 
pointing out that the US has the highest rate of infant mortality within the first day of birth and 
also is one of the few countries that has a HepB vaccine given within the first 24 hours of birth.  
She wondered whether CDC and / others have conducted research to assess this.  It concerns
her that there may be a correlation, and she requested that consideration be given to this before
making that recommendation.
Dr. Schillie replied that CDC continuously monitors the safety of HepB vaccine, including when 
administered shortly after birth.  It is a very safe vaccine.  Anaphylaxis occurs in about 1 out of a 
million cases, and CDC will continue to monitor this.  There are data to support the safety of the 
vaccine being given so shortly after birth, including that it does not increase the work-up for
sepsis in young infants.
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Dr. Riley noted that in addition to the safety data, it would be important to point out that most 
infant mortality in the US is in pre-term infants who are not the babies being vaccinated within 
the first 24 hours of life because they are <2000 grams.
Vote:  Hepatitis B Vaccine Birth Dose Amendment
Dr. Romero made a motion to approve the advised recommendation as stated, “For all
medically stable infants weighing ≥2,000 grams at birth and born to HBsAg-negative mothers, 
the first dose of vaccine should be administered before hospital discharge.  Only single-antigen 
HepB vaccine should be used for the birth dose.”  Dr. Atmar seconded the motion.  Dr. Moore 
offered an amendment to the proposed language to replace the statement “before hospital
discharge” with the statement “within 24 hours of birth.”  Dr. Belongia seconded the suggested 
amendment.  Dr. Bennett called for a vote on the amendment.  The motion carried unanimously




Vote:  Hepatitis B Vaccine Amended Birth Dose & Removal of Permissive Language 
Dr. Romero motioned to approve the overall birth dose recommendation as amended, “For all
medically stable infants weighing ≥2,000 grams at birth and born to HBsAg-negative mothers, 
the first dose of vaccine should be administered within 24 hours of birth.  Only single-antigen 
HepB vaccine should be used for the birth dose” and to remove the permissive language 
reading “On a case-by-case basis and only in rare circumstances, the first dose may be delayed 
until after hospital discharge for an infant who weighs ≥2,000 grams and whose mother is
HBsAg-negative.”  Dr. Atmar seconded the motion.  The motion carried unanimously with 14 
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     Single antigen vaccine  Single-antigen1 and combination vaccine2,3  
Birth Maternal HBsAg  Dose  Age  Dose  Age
 weight  status
 ≥2000 g  Positive  1  Birth (≤12 hrs)1  1  Birth (≤12 hrs )1 
     2  1-2 months  2  2 months
     3  6 months  3  4 months
         4  6 months
  Unknown  1  Birth (≤12 hrs)1  1  Birth (≤12 hrs)1 
     2  1-2 months  2  2 months
     3  6 months  3  4 months
         4  6 months
   Negative  1  Birth (before discharge)1  1  Birth (before discharge)1 
     2  1-2 months  2  2 months
     3 6 -18 months  3  4 months
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Vote:  Hepatitis B Vaccine Overall Recommendations
Dr. Romero motioned to approve the overall recommendations for Hepatitis B vaccination.  Dr. 
Atmar seconded the motion.  The motion carried unanimously with 14 affirmative votes, 0 
negative vote, and 0 abstentions.  The disposition of the vote was as follows:
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
Riley, Romero, Stephens, Szilagyi, Walter 
VFC Resolution
Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Santoli indicated that the purpose of this resolution was to align the VFC resolution with the 
ACIP’s updated HepB recommendations.  The eligible groups for this resolution are all children 
and adolescents birth through 18 years of age.  The tables below list the acceptable vaccination
schedules for children and adolescents birth through 18 years of age, which are directly from
the draft of the recommendations that ACIP has reviewed, discussed, and approved.  The 
change will be made that was just discussed and voted upon, such that “birth” is replaced with 
“within 24 hours” through all parts of the tables:
Table 1, Part I: Infants
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Table 1, Part 2: Infants
<2000 g Positive 1 Birth (≤12 hrs)1  1 Birth (≤12 hrs)1 
2 1 month 2 2 months 
3 2-3 months 3 4 months 
4 6 months 4 6 months 
Unknown 1 Birth (≤12 hrs)1  1 Birth (≤12 hrs)1  
2 1 month 2 2 months
3 2-3 months 3 4 months 
4 6 months 4 6 months 
Negative 1 1 
2 2 months 2 2 months 
3 6 -18 months 3 4 months 
4 6 months 
Table Notes:  
1. Only a single antigen hepatitis B vaccine (ENGERIX-B®  or RECOMBIVAX HB®) can be given at birth. 
2. Pediarix®  [DTaP-IPV-HepB] is licensed for children 6 weeks through 6 years of age.  
3. Use of brand names is not meant to preclude the use of other comparable US licensed vaccines.  
Table 2:  Children and Adolescents  
Age Schedule1, 6  
Children (1 through10 years) 0, 1, and 6 months2   
0, 2, and 4 months2  
0, 1, 2, and 12 months2,4   
Adolescents (11 through 18 years) 0, 1, and 6 months2  
0, 1, and 4 months2  
0, 2, and 4 months2  
0, 12, and 24 months2  
0 and 4-6 months3  
0, 1, 2, and 12 months2,4  
0, 7 days, 21-30 days, 12 months5  
Table Notes
1. Children and adolescents may be vaccinated according to any of the schedules indicated, except as noted. Selection of a 
schedule should consider the need to optimize compliance with vaccination.
2. Pediatric/adolescent formulation. 
3. A two-dose schedule of Recombivax-HB Adult Formulation is (10 micrograms) is licensed for adolescents aged 11 through 15
years.  When scheduled to receive the second dose, adolescents aged > 15 years should be switched to a three-dose series, with 
doses 2 and 3 consisting of the pediatric formulation administered on an appropriate schedule.  
4. A four-dose schedule of Engerix B® is licensed for all age groups.  
5. Twinrix® can be administered to persons 18 years of age before travel or any other potential exposure on an accelerated 
schedule at 0, 7, and 21-30 days, followed by a dose at 12 months. 
6. Use of brand names is not meant to preclude the use of other comparable US licensed vaccines. 
The only items to be added to Table 2 will be at the bottom of the Adolescent part of the table, 
which is the accelerated schedule that can be used when administering Twinrix®. This does 
apply to 18 year olds who are covered by the VFC program. 
There also is information about interrupted schedules and minimum dosing schedules that 
comes from the current version of the recommendations that was voted on and approved, as
well as prior versions of the recommendations:
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Interrupted Schedules and Minimum Dosing Intervals
 When the HepB vaccine schedule is interrupted, the vaccine series does not need to be 
restarted.  If the series is interrupted after the first dose, the second dose should be 
administered as soon as possible, and the second and third doses should be separated by
an interval of at least eight weeks.  If only the third dose has been delayed, it should be 
administered as soon as possible. 
 The third dose of vaccine must be administered at least eight weeks after the second dose 
and should follow the first dose by at least 16 weeks; the minimum interval between the first 
and second doses is four weeks. Inadequate doses of hepatitis B vaccine or doses received 
after a shorter-than-recommended dosing interval should be re-administered, using the 
correct dosage or schedule. 
 Vaccine doses administered ≤4 days before the minimum interval or age are considered 
valid.  Because of the unique accelerated schedule for Twinrix®, the four-day guideline does 
not apply to the first three doses of this vaccine when administered on a 0 day, 7 day, 21-30 
day, and 12 month schedule.  
 In infants, administration of the final dose is not recommended before age 24 weeks (164 
days). 
There also is guidance about revaccination to make sure those doses are included in the VFC
program, which is taken directly out of the statement in various categories for which
revaccination would be recommended:
Revaccination
Revaccination (i.e., booster dose, challenge dose, or revaccination with a complete series) is
not generally recommended for persons with a normal immune status who were vaccinated as
infants, children, or adolescents. Revaccination when anti-HBs is <10 mIU/mL is recommended 
for the following:
 Infants born to HBsAg-positive mothers.  HBsAg-negative infants with anti-HBs <10 mIU/mL 
should be revaccinated with a second three-dose series and retested (HBsAg and anti-HBs) 
1-2 months after the final dose of vaccine.
 Hemodialysis patients. For hemodialysis patients, the need for booster doses should be 
assessed by annual anti-HBs testing.  A booster dose should be administered when anti-
HBs levels decline to <10 mIU/mL.
 Other immunocompromised persons. For other immunocompromised persons (e.g., HIV-
infected persons, hematopoietic stem-cell transplant recipients, and persons receiving 
chemotherapy), the need for booster doses has not been determined.  When anti-HBs levels
decline to <10 mIU/mL, annual anti-HBs testing and booster doses should be considered for
persons with an ongoing risk for exposure.
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 Persons with postvaccination serologic testing results that do not demonstrate protection. 
This includes children and adolescents through age 18 years who are chronic hemodialysis
patients, HIV-infected, otherwise immunocompromised (e.g., hematopoietic stem-cell 
transplant recipients or persons receiving chemotherapy), or sex partners of HBsAg-positive 
persons. Persons in these groups found to have anti-HBs concentrations of <10 mIU/mL 
after the primary vaccine series should be revaccinated. 
Recommended Dosage
Refer to product package inserts.
Contraindications and Precautions
Contraindications and Precautions can be found in the package inserts available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
Statement Regarding Update Based on Published Documents
[If an ACIP recommendation regarding Hepatitis B vaccination is published within 12 months
following this resolution, the relevant language above (except in the eligible groups sections) will
be replaced with the language in the recommendation and incorporated by reference to the 
publication URL.]
Vote:  VFC Resolution for Hepatitis B Vaccine Recommendations
Dr. Stephens motioned to approve the VFC Resolution for the Hepatitis B Vaccine 
Recommendations.  Dr. Romero seconded the motion.  The motion carried unanimously with 14 
affirmative votes, 0 negative vote, and 0 abstentions. The disposition of the vote was as
follows:
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 






ACIP Pertussis Vaccine Work Group
Dr. Riley reminded everyone of the following terms of reference for the Pertussis Vaccine WG, 
indicating that only the first term of reference remained to be completed, and that the draft of the 
updated statement would be presented during this session:
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 Review existing statements on infants and young children (1997), adolescent (2006), adults
(2006), and pregnant and postpartum women and their infants (2008) and consolidate into a 
single statement
 Review new data on Tdap including
 Effectiveness of ACIP recommendations
 Interval between Td booster and Tdap
 Use of Tdap in adults ages 65 years and older
 Pregnant and breastfeeding women
• 	 Use of Tdap
• 	 Cocooning strategies
 Vaccinated HCP and need for post-exposure prophylaxis
 Tdap revaccination 
• 	 Pregnant women
• 	 Healthcare personnel
• 	 “Cocooning”
 Review updated epidemiology of tetanus and diphtheria in the US
As a reminder, there are two types of pertussis, tetanus, and diphtheria vaccines.  The first is
DTaP (diphtheria and tetanus toxoids and acellular pertussis), which is the pediatric vaccine.  
The second is Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis), which is
the same as DTaP but with reduced quantities.  This is the adolescent and adult vaccine that is
licensed for single use only.
In the time since ACIP recommended Tdap for pregnant women, additional studies have 
assessed the safety and immunogenicity of Tdap vaccination during pregnancy, and the 
effectiveness of preventing infant pertussis.  It was timely and critically important for the WG to 
review these data, given that the updated statement for pertussis, tetanus, and diphtheria 
vaccines was being prepared for ACIP’s review and affirmation.
Tdap coverage among pregnant women has steadily increased.  The current estimate during 
influenza season from an Internet Panel Survey is 48.8% [CDC. Internet Panel Survey. Women 
aged 18–49 years pregnant at any time since August of prior year (e.g. 2015 for the April 2016 
survey)].
With regard to the updated statement and the historical background of the ACIP statements, the 
first acellular DTaP vaccines were licensed by the Food and Drug Administration (FDA) and 
recommended by ACIP for the 4th and 5th dose in 1991.  In 1997, ACIP recommended DTaP for
all 5 doses in the childhood schedule.  In 2005, Tdap was first licensed by the FDA and then 
recommended by ACIP for a single dose for adolescents and adults.  Since the 2005 Tdap 
recommendations, ACIP has expanded and updated the Tdap recommendations, which were 
published as Policy Notes in the MMWR. In 2010, ACIP recommended that Tdap should be 
administered regardless of interval since last tetanus or diphtheria toxoid-containing vaccine.  
This included a permissive Tdap recommendation for adults aged 65 years or older, as well as a 
catch-up schedule for children aged 7 through 10 years to receive a single dose of Tdap1. In 
2011, ACIP recommended a dose of Tdap during pregnancy for women who previously have 
not received Tdap2. In 2012, ACIP routinely recommended a single dose of Tdap for adults
aged 65 and older and a dose of Tdap during every pregnancy3,4 [1CDC. MMWR 2011;60;13–5; 
2CDC. MMWR 2011;60:1424–6; 3CDC. MMWR 2012;61;468-470; and 4CDC. MMWR
2013;62;131-135].
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Vaccination rates among children are high. Unlike Tdap coverage among adults, adolescent 
Tdap immunization has increased steadily since its introduction:
This session focused on the guidance for the use of Tdap in pregnant women; and the updated 
ACIP statement for pertussis, tetanus, and diphtheria for a vote. 
Guidance on Timing of Tdap Administration During Pregnancy
Jennifer L. Liang, DVM, MPVM
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Before focusing on the topic of timing of Tdap administration during pregnancy, Dr. Liang 
indicated that because the pertussis WG had not presented to ACIP in over a year, she would
give an overview of the epidemiology of pertussis in the US, the current ACIP Tdap
recommendation and guidance for use for pregnant women, and the safety of Tdap 
administration to mothers and their infants.
Following the introduction of whole-cell pertussis vaccines (DTP) in the late 1940s, there was a 
dramatic decline in cases reported through the NNDSS. In the 1990s, the US transitioned from
whole-cell to acellular pertussis vaccine (DTaP).  By 1997, all 5 doses of the childhood series
were DTaP.  Tdap vaccine was introduced in 2005. Since the late 1980s, the burden of disease 
has been increasing, with notable epidemic years in 2004, 2010, and most recently in 2012, with 
over 48,000 cases reported.  The increases in reported pertussis cases over the last two 
decades are likely the result of a number of factors, including improved surveillance capacity; 
changes in diagnostic testing and reporting; increased public and provider awareness; and 
probably most importantly, waning protection from acellular pertussis vaccines.
Historically, rates of pertussis have remained about the same for all age groups until more 
recent years when the emergence of disease has been observed in 7 to 10 year olds and 11 to 
19 year olds.  A growing body of evidence, which has been presented to ACIP throughout the 
years, strongly suggests that the change in vaccines from whole-cell to acellular pertussis
vaccines in the childhood vaccine series has caused the age-specific increases due to waning 
immunity.  Infants continue to have the highest risk for disease [CDC, National Notifiable 
Diseases Surveillance System and Supplemental Pertussis Surveillance System].
33





Published studies have found that acellular pertussis vaccines provide protection within the first 
year of receipt, but that effectiveness wanes over time.  Vaccine effectiveness for DTaP was 
evaluated by time since the 5th  DTaP dose1.  Tdap vaccine effectiveness was evaluated in 
adolescents who received only acellular pertussis vaccines for the primary DTaP series2  
[1Misegades LK, et al. JAMA. 2012 Nov 28;308(20):2126-32; 2Acosta AM, et al. Pediatrics. 
2015;135:981–9]. 
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As previously mentioned, infants continue to have the highest risk for disease.  This graph 
shows the number of reported deaths by age group and year.  Infants less than 3 months of age
(in beige) account for the greatest number of reported deaths from pertussis:
Of reported infant pertussis cases who were hospitalized, more that 50% were less than 2 
months of age.  Of those who died, 86% were less than 2 months of age.  These infants were 
too young to have received any doses of pertussis vaccines. Because young infants are 
vulnerable to pertussis infection and have the highest morbidity and mortality rates of pertussis, 
as a strategy to prevent infant pertussis, ACIP first recommended a single dose of Tdap for
pregnant women in 2011.  Prior to this recommendation, Tdap was recommended to be given to 
women postpartum.  In 2012, ACIP expanded the recommendation to a dose of Tdap during 
every pregnancy. This is the ACIP Tdap recommendation for pregnant women and guidance 
for use:
ACIP Tdap Recommendation for Pregnant Women
 ACIP recommends that providers of prenatal care implement a Tdap immunization 
program for all pregnant women. Health-care personnel should administer a dose of 
Tdap during each pregnancy, irrespective of the patient’s prior history of receiving 
Tdap.
Guidance for Use
 To maximize the maternal antibody response and passive antibody transfer to the 
infant, optimal timing for Tdap administration is between 27 and 36 weeks gestation 
although Tdap may be given at any time during pregnancy. For women not 
previously vaccinated with Tdap, if Tdap is not administered during pregnancy, Tdap
should be administered immediately postpartum.
34
                                                                                                 
 
 
The focus of the WG’s review and discussion is the language in the guidance for use that 
states, “To maximize the maternal antibody response and passive antibody transfer to the 
infant, optimal timing for Tdap administration is between 27 and 36 weeks gestation although 
Tdap may be given at any time during pregnancy.” 
 
As a reminder, 2 Tdap vaccines are available in the US:  Sanofi Pasteur’s ADACEL™ and 
GlaxoSmithKline’s (GSK’s) BOOSTRIX®.  Both provide protection to pertussis, diphtheria, and 
tetanus.  For pertussis antigens, both products contain pertussis toxin (PT), filamentous 
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When ACIP first recommended Tdap to pregnant women, safety data, although reassuring, 
were limited.  ACIP stated the need for enhanced monitoring and safety studies of Tdap given
during pregnancy, especially to women who have received prior Tdap vaccination. In response 
to ACIP’s comments, the CDC Immunization Safety Office (ISO) developed an immunization 
safety plan for this population through 3 established post-licensure vaccine safety monitoring 
infrastructures:
 Vaccine Adverse Event Reporting System (VAERS)
 Vaccine Safety Datalink (VSD)
 Clinical Immunization Safety Assessment (CISA) Project
CDC monitoring activities for maternal Tdap safety include ongoing monitoring through VAERS
and VSD.  VSD provides available coverage data, as well as surveillance and research on 
safety signals including:  preterm delivery and small for gestational age (SGA), acute vaccine-
related AEs, obstetric events, and birth defects.  VSD also has access to electronic medical
records (EMRs) and medical records to validate cases and denominators for rates.  CISA 
currently has 2 projects:  1) Tdap safety in pregnant women; and 2) the safety of simultaneous
Tdap Inactivated Influenza Vaccine (IIV) in pregnant women.  Safety data from these monitoring 
activities have been presented to ACIP at past meetings.
Safety data collected in the US on Tdap in pregnant women and infants continue to be 
reassuring.  The pattern of AEs observed in VAERS in pregnant women receiving Tdap and 
their infants is consistent with expectations. Studies of over 50,000 women receiving Tdap 
during pregnancy in the VSD show no increased risk for adverse maternal or infant health 
outcomes.  A clinical study in the CISA Project shows that Tdap was well-tolerated in both 
pregnant and non-pregnant women, including pregnant women receiving a repeated Tdap dose
[Kharbanda EO et al. JAMA. 2014;312(18):1897-904.; Sukumaran L, et al. JAMA. 2015 
314(15):1581-7, Sukumaran L, et al. ObGyn. 2015;126(5): 1069–1074; Kharbanda EO et al. 
Vaccine 2016; 34: 968-73].
Although pertussis-specific antibodies likely would confer protection and modify the severity of 
pertussis illness, when ACIP first recommended Tdap for pregnant women, the effectiveness of 
Tdap vaccination during pregnancy to prevent infant pertussis was not known. Since then, 
effectiveness data and additional immunogenicity data have become available.  Recent 
immunogenicity studies have assessed the optimal timing of Tdap administration during 
pregnancy to provide maximal transfer of maternal antibodies to infants.  Before presenting a 
summary of these studies, Dr. Liang highlighted some additional information.
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For pertussis, there are no well-defined serologic correlates of protection.  PT is suggested to 
be the most important virulence factor.  After receipt of Tdap, a minimum of 2 weeks is needed 
to mount a maximal immune response to the vaccine antigens. During the course of pregnancy, 
active immunoglobulin G (IgG) transport begins around 17 weeks gestation and increases with 
gestational age, with accelerated uptake starting around 34 weeks.  The immune response in 
pregnant women to Tdap immunization is similar to non-pregnant women, and vaccine-induced 
pertussis antibodies are efficiently transplacentally transferred from a woman to her fetus. 
Studies report higher antibody concentration in infant cord blood compared to maternal serum.
An Australian study from Naidu et al examined and compared cord blood pertussis antibody
levels for PT, FHA, and PRN in infants of unvaccinated and vaccinated mothers. Compared to 
the no Tdap group, cord blood antibody levels were significantly higher in the vaccinated 
groups.  By multivariable analysis, when adjusted for maternal pre-vaccination levels, pertussis
toxin approached significance and PRN was significantly higher in the early versus late 
vaccination group. Naidu et al also found a modest to significantly positive correlation between 
the number of weeks exposed to Tdap and infant cord blood levels for the three pertussis
antibodies.  These findings suggest that longer exposure to vaccine allows for higher vaccine-
induced antibody levels produced by the mother and transferred to the infant, which supports 
earlier vaccination within the 27 through 36 week window [Naidu et al. Pertussis vaccination 
during pregnancy. Am J Obstet Gynecol 2016. (Australia)].
As with the previous study, a study from Abu Raya et al found both maternal and infant cord 
blood sera concentrations were higher in the Tdap vaccinated groups versus the unvaccinated 
group. Within the 27 through 36 week window of Tdap administration, the cord blood GMC for
PT was higher in infants whose mothers received Tdap at 27 through 30 weeks compared to 31 
through 36 wks.  It is unclear why the GMCs are higher for Tdap after 36 weeks, but this is from
a smaller group and the findings are not consistent with other studies [Abu Raya et al. The 
effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization 
during pregnancy on newborn pertussis antibody levels – A prospective study. Vaccine 2014. 
(Israel)].
A study by Dr. Mary Healy from Baylor College of Medicine looked at anti-PT specific IgG levels
in cord blood from infants born to women who received Tdap during weeks 27 through 36 
weeks gestation compared with infants of unvaccinated mothers. As part of this study, Dr. 
Healy assessed the optimal gestation for Tdap administration between 27 through 36 weeks. 
This study shows that immunization earlier within the 27 through 36 weeks appears to allow for
maximal anti-PT IgG antibodies in infants [Unpublished data courtesy of CM Healy, Baylor
College of Medicine].
The aim of a Swiss study by Eberhardt et al was to determine whether Tdap vaccination as
early as 13 through 25 weeks would elicit non-inferior geometric mean concentrations (GMCs) 
of infant cord blood antibodies compared with immunization after 25 weeks gestation. Within 
the current ACIP guidance, infant cord blood GMCs for PT and FHA tended to be higher for
infants whose mothers received Tdap between 26 through 33 weeks compared to infants whose
mothers received Tdap after 33 weeks gestation. Eberhardt also found that the GMCs were 
non-inferior for infants whose mothers received Tdap earlier than 26 weeks [Eberhardt et al. 
Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant 
Seropositivity Against Pertussis. CID 2016. (Switzerland)].
From the Eberhardt et al study, these curves represent the distribution of individual anti-PT
antibody GMCs at various time intervals between maternal Tdap immunization and delivery:
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There is a red box around the days that would fall within the 27 through 36 week window.  
Compared to no vaccination and less than 15 days before delivery (pink and blue lines), a 
longer time between maternal Tdap and before delivery resulted in similar distribution of anti-PT
infant cord blood concentrations.  Antibody concentrations markedly increased with intervals
greater than 14 days, reaching optimal GMC with intervals between 31 and 120 days.
In summary of the immunogenicity studies, infants of mothers vaccinated with Tdap during 
pregnancy were born with significantly higher anti-pertussis antibodies compared to infants of 
unvaccinated mothers. Within the 27 though 36 week window, the concentration of anti-
pertussis antibodies in infant cord blood were generally higher when mothers were vaccinated 
earlier.  In addition, longer exposure to vaccine allows for higher vaccine induced antibody
levels produced by mother and transferred to infant.  One study found infant cord blood 
concentration of anti-pertussis antibodies non-inferior when maternal Tdap was administered 
before 27 weeks.
Although the methodologies differ, several studies have shown that vaccinating women during 
pregnancy is very effective at preventing infant pertussis, from 78% to 93% effective.  The 
majority of women from these studies were vaccinated within the current guidance window of 27 
through 36 weeks:
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A retrospective cohort study from California evaluated whether infants born to mothers who 
received Tdap during pregnancy had less severe pertussis compared to infants born to 
unvaccinated mothers. Infected infants of vaccinated mothers were older when they developed 
disease and were less likely to have classic pertussis symptoms.  They also were at significantly
lower risk of hospitalization and intensive care unit (ICU) admission.  None of these infants
developed seizures, required intubation, or died [Winter K, et al. Effectiveness of prenatal Tdap 
vaccination on pertussis severity in infants. Clin Infect Dis. 2016 Sep 13. (Epub ahead of print)].
After review of available data on immunogenicity and effectiveness, the WG was cautious with 
how these immunogenicity data might relate to effectiveness.  Again, the minimal concentration
of antibodies to confer protection is unknown. Because of this unknown, the WG noted that it is
important to ensure enough time between mother’s receipt of Tdap and infant’s birth to allow for
maximizing the concentration of maternal antibodies.  This may be better achieved by
vaccinating at an earlier gestational age (e.g., before 27 weeks gestation).  However, 
vaccination too early during pregnancy may not allow for sustained levels of antibodies to 
provide protection through the infant’s first DTaP dose at age 2 months due to maternal
antibody decay.  Data are not yet available to address this concern.
Based on review of the immunogenicity and effectiveness data, the WG considered the 
following options to modifying the current window:
1.	 Expanding the window to include earlier Tdap administration (e.g., as early as 22 weeks)
2.	 Narrowing the window to 27 through 32 weeks
3.	 No change to the current window of 27 through 36 weeks, but emphasize earlier
administration within the window
When reviewing these 3 options, the WG considered what the impact any modification to the 
guidance window would have on the current program.  ACIP has been recommending Tdap for
pregnant women since 2011.  Since then, Tdap uptake in pregnant women has steadily
increased.  As Dr. Riley presented earlier, the current estimate from the 2015-2016 influenza 
Internet Panel Survey was 48%.  During the previous flu season, Tdap coverage was 23%.  The 
WG did not want to potentially disrupt this trend. Earlier administration of Tdap might increase 
the opportunity to educate and vaccinate pregnant women and increase protection among 
preterm infants.  Vaccinating pregnant women earlier might provide protection to the earliest 
preterm infants, but the great majority of preterm infants are provided protection under the 
current 27 through 36 week window. When considering narrowing the window, the WG was
concerned this would decrease the opportunity to vaccinate pregnant women.
The WG is encouraged that vaccinating pregnant women with Tdap is effective at preventing 
pertussis in infants.  The WG also was reassured that if infected with pertussis, infants born to 
vaccinated mothers are less likely to develop severe pertussis compared to infants born to 
unvaccinated mothers. Although there is variation between immunogenicity studies, and the 
studies are limited by small to modest samples sizes, these studies have shown that vaccinating
earlier within the 27 through 36 week window or even before 27 weeks may be beneficial in
optimizing the production and transfer of maternal antibodies to infants. However, it is unclear
at this time how the immunogenicity data from earlier administration will translate to
effectiveness in preventing infant pertussis.  The current strategy is effective at preventing infant 
pertussis, so the WG was reluctant to modify the current window.  Again, the WG was cautious
not to equate higher concentration of maternal antibodies from earlier vaccination to similar or
better effectiveness without knowing whether the durability and concentration of maternal
antibodies would be maintained until an infant is old enough to receive his or her first DTaP.  
38
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Without effectiveness data specific to vaccinating women earlier during pregnancy, the WG is
cautious to over-interpret results from these studies.
After considering the proposed options, the WG did not support expanding the window to 
include earlier Tdap administration.  Although the WG thought that vaccinating earlier within the 
current window likely would provide maternal antibodies for the majority of infants including 
those born preterm, WG members differed in how to modify the current guidance of 27 through 
36 weeks. A minority of the WG supported narrowing the current window to 27 through 32 
weeks; whereas, a majority supported no change to the current window of 27 through 36 weeks, 
but including language to emphasize earlier administration within this window.  This option also
was supported by the American Congress of Obstetricians and Gynecologists (ACOG) and the
American College of Nurse Midwives (ACNM) WGs.  Therefore, the language Dr. Liang 
presented was modified accordingly.
As a reminder, here is the current ACIP Tdap recommendation for pregnant women along with 
the guidance for use.  The underlined sentence in the Guidance for Use is the language the WG
is updating:
ACIP Tdap Recommendation for Pregnant Women
 ACIP recommends that providers of prenatal care implement a Tdap immunization 
program for all pregnant women. Health-care personnel should administer a dose of 
Tdap during each pregnancy, irrespective of the patient’s prior history of receiving 
Tdap.
Guidance for Use (CURRENT)
 To maximize the maternal antibody response and passive antibody transfer to the 
infant, optimal timing for Tdap administration is between 27 and 36 weeks gestation 
although Tdap may be given at any time during pregnancy. For women not 
previously vaccinated with Tdap, if Tdap is not administered during pregnancy, Tdap
should be administered immediately postpartum.
The drafted change to the Guidance for Use is shown below.  The underlined sentence is the
WG’s proposed updated language:
Guidance for Use (DRAFTED CHANGE)
 Tdap should be administered between 27 and 36 weeks gestation, although it may be 
given at any time during pregnancy.  Currently available data suggest that vaccinating 
earlier in the 27 through 36 week window will maximize passive antibody transfer to the 
infant. For women not previously vaccinated with Tdap, if it is not administered during 
pregnancy, Tdap should be administered immediately postpartum.
This guidance language will be included in the updated ACIP statement for pertussis, tetanus,
and diphtheria vaccines, which Dr. Liang presented following this discussion.
Discussion Points
Acknowledging that there are not specific data about duration of maternal antibody if given 
earlier, Dr. Kempe said she would not expect this to be very different from other situations.  She 
asked Dr. Liang to talk about what the subject matter experts (SMEs) thought about duration 
(e.g., the comparison between 22 weeks or 27 weeks).
39
                                                                                                 
 
 







































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
Dr. Liang replied that while the immunogenicity showing equivalent or non-inferior concentration
to earlier administration were promising, the WG was concerned that without knowing the 
durability and timing of maternal antibody decay, whether that higher concentration would 
translate to durability from time of birth to 2 months of age when the infant would be 
recommended to receive the first dose of DTaP.
Dr. Walter asked whether that was the WG’s main consideration in not narrowing the window to 
an earlier time.
Dr. Liang responded that that was one of the considerations.  The other concerns regarded 
potential programmatic disruption.  Any change potentially could cause confusion.  They have 
heard anecdotally that even with the current guidance window, providers are not necessarily
targeting between the 27 through 36 weeks.  Any other change potentially would result in 
misinterpretation.  Because the data are not available at this time, the WG did not want to 
change the recommendation drastically.
Dr. Riley added that the concern was that it would be making another small change in the 
context of only 48% uptake with a fairly new recommendation, which could cause more 
confusion.  It has been observed that when people do not understand a change, they tend to do 
nothing.  The goal is to get people vaccinated.  Even if women are vaccinated at 36 weeks, it is
better than not getting vaccinated at all.  Because of the goal to shift vaccination to the earlier
end of the range, ACOG intends to tell obstetricians that if this is paired with the glucose test 
that everyone has at approximately 27 to 28 weeks, this would be an ideal time to give Tdap as
well.  The hope is that people will vaccinate earlier in the window.  The other concern is that 
when vaccination is given at 34 and 36 weeks, it misses all of the late pre-term infants who get 
nothing.
Dr. Liang said that given the various studies that have evaluated the effectiveness in preventing 
pertussis in infants, and because those evaluations were done within the current window of 
administration, the WG felt that was reassuring and showed that the current program is working.  
Whether to shift it to make it earlier, they didn’t have these data.  Within the US, the 
evaluations—the coverage, they are still learning about impact.  They know that it works in the 
individual infant, but in terms of overall numbers of cases reported in infants, we’re just starting 
to be able to evaluate that as coverage increases and moving forward through time.
Dr. Szilagyi asked whether there are any healthcare utilization data that would suggest what 
percentage of pregnant women would not be seen at all if the window were narrowed, resulting 
in a missed opportunity to vaccinate them.
Dr. Liang replied that they do not have these data.  While it is known that there are providers
who are administering Tdap, it is not known when specifically they are administering it even 
during pregnancy.  There is a lot of variability.  One of the limitations of the coverage data is that 
while it is known that pregnant women are receiving Tdap, when they receive it during 
pregnancy is unknown.
Dr. Hunter asked whether it would be possible to acquire data about frequency by week of 
pregnancy.  He noticed on one of slides that there were data about that in a small group.  It 
looked like it was between 27 and 30 weeks, and then dropped off after that.  He assumed that 
had to do with the protocols of when it is given, and group-by-group how practices decide to set 
things up in their clinics.
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Dr. Riley responded that it probably reflects how people are implementing the protocol.  The 
thought is that if the ACOG statement stresses that earlier in the existing window is better for X, 
X, and X reasons and it is paired with the glucose test, more women will receive the vaccine at 
27 to 28 weeks.  The WG discussed making it 26 weeks.  The concern is that little changes
make people do odd things.
Dr. Messonnier emphasized that studying this is very difficult and there is a lot of variability in 
the datasets about when people get vaccinated.  While there are data on the overall vaccine 
efficacy of the program, there are no data that take timing into account.  It also is important to 
remember that there are two vaccines, and there are some data to suggest that the kinetics of 
the vaccines differ.  The UK will be changing their window, so this is a case in which additional
data will be available in a couple of years from a setting of high vaccination coverage.
Dr. Stanley Plotkin (Audience Member) said he thought the recommendation to maintain 27 to 
36 weeks was a reasonable public health recommendation.  However, he objected to the 
mantra that the correlates of protection are unknown.  Obviously, this is known.  The fact that 
maternal immunization protects infants shows that, in fact, antibody is the correlate of 
protection.  What is not known is an absolute threshold for the antibody.  But it is very clear that 
antibodies to PT, FIM, and PRN are protective.  Personally, he believes that vaccinating early in 
the third trimester is better than vaccinating later because of the antibody data.  He thinks it is a 
reasonable compromise under the current circumstances to maintain the breadth of the 
recommendation, particularly since the impact on later vaccination of the infant has to be taken 
into account in making the overall recommendation.
Having reviewed the data as the WG has, Dr. Neuzil (IDSA) also believes that it appears that 
earlier is better though how early is not quite clear.  However, she was not certain that the 
statement reflected the WG’s intent and that it may not be strong enough.  While she 
appreciated the issue of not wanting to tweak, she asked whether consideration was given to 
recommending that the vaccine should be administered during the first visit of the third 
trimester, or as early as possible in the third trimesters, and then putting that 27 through 36 in 
parentheses.  As Dr. Riley said, it is very protocol-driven in obstetrics.  If they could get it right 
there with the first third trimester visit, that might accomplish this without causing confusion.
Dr. Belongia supported that. He suggested that the second sentence would be stronger if it 
read, “Vaccine should be administered as early as possible within the 27 through 36 week
window.” 
Dr. Hayes (ACNM) emphasized that the WG felt that they should be careful about 
recommendation fatigue, which was one of the primary reasons that this was not changed.  In 
regard to the question about data and utilization, ACNM has a Maternal Immunization Working 
Group that is trying very hard to get a quality data measurement on this.  They were not happy
because they have been working for a year and a half on this language, which is what they
planned to measure.  She issued a plea on behalf of the ACNM Maternal Immunization Working 
Group not to change the language.  She did agree that the language could be stronger.
Dr. Riley said she was perfectly fine with saying “earlier within the window.”  She cautioned 
against saying “the first visit in the third trimester” because that definition is a moving target.  
Some people say the third trimester is 24 weeks, some say 26, and others say 28.  If the 
recommendation is too literal, someone at 25 weeks might not get the vaccine.
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Dr. Bennett noted that the plan was to vote on the updated statement, not this particular
wording.
Dr. Friedland (GSK) mentioned that in addition to the safety programs outlined by Dr. Liang, 
GSK maintains a pregnancy registry for the use of BOOSTRIX®  in the US and in other parts of 
the world.  They have ongoing pharmacovigilance systems in place to monitor the safety of the 
use of BOOSTRIX®  in pregnant women around the world. 
Dr. O’Leary (PIDS) thought that “earlier in the window” was vague.  He asked whether there 
was discussion about being more specific, such as stating 27 to 30 weeks, or 27 to 29 weeks, 
just thinking about the protocolization.
Dr. Riley stressed that from a programmatic standpoint, if it is timed with the glucose loading 
test that obstetricians do at a certain time all of the time, this probably would be earlier in the 
window.
An inquiry was posed regarding what the wording is on the glucose testing, and whether it is
tied to a trimester.
Dr. Riley replied that it is generally given at 26 to 28 weeks gestation.
Dr. Wexler (IAC) said that they do receive a lot of questions about the last statement, “For
women not previously vaccinated with Tdap, if it is not administered during pregnancy, Tdap 
should be administered immediately postpartum.”  Providers want to know, even if women were 
vaccinated at 11 or 12 years of age, why not protect them immediately with a dose of Tdap.
Dr. Belongia asked what is known about co-administration of influenza vaccine and Tdap in 
pregnancy, and whether there is a specific recommendation and if there is any evidence that 
receipt of one might influence the immunologic response to the other.
Dr. Liang replied that at this time, a CISA study is just beginning to assess this.  Currently, there 
is no language that states not to co-administer Tdap with influenza vaccine.  One study has
evaluated co-administration of these two vaccines in non-pregnant populations, which found 
that there was a slight decrease in the response in one of the pertussis antigens.  However, it is
not known what that translates to in terms of clinical outcome or the impact of the response. 
Updated ACIP Statement for Pertussis, Tetanus, and Diphtheria Vaccines
Jennifer L. Liang, DVM, MPVM
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Liang explained that the updated statement compiles and summarizes all previously
published recommendations from CDC’s ACIP regarding prevention and control of pertussis,
tetanus, and diphtheria in the US, specifically after the introduction of acellular pertussis
vaccines, and does not contain any new recommendations. This document also provides an 
overview of the current epidemiology of tetanus, diphtheria, and pertussis; and an updated list of 
current vaccines and recommendations for routine vaccination and guidance for use. The 
statement also describes the process undertaken and the rationale used in support of these 
recommendations, and is intended for use by clinicians and public health providers as a 
resource. This statement is the product of the review of published DTaP and Tdap vaccine 
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recommendations, peer-reviewed literature, and surveillance data from NNDSS and Enhanced 
Pertussis Surveillance (EPS). The WG reviewed the draft statement and provided comments. 
Prior to this meeting, ACIP voting members reviewed the draft statement and provided 
comments.
To summarize the updated statement, after the introduction of universal immunization with 
tetanus toxoid-containing vaccines in the mid-1940s, the incidence of reported tetanus in the US
declined by more than 98%.  Deaths from tetanus also declined similarly during this period.  
Currently, tetanus is rare in the US and occurs primarily among older adults. From 2005-2015, 
an average of 28 tetanus cases per year are reported.
In the US, reported diphtheria cases from all anatomical sites declined from over 200,000 in 
1921 to 15,536 in 1940.  This decline continued after the introduction of universal childhood 
immunization in the late 1940s.  In 1980, only two cases of diphtheria were reported.  During 
1996–2004, 11 cases were reported.  From 2004-2011 no cases were reported, but in 2012,
there was a probable case of nontoxigenic diphtheria, and in 2014 a confirmed case positive by
culture with non-toxigenic C. diphtheriae. As previously presented, the following graph shows
the number of reported pertussis cases in the US from 1922-2015:
Listed here are the currently licensed and available DTaP vaccines, combination vaccines with 
DTaP, and DT vaccines in the US:
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Following is a list of the currently licensed and available Tdap and Td vaccines in the US:
Note that monovalent tetanus toxoid vaccine manufacturing was discontinued and has not been 
available in the US since 2013.
The consolidated updated statement will contain the routine recommendations for DTaP, DT 
when indicated, Tdap, and Td which were last published in separate statements.  The statement 
also includes Tdap recommendations made after the 2005 recommendations and published in 
MMWR Policy Notes.  Again, there are no changes to these previously published 
recommendations. The statement also contains updates such as DTaP vaccines that became 
available after the 1997 DTaP statement, and updates to label indications for various DTaP and 
Tdap products.  Also included in the statement are the following updates:
 Mention of the discontinuation of monovalent tetanus toxoid (TT) vaccine
 Contraindications and precautions for DTaP are now consistent with AAP’s Red Book
 For persons aged 7 through 10 years who receive a dose of Tdap as part of the catch-up 
series, an adolescent Tdap vaccine dose may be given at age 11 through 12 years; this
guidance is now in line with guidance given on children for which Tdap is inadvertently
administered
Dr. Liang explained that the ACIP vote for this session would be to affirm the updated 
statement, which does not contain any new vaccine recommendations.  The statement will be 
updated with the modified Guidance for Use language of Tdap for pregnant women, along with 
a summary of supporting data.  A table summarizing safety studies on use of Tdap in pregnant 
woman and their infants also will be included.  Before the vote, Dr. Liang recognized and 
acknowledged all of the WG members from past and present who have been part of this
process since 2009. She also thanked the previous WG chair, Dr. Mark Sawyer and current 
WG chair Dr. Art Reingold for their leadership. In addition, she acknowledged several CDC 
groups and CDC contributors on the WG for providing subject matter expertise.
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Discussion Points
Given that the guidance is part of the recommendations, Dr. Kempe asked for clarity regarding 
whether they were in fact voting on the language of the guidance as well.
Dr. Cohn indicated that they were separating out recommendations from Guidance for Use.  
The Guidance for Use are CDC recommendations about how to implement the 
recommendations the ACIP votes on.  It sounded like the WG could incorporate some of the 
discussion from earlier to modify that language.
Ms. Stinchfield (NAPNAP) noted that a very common situation that she did not hear discussed
regarded how to handle an adolescent who has not had a primary DTaP series, who presents to 
catch-up.
Dr. Liang replied that there is catch-up language for a child, adolescent, or adult who presents




A Voice For Choice Advocacy
I was very interested in what you presented today, and I thank you for allowing me to give you 
public comment.  I have some questions which seem to be left unanswered by the presentation.  
You said that you’re going to give a summary of Tdap safety studies.  The vaccine package 
inserts for both Tdap studies state that there will be no clinical trial or studies on pregnant
women for both of those studies, so I’m curious to get those Tdap safety studies that you 
mentioned.  The studies that were outlined in the presentation have extremely small sample 
sizes, so I would hope that the studies that you are referring to have larger sample sizes.  I also 
wonder whether there has been review of the number of miscarriages.  The studies that I’ve 
seen actually took out stillborn deaths, and I wonder if we have any studies on the number of 
stillborn deaths and miscarriages that happen after vaccination versus those people who are not 
vaccinated.  The other piece that I would ask that you address is that both Tdap vaccines 
include aluminum—we know aluminum crosses the blood-brain barrier (BBB)—and whether that 
has been studied in fetuses and whether the aluminum from the Tdap vaccine dose, in fact, 
crosses the BBB and what that does to the fetus.  And then the other question that I have for
you is that there have been studies in baboons that have shown that the DTaP and Tdap 
vaccines actually show that you can be an asymptomatic carrier of pertussis and you can 
actually give pertussis to someone else.  And so, I wonder whether that has been addressed 
and whether the giving of Tdap and DTaP among infants, specifically Tdap among the parent, 
whether they can be an asymptomatic carrier to their infant, as well as whether giving the Tdap 
actually stops the infant from getting pertussis—whether in that first 6 months of life, whether
those infants that have had higher antibodies have actually been stopped from getting pertussis.  
Also, because we know right now, most people and—most adults and most teenagers that are 
getting pertussis are getting it having been fully vaccinated.  Thank you.
Dr. Meissonier thanked Ms. Hildebrand for her questions and comments.  She said she thought
that one issue was that a lot of the information she was asking about was presented during a 
previous ACIP meeting.  All of the ACIP members have seen those data and have had 
deliberations on it.  That information is available online.  In addition, she said that CDC’s SMEs
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would be happy to speak with Ms. Hildebrand during the break and share data.  The
pharmaceutical companies also collect data pertaining to some of Ms. Hildebrand’s points.  If 
the information is not clear in the package insert, she was sure the manufacturers would be 
happy to provide more information about that as well. 
James Grundvig  
Freelance Journalist, New York City 
Epoch Times, Financial Times, Foreign Direct Investment (FDI) Magazine 
My green investors would like to know why Zika wasn’t discussed with this particular vaccine.  
Apparently the microcephaly problems in Northeast Brazil has not been confirmed yet whether
it’s Zika, whether it’s other toxins, or whether the vaccine was given down there to pregnant 
women.
Dr. Bennett thanked Mr. Grundvig for his comment.  She explained that ACIP focuses its
attention on vaccine recommendations in the US, and that there would be an update on Zika 
during the second day of the ACIP meeting.
Vote:  Updated Statement for Pertussis, Tetanus, and Diphtheria Vaccines
Dr. Walter motioned to approve the updated statement for pertussis, tetanus, and diphtheria 
vaccines.  Dr. Riley seconded the motion.  The motion carried unanimously with 14 affirmative 
votes, 0 negative vote, and 0 abstentions.  The disposition of the vote was as follows:
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
Riley, Romero, Stephens, Szilagyi, Walter 
Human Papillomavirus (HPV) Vaccines 
Introduction
Allison Kempe, MD, MPH
Chair, ACIP HPV Vaccines WG
Dr. Kempe reminded everyone that since 2006, HPV vaccination has been recommended as a 
3-dose series.  The ACIP HPV Vaccines WG and ACIP have reviewed data on 2-dose
schedules over the last year, and a vote is scheduled for this meeting.
During the February 2016 meeting, there were presentations and deliberations on the 
background on 2-dose schedules, 9vHPV 2-dose immunogenicity trial data, and 2-dose data for
the 2vHPV and 4vHPV.
During the June 2016 meeting, there were presentations and deliberations on HPV vaccine 
supply, duration of protection after a 3-dose series of 2vHPV and 4vHPV vaccination; impact
and cost-effectiveness modeling for 2-dose schedules; review of post-licensure vaccine 
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effectiveness studies of 2vHPV and 4vHPV; Grading of Recommendation Assessment, 
Development and Evaluation (GRADE) for 2-dose schedules; and initial considerations for
recommendations.
Since June 2016, the WG has held monthly conference calls to review further data from the  
9vHPV 2-dose trial, including follow-up data through month 12 and data on intervals between 
doses; discussed policy options; and drafted recommendations.
The FDA approved a 2-dose series for persons age 9 through 14 years on October 7, 2016.  
The updated 9vHPV label includes immunogenicity data from the trial and an updated Dosage 
and Administration section shown below:
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
Potential future issues for the HPV Vaccines WG are to: 1) revisit the wording for the routine 
recommended age groups; and 2) revisit the upper age recommendation for males, as some 
WG members and liaison members feel strongly about this. The WG felt that these issues would 
require more data and more discussion; therefore, it was decided that these topics be tabled for
future meetings.
Review of Evidence for a 2-Dose Vaccination Schedule
Lauri Markowitz, MD
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention
In this presentation, Dr. Markowitz provided an overview of evidence for 2-dose schedules.  She 
started with some background information on HPV vaccines and recommendations, and then 
provided a summary of evidence of data presented to ACIP over the last two meetings on 2­
dose schedules, as well as some new data from the 9vHPV vaccine 2-dose trial.  She ended 
with data on vaccine coverage in the US and programmatic considerations.
By way of review, there are 3 HPV vaccines licensed in the US:  bivalent (2vHPV), quadrivalent 
(4vHPV), and 9-valent (9vHPV). These are all virus-like particle (VLP) vaccines composed of 
the L1 major capsid protein.  The 2vHPV is produced by GSK and 4vHPV and 9vHPV are
produced by Merck.  While all are VLP vaccines, they differ in the types they target, their
production systems, and adjuvants. The first vaccine licensed was 4vHPV in 2006, and the 
most recent was 9vHPV in 2014.
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In terms of changes in the recommendations since the beginning of the program, in 2006,
4vHPV was licensed and recommended for routine vaccination of females.  In 2009, 2vHPV
was recommended as one of the vaccines that could be used for females.  Also in that year, the 
4vHPV was licensed for use in males and ACIP made a statement that the vaccine may be 
given to males.  In 2011, 4vHPV was recommended for routine vaccination of males.  In 2015, 
after licensure of 9vHPV, that vaccine was recommended as one of 3 vaccines that could be 
used for females and one of 2 for males.  Since the beginning of the program, a 3-dose series
has been recommended.
ACIP currently recommends routine vaccination at age 11 or 12 years.  The vaccination series
can be started beginning at age 9 years.  Vaccination is recommended through age 26 for
females and through age 21 for males not vaccinated previously.  A 3-dose series is
recommended at an interval of 0, 1-2 months, and 6 months.  Since 2015, any of the three 
vaccines are recommended for females and 4vHPV or 9vHPV for males [MMWR 2015;64:300­
4].
Vaccine use and availability in the US is changing.  Through 2014, almost all HPV vaccine used 
was 4vHPV.  In 2016, almost all HPV vaccine used is 9vHPV (>90%).  GSK made the decision 
to stop supplying 2vHPV in US due to low demand.  In the US, 2vHPV supplies are expected to
be used up by November 2016.  Only 9vHPV has been on the CDC contracts since April 2016. 
Merck will distribute only 9vHPV in the US after October.  2vHPV and 4vHPV will continue to be 
available outside the US.
In terms of the evidence considered by ACIP for the 2-dose recommendation over the past two 
meetings, for initial licensure of the HPV vaccines as a 3-dose schedule, efficacy and 
immunogenicity data were obtained.  These included efficacy data from large randomized 
controlled trials (RCT) trials in 15 through 26 year olds, with trial endpoints of cervical pre­
cancer lesions and well as some other pre-cancers and genital warts for 4vHPV v [Future II 
Study Group, NEJM 2007; Garland NEJM 2007; Paavonen Lancet 2007], and data from
bridging immunogenicity trials in 9 through 15 year olds.  Licensure in 9 through 15 year olds
was based on non-inferior antibody response compared with young adult women in the efficacy
trials.
The 3-dose schedule for which vaccines were originally tested and licensed at a 0, 1 to 2, and 6 
months schedule can be considered a prime-prime-boost, with the first 2 doses being the 
priming doses and the third being the boost.  The 2-dose schedules that are being studied, such 
as the 0, 6 months schedule, can be considered a prime boost with the second prime being 
eliminated.  Memory B cells require at least 4 to 6 months to mature and differentiate into high-
affinity B cells.  The approximate 6-month interval between the first and last dose allows the last 
dose to reactivate memory B cells efficiently.
The evidence reviewed for 2-dose schedules by the WG and ACIP include data on 
immunogenicity, post-hoc analyses of efficacy data, and post-licensure effectiveness data, and 
data from modeling and duration of protection.  Dr. Markowitz reviewed each of these briefly. 
Most of the data used for evidence on 2-dose schedules are immunogenicity data. 
Immunogenicity trials comparing 2 and 3 doses have been conducted for all three HPV
vaccines.  The main analyses, and those considered by regulatory agencies, are comparisons
of the antibody response after 2 doses in young adolescents about 9 through 14 years of age, 
with 3 doses in young adult women about 16 through 26 years of age. Again, the comparison 
group in these immunobridging analyses is the age group and the vaccine schedule for which 
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efficacy demonstrated in large RCTs.  Immunobridging analyses are used because although the
basis of protection after vaccination is thought to be due to the neutralizing antibody after
vaccination, there is no established minimum threshold for protection.  Trials of all three HPV
vaccines found the antibody response after 2 doses given at a 0, 6 or 0, 12 month interval in 
those approximately 9 through 14 years of age to be non-inferior to the antibody response after
3 doses in the older age group. Some trials also compared 2 and 3 doses in those 
approximately 9 through 14 years of age, with the results varying by trial.  Antibody titers were 
lower after 2 doses versus 3 dose for some the HPV types in some of the trials.  Based on data 
from immunogenicity trials, regulatory authorities have approved 2-dose vaccination schedules
for HPV vaccines. These schedules are being used in multiple countries worldwide.
With regard to the study design of the 9vHPV trial which led to FDA approval of a 2-dose 
schedule, there were 5 study arms.  Three arms were among 9 through 14 year olds: 1) girls
who received vaccine at a 0, 6 months interval; 2) boys who received vaccine at a 0, 6 months
interval, and 3) a combined group of girls and boys who received vaccine at 0, 12 months
interval.  Two groups received a 3-dose schedule:  1) females 16 through 26 years of age, who 
were defined as the control group, and 2) females 9 through 14 years of age, who were used for
an exploratory comparison.  The primary analyses were at 1 month post-last dose.  These were 
the data reviewed by the FDA and results were presented to CDC and ACIP in February 2016.  
Follow-up to assess antibody persistence is planned at months 12, 24, and 36.
At one month after the last dose, there were non-inferior geometric mean titers (GMTs) in girls
who received 2 doses at 0,6 months compared with women who received 3 doses at 0,2,6 
months.  The GMTs were, in fact, higher at the younger age.  The GMT ratios range from 1.60 
to 2.96 for the different types, with lower bound of the confidence interval (CI) above 1 for all
types.  The results for the comparison with the boys who received vaccine at 0, 6 months were 
similar. There were similar findings in the 2-dose 0,12 month group with non-inferior GMTs at 
one month post-last dose in girls and boys who received 2 doses at 0,12 months compared with
women who received 3 doses at 0,2,6 months.  Again, the GMTs were not only non-inferior, but 
also were higher in the younger age group that received 2 doses. The GMT ratios for each of 
the 9 types ranged from 1.96 to 6.31 [http://www.fda.gov/downloads/ 
BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf].
At the time of the presentation to ACIP in February 2016, only the data from 1 month after the 
last dose were available.  Recently, the WG reviewed data from 6 months after the last dose. 
Data from 6 months after the last dose are not yet available for the 2-dose 0, 12 month group.
Just looking at HPV6 as an example, GMTs decreased in all groups between these two time 
points, consistent with what has been seen for other HPV vaccination follow-up studies.  At 
month 12, which is 6 months after the last dose, GMTs in both of the 2-dose groups were non-
inferior and higher than those in women who received 3 doses.  The GMT ratios for girls
compared with women was 2.15 at month 7 and 1.69 at month 12.  There were similar findings
for HPV 11 and 16.  In terms of the other types targeted by the 9vHPV at 1 and 6 months after
the last dose (months 7 and 12), for types 18, 31, and 33, GMTs were higher in the 2-dose 
groups compared with women who received 3 doses at both time points. For types 45, 52, and 
58 comparing the 2-dose 9 through 14 year olds and the 3-dose 16 through 26 year olds, GMTs
decreased between 1 month and 6 months after the last dose.  This is not unexpected and also 
was seen in the 4vHPV 2-dose trial in which GMT ratios also decreased initially, but stabilized 
between months 24 and 36.
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Additional data reviewed by the WG from the 9vHPV 2-dose trial included data on GMTs by the
interval between dose 1 and dose 2 in the 2-dose groups.  This was to inform decisions about 
minimum intervals.  In the 2-dose trial, the interval between 2 doses in the 0, 6 month group was
6 months plus or minus 4 weeks. Over half of the vaccinees received dose 2 between 5 and 
less than 6 months after dose 1.  This table shows GMTs for 4 of the types by interval between 
dose 1 and dose 2 in the 0, 6 month 2-dose group:
Assay (cLIA)










Anti-HPV 6 1613 1720 771
Anti-HPV 11 1333 1468 581
Anti-HPV 16 7845 8238 3154
Anti-HPV 18 1821 1949 762
N=number of subjects in the per-protocol population for ≥1 HPV type
cLIA = Competitive Luminex immunoassay
GMTs expressed in milli-Merck units per milliliters (mMU/mL)
GMTs were similar if dose 2 was administered at 5 to less than 6 months or ≥6 months to 7 
months after dose 1.  For both intervals and all HPV types, GMTs were numerically higher than 
in women who received 3 doses, shown in the last column above.  The updated 9vHPV label
indicates a 2-dose series at 0 and 6-12 months and also states a minimum interval between 
dose 1 and dose 2 of 5 months.
In summary, in the 9vHPV immunogenicity trials, immunogenicity is 97.8% to 100% seropositive
to all 9 types 1 month after last dose.  Compared with 3 doses in 16 through 26 year olds, 
antibody titers were non-inferior and significantly higher 1 month after the last dose. After2­
doses (0, 6 months or 0, 12 months) in the 9 through 14 year olds GMTs remained non-inferior
and higher 6 months after the last dose.  GMTs by interval between 2 doses in the 2-dose 0, 6 
month group support a minimum interval of 5 months between the two doses.  Follow-up of the 
9vHPV 2-dose trial will continue through 36 months.  As Dr. Kempe showed earlier, the FDA
approved a 2-dose schedule for persons age 9 through 14 years on October 7, 2016.  The label
includes data from the 2-dose trial, as well as an updated Dosage and Administration section 
that states a 0, 6-12 month regimen and the minimum interval between doses.
ACIP also reviewed immunogenicity data on 2-dose vaccination schedules for 2vHPV and 
4vHPV.  As just discussed, in all trials, 2 doses at 0, 6 or 0, 12 months in those 9 through 14 
years of age were non-inferior to 3 doses in older age group.  These trials provide important 
information because there is longer follow-up than in the trial of the 9vHPV vaccine.  While there 
are differences in the vaccines, these studies do provide relevant data on persistence of 
antibody after vaccination.  The longest follow-up for the 2vHPV is 60 months, for 4vHPV is 36 
months, and for 9vHPV vaccine is 12 months [Romanowski, Hum Vaccin Immunother 2016; 
Puthanakit, JID 2016; Lazcano-Ponce, Vaccine 2014; Dobson, JAMA 2013; Hernández-Ávila, 
Hum Vaccin Immunother 2016].  Another reason that these data were reviewed is that although 
4vHPV will not be marketed in the US after October, many individuals have received 4vHPV in 
the US and some have not completed the 3-dose series.  Recommendations will need to be 
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made for those individuals.  Data from the 2vHPV and 4vHPV immunogenicity trials were 
included in the WG’s GRADE evaluation.
Regarding the GMTs through 60 months of follow-up in one of the 2vHPV trials, for the group 
who received 2 doses on a 0, 6 month schedule at age 9 through 14 years and the group who
received a 3 dose schedule at 15 through 25 years of age, the antibody kinetics were identical
in the two groups with the peak titers 1 month after the last dose, a decline, and then plateau at 
about 18 to 24 months [Romanowski, Hum Vaccin 2016]. A similar curve of the antibody
kinetics has been seen in all of the HPV vaccine trials.
GMTs through 36 months of follow-up in one of the 4vHPV trials was also shown. In this trial,
there were 3 groups: a group that received a 0, 6 month schedule at 9 through 13 years of age, 
a group that received a 3-dose schedule at age 9 through 13 years of age and a group that 
received a 3-dose schedule at 16 through 26 years of age. The antibody kinetics were similar in 
the groups with the peak titers one month after the last dose, a decline, and then plateau at 
about 18 to 24 months.  The 2-dose group remained higher than the 3-dose women [Adapted 
from: Dobson, JAMA 2013].
As discussed during past ACIP meetings, there are no data from RCTs trials of 2- vs 3-doses of 
HPV vaccines evaluating efficacy against infection or disease outcomes.  For the 2vHPV, there 
are data from post-hoc analyses of a 3-dose efficacy trial.  These were some of the first data 
that stimulated interest in reduced dose schedules.  For the 4vHPV, data are available from
analysis of an interrupted 2- vs 3-dose efficacy trial that was analyzed as an observational
study.  All of these analyses suggest efficacy with less than a 3-dose schedule [Kreimer, Lancet 
Oncol 2011; Kreimer, JNCI 2015; Sankaranarayanan, Lancet Oncol 2016; Markowitz, presented 
at February 2016 ACIP].
Post-licensure studies have been used to evaluate other vaccines; however, these types of 
studies are challenging for HPV vaccines at this point in the program.  There are 10 published 
studies that have evaluated post-licensure effectiveness by number of doses in settings of a 
recommended 3-dose schedule for 2vHPV or 4vHPV. All of these found that 2 doses were not 
as effective as 3 doses.  However, there are many limitations for post-licensure effectiveness
studies at this time in the vaccination program. First of all, most 2-dose vaccinees had received 
vaccine at a 0, 1 month or a 0, 2 month interval since these studies were in the setting of a 3­
dose recommendation.  Persons who received only 2 doses differed from those completing the 
schedule.  In some studies, they were older, of lower socioeconomic status (SES), and had 
earlier cervical cancer screening, suggesting differences in exposure to HPV prior to 
vaccination.  One study evaluated different intervals between 2 doses, and found that 
effectiveness increased as the interval between doses increased [Herweijer, 2014; Dominiak-
Felden 2015; Blomberg, 2015; Gertig, 2013; Crowe, 2014; Brotherton, 2015; Kavanagh, 2014; 
Cuschieri, 2016; Hofstetter, 2016; Pollock, 2014; Oliver, presented at June 2016 ACIP].
The WG’s conclusion is that there are many challenges for vaccine effectiveness evaluations in
the context of a 3-dose program.  Data from these effectiveness studies may not be directly
applicable to the currently policy question of a 2-dose recommendation due to differences in age 
at vaccination, the interval between the 2 doses, and differences in population in the populations
receiving 2 doses and 3 doses in these studies.  The WG did not include post-licensure
effectiveness evaluations in its GRADE evaluation.
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To examine different aspects of shifting to a 2-dose schedule, results were considered from
health economic models.  The model used was an individual-based transmission-dynamic
model.  This model takes into account the direct effects of vaccination, as well as herd immunity
effects.  This model uses a variety of inputs and includes 6 important components: 
demographics, sexual behavior and HPV transmission, natural history, vaccination, screening 
and treatment of cervical lesions and cervical cancer, and economics.  The objective was to 
evaluate the population-level effectiveness and cost-effectiveness of a 3-dose versus 2-dose 9­
valent vaccination program in the US.
To summarize the modeling results, the conclusions were that if efficacy and duration of 
protection after 2 doses are similar, 2 doses would be cost-saving compared with 3 doses.  
Exploration of important parameters showed that the incremental health benefits and cost-
effectiveness of a 3rd  dose of HPV vaccine depend most on relative duration of efficacy provided 
by a 2-dose versus 3-dose schedule.  Vaccination is predicted to reduce HPV-burden of disease 
substantially after any schedule if protection is at least 20 years.  A 2-dose vaccination program 
would provide similar population-level health benefits to 3-dose vaccination, unless 2 doses 
provide shorter duration of protection and do not enable higher vaccination coverage.  A 3-dose 
vaccination program is predicted to have high incremental cost per Quality Adjusted Life Years 
(QALY) gained of over $118,000 compared to a 2-dose vaccination program, except when 2­
dose protection is less than 20 years [Laprise, JID 2016; Brisson, presented at June 2016 
ACIP]. 
Because duration of protection is found in the model to be the most important parameter
influencing population impact, the WG reviewed data on duration of protection for HPV vaccines
with the ACIP during the last meeting.  Most of these data came from follow-up of clinical trials. 
In summary of what was presented to ACIP in June 2016, there is no evidence of waning 
protection after a 3-dose schedule to date.  Data are available through about 10 years after the
2vHPV and 4vHPV became available. Longer follow-up, through about 14 years, is on-going in 
some of these studies.  Antibody responses are maintained over time after a 3-dose schedule. 
Again, data are available for about 10 years for 2vHPV and 4vHPV.  Longer follow-up, through 
14 years, is on-going in some studies.  Waning of detectable antibody to HPV 18 by competitive 
luminex immunoassay (cLIA) in 4vHPV v is not associated with loss of protection.  For 2-dose 
schedules, long-term protection data are not available yet from 2-dose trials.  However, antibody
kinetics shown earlier are similar between 2-dose and 3-dose schedules with 2vHPV and 
4vHPV , which suggests that duration of protection will be very similar for a 2-dose and 3-dose 
schedule [Markowitz, presented to June ACIP 2016].
Evidence was evaluated using GRADE and was presented to ACIP in June 2016.  The main 
policy question was: “Should 2 doses of any HPV vaccine be recommended for 9 through 14 
year-olds?” The population was girls and boys aged 9 through 14 years.  The intervention was
2 doses of HPV vaccine separated by 6 to 12 months.  The comparison was 3 doses of HPV
vaccine at 0, 1–2, and 6 months among women in the age group in which efficacy has been 
demonstrated.  The outcome was immunogenicity.
For the GRADE summary, for 2 doses of HPV vaccine in girls or boys aged 9 through 14 years
compared with 3 doses of HPV vaccine in women about 15 through 26 years of age, the age 
group in which clinical efficacy was demonstrated, data were available on immunogenicity
outcomes for 9vHPV vaccine from 1 study, 4vHPV from 2 studies, and 2vHPV from 4 studies.  
All of these studies found evidence of non-inferior immunogenicity with 2 doses.  These were 
observational studies, because it was not possible to randomize participants in two different age 
groups.  The overall evidence type is 3.
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For the summary of considerations for formulating recommendations, if benefits are expected to 
be the same and the potential AEs are lower, the balance of benefits over harms is greater. 
Again, the evidence type for benefits was type 3.  The workgroup placed a high value on 
programmatic considerations, as well as prevention of outcomes due to HPV vaccine types. A 
2-dose schedule is likely to be cost-effective compared to 3 doses.  The proposed 
recommendation is a Category A.  The specific recommendation language follows in Dr. Meites’
presentation.
Dr. Markowitz briefly mentioned some programmatic considerations.  In terms of vaccine 
coverage from 2006-2015, in spite of HPV vaccine recommendations for females being 
published around the same time as those for Tdap and quadrivalent meningococcal conjugate 
vaccine (MenACWY), HPV vaccination coverage in females has increased at a comparatively
slow pace.  Coverage for at least 1 and 3 dose among females has reached 62% for 1 dose and 
42% for 3 doses. Coverage among males began to increase after 2011 when the routine 
recommendation was made for males.  In 2015, it was 50% for at least one dose and 28% for 3
doses [Reagan-Steiner MMWR 2016].  A variety of efforts are ongoing to increase coverage, 
and these have been reviewed with ACIP in the past.
It is unknown how a 2-dose recommendation would impact vaccination initiation or series 
completion in the US, although it is generally thought that a 2-dose schedule would be easier to 
implement and would be more acceptable.  Many other countries have switched to a 2-dose 
schedule.  Most of these have school-based vaccination and many already had high coverage, 
so information may not inform the situation in the US.  In the US, a 2-dose 0, 6-12 month 
schedule would allow flexibility and vaccinations could coincide with preventive health care 
visits.
Examination of current coverage data can provide information on the impact of a potential
change in recommendation on current coverage estimates, and also on the need for
recommendations that address incomplete schedules. In terms of the percentage of girls and 
boys who received 3, 2, and 1 doses as determined in the 2015 National Immunization Survey-
Teen (NIS-Teen), about 10% to 11% received only 2 doses and an additional 10% to 11%
percent received only 1 dose. Recommendations will need to be made for these individuals as
well.  With regard to the interval in months between the first and second dose among teens who 
started the HPV vaccination series before age 15 years in the US, most received a second dose 
close to the recommended interval of 2 months in the current 3-dose schedule.  These data 
include persons who completed a 3-dose schedule as well as those who did not.  When looking 
at teens who completed only 2 doses, there is a slightly different picture.  Among teens who 
received 2 doses only and the percent who received 2 doses only both at least 5 months apart 
and started the series before age 15, 10.6% of 13 through 17 year olds received only 2 doses, 
and 5.4% received only 2 doses at least 5 months apart and started the series before age 15 
years [NIS-Teen, United States, 2015].  If ACIP votes to accept a 2-dose schedule, these 
individuals could be considered fully vaccinated, and the other 2-dose vaccinees would be 
recommended to receive a third dose in this age group.
In summary, although three HPV vaccines are licensed for use in the US, after the end of 2016 
only 9vHPV will be available in the US.  In October 2016, FDA approved 9vHPV as a 2-dose 
series for persons aged 9 through 14 years.  During the past year, ACIP has been reviewing 
data related to 2-dose schedules, including immunogenicity, post-hoc analyses of efficacy trials, 
post-licensure effectiveness, health economic models, and duration of protection.  Importantly, 
trials of all HPV vaccines found that the antibody response after 2 doses at 0, 6 months or 0, 12 
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months in 9 through 14 year olds is non-inferior to the response after 3 doses in the group in 
which efficacy was demonstrated.  Post-licensure studies examining HPV vaccine effectiveness
by number of doses are difficult to interpret at this time in the vaccination program.  Data from
follow-up of 3-dose vaccine trials show that duration of protection after HPV vaccination is long 
lasting.  Data from follow-up of immunogenicity trials suggest that duration of protection will be 
the same after 2-dose and 3-dose schedules.  ACIP used GRADE to evaluate evidence on 2­
dose HPV vaccination schedules.  The HPV Vaccines WG proposes a Category A
recommendation for a 2-dose schedule for persons initiating the series at age 9 through 14 
years.  A 2-dose HPV vaccination schedule might facilitate vaccine initiation and series
completion in the US.
Proposed Recommendations for 2-Dose HPV Vaccination
Elissa Meites, MD, MPH
Medical Epidemiologist
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention
Dr. Meites reminded everyone that three HPV vaccines are licensed for use in the US: 2vHPV, 
4vHPV, and 9vHPV.  Recently, on October 7th, 9vHPV was approved by the FDA for use in a 2­
dose series for girls and boys at ages 9 through 14 years.  The current ACIP recommendations
are as follows:
 HPV vaccine is recommended for routine vaccination at age 11 or 12 years.  The 

vaccination series can be started beginning at age 9 years. 

 ACIP also recommends HPV vaccination for:
 Females aged 13 through 26 years not vaccinated previously,
 Males aged 13 through 21 years not vaccinated previously* 
 Immunocompromised persons (including those with HIV infection) and men who 
have sex with men through age 26 years, if not vaccinated previously
* Males aged 22 through 26 years may be vaccinated
The rationale for the vote during this session is that HPV vaccines are highly effective and safe, 
and a powerful prevention tool for reducing the burden of HPV infections and associated 
disease; evidence suggests that a 2-dose schedule (administered at 0, and 6–12 months) will
have efficacy equivalent to a 3-dose schedule (administered at 0, 1–2, and 6 months) if the HPV
vaccination series is initiated before the 15th birthday.
Here is the outline of the proposed recommendations that would be included in a Policy Note:
 Routine and catch-up age groups (no changes)
 Dosing schedules




 Contraindications and precautions (no changes)
 Summary
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No changes are proposed to the routine and catch-up age groups for HPV vaccination. Major
additions are proposed to the sections on dosing schedules and persons with prior vaccination.
Clarifying language is proposed for the sections on interrupted schedules, special populations, 
and medical conditions.  For contraindications and precautions, no changes are proposed. The 
summary includes the proposed recommendation category.
The routine and catch-up age groups, for whom HPV vaccination is recommended, would not 
change.  The text of this section would continue to emphasize that: 
 ACIP recommends routine HPV vaccination for girls and boys at age 11 or 12 years.
Vaccination can be given starting at age 9 years.
 ACIP also recommends vaccination for females through age 26 years and for males
through age 21 years who were not adequately vaccinated previously. Males aged 22
through 26 years may be vaccinated.
 Additional details will be presented in the sections on Special Populations, and Medical
Conditions.
Beginning with the section on dosing schedules, underlined text indicates new information or
changes to the current recommendations. Based on the evidence previously presented to ACIP
on 2-dose immunogenicity, efficacy, cost-effectiveness, duration of protection, GRADE
evaluation, and additional considerations, the proposed dosing schedules for HPV vaccination
are:
 For persons initiating vaccination before the 15th birthday, the recommended
immunization schedule is 2 doses of HPV vaccine. The second dose should be
administered 6–12 months after the first dose (0, 6–12 month schedule).*
 For persons initiating vaccination on or after the 15th birthday, the recommended
immunization schedule is 3 doses of HPV vaccine.  The second dose should be
administered 1–2 months after the first dose, and the third dose should be administered
6 months after the first dose (0, 1–2, 6 month schedule).* 
* See footnote defining minimum intervals
The next section with major changes is on evaluating persons with prior vaccination.  This is a 
new section proposed to address questions about persons who have received any HPV vaccine 
in the past.  The proposed text is: 
 Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV before the 15th
birthday, and received 2 doses at the recommended dosing schedule, or 3 doses at the
recommended dosing schedule, are considered adequately vaccinated.
 Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV on or after the 15th
birthday, and received 3 doses at the recommended dosing schedule, are considered
adequately vaccinated.
In addition, this section could formalize current CDC supplemental guidance for vaccination 
providers which appears online at: www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf. This 
states that 9vHPV may be used to continue or complete a series started with 4vHPV or 2vHPV.  
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Furthermore, the workgroup would like to include an explicit statement that for persons who 
have been adequately vaccinated with 2vHPV or 4vHPV, there is currently no ACIP
recommendation regarding additional vaccination with 9vHPV.
In the section on interrupted schedules, the following is proposed:




 Number of recommended doses is based on age at administration of the first dose.
Before presenting the proposed minimum intervals, Dr. Meites reviewed the current 
recommendations and evidence considered on this topic.  In current guidelines, the minimum 
interval between the 1st  and 3rd  dose in a 3-dose series is given at 24 weeks, slightly less than 6 
months.  The WG noted that in both the new 2-dose and the original 3-dose trials of 9vHPV, 
doses given at a target 6-month interval were scheduled for 180 days after the first dose, which 
is equivalent to 26 weeks.  However, participants were included if they received vaccine within 4 
weeks of this target date, and many participants in the 2-dose trial did receive their second dose 
in this window.  Therefore, the 9vHPV trial data support a minimum interval of 5 months, which 
is equivalent to 22 weeks.  Furthermore, the updated FDA-approved label for 9vHPV vaccine 
states a minimum interval of 5 months between doses in a 2-dose series.  For these reasons, 
the WG proposed that a footnote defining the minimum intervals include the following: 
 In a 2-dose series of HPV vaccine, the minimum interval is 5 months between the 
first and second dose.
 In a 3-dose series of HPV vaccine, the minimum intervals are:
1 month between the first and second doses, 
3 months between the second and third doses, and 
5 months between the first and third doses. 
 A vaccine dose administered at a shorter interval should be re-administered at 
the recommended interval.
The section on special populations is largely unchanged. Currently, for children with a history of 
sexual abuse or assault, ACIP recommends routine HPV vaccination beginning at age 9 years.
In addition, ACIP currently recommends an extended catch-up age range for MSM, and for
immunocompromised persons.  The WG proposed to add clarifying text to the current guidance 
that defines these populations more clearly.
To the current recommendation for MSM, the proposed clarification would add terms that are 
used elsewhere to recognize diversity in sexuality and gender identity and expression among 
men whose behavior may include sex with men.  The proposed text is:
 For gay, bisexual, and other men who have sex with men (MSM), ACIP recommends 
routine HPV vaccination as for all adolescents, and initiation of vaccination through age 
26 years for those who were not adequately vaccinated previously.  For transgender 
persons, ACIP recommends HPV vaccination through age 26 years for those who were 
not adequately vaccinated previously. 
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For immunocompromised persons, the WG did not feel that a 2-dose schedule should be 
recommended for all types of immunocompromise.  The purpose of this addition is to clarify
which immunocompromising conditions should continue to receive 3 doses, based on expert 
opinion and consistent with the Infectious Disease Society of America (IDSA) clinical practice 
guidelines for vaccination of the immunocompromised host.  The current recommendation with 
the full text of the proposed clarifying addition and footnote is:
 ACIP recommends HPV vaccination for immunocompromised females and males aged 
9 through 26 years with three doses of HPV vaccine (0, 1–2, 6 months). Persons who 
should receive 3 doses are those with primary or secondary immunocompromising 
conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte 
antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant 
neoplasm, transplantation, autoimmune disease, or immunosuppressive therapy, since 
immune response to vaccination may be attenuated.*
* The recommendation for a 3-dose schedule does not apply to children aged <15 years
with asplenia, asthma, chronic granulomatous disease, chronic heart/liver/lung/renal
disease, CNS anatomic barrier defects (e.g., cochlear implant), complement deficiency, 
diabetes, or sickle cell disease. 
Finally, contraindications and precautions, including those related to pregnancy, are unchanged 
from previous recommendations.  Standard language is included on the Vaccine Adverse Event 
Reporting System (VAERS).  Reports can be submitted to VAERS online, by fax, or by mail. 
Additional information about VAERS is available by telephone (1-800-822-7967) or online 
(https://vaers.hhs.gov).
To summarize, the proposal is for ACIP to recommend a 2-dose schedule of HPV vaccine for
girls and boys who initiate the vaccination series at ages 9 through 14 years. The proposed 
category is a Category A recommendation, for everyone in this age range.  As discussed in this
presentation, the WG proposed text for each of the sections shown here, for ACIP to consider:
 Routine and catch-up age groups (no changes)
 Dosing schedules




 Contraindications and precautions (no changes)
 Summary
In terms of next steps, the WG anticipates that a Policy Note could be published in the MMWR
before the end of this year, and detailed methods and GRADE tables would be linked and 
posted online.
Discussion Points
Regarding the 6 to 12 month interval and how this may play out in the real world, Dr. Szilagyi
pointed out that education for pediatricians and family physicians is important.  He suspects that
many practitioners will bring adolescents back at their next well-child visit.  There is one 
complication with that in that some commercial insurance plans will not pay for a well-child visit
if it is within 12 months.  That does not include Medicaid or public health insurance, so he did 
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not know what percentage of the population that would include, but thought that it would be 
small but measurable.  That means that many practitioners may bring their adolescents back at
13, 14, or 15 months.
Dr. Hunter asked about the current rates of 1-dose vaccination amongst 9 through 14 year olds, 
especially in comparison to whether that is higher than the current rates of 3-dose vaccination 
amongst 15 through 26 year olds to understand how much rates may bump up. Dr. Markowitz
replied that those are not the age groups in NIS-Teen, but Dr. Wharton could provide additional
information. 
Dr. Messonnier added that there may be people who are not initiating the series because of the
complicated schedule.  While this question can be answered based on who is getting the 
vaccine now, the hope is that by simplifying the regimen, more people will access it and this will
help providers make a stronger vaccine recommendation. Dr. Wharton indicated that reported in 
the most recent publication of NIS-Teen, was that 3-dose coverage in the 13 to 15 year old age 
group, which corresponds to the Healthy People 2020 target, coverage was pretty low at 27%
coverage in males and 37% coverage in females.  She emphasized the point that Dr. 
Messonnier made, that a recommendation for a 2-dose series at younger ages might very well
result in better completion than with the current recommendation.
Ms. Pellegrini stressed that the 0, 2, 6 month schedule is very hard for families with teenagers.  
Going to the pediatrician 3 times in 6 months is very difficult.  The more flexible schedule and 
wider interval proposed would allow for the next well-child visit, sports physical, or sick visit 
could make a real difference in increasing the completion rates in a timely fashion and in 
incentivizing families to begin the schedule.  There are people who look at the 0, 2, 6 schedule 
and say they know they cannot do it and will not start it.
Dr. Lett (AIM) heard that ACIP would not be considering recommendations to change the 
wording of the age at which to begin HPV vaccine in this statement.  She asked if there was any
other permissive use language that could be considered including in the statement about 
starting the vaccination earlier.
Dr. Bennett emphasized that the goal for this session was to focus on the 2-dose schedule; 
however, the WG does intend to reassess the language around the recommended age 
parameters downward and upward (within the 9 through 26 year age range).  That probably will
be brought back at a later time.
Referring to Slide 9 regarding persons with prior vaccination, Dr. O’Leary (PIDS) thought the 
wording might be confusing.  The statement in the first bullet might be interpreted by providers
as the old recommended schedule of 2 doses at 0 and 1-2 months.  He suggested specifying 
the number of months so providers understand whether it indicates the old schedule (0, 1-2, 6 
months) versus the newly recommended schedule (0, 6-12 months).
Dr. Gemmill (NACI) reported that while Canada took a different route, they came to the same 
position in time.  They went to a 2-dose schedule with the 4vHPV vaccine, and are now
discussing for future consideration the same thing ACIP was discussing during this session.  He 
thought he heard stated that anybody who had 2 or 3 doses with any vaccine is considered to 
be completely immunized.  Inevitably, some people who have had 2vHPV+ or 4vHPV will want 
protection from the other types.  He asked whether there would be a permissive 
recommendation that would allow for this and, if so, what it would be.  Canada is struggling with 
this.
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Dr. Meites replied that the current proposal includes the language that, for those who have been 
adequately vaccinated previously, there is no ACIP recommendation regarding additional
vaccination with 9vHPV.
Referring to Slide 13 regarding minimal intervals, Dr. Walter pointed out that the third bullet may
need further clarification: “A vaccine dose administered at a shorter interval should be re-
administered at the recommended interval.”  For example, if someone gave a vaccine at 0 and 4 
months, he would assume that would mean the next dose should be given at 5 months.  
However, someone might assume that this meant 6 from the dose given at 4 months.
Dr. Meites pointed out that the text on Slide 13 was abbreviated to avoid distracting from the 
main presentation, and explained that the full text of the footnotes (shown on Slide 27) would 
include full details about the recommended minimum intervals between each dose for both 2­
dose and 3-dose schedules, along with guidance on re-administration of an early dose.
Dr. Hayes (ACNM) said she thought there was an International Classification of Diseases (ICD)­
10 code so that a well-child visit does not have to be coded in order to give the vaccine.  She 
said she loved the liberal language about recommended time frames for giving the vaccine, in 
that if the child presents late it can still be given.  When administering the vaccine at family 
planning visits at the same time as giving Depo-Provera, her colleagues were unclear about 
whether a second dose of vaccine could be given a year later.
Dr. Messonnier pointed out that a number of complicated clinical decision issues could come 
from this policy change.  CDC will try to work through all of those with the professional
organizations.  She requested that any questions be submitted to Dr. Wharton, and CDC will try
to ensure that they are included in the massive health communication materials that CDC will
develop to help clinicians work their way through this.
Referring to Slide 9, Dr. Hahn (CSTE) commented that someone she knows has had the first 2 
doses at 2 months apart, and she suggested that it read “and received 2 doses at least 5 
months apart” to be more clear.
Dr. Middleman (SAHM) read the following statement into the record:  “Members from the 
Society for Adolescent Health and Medicine, including the Vaccination Committee and the 
President-elect and current President have significant concerns regarding the new policy’s use 
of the labels “gay” and “bisexual” as proxies for behavior that places men 22 to 26 years of age 
at increased risk of HPV acquisition.  Labels that characterize sexual orientation do not 
necessarily characterize behavior.  If a behavior puts a person at greater risk for disease and 
greater need for vaccination, then it is more accurate to describe the specific behavior, for
example “men who may have or have had sex with men.”  Men who identify as gay or bisexual
may not engage in behaviors that place them at increased risk for HPV acquisition and 
conversely, men who do not identify as gay or bisexual may engage in sexual behaviors that 
place them at increased risk.  Importantly, many HCP do not routinely screen their patients in 
great detail regarding sexual orientation or sexual behaviors.  The evolving nature of sexual and 
gender expression makes generalizing with the use of labels obsolete and inaccurate.  We 
potentially miss vaccinating many young men who should be protected against disease.  
Furthermore, we know from past experiences, as Dr. Schaffner noted earlier today, that 
targeting vaccination for specific groups has not been an effective public health strategy.  The 
most inclusive and effective strategy to protect young men is to avoid assumptions based on 
generic labels. We recommend:  1) eliminate imprecise labels from vaccination 
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recommendations that falsely assume an equivalence between sexual orientation and risk
behaviors, potentially resulting in missed opportunities for vaccination; and 2) update the 
recommendations for young men, hopefully at the next meeting, to include catch-up for all 22 to 
26 year olds in order to protect all young men, including those whose behaviors defy labels, 
from the morbidity and mortality associated with HPV infection.  We have an extremely effective 
vaccine that is more cost-effective than initially predicted.  The number of vaccines distributed 
for 22 to 26 year old males is reportedly extremely low, implying poor uptake among this group 
of men.  The goal for our young men at this point should be to use fewer labels, make fewer
assumptions, have fewer restrictions, and strive to be more inclusive, immunize more men, and 
save more lives.  Thank you.”
Dr. Meites thanked Dr. Middleman for her commitment to this issue and her work with 
adolescent patients.  She stressed that it certainly was the intent of the proposal to make the 
language inclusive of the populations who should receive vaccine.  As far as the particular
phrasing of the terms, she pointed out that these terms are widely used at CDC.  She showed 
an assortment of websites from different CDC programs that focus on lesbian, gay, bisexual, 
and transgender (LGBT) health.  She pointed out that the language included in the CDC fact 
sheet on “HPV in Men,” under the heading “Can I get an HPV vaccine?” already specifically
includes, “Gay, bisexual, and other men who have sex with men.” Dr. Meites explained that the 
focus for this session was to propose formalizing the language already in use to describe the 
existing ACIP recommendation for MSM.  As mentioned, the topic of recommendation language
over the full age range for which HPV vaccine is licensed (i.e., for males ages 22 through 26 
years) is a topic that the WG would like to continue discussing in the future.
Dr. Messonnier thanked the HPV WG and expressed appreciation for SAHM’s concern, 
recognizing that SAHM is an incredibly important partner for this age group and on this vaccine.  
CDC wants to find a way to make this work.  The WG came to this language as everyone heard, 
but outside of the bullet, there is clinical language that CDC uses in its health communication 
materials that derive from the kind of conversations they have, but the wording is not always
exactly what is voted on.  CDC commits to SAHM that the agency will engage with the experts
who are putting out this information to try to find something that is acceptable to SAHM and also 
meets the purpose of the WG, which is actually to be more inclusive, not less inclusive.
Dr. Middleman (SAHM) expressed her appreciation, and said that SAHM appreciates the 
opportunity to contribute.
Dr. Bennett thanked Dr. Middleman for raising this important issue.
Referring to Slide 13 regarding minimum intervals, Dr. Wexler (IAC) pointed out that this was a 
divergence from how CDC usually writes recommendations for spacing minimum intervals.  
Usually, ACIP would say 4 weeks instead of 1 month and 12 weeks instead of 3 months.  
Language in the childhood schedule says, “For purposes of calculating intervals between doses, 
4 weeks equals 28 days.  Intervals of 4 months or greater are determined by calendar months.”
That is, 4 months is the cutoff for using month terminology. 
Dr. Meites said it was also her understanding that these were used interchangeably.  Since 
preferable, she expected the WG would be supportive of using the terms “4 weeks” and “12 
weeks” rather than the terms “1 month” and “3 months.”
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Dr. Offit (Children’s Hospital Philadelphia) said that while he understood that there was no 
additional recommendation for those who have completed either the 2vHPV or 4vHPV series, it 
was not clear to him why.  There is a 9vHPV vaccine that will protect against an additional
several thousand cases of cancer and presumably hundreds of deaths.  One could argue that 
the best medical recommendation is for someone who has completed either 2vHPV or 4vHPV 
to get 2 doses of 9vHPV vaccine separated by at least 6 months.  That would save lives.  He 
asked whether the reason the WG was not making that recommendation was programmatic or
financial. Dr. Markowitz replied that this had not been brought before the entire ACIP, and for a 
variety of reasons was not part of the earlier recommendations.  However, the WG may revisit 
this discussion going forward.
Regarding Slide 15 on special populations, Dr. Thompson (NVAC) said she did not understand 
why there was different language used for these different populations of gay, bisexual, and 
other MSM and transgender individuals.  The language in the slide differed in a way that did not 
make sense to her, and she wondered what the rationale was for the actual language on which 
the committee would be voting.  That is, why was vaccination for all adolescents recommended 
for the first group but not the second?  She also wondered about the language for proposed 
medical conditions in terms of what evidence there is about the 3-dose schedule in these 
special populations with respect to the timing.  Is it better for these individuals to have the 0, 1-2, 
and 6 month schedule or 0, 6 to 12 month and then a booster later.  If this is not known, she 
asked whether any research is being done to figure out the right timing for immunocompromised
populations.
Dr. Meites replied that the language in the two sentences on Slide 15 originally was one 
sentence, and the WG revised it into two sentences for clarity.  They certainly could repeat, 
“ACIP recommends routine HPV vaccine as for all adolescents” in the second sentence.
Dr. Cohn said that she wanted to make it clear that the proposed recommendation from the WG
was solely about the 2 doses, and that all of the clinical guidance language they were seeing 
could be modified before publication of the MMWR.
Regarding Dr. Thompson’s second question on the timing of the 3-dose regimen for those who 
are immunocompromised, Dr. Meites referred to Slide 28.  She pointed out that it is known that 
HPV vaccines are non-infectious.  The concern is that the immune response following 
vaccination may be attenuated in persons with certain immunocompromising conditions; that is,
they might produce lower GMTs and antibody responses if their cell-mediated or humoral
immune responses are reduced.  As far as the timing of doses, she said she was not aware of 
any studies that have evaluated a 6 to 12 month schedule in immunocompromised patients.  
For these reasons, the standard 3-dose recommendation has been left in place for these 
persons as well as for those who initiate the vaccine series as an older teen.
Dr. Maldonado (AAP) indicated that COID met to discuss the proposed wording.  COID strongly
supports the 2-dose recommendation, taking into account the other issues that were brought up 
around operational issues, opportunities for missed second doses, et cetera.  In particular, one 
of the areas that COID is concerned about and would recommend some thoughtful
consideration is expanding to the larger age range for the purposes of including optimal
vaccination periods for younger children.
Requesting that Slide 27 with the full footnotes for minimum intervals be redisplayed, Dr. Lett 
(AIM) asked if the proposed minimum interval was 4 months.
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Dr. Meites indicated that this slide articulates the proposed minimum intervals and proposed 
language about what to do if a vaccine dose has been administered at an interval that was
shorter than that.  The proposal was, in a 2-dose schedule, “If the second dose is administered 
at a shorter interval, an additional dose should be administered at least 4 months later,” and in a 
3-dose schedule, “If a vaccine dose is administered at a shorter interval, it should be re-
administered after another minimum interval.”




A Voice For Choice Advocacy
I agree with dosing going down to 2.  My concern, and I know this isn’t your choice, but with the 
9vHPV vaccine being the only one available, the increase in aluminum is double for every dose.  
That is a concern, and I wonder if the safety studies have been done surrounding the aluminum
specifically and looking at things like premature ovarian failure and other adverse reactions that 
have been reported, and looking at the long-term.  I know that the 2-dose brings it down, but it’s
still higher than the 3-doses of the initial 4- or 2-variant GARDASIL®.
Dr. Bennett thanked Ms. Hildebrand for her comments and referred her to the SMEs and CDC‘s
vaccine safety personnel to discuss that issue.
Kristen Morelli
Richmond, Rhode Island
Submitted Via Email to be Included in the Record
I am deeply concerned about the safety, effectiveness, and necessity for the HPV vaccine for
the following reasons. 
•	 Concern was publicly raised about ovarian failure related to the HPV vaccine. This
should not be ignored and further detailed studies should be done immediately, and prior
to more vaccines being recommended.
•	 Advertising the HPV vaccine for cancer prevention should cease immediately. Not one 
study proves cancer prevention, it is an assumed result that does not have solid proof
yet. This is extremely misleading to the public and does not permit proper informed 
consent.
•	 CDC should cease and desist on any form of advertising of any vaccines to the public. 
Vaccine manufacturers are free from liability when a vaccine causes a negative side 
effect. They benefit full profits of all vaccine sales. Our tax dollars and government 
agencies should not be paying to advertise a product that produces billions in profits for
the manufacturer.
•	 Multiple countries are no longer recommending the HPV vaccine due to a high level of 
young adults having serious side effects of the vaccine. The CDC and ACIP need to take 
this seriously and show the US public that they do care about the youth, and will also do 
more follow up studies and further investigation of the HPV vaccine.
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The fact that vaccine manufacturers are not liable in a similar fashion to all other pharmaceutical
manufacturers is also a big concern for me. These ARE pharmaceuticals, being shot into the 
veins of small children. Testing should be as thorough as any other pharmaceutical.
Vote:  2-Dose HPV Vaccination Recommendations
Dr. Kempe motioned to approve the proposed 2-Dose HPV Vaccination Recommendations.  Dr.
Lee seconded the motion.  The motion carried unanimously with 13 affirmative votes, 0 negative 
vote, and 1 abstention.  The disposition of the vote was as follows:
13 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
Riley, Stephens, Szilagyi, Walter 
 
1 Abstained: Romero (due to non-vaccine-related
 
VFC Resolution
Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Santoli explained that the purpose of this resolution was to reflect the new dosing schedules
for HPV vaccine. Eligible groups include all children 9 through 18 years of age. ACIP 
recommends routine HPV vaccination at age 11 or 12 years, and vaccination can be given 
starting at age 9 years.  ACIP also recommends vaccination for females and males aged 13 
through 18 years who were not adequately vaccinated previously. The table below summarizes
the recommended number of HPV vaccine doses and schedule for specific groups of children:
0, 6–12 months1  Persons initiating vaccination at age 
9 through 14 years, except 
immunocompromised persons2  
0, 1–2, 6 months3  Persons initiating vaccination at age 
15 through 18 years, and 
immunocompromised persons2  







1. In a 2-dose schedule of HPV vaccine, the minimum interval is 5 months between the first and the second dose.  
2. Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral
immunity. 
3. In a 3-dose schedule of HPV vaccine, the minimum intervals are 1 month between the first and second dose, 3 months
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Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV before the 15th  birthday, and 
received 2 doses at the recommended dosing schedule, or 3 doses at the recommended dosing 
schedule, are considered adequately vaccinated.  Persons who initiated vaccination with 
9vHPV, 4vHPV, or 2vHPV on or after the 15th birthday, and received 3 doses at the 
recommended dosing schedule, are considered adequately vaccinated.  Vaccine doses 
administered at shorter than minimum intervals should be re-administered as recommended.  
9vHPV may be used to continue or complete a series started with another HPV vaccine.  If the 
vaccine schedule is interrupted, the series does not need to be restarted. 
 
Refer to product package inserts. 
Contraindications and Precautions can be found in the package inserts available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
Statement Regarding Update Based on Published Documents
[If an ACIP recommendation regarding Hepatitis B vaccination is published within 12 months
following this resolution, the relevant language above (except in the eligible groups sections) will
be replaced with the language in the recommendation and incorporated by reference to the 
publication URL.]
Vote:  VFC Resolution for 2-Dose HPV Vaccination Recommendations
Ms. Pellegrini motioned to approve the VFC Resolution for the 2-Dose HPV Vaccination
Recommendations.  Dr. Walter seconded the motion.  The motion carried unanimously with 13 
affirmative votes, 0 negative vote, and 1 abstention.  The disposition of the vote was as follows:
13 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
Riley, Stephens, Szilagyi, Walter 
 




David S. Stephens, MD
Chair, Meningococcal Work Group
Advisory Committee on Immunization Practices
Dr. Stephens reminded everyone that a revised dosing schedule was approved for Trumenba®, 
Pfizer Vaccines’ MenB-FHbp vaccine.  The dosing schedule was approved by FDA on April 14, 
2016 to change the original language of the 3-dose schedule from 0, 2, and 6 month to 0, 1-2, 
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and 6 months and to approve a 2-dose schedule with administration at 0 and 6 months.  The 
revised schedule indicates that the choice and dosing schedule may depend upon the risk of 
exposure and the patient’s susceptibility to serogroup B meningococcal (MenB) disease.
Dr. Stephens indicated that the presentation topics for this session would include the following:
 Impact of MenB-FHbp (Trumenba®) on meningococcal carriage
 Immunogenicity studies of two MenB vaccines in adults
 MenB-FHbp update
 Considerations for use of 2- and 3-dose schedules of MenB-FHbp
 ACIP and VFC votes anticipated
The policy options for 2- or 3-dose schedules of MenB-FHbp (Trumenba®) are:
 For persons at increased risk and for use during outbreaks:
 Preference for 3-dose schedule (0, 1-2, 6 months)
 When given to healthy adolescents:
 Preference for 2-dose schedule (0, 6 months)
OR
 Option for 2- (0, 6 months) or 3-dose (0, 1-2, 6 months) schedule 
OR
 Preference for 3-dose schedule (0, 1-2, 6 months)
Additional WG activities include a Policy Note regarding the recommendations for use of 
meningococcal conjugate vaccines in HIV-infected persons, which is to be published in the 
MMWR on November 4, 2016.  The WG is continuing to review additional data on MenB
vaccines as it becomes available, and considering the issue of booster doses of MenB vaccine 
for persons at increased risk.
Impact of MenB-FHbp (Trumenba®) on Meningococcal Carriage
Heidi M. Soeters, PhD, MPH
Meningitis and Vaccine Preventable Diseases Branch
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
During this session, Dr. Soeters discussed a meningococcal carriage evaluation conducted in 
response to a serogroup B meningococcal disease outbreak and the resulting mass vaccination
campaign that occurred at a college in Rhode Island.
In terms of background and context, meningococcal disease most commonly takes the form of 
meningitis or bacteremia.  It often starts with influenza-like symptoms but can progress within 
hours to a serious illness that can include high fever, severe headache, stiff neck, confusion, 
and a purpuric rash.  This disease has a 10% to 15% case-fatality ratio, even with appropriate 
antibiotic treatment. Of survivors, 11% to 19% have permanent sequelae, such as cognitive 
deficits or amputations due to necrosis of the extremities. Meningococcal disease is caused by
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the bacterium Neisseria meningitidis, which is a gram-negative diplococcus. Invasive 
meningococci generally have a polysaccharide capsule surrounding the cell, which confers the 
serogroup. Of the 12 different serogroups of meningococci that have been identified, only 6 
primarily cause invasive disease.
Traditionally, meningococcal vaccines are based on the capsular polysaccharide that is specific
to each serogroup.  Therefore, the resulting protection is serogroup-specific. There are 
polysaccharide vaccines composed of purified capsular polysaccharide. Formulations include
monovalent A, monovalent C, bivalent A-C, and quadrivalent A-C-W-Y. There also are 
conjugate vaccines, where the capsular polysaccharides are conjugated to proteins, such as
tetanus or diphtheria toxoids.  These vaccines achieve similar or greater immunogenicity and 
duration of protection than polysaccharide vaccines, and are formulated as monovalent A, 
monovalent C, or quadrivalent A-C-W-Y. The conjugate quadrivalent ACWY, or MenACWY, 
vaccine is routinely recommended for adolescents in the US. This same approach of basing a 
vaccine on the capsular polysaccharides has not worked for serogroup B, because the
serogroup B polysaccharide antigen is similar to human antigens, leading to poor
immunogenicity and concerns about potential autoimmunity.
As a result, serogroup B, or MenB, vaccines have to take a different approach and focus on 
outer membrane proteins. These antigens have multiple alleles and variable expression in 
different strains of the bacteria.  Not all serogroup B bacteria will express the antigens that are 
present in a particular vaccine, and the serogroup B polysaccharide capsule, which is required 
for virulence, is not contained in MenB vaccines. Unlike vaccines for other meningococcal
serogroups, MenB vaccines are not expected to be protective against all serogroup B strains in 
circulation.  Also, since they are based on outer membrane proteins, and not on the serogroup­
specific capsule, they may help protect against other serogroups as well.
There are two MenB vaccines licensed in the US:  MenB-FHbp (Trumenba®) and MenB-4C 
(Bexsero®).  MenB-FHbp is a 2-component vaccine, containing a FHbp variant from each 
subfamily A and B.  It is given in 2 or 3 doses.  Bexsero®  is a 4-component vaccine, containing 
NadA, a FHbp from subfamily B, NHBA, and porA and is given in 2 doses. 
In terms of transmission, meningococcal bacteria are carried in the human nasopharynx, and 
most carriers remain completely asymptomatic.  Less than 1% of persons exposed to the 
organism develop invasive disease.  The bacteria are spread through close contact, specifically 
via respiratory or oral secretions from patients or asymptomatic carriers.  Important risk factors 
for both disease and carriage among adolescents include age1,2, social mixing3, and smoking1.  
As the majority of transmission is thought to be attributable to asymptomatic carriers, 
decreasing carriage is the main way to provide herd immunity against meningococcal disease 
[1Harrison et al. JID 2014. (US); 2Jeppesen et al. J Infect 2015. (UK); and 3Mandel et al. JID 
2013. (US)]. 
 
Looking at what we know about vaccine impact on meningococcal carriage, in the United 
Kingdom (UK), vaccines targeting serogroup C were shown to decrease nasopharyngeal 
carriage of serogroup C by 66% one year post-vaccination, thereby decreasing transmission 
and providing herd protection1. MenA conjugate vaccine nearly eliminated serogroup A 
carriage2,3.  The understanding of MenB vaccine impact on carriage is currently limited.  The 
only previous study was conducted using MenB-4C, and found an 18% reduction in carriage of 
any meningococcal bacteria, and no effect specifically on serogroup B carriage by 3 months 
after completion of the 2-dose series4.  To date, no data has been published regarding the effect 
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In the US, 3 serogroups (B, C, and Y) are the primary causes of meningococcal disease. This
graph shows the incidence of these serogroups in adolescents and young adults following the 
introduction of conjugate MenACWY vaccine in 2005:
While incidence of all serogroups is low, serogroup B (in black) is the leading cause of 
meningococcal disease in this age group. In fact, serogroup B caused 7 outbreaks on college 
campuses since 2009, resulting in 41 cases and 3 deaths [Source: NNDSS data with additional
serogroup data from Active Bacterial Core surveillance (ABCs) and state health departments.  
Unknown serogroup (21%) and other serogroups (7%) excluded].
To provide some background on this particular outbreak at Providence College in Rhode Island, 
2 cases of serogroup B occurred in undergraduate students on January 31 and February 5, 
2015. The cases resided in different dormitories and had no known epidemiologic links. Both 
were determined to have a rare sequence type, ST-9069, never before seen in the US. Both 
case-patients survived. These 2 cases among a population of 4500 students indicated an 
attack rate of 44 cases per 100,000, nearly 500 times higher than the national incidence among 
persons aged 17 through 22 years. In response to the outbreak, Providence College rapidly
implemented a mass vaccination campaign using MenB-FHbp. The three doses were provided 
in February, April, and September of 2015, with remarkably high vaccination coverage of 94%
with the first dose, 80% with the second, and 77% with the third. Incoming freshman in the fall
of 2015 also were offered to begin the series.
CDC incorporated a meningococcal carriage evaluation into this vaccination campaign. It had 2 
objectives, which were to:  1) determine the baseline prevalence of nasopharyngeal carriage of 
Neisseria meningitidis, and 2) assess the impact of MenB-FHbp vaccination on carriage. The 
evaluation consisted of a short questionnaire assessing risk factors for meningococcal carriage 
and disease, followed by an oropharyngeal swab. All undergraduate students at Providence 
College and graduate students who lived on campus were eligible to participate. Specimens
were evaluated using culture, slide agglutination, real-time polymerase chain reaction (rt-PCR), 
and whole genome sequencing.
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As mentioned, 2 methods were used to determine the serogroup of each isolate:  rt-PCR and 
slide agglutination. PCR is a genotypic test that detects the presence of capsule biosynthesis
genes for each serogroup, regardless of whether they are expressed. PCR can detect 
serogroups A, B, C, W, X, and Y and any specimen that does not contain the genes for one of 
these serogroup capsules is considered non-groupable. Slide agglutination, on the other hand, 
is a phenotypic test which uses antiserum to look for expression of each serogroup, and can 
detect the same 6 serogroups as PCR, in addition to serogroups E and Z, which rarely cause 
invasive disease.  Any specimen that does not clump with the antiserum for any of the 
serogroups is considered non-groupable according to slide agglutination. Meningococcal
bacteria can possess the genes for a serogroup but not be expressing them in their current 
environment, which would produce discordant results according to these 2 methods.  Therefore, 
both methods were used in conjunction to get a more precise picture of meningococcal
dynamics in this setting.
Additionally, meningococcal vaccination records were abstracted for each participant, recording 
the doses and dates of previous MenACWY or MenB vaccination. This process was repeated 4
times, resulting in 4 cross-sectional snapshots of carriage on-campus. Round 1 occurred in 
February 2015, the week after the outbreak and dose 1 clinics. Round 2 occurred in 
conjunction with dose 2 in April. Round 3 occurred in September, as upperclassmen received 
dose 3 and incoming freshmen received dose 1. Round 4 occurred one year post-outbreak, 
including fully vaccinated upperclassmen and freshmen receiving dose 3.
For analysis, descriptive statistics were performed on participant characteristics. The proportion
of students were assessed in terms of overall meningococcal carriage and specifically
serogroup B carriage, and how this changed over time.  Prevalence ratios were estimated using 
general estimating equation methods for repeated measures. Finally, as a number of students
participated in multiple rounds, within-individual changes in carriage over time are being 
examined.
The number of participants in each round ranged from 622 to 878.  In total, 2843 swabs were 
collected from 2014 unique individuals. This table shows participant characteristics across the 4 
rounds:
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Note that as the evaluation took place across 2 academic school years, the class of 2019 was
only included in rounds 3 and 4. The proportion of participants who lived on campus was high, 
but varied each round. Of the participants, 34% to 42% were male. Recent antibiotic use and 
recent upper respiratory symptoms were both highest during round 1, which took place during 
the winter. A high proportion of students smoked or had second-hand smoke exposure. Social
mixing was common, as 67% to 74% of students reported visiting bars, clubs, or parties at least 
once per week.
Also assessed were meningococcal vaccine doses received at least 2 weeks prior to specimen 
collection, to allow time to mount an immune response.  A high proportion of students had 
documented MenACWY vaccine, which generally was received the summer before college 
entry.  In round 1, no students had received MenB-FHbp more than 2 weeks prior. In round 2, 
most participants had received 1 dose. In round 3, most had received 2 doses. In round 4, the 
majority had received either 2 or 3 doses.
In terms of overall meningococcal and serogroup B carriage, in round 1, 24% of participants
were carrying Neisseria meningitidis. This proportion remained fairly stable over the next year, 
with 24% carriage in round 2, 20% carriage in round 3, and 21% carriage in round 4.  When 
looking at serogroup B carriage, 4% of participants carried serogroup B by PCR in each of the 4 
rounds. By slide agglutination, just over 1% of students were carrying bacteria that express the 
serogroup B capsule in each round.
Regarding serogroup results by PCR over time, as with previous meningococcal carriage 
studies, most isolates were non-groupable, meaning the bacteria are unencapsulated and 
therefore better adapted for colonizing the nasopharynx. Serogroup B was the most common, 
and a handful of serogroups C, Y, W, and X were detected in each round. The majority of 
isolates were non-groupable according to slide agglutination as well.  With respect to the 
groupable isolates, serogroup B was the most commonly expressed capsule, though serogroup 
E increased over time and a handful of isolates expressed serogroups X, Y, C, and Z as well.
Next, associations with carriage of any meningococcal bacteria were examined. As compared 
with round 1, there was no difference for rounds 2 or 4, but round 3 had a slight association with 
decreased carriage. In comparison to the class of 2018, who were freshmen during outbreak, 
the class of 2017 had the highest carriage prevalence.  Male sex, smoking, and partying at least 
once per week were associated with increased carriage.  Recent antibiotic use was associated 
with decreased carriage.  Receipt of 1, 2, or 3 MenB-FHbp vaccine doses was not significantly
associated with carriage.
When the same models were repeated with the outcome of serogroup B carriage by PCR
instead of any meningococcal carriage, very similar associations were observed. During the 
evaluation, only 1 individual was found to be carrying the outbreak strain.  This individual
participated only in rounds 2 and 3, and was carrying this strain during both rounds.  The carried 
strain was serogroup B by PCR, but was non-groupable by slide agglutination. Whole genome 
sequencing (WGS) revealed that this was due to phase-variation in the capsule locus, meaning 
the bacteria were temporarily not expressing the capsule.  It is unclear whether this change in 
expression occurred in vivo or after the specimen was collected and cultured.
In total, 615 students participated in multiple carriage evaluation rounds. Of these students, 
71% were not carrying any meningococcal bacteria during any round; 14% were consistently
carrying meningococcal bacteria during each round in which they participated, though not 
necessarily the same strain or serogroup; 8% were carrying meningococcal bacteria during one 
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round, but then were not carrying any meningococci during a later round; and 7% did not have 
carriage, but then acquired carriage that was detected during a later round.
Of the 50 students who lost meningococcal carriage, 13 lost carriage after one MenB-FHbp 
dose, 32 after two doses, and 5 after three doses.  Of the students, 45 acquired meningococcal 
carriage (20 after one dose, 16 after two doses, and 9 after three doses).  Looking at serogroup 
B, 11 students lost serogroup B carriage (2 after one dose, 8 after two doses, and 1 after three 
doses), and 10 students acquired serogroup B carriage (3 after one dose, 4 after two doses, 
and 3 after three doses).
In conclusion, in each round, 20% to 24% of students carried meningococcal bacteria and 4%
specifically carried serogroup B by PCR.  This overall carriage prevalence is comparable to 
previously reported prevalences of up to 34% among university students in the UK.  However, 
the observed carriage prevalence was quite a bit higher than recent US estimates of 1% to 8%
among the general population. Despite this high carriage prevalence, only 1 carrier of the 
outbreak strain was identified and no further serogroup B cases associated with the college 
have occurred.  No evidence was found that MenB-FHbp vaccination impacts carriage, at either
the population or individual level.
These results help inform US MenB vaccine guidelines, both for use in adolescents and young 
adults, and specifically in outbreak settings. Also, if MenB vaccines do not appear to affect 
carriage and therefore provide some herd immunity, this reinforces the need for high vaccination
coverage during outbreaks to protect each individual and emphasizes the role of 
chemoprophylaxis for close contacts. WGS is underway to further characterize the isolates, 
compare carriage versus invasive isolates, examine within-individual longitudinal data, and 
investigate MenB vaccine antigens among the carriage isolates. Additionally, concurrent 
meningococcal carriage evaluations were conducted at two other universities, and the findings
will be compared from all 3 evaluations once they are complete.
Immunogenicity Studies of Two MenB Vaccines in Adults
Dan Granoff, MD, FPIDS
Center for Immunobiology and Vaccine Development
UCSF Benioff Children's Hospital Oakland
Dr. Granoff noted that Men A, C, Y and W capsular based vaccines have minimal antigenic
variability within a capsular group.  For disease-causing MenB strains, protein antigens have 
large variability in amino acid sequence and expression, which can affect susceptibility to serum
bactericidal activity.  For MenB vaccine licensure, efficacy was inferred based on data against a 
limited number of reference strains.  Gaps in knowledge include the extent of protection against 
more diverse disease-causing strains, as well as the effect of vaccination schedules (2 doses
versus 3 doses), and duration of protection.
During this session, Dr. Granoff discussed the results from three MenB immunogenicity studies
in adults.  These studies were not designed to provide comparison data between vaccines.  
Each study tested one vaccine.  The studies were performed independent of industry.  Dr. 
Granoff pointed out that he has no relevant potential conflicts of interest other than being the 
inventor on patents related to meningococcal vaccines.
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Dr. Granoff began by sharing the conclusions so that everyone could be thinking about them
while he described the studies.  One month post-dose 2, both vaccines elicited protective 
bactericidal antibody (titers ≥1:4) against most strains.  Some strains are relatively resistant to 
bactericidal activity despite prediction of susceptibility by sequence analysis and antigen 
expression.  After dose 2, titers can decline within 4 to 6 months, especially for strains with low
antigen expression.
Study 1 was of MenB-4C (BEXSERO®) to assess immunogenicity in adults.  There were two 
studies sites: Oxford Vaccine Clinic, UK (N=15) and University of California, San Francisco 
(UCSF) Benioff Children’s Hospital Oakland (N=5).  The median age was 29.  Of the 
participants, 12 (60%) were healthcare or laboratory workers.  Participants received 2 doses on 
either a 0,1 or 0, 2 schedule.  As noted earlier, MenB-4C vaccine contains four components that 
are largely responsible for bactericidal antibody:  FHbp (sub-family B), NHba, NadA, and PorA 
(P1.4).  A reference strain for FHbp would be considered one that was absent of NadA, PorA
that did not have P1.4, and low expression of NHba.  This would allow for inference that most of 
the bactericidal antibody was directed at FHbp.
Regarding data on ≥4-fold increases in serum bactericidal antibody titer to MenB-4C, the titer
one month post-dose 2 is divided by the pre-titer.  So, if the subject had a titer of 16 one month 
after 2 doses and a titer of 4 before, that would be a 4-fold increase.  Data from two studies
conducted by the manufacturer for vaccine licensure that are included in the FDA package 
insert, were compared to results from Study 1 for the three reference strains. The Study 1 data 
are very comparable to the data provided in the package insert.  Of the subjects, 95% to 100%
are achieving 4-fold increases to the FHbp strain and NadA strain, and about 70% to the PorA
strain.  This is very similar to Study 2 and is higher than the manufacturer.
In real life, there is a lot of sequence variability as illustrated by this image: 
Each of the FHbp variants can be given a different identification number (ID).  The MenB-4C
vaccine contains ID 1.  The closer a variant is in the tree to the MenB-4C vaccine variant (ID 1)
indicates the variant has a similar sequence to the vaccine variant. But they all are within the 
same FHbp family and predicted to be covered by the vaccine.
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Serum bactericidal antibody responses to a number of strains were assessed that were largely
from outbreaks of disease on college campuses in the US (UC Santa Barbara, Providence 
College, Ohio University, Santa Clara University, and Princeton University) and two strains from
Quebec where there has been hyperendemic disease for a number of years.  First, serum
bactericidal antibody responses of healthy adults immunized with 2 doses of MenB-4C were 
presented for FHbp sub-family B containing strains.  Dr. Granoff noted that the strains also had 
other antigens in the vaccine present.  Although all strains had at least 2 antigens and some 
had 3, the 4-fold increases were very similar to the reference strain, which had an FHbp that 
was an exact match with ID 1 that is contained in the MenB-4C vaccine.  The 4-fold increases
were much lower with strains that had other FHbp variants [Giuntini et al, Clin Vac Immunol
2016, in press].  Dr. Granoff emphasized that a 4-fold response is a measure of a robust 
response; however, it does not indicate whether the individual is protected.  He indicated that he 
would show some data from the Quebec strain where there was 35% 4-fold rise, and most of 
the persons at 1 month post-dose 2 actually had protective titers.  So, there are really two 
different measures.  His working model is that the portion with 1:4 or greater is a good measure 
of short-term protection; whereas, the 4-fold response gives a sense of the magnitude of the 
response and is likely to correlate with duration of protection.  Again, this is a model.
In terms of the data for the same sera looking at a group of strains from FHbp sub-family A, the 
FHbp was mismatched and depended on the other antigens in the MenB-4C vaccine (NHba and 
NadA).  The serum bactericidal antibody responses of adults immunized with 2 doses of MenB­
4C were pretty uniform, even for the strain that was mismatched for all 4 antigens, with around 
30% to 40% 4-fold increases in bactericidal titer.
Study 2 was of MenB-FHbp (Trumenba®) to assess immunogenicity in adults.  There were two 
study sites:  UCSF Benioff Children’s Hospital Oakland (N=12) and University of Massachusetts 
Medical Center (N=5).  The median age was 40.  Of the subjects, 100% (N=17) were healthcare 
or laboratory workers.  Three doses were used at the recommended schedule (0, 2, 6).  There 
are two FHbp antigens in this vaccine, sub-family A and B.  The Pfizer nomenclature is BO1, 
which is ID 55 and AO5 for the sub-family A, which is ID 45.  There is a relationship to a number 
of the other variants, which were contained in the strains that were tested. 
In terms of the serum bactericidal antibody responses of adults immunized with MenB-FHbp on 
a 2-dose (0,2) schedule, for many of the sub-family A strains more than 70% of subjects had ≥4­
fold increases in hSBA titers [Lujan et al, IPNC 2016]. With the MenB-4C vaccine, 40% of 
subjects had ≥4-fold increases in hSBA titers for sub-family A strains.  Dr. Granoff noted that 
they do not actually have the Pfizer reference strains in their laboratory to test, and that he was
showing the data from the package insert.  He has found similar responses for the 2 doses of 
this vaccine to the two sub-family A strains that were used by Pfizer.
With MenB-FHbp, a third dose is given at 6 months.  In terms of the data showing the 4-fold 
responses after 2 doses and 3 doses, the 3-dose data is one month post-dose 3 compared to 
the pre-titer.  With the third dose, there was a significant increase for many of the subjects and 
strains, with most having 80% to 90% 4-fold increases [Lujan et al, IPNC 2016].  Again, Dr. 
Granoff’s data are similar to what were reported for sub-family A.
For sub-family B, Dr. Granoff showed data for 2 doses at the 0, 2 schedule.  There was quite a 
lot of variability.  A mutant strain, H4476, was included.  This is a low expressing mutant, with 
about 50% lower expression than in a wild type.  Having lower expression affects the ability of 
the antibodies elicited by the vaccine to result in a robust bactericidal response.  The results
with the two doses of MenB-FHbp vaccine administered at 0,2 months were within in the same 
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range as the MenB-4C vaccine.  The Pfizer data were very similar to what were reported for the 
sub-family B strains.  Giving a third dose of MenB-FHbp vaccine at 6 months results in 
significant increases for many of the strains, with almost all being over 70% 4-fold [Lujan et al, 
IPNC 2016].  Again, the data are quite similar to what was reported.
Turning to comparative bactericidal titers for a representative strain from Quebec, Dr. Granoff 
pointed out that persons who are likely to benefit most from vaccination are those who have 
titers of <1:4 before vaccination with MenB-4C.  Out of a group of 20 subjects, 14 had titers <4.  
Although most of them did not achieve 4-fold response, 11 of 13 had protective titers after dose 
2. A small number of subjects had samples obtained 4 months post-dose 2, and they tended to 
decline.  Individuals with low titers tend to decline to below 1:4.  The results were very similar for 
MenB-FHbp.  After 2 doses, 13 of 16 had titers of 1:4 or greater and then there was a decline in 
titers.  After a third dose of MenB-FHbp, 11 of 12 subjects had a boost in protective titers.  
There are no follow-up sera on these at this point [Quebec 2013, Hyperendemic]. 
Study 3 assessed immunogenicity among students from Santa Clara University who received 
MenB-4C.  Between January 31 through February 3, 2016, there were 3 cases (2 culture-
confirmed and 1 suspect) at Santa Clara University caused by a strain that was in the ST 32 
clonal complex.  Within a few days, MenB-4C vaccination clinics were organized at the 
university.  From February 4-8, the first dose of vaccine was administered to 4921 persons.  The 
vaccine was administered on March 18 and April 6-8 to 4731 persons, most of whom were
receiving a second dose.  Sera were collected May 23-25 from 246 students (0 dose, N=52; 1 
dose, N=91; and 2 doses, N=101).
Serum bactericidal was measured against the three college outbreak strains from Santa Clara, 
Princeton, and Ohio Universities.  Santa Clara University students were immunized with MenB­
4C; that strain was positive for three MenB-4C antigens:  FHbp subfamily B (ID 510), NadA, and 
NHba. Protective titers of ≥1:4 were 92% post-dose 2 and 66% post-dose 1.  Interestingly
against this strain, about 40% already had protective titers before vaccination and 20% had high 
titers [Interim analysis of results on 160 sera by Dr. Qin Liu, Wistar Institute, Philadelphia].
The investigators also evaluated the strain causing the outbreak at Princeton University where 
there were 9 cases and 1 death.  This strain expressed two MenB-4C antigens:  FHbp subfamily
B and NHba.  A previous study showed that 66% of the students immunized with 2 doses of 
MenB-4C had developed protective serum bactericidal titers ≥1:4 [Basta et al, NEJM 2016].
Looking at the Santa Clara University sera against the Princeton strain, the prevalence of 
background antibody was much lower with almost nobody having a titer of ≥1:16.  There was a 
significant increase in serum bactericidal activity after 1 dose.  After 2 doses, 69% had titers of 
1:4 or greater.  So the investigators actually replicated the data from Basta at Princeton 
University, indicating that the strain is relatively resistant, especially when compared to the 92% 
protective titers against the Santa Clara University strain. 
 
Finally, they looked at an outbreak strain from Ohio University where there had been 13 cases
and 1 death for the outbreak strain that expressed of three MenB-4C antigens: FHbp subfamily
B (ID 15), NadA, and NHba.  Looking at the data again from the interim results, the background 
level of antibody was very low in the Santa Clara students against this strain.  After 2 doses, 
approximately 52% had titers of 1:4 or greater and about 10% had titers of greater than 1:16 
despite the fact that there was a match in the antigen and expression of MenB-4C FHbp, NadA, 
and NHba.
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To conclude about these vaccines, first of all, they are complex. At least 4 antigens are capable 
of eliciting serum bactericidal activity.  The antigen-specific reference strains that were used for
licensure are more susceptible to vaccine-induced bactericidal antibodies than many circulating 
disease-causing strains.  Some strains are relatively resistant to bactericidal activity despite
prediction of susceptibility by sequence analysis and antigen expression, such as the Princeton 
University and Ohio University strains.  The great majority of subjects have titers of ≥1:4 at 1
month post-dose 2 against most strains.  Titers decline by 4 to 6 months, especially against low
FHbp-expressing strains.
For the MenB-FHbp, Dr. Granoff said he thought the 2-injection data were the most interesting 
because they basically saw very similar or higher ≥4-fold increases in serum bactericidal activity
as MenB-4C at 1 month post-dose 2.  The great majority of subjects, had titers of ≥1:4 at 1
month post-dose 2 against most strains.  Titers decline by 4 months, especially against low
FHbp-expressing strains.  The recommended third dose of MenB-FHbp at 6 months boosted
titers.  Additional data on antibody persistence are needed, which should include strains
relatively resistant to vaccine-induced bactericidal activity to get a sense of the variability on 
antibody persistence.
In terms of the limitations, these were independent studies that were not designed to provide 
comparison data between vaccines, and the populations are different.  There are relatively few
sera 4 to 6 months post-dose 2.  That was added at the end of the protocol and it was not 
possible to get everybody.  The serum bactericidal assays used research assays and were not 
the type that would be FDA-validated, although the assays are robust.  The data on the Santa 
Clara University study are on antibody prevalence.  They do not have pre-vaccination sera, but 
it is possible to compare the 0 dose to the 1 doses and 2 doses.  Dr. Granoff emphasized that 
this is an interim analysis that requires much more work.
Discussion Points
Rino Rappuoli (GSK) commented that it is important to keep in mind that Bexsero® has 4 
different components targeting completely different antigens, and each of them can kill the same 
bacteria.  He noticed that in the Trumenba®  between 2 and 3 doses, there was a pretty good 
increase in immunogenicity and coverage.  That is more or less what has been observed with 
Bexsero®  between 1 and 2 doses.  Bexsero®  was licensed as a 2-dose vaccine after multiple 
studies.  In one case during the Phase 3 trials, they also did 3 doses and did not see that kind of 
increase.  So, it looks like Bexsero®  increases between 1 and 2 and Trumenba®  increases 
between 2 and 3 doses.  Also important to remember is that while the 4-fold increase is a way to 
look at the longevity of protection, that may underestimate the number of protected people 
because many people may have a protective titer above 1:4 by bacterial assay and still not have 
a 4-fold increase.  Obviously, all of the serological findings are important, but they are always a 
surrogate for real data in the field.  That is what has been missing during the development of 
vaccines for so long.  In the case of Bexsero®, there are two types of data.  One comes from 
multiple uses in outbreaks in the US and Canada where 2 doses have been used in many 
instances.  There have not been breakthrough cases, which is very important to remember.  
Second, are the data from the UK where Bexsero®  is being used in infants to vaccinate all of the 
newborns beginning September 2015.  Two doses were used in infants.  Infants are completely 
naïve to meningococcus, so they are more difficult to protect than adolescents.  With 2 doses, 
Public Health England (PHE) reported effectiveness of 83% a month ago in a meeting in 




















Dr. Friedland (GSK) congratulated the Rhode Island meningococcal carriage group for 
undertaking such an important study.  Certainly, the evaluation of the impact of the 
meningococcal B vaccines Trumenba®  and Bexsero®  on carriage is very important.  GSK is 
committed to continue to evaluate the impact of Bexsero®  on carriage, and is in the final stages 
of finalizing the protocol to evaluate the impact of Bexsero®  on carriage in over 30,000 
individuals that will be powered to detect even small differences in carriage.  GSK thinks this is 
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Dr. Walter said he noticed from Dr. Soeters’ presentation that the coverage for vaccination 
declined from 94% for the first dose to about 80% to 77% for the second and third doses 
respectively in the campaign.  He asked whether there was any sense for why that was, in 
terms of whether it was that people were concerned at the start of the campaign about disease, 
or if it was due to concern about side effects.
Dr. Soeters responded that overall, a drop-off has been observed in MenB vaccine campaigns
at a lot of the colleges that have had outbreaks.  In this particular case, the school did 
something unusual, which was that they required all students to come to the vaccination clinics
and they could sign declination forms that they did not want a vaccine.  That is how they
achieved high coverage during the first round.  They did continue to require it, but students
seem to have caught on that if they did not appear, nothing happened to them.  A lot of the 
students experienced and mentioned sore arms, but she did not hear students saying that that 
was a reason they did not return for vaccination.  Other surveys are being conducted to gather
more information about students’ opinions about the vaccine and what was influencing their
decision to get vaccinated or not.
Dr. Belongia requested clarification about the titer of 1:4 as a protective titer and the basis for
using that as a correlate of protection.
Dr. Granoff responded that it went back to a Goldschneider study in the 1960s published in the 
Journal of Experimental Medicine (JEM) in which they looked at military recruits.  They collected 
serum samples at the time recruits began training.  There was a serogroup C outbreak, and 
quite a few cases occurred over the next few months.  Then they retrospectively collected sera 
from the people who got disease and had a sample of about 500 sera for people who did not get 
disease.  A titer of 1:4 or greater essentially offered about 90% to 95% protection against 
developing serogroup C disease.  Almost all of the cases were among people who lacked titers.  
There also was a carriage study going on, and they detected about 30 carriers.  About a third of 
those actually went on to get disease.  This was serogroup C, and this was natural antibody.  It 
was not vaccine.  Having a titer of 1:4 really correlated with protection.  Suffice it to say that 
collectively, the data are pretty convincing that a titer of 1:4 does predict protection.  A titer of 
less than 4 does not necessarily mean that someone is susceptible, but was associated with all 
of those cases.  This has been accepted by regulatory authorities all over the world, including 
the FDA as the basis of licensure.  These vaccines were not tested in efficacy studies.  They 
used the 1:4 and the 4-fold composite to look at the immune responses, and that was the basis 
of deciding vaccination schedules and inferring efficacy for the vaccine. 
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Dr. Paradiso (Paradiso Biologics Consulting) pointed out that when looking at bacterial carriage 
in the nasopharynx, it is generally considered that clearing bacteria is totally different than 
affecting acquisition of new bacteria.  Often in carriage studies, it is looking at blocking the 
acquisition of new bacteria.  He noted that those were separated out in the carriage study, but 
the numbers were very small.  Of these subjects aged through 20 years of age, 20% or more 
had carriage that they had gained somewhere along the way probably based on the 
epidemiology when they were 14, 15, or 16 years old.  He wondered whether there was an 
opportunity or a plan to back up in the age group to see if acquisition could be stopped in a 
younger age group before it builds up to the 15 or 16 year olds, or if that is even feasible to do.  
He also thought it was interesting that these two vaccines are not really group-specific 
completely, because they are protein antigens.  For all of the strains for which a group could not 
be assigned, there was little impact.
Dr. Soeters replied that there are no current plans to look at carriage in adolescents, but they
are beginning to examine the within-individual dynamics in carriage over time in this particular
population to determine if they are carrying the same strain or if it changes. It seems like some 
of the students can carry for a couple weeks, while some can carry for a couple of months.  It is
not clear whether they are acquiring some of these strains in adolescence and then bringing 
them to college with them, or if there is just a lot of circulation and transient carriage occurring.  
Incoming freshman entering campus the year after the outbreak were seen their first week on 
campus and then again 6 months later, and an increase in carriage was seen in those incoming 
freshman.
Dr. Maldenado (AAP) asked whether there was a possibility of comparing current data to the 
nicely done natural history colonization studies from the 1950s looking at some of the Army
studies done in California and other places in terms of baseline colonization and what happened
and the impact of antibiotic prophylaxis and resistance.  Obviously, there are better genetic data
now.  There seem to be many parallels in terms of what happens to these people and, more 
importantly, if someone is known to be carrying, what should be done with that patient.  What 
was shown in the Army studies was that it did not have a huge impact if there was a lot of 
rifampin resistance.
Dr. Soeters replied that while this has not been done, it can be.
Dr. Messonnier added that there is a variety of literature on this, including studies that Dr. 
Stephens and she tried to conduct in adolescents and high school students 10 years ago, 
getting really low carriage.  This is a complicated field, and CDC is very much looking forward to 
the data from pharmaceutical companies with much higher enrollment rates.  The prospective 
studies CDC has tried to conduct have had sample size power problems.  When they have tried 
to do it in convenience around outbreaks, there have been numerous problems.  The large 
study being planned may help.
Dr. Stephens added that one of the issues is that there is now a lot better typing systems and 
understanding very specifically, for example, in the study only one individual was carrying the 
outbreak strain.  That is quite a difference from what was known in the old military studies.
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MenB-FHbp (Trumenba®) Vaccine Update 
Dr. Laura York
Medical Development
Scientific and Clinical Affairs
Pfizer
Dr. York presented an update on Trumenba®, which was licensed in October 2014 and received 
FDA approval through the accelerated approval regulations to be used in a 3-dose series of 0, 
2, and 6 months for prevention of meningococcal B disease in individuals 10 through 25 years 
of age. This was in response to the unmet need with the outbreaks occurring in the US.  Pfizer 
continued to discuss the schedules with the FDA, and the FDA approved a label change under 
the same regulations on April 14, 2016.  The schedules now include a flexible 3-dose schedule 
(0, 1-2 months and 6 months) and a 2-dose schedule (0, 6 months).  Both schedules were 
determined by the FDA to be safe and effective.  With the two different schedules in the 
labeling, ACIP guidance is needed in reference to the existing recommendations for providers 
as they move forward with use of these vaccines.  Dr. York briefly reviewed the data that 
supported the change in the label, and provided some new data on persistence and immune 
responses following a booster in terms of both schedules. 
Pfizer’s MenB vaccine, Trumenba®, is based on a surface-exposed factor H binding protein 
(FHbp), which functions as an important immune evasion mechanism.  It actually downregulates 
the complement cascade and limits the bactericidal activity of complement in that membrane 
attack system.  This protein is expressed in over 97% of the invasive MenB strains that Pfizer 
has examined, and there has been a comprehensive evaluation survey of invasive 
meningococcal isolates from 2000 on from the US, several countries in Europe, and Canada.  
The FHbp sequences segregate into two genetically and immunologically distinct subfamilies 
referred to as A and B.  Trumenba®  is composed of two lipidated proteins, A05 and B01, one 
from each subfamily.  The lipidation of that protein is important and really contributes to the 
breadth of protection observed in terms of the ability to elicit antibodies that could recognize 
across the diversity of this particular antigen; that is, recognizing across that subfamily and the 
variance within that subfamily.  The vaccine-elicited protective responses are actually 
demonstrated not through efficacy studies because of the disease incidence of meningococcal, 
but through the correlate used to predict protection which is the serum bactericidal assay using 
human complement (hSBA).  Pfizer uses 4 invasive MenB strains that are representative of 
prevalent strains in the US and Europe.  The 4 strains express fHBP variants that are different 
from what is in Pfizer’s vaccine (A22, A56, B24, B44).  The approach was designed to 
demonstrate the breadth of coverage.  Where those 4 strains are representative, they would be 
expected to predict the activity against other strains. 
The data that contributed to being able to have two schedules and the change in the dosing and
administration was from a study (B1971012) that was done in Europe that included individuals
11 through 18 years of age who were randomized into 5 groups to examine two 3-dose 
schedules and three 2-dose schedules.  The participants were enrolled into an additional study, 
or a follow-on study, with a different number (B1971033) to evaluate the antibody persistence 
annually and the response to a booster dose at approximately 4 years.  The choice of that 
timing was not to determine when to give a booster dose, but to look at the ability to boost the 
response—to look for memory.  Pfizer knew that these data would be important to ACIP in their
considerations of use of the vaccine, so the timing for Pfizer to have these data was based on 
being able to provide additional information for ACIP’s consideration.
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The immune response was evaluated on the 4 representative strains, and the proportion of
individuals who have a 4-fold response are assessed.  As Dr. Granoff said, this is really looking
at the vaccine response and the robustness of the response.  The minimum titer that a person 
has to achieve is 1:16 to be recognized as a responder with a 4-fold response.  A composite 
response also was assessed, which is looking at the ability of the antibody generated in an 
individual to recognize each of the 4 strains all together.  This shows the ability of the antibody
to recognize across a diversity of the antigens.  Dr. York reminded everyone that she had 
already shown data on 10 additional strains to highlight how these data demonstrate the 
immune response that is elicited by Trumenba®.
Looking at the immune response in terms of 2-dose schedules at different intervals (0,1 / 0,2 / 
0,4 / 0, 6), 0,1 comes from the 3-dose schedule looking post-dose 2 on a 0, 1, 6 interval.  In 
terms of 4-fold and the composite response, as the interval between vaccine doses is
increased, there is an improvement on the immune response acquired from receiving the 
vaccine.  This is very important in terms of the 0,6 interval providing robust responses and 
substantial protective responses in terms of the 4-fold response, and also in terms of composite 
response with a point estimate of 73.5%.  This is a nice, robust, substantial protective immune 
response with a 2-dose interval that is 6 months.
In terms of 3-dose schedules, there are circumstances in which it is desirable to give 2 doses in 
close interval.  In an outbreak, for example, the goal is to achieve an immune response as
quickly as possible in as high a number of individuals as possible.  It is known from the 3-dose 
schedule that a 0,1 or 0, 2 schedule can be used to quickly achieve a comparable type of 
response.  But, in fact, there is an improvement in terms of the percent of responders observed 
with the third dose in the 3-dose schedules.  Dr. Granoff’s data show very clearly in terms of a 
2-dose schedule at 0,2 or 0,1 that there is a very effective immune response.  But, in order to 
have a high proportion of individuals who are going to respond and have a broadly protective 
response, the third dose will provide it in the 3-dose series.
This trend also is observed when looking at the response in terms of the percent of subjects
who have an hSBA titer of greater than 1:8 and 1:16 on one of Pfizer’s test strains.  Again, this
is higher than the protective correlate of 1:4 that is accepted from the studies conducted very
early in the military in terms of the effect of that interval, the range of response anticipated to 
provide a short interval versus a longer interval of a 2-dose series, and the 3-dose series also 
giving a robust response, a high percentage of individuals, and a high range of response that 
would be predicted to be seen against other diverse strains.  This also is seen in the GMT with 
the 6-month interval resulting in slightly higher responses in terms of GMT that are, in fact, more 
comparable to the 3-dose series.  For some of these responses in terms of the percent of 
individuals with a titer greater than 1:8 or on the GMT that there are overlapping confidence 
intervals, the two schedules are expected to be effective, and that is why Pfizer has these two 
schedules in its label.  There is no differentiation in terms of safety between the second or the 
third dose, so consequently there was FDA approval in terms of safety and efficacy of this
vaccine on a 2-dose schedule at 0,6 or a 3-dose schedule of 0, 1-2, or 6 months.
Regarding the persistence data following either a 0,6 or 0, 2, 6 schedule of Trumenba®  in terms 
of the percent of subjects with an hSBA titer of greater than 1:4 among two cohorts against the 
4 representative strains. As found in a previous study and presented to ACIP, a plateau is 
established after a waning of the persistence in terms of the percent responders.  There seems 
to be a consistent plateau over the 48 months for Trumenba®. There is a divergence with two of 
the strains, but the confidence intervals do overlap, which suggests that the response after a 2­
dose schedule or a 3-dose schedule will provide persistence in terms of the protective 
78
































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
response.  There is a lowering of the response in terms of the percent or the range observed 
against diverse strains, but clearly in terms of the population, there still is a protective response 
against MenB.
It was interesting for Pfizer to look at the hSBA responses following a booster about 4 years out 
of individuals having either a 2-dose schedule at 0,6 or a 3-dose primary schedule at 0,2,6.  For
simplicity, Dr. York showed a graphic reflecting the response in terms of the pre- and post- 
primary series and then 48 months post-primary series.
These are the data shown previously but without all of the additional time points from 12 months
through to 48 to make a point in terms of the booster response that is observed against these 4 
representative strains showing a significant percentage of individuals who are responding to a 
single booster dose.  The composite of this is now well over 90%.  Clearly, there has been 
induction of memory at approximately the same level of memory with either a primary series of 
the 0,6 or a primary series of 0,2,6.
The memory response is also well-defined in terms of the hSBA GMT responses to the booster
dose, with significant responses shown in terms of GMT after a primary series of the 2-dose or
the 3-dose schedule, maintaining the plateau in terms of the persistence above the protective 
level of 1:4.  There is a significant increase in the GMT post-booster, which demonstrates the 
memory response.  Regarding the safety of a booster dose, a difference is not observed in 
terms of the safety profile.  Therefore, there is nothing untoward in terms of receiving a booster
for approximately 4 years post-primary series.
In summary, Trumenba®  (MenB-FHbp) was granted FDA approval under Accelerated Approval 
regulations in April 2016 resulting in a flexible schedule for use in a 3-dose series at 0,2,6 
months or a 2-dose schedule at 0,6.  Either schedule can be used to provide protection against 
invasive meningococcal disease caused by serogroup B in individuals 10 years through 25 
years.  These data demonstrate that both schedules provide a significant benefit in terms of the 
breadth of coverage against the diverse MenB strains causing disease.  There is flexibility within 
the 3-dose schedule that may be beneficial when an individual is at significant risk of disease 
(e.g., outbreak).  A 2-dose schedule may improve compliance in an age group where 
completion of a multi-dose series is challenging.  Based on the data, there is similar persistence 
of the hSBA response.  Clearly, after either series the immunological memory is established and 
a booster dose elicits a response that is actually higher than the response after the primary 
series. 
Discussion Points
In terms of receiving the FDA labeling and both schedules were determined to be safe and 
effective, Dr. Lee asked at what time point the effectiveness was assessed.  In addition, she 
asked whether there were any long-term follow-up studies that go beyond what Dr. York
showed.
Dr. York replied that it was always one month after the primary series.  All of the vaccines are 
licensed on that. No long-term follow-up studies are planned.  However, there will be another
blood draw after the booster dose, so they will be able to present data to ACIP about a year out 
from that booster dose.  This will show whether the waning is less and plateauing within that.
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Ms. MacNeil presented a summary of the WG’s considerations for the use of 2- and 3-dose 
schedules of MenB-FHbp or Trumenba®. As a reminder, there are two serogroup B MenB 
vaccines licensed for use in the US in persons 10 through 25 years of age.  MenB-FHbp 
(Trumenba®) contains two components (fHbp subfamily A/v2,3; subfamily B/v1) and originally 
was licensed by the FDA in October 2014 for administration as a 3-dose series.  MenB-4C 
(Bexsero®) contains four components (fHbp subfamily B/v1; NhbA; NadA; Por A1.4) and was 
licensed by FDA in January 2015 for administration as a 2-dose series.  MenB-4C also is 
licensed in a number of other countries for use in persons 2 months of age and older. 
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Considerations for Use of 2- and 3-Dose Schedules of MenB-FHbp
Jessica MacNeil, MPH
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Current ACIP Recommendations for the use of serogroup B MenB vaccines are:
Certain persons aged ≥10 years who are at increased risk for meningococcal disease 
should receive MenB vaccine (Category A)1   
A MenB vaccine series may be administered to adolescents and young adults aged 16– 
23 years to provide short-term protection against most strains of serogroup B 
meningococcal disease (Category B)2  
In both of the MenB Policy Notes, the following additional guidance is provided that is consistent 
with the original licensure:
MenB vaccine should either be administered as a 3-dose series of MenB-FHbp 

(Trumenba®) or a 2-dose series of MenB-4C (Bexsero®)1,2
 
[1Folaranmi T., et al. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years 
at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory 
Committee on Immunization Practices, 2015. MMWR; June 12, 2015; Vol. 64, No. 22, p 608­
612; 2MacNeil JR, et al. Use of Serogroup B Meningococcal Vaccines in Adolescents and 
Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2014. 
MMWR; October 23, 2015, Vol. 64, No. 41, p 1171-1176]. 
The FDA approved updates on April 14, 2016 to the dosage and administration section for
MenB-FHbp.  The original and updated language follows, with the changes underlined:
Original Language:
 Three doses according to a 0, 2, and 6 month schedule
Updated Language:
 Three-dose schedule: Administer a dose at 0, 1-2, and 6 months
 Two-dose schedule: Administer a dose at 0 and 6 months
80




























     
 
  






 A MenB vaccine series may be administered to adolescents and young adults aged 16– 
23 years to provide short-term protection against most strains of serogroup B 
meningococcal disease (Category B)  
 
However, because of the recent change in licensure for MenB-FHbp during the remainder of 
this discussion, the focus was specifically on MenB-FHbp in order to provide guidance from 
ACIP on when the 2- and 3-dose schedules of MenB-FHbp (Trumenba®) should be used.  After 
reviewing the data, the WG discussed several different policy options.  First, for persons at 
increased risk and for use during outbreaks, a preference for 3-dose schedule of MenB-FHbp 
was proposed.  For healthy adolescents, three possible policy options were proposed: 1) A 
preference for 2-dose schedule (0, 6 months); 2) An option for either the 2- (0, 6 months) or 3­
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The choice and dosing schedule may depend on the risk of exposure and the patient’s
susceptibility to meningococcal serogroup B disease
Ms. MacNeil discussed the WG’s interpretation of the MenB-FHbp data pertaining to short-term
immunogenicity, antibody persistence, safety, the proposed policy options for 2- and 3-dose 
schedules of MenB-FHbp, and the WG’s discussions.  As a reminder, several dosing schedules
were evaluated for MenB-FHbp, including two 3-dose schedules and four 2-dose schedules.  
For this presentation, Ms. MacNeil focused on the data presented for the 2-dose schedule at 0,6 
months and two 3-dose schedules.
Regarding the short-term immunogenicity data one month following the last dose, among the 2­
dose schedules evaluated, the 0, 6 month schedule had the highest proportion of responders
and GMTs and is most similar to a 3-dose schedule.  However, the proportion of subjects
demonstrating a composite response to all four primary strains is slightly lower with a 2-dose 
schedule at 0, 6 months compared to either 3-dose schedule. Similarly, for most strains, the 
GMTs are lower with a 2-dose schedule at 0, 6 months compared to either 3-dose schedule.  
For some strains, the 95% confidence interval around the GMTs do not overlap.
Antibody persistence to the four primary strains is shown here for participants who received 2 
doses at 0,6 months or 3 doses at 0,2,6 months.  The percent of subjects with hSBA titers ≥1:4 
to the four primary strains is similar through 48 months for adolescents who received either 2 or
3 doses of MenB-FHbp.
In addition, the GMT responses to a single booster dose 4 years following the receipt of either 2 
or 3 doses of MenB-FHbp are similar.  As has been presented to ACIP previously, the MenB
vaccines are more reactogenic than other vaccines given during adolescence.  The most 
common AE reported is pain at injection site.  Overall, the safety and tolerability profiles are 
similar for the 2-dose and 3-dose schedules of MenB-FHbp.
Again, there are two MenB vaccines in the US for persons aged 10 through 25 years of age: 
MenB-FHbp (Trumenba®, Pfizer) and MenB-4C (Bexsero®, GlaxoSmithKline).  ACIP does not 
express a preference for either vaccine product.  The current ACIP recommendations for the 
use of serogroup B meningococcal vaccines are show here as a reminder, with no changes
proposed during this session:
Certain persons aged ≥10 years who are at increased risk for meningococcal disease 
should receive MenB vaccine (Category A) 
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Based on the discussions of the WG, there was agreement that ACIP guidance for which 
schedule to use in each population is needed.  There was strong consensus in the WG to 
express a preference for the 3-dose schedule for persons at increased risk, including during 
outbreaks, to provide early protection and to maximize immune response.  For healthy
adolescents, the WG’s considerations included the following:
Preference for 2-dose schedule OR option for 2- and 3­
dose schedules the key considerations were as follows:
Persistence of the hSBA responses for the 2-dose 
(0, 6 m) schedule is similar to the 3-dose (0, 2, 6 
m) schedule
hSBA GMT responses following a booster dose are 
also similar for 2-dose.
However, the WG noted that providing an option 
for either the 2- or 3- dose schedule does not
provide explicit guidance to the physician on which 
schedule to use in healthy adolescents
When considering a preference for the 3-dose 
schedule, the key considerations were as follows:
For people who want to maximize short- term 
protection, 3 doses is preferred
Both the 2- and 3-dose schedules take 6 months to 
complete
ACIP could provide guidance that if someone
receives their second dose of MenB-FHbp 6 
months or more after the first dose, no additional
doses would be needed
Based on these considerations, the strong consensus of the WG was to express a preference 
for 2- and 3-dose schedules as follows:
1.	 For persons at increased risk for meningococcal disease and for use during serogroup B
outbreaks, 3 doses of MenB-FHbp should be administered at 0, 1-2, 6 months
2.	 When given to healthy adolescents who are not at increased risk for meningococcal
disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months
Discussion Points
Dr. Walter asked whether the WG discussed harmonization of the schedule to 0,6 months for
both vaccines when given to healthy adolescents.
Dr. MacNeil responded that the WG did not discuss that.
Dr. Atmar pointed out that the data shown reflected clear differences at 7 months, but in terms
of the early protection, he wondered whether there were data about immunogenicity or serum
antibody levels at earlier time points.  That is, other than the benefit at 7 months, what is the 
benefit of receiving an extra dose at 1 to 2 months or 2 to 3 months compared to not getting that 
dose.
Ms. MacNeil replied that the data show that the longer the interval between the doses, the better
the response is.
Dr. Atmar clarified that his question pertained to the early protection implying that within several
months as opposed to at the 7-month time point, there were clear-cut differences.  Usually in 
these studies, blood is drawn in each vaccination time point.  He wondered whether this
information was available to the WG and, if so, just was not presented to ACIP.
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Dr. Cohn clarified that with the 0,6 schedule, data show that there is a similar response after the 
second dose.  If doing the 0, 1-2, 6 schedule, there will be some protection earlier than if using 
the 0, 6 schedule.  That is why the preference was for people at increased risk or at an 
immediate risk to use the 3-dose schedule.
Dr. Maldonado (AAP) asked whether consideration was given to the scenario of a fully
vaccinated high-risk person who is past the point of antibody titers dropping off being placed in 
a high-risk situation.
Ms. MacNeil replied that the next topic the WG will discuss is boosters for people at increased 
risk, and whether someone would need to be re-boosted if placed at increased risk.
Dr. Zucker (New York City Department of Health and Mental Hygiene (DOHMH)) pointed out 
that from a programmatic point of view, for registries this will mean that they will schedule the 
MenB series at 0, 6.  There is a challenge translating the ACIP guidance into what registries will
tell providers to do.  Most often, providers will listen to the registry and they may not think about 
whether someone is at increased risk.  As long as that is the intent, that is fine.  They could 
translate that into guidance for the pediatric community.
Dr. Moore recalled that Dr. Hunter had mentioned whether immunization registries could key the 
forecasting based off of the brand of initial vaccine given, so that it would be keyed at a different 
interval if it were Bexsero®  given first versus Trumenba®  given first.  She wondered whether Dr. 
Zucker could speak to this issue. 
Dr. Zucker (New York City Department of Health and Mental Hygiene (DOHMH)) replied that 
most registries can do this, but it depends upon whether they receive a lot number and whether
it has been reported as a particular product.  It could come in as a MenB such that the product 
is not specified for them.
Dr. Moore emphasized that this created its own complications, because this is one vaccine for
which the brands are not supposed to be mixed.  That is, 2 or 3 doses should be given of the 
same brand of vaccine.
Dr. Lee asked whether data would be presented at the next meeting about Bexsero®  and 0,6 
versus 0,1.  She agreed with Dr. Walter that this can be done in an incremental way, but it 
would be helpful to know where they are headed in the long-term.  Otherwise, it will not be 
practical to implement this from a programmatic standpoint. 
Dr. Friedland (GSK) indicated that the 3-dose data have been reviewed by the FDA and the 
ACIP WG in the past.  The vast majority of all of the clinical trials with Bexsero®  were with 2 
doses, and 2 doses were examined on different schedules:  1 month after, 2 months after, or 6 
months after the first dose.  In this situation, the percentage of subjects who achieved the 
protective titer of 1:4 was high regardless of the schedule.  That is, a very high proportion of 
subjects achieved seroprotection on the 0,1 schedule and there was no increase in the 
percentage of subjects getting a seroprotective level when given 6 months later versus 1 month 
later.  This was the rationale for the indication that the second dose of Bexsero®  can be given as 
soon as 1 month after the first dose. 
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Dr. Lee requested that this be considered more broadly in terms of thinking about whether
someone at high risk could receive a 0,1 or 0,1,6 schedule and if doing this for a permissive 
routine recommendation, that they just do 0,6.  From a clinical standpoint, it will be easier not to 
have confusing recommendations.
Ms. MacNeil replied that the WG certainly can discuss this.
Dr. Friedland (GSK) said that when they speak to healthcare providers about the use of 
Bexsero®  in clinical practice, they hear that the flexibility of giving the second dose as soon as 1 
month after the first dose can be very important.  For example, if a student presents to their 
practice during the summer months, the family can complete the full series of both doses over 
the summer before they go to college.  They are hearing that having flexibility is quite important 
to and valued by healthcare providers. 
Dr. Middleman (SAHM) asked for clarity regarding the statement “for persons at increased risk
and for use during outbreaks” preference for a 3-dose schedule meant that the WG had a 
preference to only recommend the 3-dose schedule or that the WG would allow for either one, 
but a preference for the 3-doses.  She would like to be able to still have the option for those 
healthy adolescents who want 3 doses to be able to get 3 doses and not be limited to 2 doses.
Ms. MacNeil clarified that the intent is for people who are at increased risk or during outbreaks
to receive 3 doses so that they would have the early protection.
Dr. Messonnier clarified that the WG does not make recommendations and was just expressing 
their preferences for ACIP to make recommendations.  The vaccine licensure allows for clinician 
flexibility.  CDC has received feedback that it is already incredibly confusing to have the A
versus B recommendation and the two different vaccines.  There is a value placed on ACIP
trying to make a recommendation that is as simple as possible in this area in a space that is
already very complicated.
Dr. Stephens added that the WG spent a lot of time on this question and trying to wrestle with 
the question in terms of whether they preferred a specific 0,6 or an option.  They came to the 
conclusion that it would create more confusion with a mixed signal in terms of being able to do 
either one.  In the view of the majority of the WG, the data would support the 0,6 schedule for
healthy adolescents not at risk in a routine administration setting.
Dr. Kempe emphasized that insurance companies will or will not cover 3 doses for healthy
adolescents, which is an implementation issue.  She asked whether this was the ACIP saying 
that either is okay, but they have a preference for one.  It did not sound like the objective was to 
make a recommendation for one.
Dr. Messonnier reminded everyone that there are two places in which decisions are made about 
coverage.  One of them is a VFC vote, which ACIP has the power to make.  However, the VFC
vote’s purpose is separate from the ACIP recommendation because it is meant to be a second 
step.  Then there is the ACA, which is set up to be driven by what is on the immunization 
schedule.  That is different, separate, and a discussion that would occur the next day during the 
schedule session.  It does not have to be in the colored bars on the schedule.  It can be in one 
of the footnotes.
Dr. Stephens made a motion to approve the option reflecting the WG’s stated preference.
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Dr. Bennett indicated that they have had the issue regarding preferences previously, and it is
very difficult in the implementation phase when stated as a preference.  She requested 
additional guidance.
Dr. Messonnier pointed out that a preference implies that the WG would be okay with any of the 
groups receiving any schedule.  They have been concerned about the language of preference 
due to implementation difficulties.  If ACIP considered either schedule to be acceptable for
either high-risk or healthy adolescents, but express a preference, they certainly could say that.  
The issue regarded how a clinician should interpret that.  It already is difficult to articulate what 
ACIP meant by a Category B recommendation.  Adding another layer of complexity on top of 
two different vaccines would make this harder.
Dr. Lee said she thought the problem was the specificity for the vaccine product, and she was
not used to thinking of it that way.  She proposed that the vote be: 1) for persons at increased 
risk and for use during outbreaks, a preference for a 3-dose schedule of one product or a 2­
dose schedule of another product, but with the intent of it being in a shorter timeframe; and 2)
when given to healthy adolescents, a preference for a 2-dose schedule of either product.
Dr. Kempe said that alternatively, she thought it should be a recommendation because it 
already is problematic and this compounds the degree of complexity.  She thought that 
particular statement should be a recommendation.
Dr. Lee clarified that she meant “recommendation” and just wanted to flip it around in terms of 
the framing.
Dr. Belongia emphasized that there is a difference between “preference” and 
“recommendation.”  He thought it would be most clear for clinicians if stated that ACIP 
“recommends a 2-dose schedule for healthy adolescents.”
Dr. Messonnier suggested that the members spend time during the break crafting revised 
language to pose for a vote. 
Dr. Moore said that operationally, while she appreciated the scheduling idea of bringing things
together, since these are two products that cannot be interchanged unlike all of the other
products that can, it would not be that much more complicated to make a specific FHbp
recommendation in this case, because the other stands alone. While she recognized in terms
of the schedule it is nice to work on the timing, but here she thought the recommendation could 
be narrower.
Dr. Middleman (SAHM) requested that if there was a vote for a healthy adolescent to have a 2­
dose series, it could still be on the immunization schedule that a 3-dose series would be okay
and would, therefore, be covered if there were a healthy adolescent who would like a 3-dose 
series.
Dr. Messonnier indicated that the discussion for the next day regarding the schedule would 
allow for flexibility about what to put in the footnotes.
Dr. Cohn added that there is always language in all of the statements that if someone receives a 
dose at the wrong time or received the second dose at 1 to 2 months, the third dose should be 
received to complete the schedule because the dose was not given at the right time.  That is a 
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back-up safety net for people to complete to be fully protected if they did not receive the second 
dose after 6 months.
Dr. Middleman (SAHM) expressed concern that this may penalize the provider in some cases in 
terms of coverage.
Dr. Bennett suggested taking a half hour break to craft some specific language for the motion 
and vote.  Upon returning, the new language was displayed for a revised motion:
1.	 For persons at increased risk for meningococcal disease and for use during serogroup B
outbreaks, 3 doses of MenB-FHbp should be administered at 0, 1-2, 6 months
2.	 When given to healthy adolescents who are not at increased risk for meningococcal
disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months
*	  If the second dose is given at an interval of <6 months a third dose should be given at 
least 6 months after the first dose 
Ms. MacNeil indicated that context would appear before the actual language in the Policy Note 
stating that there are two vaccines that are licensed for people aged 10 through 25 years in the 
US, and there is no vaccine preference.  This also could include information about the current 
ACIP recommendation so that it is clear that there is a Category A recommendation for one and 
a Category B for the other.
Regarding the footnote, Dr. Atmar asked whether there would be a minimal interval.  For
example, what if the second dose was given at 5.5 months.
Ms. MacNeil replied that they could work on that language.
Dr. Kempe wondered about the need for Bullet 2 since it was a Category B individual
recommendation anyway.  Bullet 1 was clear and was related to a Category A, so a firm
recommendation made sense to her.
Dr. Bennett said at first she suggested stating something such as “when a physician chooses to 
give to a healthy adolescent,” but she thought “when given to healthy adolescents” summed that 
up and implied that it would not be given to every healthy adolescent because it is a Category B
recommendation and it would be in the context of the statement.
Dr. Moore said that the WG would like to have further conversations about a booster dose for
otherwise healthy adolescents immunized during a low-risk period of time who later find 
themselves involved in an outbreak setting or at high-risk.
Ms. Stinchfield (NAPNAP) pointed out that one issue that seemed complicated was that risks
were being lumped.  There should be clarity about a person with an innate risk such as an 
immunodeficiency or a complement deficiency versus the immediate risk of a college outbreak.  
Those are two different risks that could have two different products and two different schedules. 
It would be helpful to keep those separated for clinicians.  It might be that a clinic setting has
one product, while a college and public health might have a different product.
Dr. Bennett said her understanding was that this would be covered in the statement by creating 
the context.
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Dr. Kimberlain (AAP) said he thought he was satisfied with what Dr. Kempe was asking about it 
being a Category B for the second portion of the second sentence.  He asked for confirmation 
that for the first sentence, this was not a recommendation for Trumenba® over the other product.  
It simply was the part of the statement that dealt with Trumenba®. 
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Ms. MacNeil confirmed this and indicated that each group at risk would be listed in the 
statement.
Dr. Hunter asked whether there would be CDC guidance regarding how to handle persons who 
receive the 2-dose series when healthy, but then are exposed to an outbreak situation.
Ms. MacNeil replied that this is something that can be discussed in the future.  The next topic
the WG wants to discuss is booster doses for people at increased risk, and this would fit into 
that category.
Dr. Weber emphasized that increased risk could be increased risk of exposure or increased risk
due to an immunodeficiency.  His particular interest is in microbiologists in hospitals who are at 
increased risk of exposure, but who are normal immunologically.  This would be long-term risk
versus immediate risk, so he thought some clarification was needed regarding whether the 2- or 
3-dose schedule is recommended for those individuals.
Ms. MacNeil replied that this would depend upon when the exposure would occur, but the 3­
dose schedule maximizes immune response, so if they are at increased risk, it may make sense 
for them to receive a 3-dose schedule.




A Voice For Choice Advocacy
I have three comments.  The first is that you’re recommending this—I know you’re not saying it 
should be given to all healthy adolescents, but you’re recommending it for healthy adolescents. 
Yet, the efficacy of it that was shown in the slides showed that it had severe wear-off after 12 
months.  It is not efficacious, or that efficacious after 12 months, I wonder why you are 
recommending it at that point, especially when you look at the number of side effects and 
deaths that come from the actual vaccine versus the number of deaths from meningococcal, 
which if you look at those numbers, the number of deaths from the vaccine are higher than the 
number of deaths that we’ve had from meningococcal.  The other thing that I wanted to say is
that as a public person and as a statistician, it really surprises me the data that you use.  So, the 
base sizes of 12, 25, 60, 71 that were up on the screen earlier, you know, I don’t know if the WG
uses different numbers or sees more information, but to me, those numbers are extremely small
for studies that you are projecting onto the general population, even if it’s the general population 
of adolescents.  Similarly you have—the largest study that you showed was Pfizer data, which is
one of the companies that makes the vaccine.  Of course, they’re going to say good stuff about 
it.  You know, we’ve got ethics issues in the CDC.  We know that.  So sitting here and watching
this data just really surprises me that this is the data that you’re working off to make vaccine 
recommendations.  Thank you.
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Dr. Bennett thanked Ms. Hildebrand for her comments and referred her to CDC’s SMEs for
clarification.
Vote:  2-Dose and 3-Dose Recommended Schedules for MenB-FHbp
Dr. Stephens motioned to approve the language as revised.  Dr. Romero seconded the motion.  
The motion carried unanimously with 14 affirmative votes, 0 negative votes, and 0 abstentions.  
The disposition of the vote was as follows:
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 




Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Santoli indicated that the purpose of this revision was to update the recommended 
vaccination schedule and intervals for serogroup B meningococcal vaccine.  The resolution has
two parts, and there are no proposed changes to the meningococcal conjugate vaccine section 
of the resolution. In the serogroup B meningococcal resolution, there is no change to the 
eligible groups.
Eligible groups include:
 Children aged 10 through 18 years at increased risk for meningococcal disease 

attributable to serogroup B, including:
 
 Children who have persistent complement component deficiencies (including 
inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or
taking eculizumab [Soliris®])
 Children who have anatomic or functional asplenia, including sickle cell disease
 Children identified to be at increased risk because of a meningococcal disease 
outbreak attributable to serogroup B
 Children aged 16 through18 years without high risk conditions may also be vaccinated
The recommended schedule and intervals are shown in the following table, summarizing the 
recommendation that was just approved:
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Vote:  VFC Resolution for 2-Dose and 3-Dose Recommended Schedules for MenB-FHbp
Dr. Stephens motioned to approve the VFC Resolution for the 2-Dose and 3-Dose 
Recommended Schedules of MenB-FHbp.  Dr. Belongia seconded the motion.  The motion 
carried unanimously with 14 affirmative votes, 0 negative votes, and 0 abstentions.  The 
disposition of the vote was as follows:
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MenB (Bexsero®, 
GSK)  
Two doses, at least one month 
apart (0 and 1-6 month schedule) 
MenB (Trumenba®, 
Pfizer) 
Persons at increased risk for 
meningococcal disease and for 
use during serogroup B outbreaks: 
Three doses (0, 1-2, and 6 month 
schedule) 
Healthy adolescents who are not 
at increased risk for 
meningococcal disease: Two 
doses (0, 6 months)2  
 
Age Group Vaccine1  Dosing Schedule 
10–18 years
10–18 years 
1. Use of brand names is not meant to preclude the use of other serogroup B meningococcal vaccines where appropriate.
2. If the second dose is given at an interval of <6 months a third dose should be given at least 6 months after the first dose
For the recommended dosage and contraindications and precautions, the reader is referred to 
the product package inserts.
Contraindications and Precautions can be found in the package inserts available at 
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
Statement Regarding Update Based on Published Documents
[If an ACIP recommendation regarding Hepatitis B vaccination is published within 12 months
following this resolution, the relevant language above (except in the eligible groups sections) will
be replaced with the language in the recommendation and incorporated by reference to the 
publication URL.]
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
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Herpes Zoster Vaccines 
Introduction
Edward Belongia, MD
Chair, Herpes Zoster Work Group
Dr. Belongia updated ACIP on the Herpes Zoster (HZ) WG activities, reporting that there 
currently are two investigational vaccines:
 HZ subunit vaccine (HZ/su) from GSK, which has been evaluated in non-immunocompromised populations
and is currently being evaluated in immunocompromised populations
 Inactivated vaccine (V212) from Merck that is being assessed in immunocompromised populations.
Recently, the WG has received updates on the currently licensed vaccine, ZOSTAVAX™, as
well as presentations from manufacturers of the pre-licensure vaccines just mentioned 
regarding their current status and future plans.
ACIP received a presentation during the June 2015 meeting on HZ epidemiology and interim
Phase 3 efficacy studies on the HZ/su vaccine in adults ≥ 50 years old. Within the past month, 
results were published for the HZ/su vaccine in adults ≥ 70 years old.  During this session, 
updates will be provided on HZ epidemiology and vaccine coverage and the final Phase 3 
efficacy study of HZ/su vaccine.  In the coming year, the WG will be considering the policy
options in anticipation of future licensed products.
Herpes Zoster Background
Kathleen Dooling, MD, MPH
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Dooling indicated that the objective of this presentation was to provide background on HZ 
disease and the current vaccine program for the purpose of information and discussion.  She 
presented information on the clinical manifestations, evolving epidemiology, and prevention of 
HZ.  There is a licensed vaccine for the prevention of HZ in adults, and two investigational
vaccines are in development for the prevention of this disease.
Varicella Zoster Virus (VZV) can cause two distinct forms of disease, primary infection that 
leads to chicken pox or varicella.  Following primary infection, the virus establishes latent 
infection in the dorsal root ganglia near the spinal cord.  Reactivation of the virus leads to 
shingles or HZ.  The reactivated virus travels up the nerve root to discrete dermatomes to 
produce the characteristic shingles rash.  Reactivation of virus may affect any dermatome of the 
body to produce the vesicular rash.  The rash usually is unilateral and may involve as many as 3 
adjacent dermatomes.  It typically arises over a 5 to 7day period, with resolution in 5 to 25 days. 
Occasional consequences of the rash may include secondary bacterial infections or 
transmission of VZV to susceptible individuals, resulting in chicken pox.
About 90% of HZ episodes are associated with pain or discomfort.  The pain is variable in 
character and intensity, and precedes rash onset in about 84% of cases.  Pain without rash 
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typically lasts from 1 to 5 days, but it can be weeks.  Localized pain in the absence of rash can 
lead to diagnostic dilemmas, such as unnecessary investigation, treatment, or even surgery. 
Another severe manifestation of HZ is involvement of the ophthalmic division of the trigeminal
nerve.  This occurs in approximately 15% of HZ cases.  Ophthalmic involvement can cause 
chronic complications and in some cases loss of vision.
Many people think of HZ as a self-limited illness.  On the contrary, post-herpetic neuralgia 
(PHN), which is a common complication of HZ, can be a devastating illness and may persist for
years.  PHN is prolonged pain that lasts for at least 90 days following the resolution of rash.  
Approximately 10% to 18% of HZ patients will go on to have PHN.  This pain may persist for
months to years, and may be incapacitating.  In terms of PHN prevention, antivirals and steroids
have been shown to shorten duration of HZ, but do not conclusively reduce risk of PHN.  
Multiple modalities have been used for PHN treatment with partial or inconsistent efficacy, and 
have many side effects, especially in the elderly.
The following quote is from an email recently received by CDC from a patient with PHN:
“My shingles post herpetic neuralgia is still painful seven years after my shingles
episode.  My PHN is worse than my cancer and chemotherapy… [it] has made me 
depressed and suicidal in the past.”
Regarding the epidemiology, HZ has an annual rate of approximately 4 cases per 1000 
population.  That translates into about 1 million cases of disease in the US annually.  The 
lifetime risk of developing HZ is about 1 in 3 and the age-adjusted rates appear to be increasing.  
Age appears to be the dominant factor driving incidence, with incidence in 80 year olds being 
about 10 times more than the incidence in children.  Immunosuppression also is a risk factor. 
Blood malignancies, bone marrow transplant, and HIV all have been shown to increase the risk
of HZ by up to 50-fold.  In addition to being more common, HZ is more severe in the 
immunocompromised population, resulting in more disseminated disease and more 
hospitalizations.  Ultimately, the underlying mechanism appears to be related to reduced cell-
mediated immunity, which allows VZV to reactivate or progress to HZ.
Data derived from MarketScan, a large healthcare administrative database, demonstrate how
the incidence of HZ increases with age.  MarketScan contains records for hundreds of 
thousands of insured people.  In the youngest age group, 0 through 14 years of age, the rate of 
HZ is about 1 case per 1000 population.  The incidence increases with age sharply after age 50 
[Insinga et al., J Gen Intern Med.  2005, 20:748-53 (MarketScan administrative data].
Similarly, the incidence of PHN increases with age.  In this case, data were derived from a 
population-based cohort in Olmstead County, Minnesota.  Recall that only a fraction of 
individuals with HZ will go on to get PHN.  In fact, PHN is rare in individuals younger than 50 
years of age, but risk increases steeply after age 60.  An 80 year old is approximately 10 times
more likely to get PHN than a 50 year old [Yawn, et al., Mayo Clin Proc. 2007; 82:1341-9 
(Olmsted County, MN)].
Over time, the incidence of HZ has increased for almost all age groups.  This graph shows the 
increasing incidence by year from 1993 to 2014:
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For adults 65 years of age and older, which is the top line on the graph, the incidence plateaued 
around 2007.  For all other adults, the incidence seems to be increasing.  For children, 
displayed on the bottom, there has been a downward trend since about 2005.  The reasons for 
this increasing or plateauing incidence in adults are unknown, but it has been confirmed by 
numerous data sources.  Looking specifically in children, precipitous drops of HZ incidence 
have occurred during the same time period, which is likely due to the direct effects of 
vaccination with VARIVAX®, as well as a decrease in circulating VZV, which has resulted in 
some children not ever having had a primary infection.  Thus, they are not at risk for HZ 










      
   






Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
Regarding prevention, ZOSTAVAX™ was licensed by the FDA in 2006.  Phase 3 clinical trials 
involved 38,500 non-immunocompromised adults ≥60 years old with a median follow-up of 3.1 
years.  This vaccine consists of a live-attenuated Oka-strain VZV, which is about 14 times the 
concentration in VARIVAX®. Vaccine efficacy (VE) was 51% against HZ and 67% against PHN.  
SAEs were not more common in the vaccinated group; however, local reactions were more 
common. 
 
In terms of the results for vaccine efficacy in the Phase 3 clinical trial, overall, the vaccine was
51% effective for the prevention of HZ and 67% effective for the prevention of PHN.  The 
efficacy decreases with increasing age.  The protection against HZ ranges from 64% for
recipients in their 60s down to 18% for recipients 80 years of age and older.  From the same 
Phase 3 clinical trial, efficacy against PHN was maintained against disease of longer duration.  
PHN was categorized according to how long the episode lasted, ranging from 30 days to 180 
days.  ZOSTAVAX™ provided over 70% protection against PHN that lasted for 180 days
[Oxman et al. Shingles Prevention Study, 2005].
In 2008, ZOSTAVAX™ was recommended by ACIP to be given as 1 dose in adults ≥60 years.  
As a live vaccine, it is contraindicated in immunocompromised persons.  In 2011, there was no
change to the ACIP recommendation following an FDA age expansion of the license to 50
through 59 years of age.  There were several reasons for this decision.  First, there were 
vaccine shortages at the time that left people in the recommended group without access to the 
vaccine.  This, combined with the fact that that the burden of HZ increases in people ≥60 years
of age and over, resulted in maintaining the recommendation as it stood.  After vaccine supply
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issues were resolved, ACIP revisited the issue in 2013 and affirmed the recommendation for
adults 60 years and older.  This was based on data that showed waning of immunity.  This
graph shows the duration of protection provided by ZOSTAVAX™:
VE is shown by year following administration.  The first four years of data were contributed by
the Phase 3 efficacy trial previously discussed.  Years 5 through 7 are contributed by a follow-
on study, and years 8 through 11 by following a subset of the vaccinated cohort and a modeled 
control group.  As shown in the above graph, efficacy decreases every year in the 5 years
following vaccine receipt.  The vaccine may not provide any significant protection after 8 years.
As the risk of HZ and PHN increase with age, a higher burden of disease can be prevented with 
administration after 60 years of age and above [Tseng, et al., JID, 2016].
This graph also shows waning of immunity protection of ZOSTAVAX™, but the data come from
an observational study in a large health maintenance organization (HMO), Kaiser Permanente:
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In the Kaiser Permanente study, protection among all vaccinees started at 69%.  However, by
years 7 to 8 post-vaccination, vaccine protection decreased to 4% and it was not statistically
significant [Tseng, et al., JID, 2016].
ZOSTAVAX™ uptake has shown slow and steady progress since 2007.  By 2014, 28% of adults
60 years of age and older in the US reported prior ZOSTAVAX™ receipt [2007: National
Immunization Survey (Lu et al, Vaccine 27:882-7); 2008-13: NHIS (Am J Prev Med 40:e1-6 & 
MMWR February 5, 2016 / 65(1);1–36)].  In terms of why uptake has been sluggish, the price is
high and there may be significant co-pays.  In addition, the storage and handling of the vaccine 
requires freezing and reconstitution.  This may dissuade some providers from carrying the 
vaccine.  Also, supply shortages were a problem in the early years.  However, this has since 
been resolved.  For Medicare recipients, the vaccine is covered only by Part D and 
reimbursement can be complicated.  Finally, the lower prioritization of adult vaccines as
compared to the pediatric program and the general fragmentation of preventive care for seniors
may contribute to low uptake.  The first three factors described are vaccine-specific and may be 
ameliorated by modification of the existing vaccine or introduction of a new vaccine.  The 
second three factors are system-related and must be addressed on a broader scale if there are 
to be meaningful increases in ZOSTAVAX™ vaccination.
There are new vaccines on the horizon.  The HZ/su vaccine developed by GSK is a vaccine 
consisting of VZV glycoprotein E as well as an adjuvant system.  It is administered in 2 doses, 2
months apart and it is refrigerator-stable.  It was tested in a Phase 3 clinical trial in over 30,000 
non-immunocompromised adults 50 years of age and older.  The primary endpoint was
prevention of HZ, and the secondary endpoints were prevention of PHN, safety, and
reactogenicity.  In those Phase 3 clinical trials, VE for the prevention of HZ ranged from 97% for
50 through 59 years olds to 91% for recipients 80 years and older.  VE of at least 85% was
maintained for all 4 years after administration in all age groups.  This vaccine was found to be 
highly reactogenic.  In study participants 70 years of age and older, 79% of vaccine recipients
reported local symptoms compared to 30% of placebo recipients, and 12% of vaccine recipients
reported Grade 3 reactions (e.g., symptoms that interfered with their daily lives) compared to 
2% of placebo recipients.
Prevention of HZ in the immunocompromised population remains an unmet need.  Two 
vaccines are in development for just this purpose.  V212 developed by Merck is an inactivated 
formulation of ZOSTAVAX™.  It is a 4-dose series in persons 18 years of age and older.  There 
is an ongoing Phase 3 efficacy trial of V212.  HZ/su developed by GSK consists of a formulation 
of VZV glycoprotein E as well as an adjuvant system.  It is administered as a 2-dose series in 
persons 18 years of age and older.  There is an ongoing Phase 3 efficacy trial of HZ/su as well.
Thus, there are exciting developments in the prevention of HZ.  The WG anticipates deliberating 
on policy issues for non-immunocompromised and immunocompromised persons for several
years to come.
In conclusion, the epidemiology of HZ is changing.  However, the reason for this is not fully
understood.  Approximately 28% of adults 60 years of age and older have been vaccinated with 
ZOSTAVAX™ in the US.  Vaccines to prevent varicella and HZ are reducing the amount of 
circulating VZV in the US population.  The two new vaccines for the prevention of HZ that have 
been developed and are being evaluated may further reduce the disease burden. 
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Update:  Herpes Zoster Subunit (HZ/su) Vaccine
Romulo Colindres, MD, MPH
Global Medical Affairs Lead, Zoster
GlaxoSmithKline
Before beginning, Dr. Colindres indicated that he is a former EIS Officer and was really enjoying 
being back in Atlanta and connecting with old colleagues and friends, and being back on the 
CDC campus.  He noted that he would be presenting on behalf of a very large team at GSK and 
many study investigators across the world on GSK’s HZ adjuvanted subunit vaccine, HZ/su, 
specifically with regard to recent trial results in people 70 years of age and older.
Dr. Colindres highlighted the burden of disease of HZ, with approximately 1 million cases of 
disease being reported annually in the US1. Per CDC statistics, everyone has a 32% estimated 
lifetime risk of HZ1. With such a high percentage, it is not difficult to find someone who has 
been impacted by this disease.  In his case, his 72 year old mother suffered from a very serious 
case of shingles 5 years ago, which included facial nerve involvement.  Given her painful 
experience, he was sure she would be happy to learn about the new advances being made to 
prevent this disease.  The risk of shingles also increases with age, such that above 85 years of 
age, the risk is 50%1. The most important risk factor is increasing age due to a natural decline 
in immune system function, immunosenescence, and also immunosuppression either because 
of disease or immunosuppressive therapy.  HZ is generally not life-threatening.  However, there 
can be some very serious complications, the most common being PHN with pain lasting greater 
than 3 months.  Also, HZ opthalmicus can cause dangerous eye involvement, and there also 
can be cranial nerve palsies [1CDC. Epidemiology and Prevention of Vaccine-Preventable 
Diseases. 13th ed. 2015]. 
The development of the HZ/su vaccine began at GSK 16 years ago at which time two target 
populations were chosen, adults ≥50 years of age and immunocompromised adults ≥18 years of 
age.  From early in the development program and also specifically as Phase 3 clinical studies
were being designed, several key aspirations were considered.  The first was to achieve high 
vaccine coverage in persons ≥50 years of age. Because GSK did not think that was sufficient, 
they also wanted to increase VE in the older age groups ≥70 years and above.  Again, these 
groups are the most susceptible and are at the highest risk for shingles and shingles
complications.  At the core of the aspirations was having a safe vaccine for all persons.  This
includes safety / efficacy in all persons at increased risk for HZ, including immunocompromised 
populations.  The fourth aspiration was to have prolonged duration of protection.  The final
aspiration was ease of manufacture and reliability of supply.  Many of these aspirations have 
been met.
The following illustrates the composition of the non-live, adjuvanted subunit vaccine:
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On the left in turquoise is the antigen, which is 50 µg of recombinant glycoprotein E.  This is the 
most abundant protein found on the envelope of VZV, which elicits a specific cellular and 
humoral immune response.  On the right is the adjuvant system, which is ASO1B.  ASO1B is a 
liposome-based adjuvant system that contains immunostimulants MPL and QS-21.  MPL 
enhances cellular and humoral immunity, while QS-21 stimulates Th1 cell-mediated immunity as 
well as cytotoxic T- lymphocyte activity.  Synergistically, when MPL and QS-21 are combined, 
there is an enhanced proinflammatory response or innate immunity, as well as cellular and 
humoral response increases.  Overall, this results in a faster, stronger, and longer lasting 
immune response [Dendouga et al. Vaccine 2012;30:3126–35; Garçon et al. Understanding 
Modern Vaccines, Perspectives in Vaccinology, Vol 1, Amsterdam: Elsevier; 2011; chapter 4: 
p89–113; Dendouga et al. Vaccine 2012;30:3126–35; Grunewald et al. Science 
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In terms of background conclusions from the early phase studies, early phase safety and 
immunogenicity studies determined the combination of adjuvant and antigen and the dosing 
scheme.  That led to the composition just described to be given as a 2-dose regimen.  With 
regard to long-term immunogenicity in people 60 years of age and older, two doses of HZ/su 
induced a strong cell-mediated immune response of 19-fold higher than baseline at 1 month 
after dose 2.  The immune response was maintained with age, including in adults ≥70 years of 
age.  While a decline is observed in immune response after the first few years, this plateaus by
year 4 and still remains 4 times above baseline 6 years post-vaccination [Chilbek R, Pauksens
K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster
subunit vaccine in older adults 2015; Vaccine, Volume 34, Issue 6, Pages 863-868].
Three Phase 3 efficacy studies make up the HZ/su development program.  ZOE-50 (006)1  and 
ZOE-70 (022)2  are studies that evaluate HZ efficacy safety and immunogenicity in populations 
50 years and older and 70 years and older, respectively.  These studies were begun in 2010 
and were recently completed.  ZOE-50 results were presented to ACIP in 2015 and were 
published in the New England Journal of Medicine (NEJM).  As a reminder, the primary results 
of ZOE-70 as well as pooled results from ZOE-50 and ZOE-70 were published in the NEJM in 
September 2016 [1Lal H. NEJM 2015;372:2087-96; 2Cunningham AL. NEJM 2016;375:1019­
1032].  Study 002 is evaluating HZ efficacy, safety, and immunogenicity in adults ≥18 years of 
age receiving an autologous hematopoietic stem cell transplant (aHCST).  
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In terms of the general study design and objectives for ZOE-50 and ZOE-70, both studies were 
randomized, placebo-controlled, multi-center studies running parallel in 18 countries across
North America, Europe, Latin America, and Asia-Pacific.  The primary objectives were HZ 
efficacy in persons ≥50 years of age or ≥70, respectively. Since the studies were conducted at 
the same sites, individuals who were 70 years or older were randomly assigned to either ZOE­
50 or ZOE-70.  There also were pre-specified primary objectives for a pooled analysis, which 
included all subjects 70 years of age and older from both studies.  These objectives were PHN
efficacy and HZ efficacy.  There were 16,160 subjects enrolled in ZOE-50 and approximately
14,800 enrolled in ZOE-70.  Subjects were randomized 1:1 in two groups.  The vaccine group 
received 2 doses of HZ/su at 2-month intervals and the placebo group received 2 doses of 0.9%
saline solution at 2-month intervals.  There were 3 exclusion criteria:  1) having a previous
episode of HZ disease, 2) having previous varicella or HZ vaccination, and 3) having an 
immunocompromising condition.
In terms of the results in ZOE-50, for the primary objective, 6 cases were detected in the 
vaccine group versus 210 in the placebo group for a VE of 97% in individuals 50 years of age 
and older.  That 97% was maintained independent of age, even in subjects 70 years of age and 
older with quite tight confidence intervals.  The primary objective for ZOE-70 was to evaluate VE
in the prevention of HZ, with secondary objectives to evaluate VE in the prevention of PHN and 
evaluate vaccine safety and reactogenicity. The pooled analyses has 2 pre-specified primary
objectives, which were to evaluate VE in the prevention of PHN in subjects ≥70 years of age
across both Phase 3 studies, and evaluate VE in the prevention of HZ in subjects ≥70 year of 
age across both Phase 3 studies.
It is important to have a good understanding of the cohorts that were used for each of the 
analyses.  The total vaccine cohort (TVC) included 13,900 subjects who all received at least 1 
dose of HZ/su.  The follow-up time was 4 years.  This was the primary cohort used for the safety
analysis.  The modified total vaccinated cohort (mTVC), excluded subjects not receiving dose 2 
or those who developed HZ within 1 month after dose 2.  There were 13,163 subjects in this
cohort.  The mean follow-up time was 3.7 years.  This was the primary cohort used for the
efficacy analyses.  The diary card cohort was a subset of TVC of approximately 1000 subjects, 
which was used for the reactogenicity analyses.  Here are the ZOE-70 demographics results:
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Another important aspect to look at is VE by year post-vaccination.  From the pooled analysis, 
including all subjects 70 years of age and older, only 2 cases were detected in year 1 in the 
vaccine group versus 83 cases in the placebo group for a VE of approximately 98%.  This year 
seems to be an outlier.  In year 4, 4 years post-vaccination, VE was stilled maintained at 88%.  
Although these VE estimates are a snapshot, there is some consistency between years as can 
be seen by the overlapping confidence intervals.  In terms of the pooled results of VE against 
PHN, the most important complication of shingles, there were 4 PHN cases in the vaccine group 
compared to 36 in the placebo group for a VE of 89% in individuals 70 years of age and older.  
Looking across all age groups, in general, VE is maintained with the exception of those 80 years 
of age and older in which there were too few cases to have statistical significance.  This differs 
from what was observed in the ≥80 group for HZ where there was quite robust significance and 
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The mean age at dose 1 was 75.6 years, 54% of subjects were female, and there were virtually
no differences between the vaccine and placebo groups for age, gender, region, or race.  
Approximately 20% of subjects were recruited from North America.
In terms of VE against HZ overall and by age group as derived from the mTVC for ZOE-70, 23 
shingles cases were detected in the vaccine group compared to 223 cases in the placebo group 
for a VE of approximately 90%.  This VE was maintained even in the older age group of 80 
years of age and older.  The pooled ZOE-70 and ZOE-50 analyses include all subjects 70 years
of age and older from both studies, the primary objective.  These results are considered the 
most robust as there were approximately 3400 additional subjects who came from the ZOE-50 
study.  With respect to the primary objective, 25 shingles cases were seen in the vaccine group 
versus 284 cases in the placebo group for a VE of 91%.  Even among those individuals 80 
years of age and older, the VE of 91% was maintained with consistent and narrow confidence 
intervals.
Turning to safety and reactogenicity as observed in ZOE-50 and ZOE-70, one observation as
might be expected due to comorbidities and older age is that there were more SAEs and deaths
reported from ZOE-70 than from ZOE-50.  However, the important take-home message is that 
independent of coming from ZOE-50 or ZOE-70, there were no imbalances between vaccine 
recipients and placebo recipients for any of the endpoints (SAEs, pIMDs, or deaths). ZOE-50 
and ZOE-70 also provided some interesting information regarding reactogencity.  In terms of 
solicited local symptoms reported 7 days post-vaccination of any grade comparing the 
vaccinated to the placebo group, as may be expected with an adjuvanted vaccine, injection site 
reactions were common and were more common in vaccine recipients than in placebo 
recipients. The median duration of these symptoms was 2 to 3 days, and most were mild to 
moderate in intensity.
Looking specifically at reactogencity for Grade 3 reactions (greater than 100 mm for redness
and swelling and impeding normal activities for pain) for local symptoms, 8% or less of Grade 3 
reactions were reported.  However, these were reported more often in vaccine recipients than in 
placebo recipients.  The mean duration for these symptoms was 1 to 2 days.  Looking at 
solicited systemic symptoms reported 7 days post-vaccination of any grade, the 3 most common 
systemic symptoms were fatigue, headache, and myalgia.  These were more commonly
reported in the vaccine recipients compared to placebo recipients.  Most were mild to moderate 
in intensity, and the median duration was 1 to 2 days.  Regarding the Grade 3 systemic
symptoms reported, 6% or less were reported across the study.  They were more frequent in 
vaccine recipients compared to placebo recipients specifically for fatigue, headache, myalgia, 
and shivering.  The median duration was 1 to 2 days.
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Regarding compliance with the second dose, for ZOE-50 compliance with the second dose was
96% for both vaccine and placebo groups.  For ZOE-70, it was 95% or 96% for vaccine and 
placebo groups.  Essentially across the board, there was very high second dose compliance.
In summary of safety and reactogenicity for ZOE-70 and ZOE-50 / ZOE-70, no safety signal has
been detected.  There was no imbalance in the incidence of safety endpoints (SAEs, pIMDs, 
deaths) were observed between the HZ/su and placebo groups.  Additionally, AEs and safety
endpoints were as expected in this patient population.  Local and systemic reactions to HZ/su 
were common in the first 7 days after vaccination.  The large majority were of mild-moderate 
intensity and of short duration.
In summary of efficacy for ZOE-70 and ZOE-50 / ZOE-70, ZOE-70 VE in adults 70 years and 
older was >90% for the prevention of HZ.  These results are fairly consistent with the previous
97% VE in this age group from ZOE-50 trial. In the pooled analyses, considered to be the most 
robust analysis, VE for the prevention of HZ in adults 80 years and older was 91%.  HZ/su VE of
88% was demonstrated through year 4, and exhibited similarly high efficacy of 89% in the 
prevention of PHN in individuals 70 years and older.
With respect to upcoming evidence generation, GSK has quite a bit of ongoing evidence 
generation activity.  There is a revaccination study that is evaluating the immunogenicity, safety,
and reactogenicity in individuals with a history of ZOSTAVAX™ immunization at least 5 years
prior who were subsequently vaccinated with HZ/su.  There are a series of co-administration 
studies to evaluate the immunogenicity, safety, and reactogenicity of the vaccine when co-
administered with quadrivalent influenza, pneumococcal polysaccharide vaccine 23 (PPSV23), 
and Tdap. There also is a duration of protection study in which efficacy, safety, and 
immunogenicity persistence are being assessed over a long period of time up to 10 years post-
vaccination as an extension of the ZOE-50 and ZOE-70 studies.
The other exciting news is that GSK plans to submit a BLA for Center for Biologics Evaluation 
and Research (CBER) review of the candidate HZ/su vaccine before the end of 2016, with the 
expected indication of prevention of HZ in adults 50 years of age and older.  GSK is very proud 
of HZ/su and believes this vaccine not only has the real potential to improve the prevention of 
shingles and its complications, but also could shed light on the way future vaccines are 
developed to overcome the challenges of decreasing immunity in older adults and the elderly.
Discussion Points
An inquiry was posed regarding whether GSK planned to assess the use of HZ/su vaccine in
individuals who have a previous history of HZ.  In addition, there was a low number of Black
participants in the study of only 1%.
Dr. Colindres replied that GSK has conducted a study looking at vaccinating individuals who 
had a previous episode of HZ disease, which should be published soon.  The results were that 
the vaccine was immunogenic and safe.  With regard to the percentage of Black participants in 
the study, there are two considerations.  The first is that this study was conducted worldwide in 
a lot of countries throughout the world including Europe, Asia-Pacific, and Latin America.  
Looking at that number for North America in the US, it would be approximately 4%.  It is still less
than the percentage of African Americans in the US population, but it is slightly higher.
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Regarding ZOE-50, Dr. Middleman (SAHM) pointed out that slide 9 showed that the efficacy
among those ≥70 is 97.9% with a pretty nice confidence interval.  In ZOE-70, the efficacy for 70 
through 79 years was 90% with still a pretty tight confidence interval.  She asked whether there 
had been any thought about why the two studies would have different VE findings.
Dr. Colindres responded that he did not have a magic answer to that, other than it was what 
came out in the clinical study.  There was some degree of overlap in the confidence intervals, 
which accounts for some of it.
Dr. Kimberlain (AAP) noted that on the pooled analysis for HZ, the sample sizes were in the 
8200 to 8300 range.  However, the PHN pooled analyses that increased to 13,000 for the 
sample sizes.  He asked whether Dr. Colindres could explain why.
Dr. Colindres replied that this essentially was because the 50 year old group also was included.  
For the pooled analyses, which would include the primary objective, the other sample size of 
8000 or so is correct.  This sample size included those 50 years and above, which included all
subjects including the 50.
Dr. Atmar noted that the frequency of PHN in persons over 80 years of age was remarkably
lower in the placebo group compared to younger age groups where it was about 50% to 60% of 
people who develop HZ.  He asked whether there was an explanation for that.
Dr. Colindres replied that he did not have an explanation of why it was lower in those 80 years
of age and above, although they did observe that as well.  The prevention of PHN was clearly 
associated with decreased incidence of HZ disease, so clearly one was linked to the other.
Dr. Walter requested clarification regarding whether the efficacy analyses included only the 
period following 1 month after the second dose, and if he had any information on the distribution
of cases that occurred following the first dose in that time period.
Dr. Colindres responded that the efficacy analyses included after 30 days essentially, and there 
were under 20 cases during that time period following the first dose.
Dr. Messonnier asked whether Dr. Colindres to provide some sense of the timing of when data 
would be available from the upcoming evidence generation, and Dr. Bennett asked about 
vaccination of people who have previously received HZ vaccine.
Dr. Colindres replied that they are actively working on the revaccination study and should have 
results by about April or May of 2017.  They are working closely with the ACIP HZ WG to have 
that information reviewed as soon as possible.  The co-administration studies are completed 
and in the analysis phase.  An abstract of the influenza co-administration study will be 
presented during IDWeek and showed quite good results.  The duration of protection study is
still a way off.  The study of people who previously have had HZ has been completed, and GSK
is in the process of writing the manuscript.
Dr. Hahn (CSTE) asked whether Dr. Colindres had data on AEs from first dose compared to 
second dose, and if a person had an AE the first time, did they had a worse reaction from the 
second dose.
Dr. Colindres indicated that there does seem to be some correlation, but GSK is still in the 
process of analyzing these data.  They will share it as soon as it is available.
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YF vaccine is a live-attenuated viral vaccine produced in chick embryos.  There are 4 WHO­
prequalified vaccines available globally.  Vaccine Prequalification is a process established by 
WHO to ensure the quality and safety of vaccines provided through the United Nations (UN) for 
use in national immunization programs.  There is only one YF vaccine licensed for use in the 
US, which is YF-VAX®  that is manufactured by Sanofi Pasteur.  YF-VAX®  is not WHO­
prequalified and is, therefore, not part of the global supply.  YF vaccine is the only one for which 
proof of vaccination can be required by countries from arriving travelers under International 
Health Regulations (IHR) of 2005. 
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Dr. Whitley-Williams (NMA) noted that in addition to under-representation of Blacks in the study, 
she did not see Hispanics in the US population.  While she recognized how difficult it can be to 
conduct studies in the US, she emphasized that studies should reflect the population as it is
represented in the US, particularly regarding immunogenicity and AEs.  If this was rolled out and 
for whatever reason there was an increase in AEs in a particular ethnic group, this could 
negatively impact an already challenging adult immunization system.
Dr. Friedland (GSK) indicated that GSK works extremely diligently to identify investigators and 
patients who are representative of the US population in its clinical trials.  These results are not 
different from other clinical trials with other vaccines.  It is very difficult to identify patients and 
investigators who can enroll in these clinical studies in order to have representative populations.
GSK is not giving up and will continue to work on this.
Yellow Fever Vaccine 
Mark Gershman, MD
Travelers’ Health Branch
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Dr. Gershman reminded everyone that Yellow Fever (YF) is caused by the YF virus, which is in 
the genus flavivirus. This virus is transmitted predominantly by Aedes mosquitoes. YF disease 
is endemic in sub-Saharan Africa and tropical South America.  Asymptomatic infection occurs in
most people.  When clinical disease occurs, it ranges from mild febrile illness to severe disease 
with jaundice and hemorrhage, and can be fatal. Outbreaks occurred in 2016 in areas of Africa 
where cases had not been reported for decades, with the most notable being a large outbreak in 
Angola that is now subsiding.
Regarding the global YF vaccine supply in 2016, 6 million doses of YF vaccine are placed in a
global emergency stockpile annually. This stockpile is managed by the International
Coordinating Group (ICG) on Yellow Fever Vaccine Provision (WHO, UNICEF, MSF, Red 
Cross/Red Crescent). The emergency response to large outbreaks in Africa this year depleted 
this stockpile several times. Consequently, YF vaccine doses allotted for childhood and 
prevention campaigns were rerouted for response efforts. Also, as a dose-sparing measure in 
the face of global shortages, fractional doses of YF vaccine were used in Democratic Republic
of the Congo (DRC) for preemptive vaccination of residents of Kinshasa.
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In the US, YF vaccine is used to vaccinate people travelling internationally, including the 
military.  This is for travel to countries where there is risk of YF virus transmission, and for travel
to countries that have entry requirements for proof of YF vaccination as allowed under IHR
2005. Also, YF vaccine is used to vaccinate laboratory workers potentially exposed to YF virus
in their line of work. Regarding the YF vaccine supply in the US, historically, intermittent 
manufacturing issues have led to temporary supply shortages. Since the end of 2015, there has
been an ongoing YF vaccine shortage in the US, with ordering restrictions in place this entire 
time. This was compounded by the anticipation of additional demands on the vaccine supply for
travel to the Brazil Olympics this past summer by athletes, official delegations, and tourists.
In conjunction with the large YF outbreak in Africa and global supply issues, concerns about the
US YF vaccine supply led to the initiation of stakeholder discussions in spring 2016.  The focus
of these discussions was how to assure a stable YF vaccine supply for travelers, military, and 
response personnel in the US. Participants included CDC, Sanofi Pasteur, FDA, and the 
Department of Defense (DoD).  The options to assure the US YF vaccine supply reviewed in 
these discussions included the following:
 Maintaining the status quo by relying on the release of new YF-VAX® lots currently in 
production
 Implementing an Expanded Access Investigational New Drug (IND) application to allow
for importation and use of YF vaccine licensed outside the US
• 	 This vaccine would be STAMARIL®, which is manufactured in France by Sanofi
Pasteur and is licensed and marketed in more than 70 countries
 Using fractional dosing of YF vaccine as was done in the DRC
At present, the status of these options for the US YF vaccine supply is that YF-VAX®  lots 
currently being produced are scheduled to be released before the current inventory is 
exhausted.  Notably, the current inventory is lasting longer than anticipated because the level of 
increased demand for the Olympics did not occur.  Current ordering restrictions for YF-VAX®  
would remain in place to help modulate the future depletion of current inventory.  A contingency 
plan is being developed with submission of an IND application to import and use STAMARIL®, 
the YF vaccine licensed outside the US.  The IND application is presently under a 30-day review 
by the FDA.  The IND protocol, including training of clinicians, would be implemented should 
there not be an adequate US supply of YF vaccine.  Fractional dosing was not considered to be 
a viable option based on limited data and many uncertainties. 
In conclusion, in 2016, limitations occurred in both the global and the US YF vaccine supply. 
Contingency plans are being developed for the US YF vaccine supply.  These plans will be 
enacted as needed based on demand and supply.
Discussion Points
Dr. Belongia asked for additional explanation about how the IND works with a vaccine licensed 
in another country, and what the protocol is.
Dr. Gershman replied that the protocol is basically the plan regarding how to get the vaccine 
distributed to the clinicians who will use it, the conditions of distribution, the conditions of 
monitoring safety, et cetera.  It is not an experimental protocol.  Expanded access is a clinical
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Dr. Greenburg (Medical Affairs, Sanofi Pasteur) agreed with Dr. Gershman’s summation.  This 
is a clinical protocol as opposed to a study per se, such as a clinical trial with hypotheses and 
specific statistical questions being asked.  Instead, it is a mechanism that is reviewed and 
approved by the FDA to import STAMARIL®  as an unlicensed product into the US and distribute 
it to clinicians throughout the US at specific sites that use a lot of YF vaccine.  These will be 
clinicians who are used to administering YF vaccine, who would administer the vaccine as they 
normally would with YF-VAX®  and monitor / report safety issues to Sanofi Pasteur as the 
manufacturer and to the FDA.  Otherwise, use of the vaccine is fairly routine with some 
additional safety follow-up. 
 
Dr. Gershman added that the challenge with this is that it is a unique vaccine and a unique 
situation.  Over 5000 civilian clinics administer YF vaccine, so it would not be practical or 
achievable to distribute STAMARIL®  to all of those clinics.  It would be virtually impossible.  Part 
of the protocol involves how site selection is accomplished.  What seems to be a reasonable 
situation has been worked out to distribute to those clinics that appear to be the top users by 
volume, and such that geographical access is maintained for people in all states.  It is a delicate 
balance, because the amount of work involved is quite a lot.  However, the vaccine needs to be 
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protocol, similar to that for an orphan drug, to supply a vaccine or drug that otherwise would not 
be available and is deemed to be absolutely necessary.  He deferred to Dr. Sun from the FDA
or representatives from Sanofi Pasteur to offer further information, given that Sanofi Pasteur
wrote the protocol.
 
Dr. Hunter asked whether the current situation with the US supply being separate from the 
global supply was a conscious policy decision, or if it developed historically for market reasons.
Dr. Gershman replied that he thought it had developed historically for market reasons because 
in general, YF  vaccine is used for two main purposes:  1) for international travelers, in which 
case it is used only in the country in which it is produced, which is a very circumscribed market; 
and 2) for vaccines provided through the UN for use in national immunization programs, which 
go through the rigorous WHO Vaccine Prequalification process to ensure the quality and safety 
of those vaccines for mass vaccination campaigns.  Sanofi Pasteur did not pursue WHO 
prequalification for the US-manufactured vaccine YF-VAX®, but justifiably so.  Why would it 
need to be done?  It is a lengthy and expensive process.  STAMARIL®  is produced in France 
and is one of the WHO prequalified vaccines used globally, including in routine infant 
immunization programs and in mass vaccination campaigns - preemptively, and in response to 
outbreaks. 
Dr. Plotkin (Vaccine Consultant) apologized at this late hour, but wanted to make a specific
request since he did not know when YF would come up again.  He requested that CDC
reconvene the YF WG to reconsider its recommendation regarding YF vaccine boosters, and 
indicated that he had data.  In February 2016, the YF WG recommended that revaccination is
unnecessary for YF.  They stated and printed that 92% of vaccinees are seropositive at 10 
years, that there is a paucity of vaccine failures, and evidence of seropositivity.  Recently, an 
article was published by Amanna and Slifka in which they reviewed the literature and concluded 
that immunity is lost in 20% to 33% at 10 years, and that children are at greater risk for losing 
their seropositivity.  He quoted from their article, “An extensive study examining cases of yellow
fever in Brazil has provided much needed insight.  In this study, patients were not only queried 
about their vaccination status, but also asked whether they had been vaccinated within 10 years
prior to contracting yellow fever.  There were 831 cases of yellow fever identified between 1973 
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and 2008. Vaccination status was unavailable for 372 of the patients, but the remaining 459 
cases had received prior yellow fever vaccination, and yet still contracted yellow fever.  Since all
of the cases of yellow fever were virologically confirmed, we believe that this is likely to be a 
more accurate representation of vaccine failures than the previous estimate of only 23 
worldwide vaccine failures.”  Then the comment that “52% of those had been vaccinated more 
than 10 years previously” [Ian J. Amanna & Mark K. Slifka, Questions regarding the safety and 
duration of immunity following live yellow fever vaccination, Pages 1519-1533 | Received 01 
Mar 2016, Accepted 02 Jun 2016, Accepted author version posted online: 08 Jun 2016, 
Published online: 20 Jun 2016].  Dr. Plotkin recommended that the WG read this paper.  There 
also is a study from Brazil specifically in children, which shows seroconversion rates after the 
first vaccination of only about between 80% and 85%.  Michael Tauraso reviewed the situation.  
It is true in the abstract he says that duration of immunity is good, but looking at his table, for
those studies in which there were more than 100 people involved, the persistence was 76% at 
17 years, 81% at 30 years, 75% at 10 years, 69% at 4 years, and 65% at 10 years.  There was
no study of Africa where YF is epidemic, so the duration of immunity is unknown in an African 
population.  He thinks that duration of immunity of the YF vaccine has been exaggerated.  He 
thought this should be reevaluated in light of all of the data available, not simply those that 
apparently were used by the initial group. 
Dr. Bennett thanked Dr. Plotkin for his comments and said she thought the issue would be taken 
into consideration by the WG.
Ms.  Pellegrini asked whether there was any explanation for why YF has reemerged so 
suddenly and so aggressively in parts of Africa.  Over the last couple of years, there seem to 
have been a number of cases where flaviviruses have done this, or left continents and wreaked 
havoc.  She wondered whether they should be worried about YF perhaps spreading to 
additional areas.
Dr. Gershman replied that while he did not think anyone knew for sure, he thought it was
partially a result of a combination of global climate change, and El Niño cycles that are periodic
and normal. This can lead to an increase in the density of mosquito vectors, which has occurred 
during a time of growing populations in urban areas in Africa.  This is an urban cycle YF 
outbreak that has been so severe in Africa.  In general, there are several different cycles of YF 
virus transmission.  The urban cycle has as its vector the Aedes aegypti mosquito, and involves
person-to-mosquito to person transmission of the YF virus. The sylvatic cycle is jungle YF 
where people wander into the jungle and are bitten randomly by mosquitos that usually prefer to 
bite monkeys. As more roads are being built, more access is created to people from areas
where they might be exposed to YF virus by the jungle transmission cycle, to urban areas, 
where they can then introduce it to heavily populated areas with dense levels of Aedes aegypti
mosquitos.  He thinks it is a host of all of these factors.
In the context of the events that occurred, Dr. Thompson (NVAC) requested further information 
about what occurred to cause the supply disruption and whether anything is being done to 
increase the safety stock to address this.
Dr. Gershman replied that it is a manufacturing issue, and deferred to the Sanofi Pasteur
representative to provide more details.
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Julian Ritchey (Sanofi Pasteur) confirmed that it is a manufacturing issue and for some time, 
Sanofi Pasteur has been looking to move to a new manufacturing facility.  The current 
manufacturing facility is older, and they are in the process of making that transition and making 
it seamless.
Regarding Ms. Pellegrini’s question, Dr. Sun (FDA) added that YF cases from the recent 
outbreak in Africa were imported to China.  Even though the mosquito that transmits YF has 
been endemic in Asia, Asia has not had YF.  This is an enigma for flavivirology.  Travel-
associated YF that is imported from areas of outbreak is of great concern.  Regarding IND, Dr. 
Sun explained that the Expanded Access IND is a mechanism by which unapproved products 
can be made available for use, and in this case, for wider use.  The same mechanism was used 
for Bexsero®  for MenB in university outbreaks.  There are various versions of the Expanded 
Access IND.  There is one for products that are to be licensed, and one for products that are not 
headed for licensure.  They are dealt with somewhat differently, but the basic principle is that it 
is still considered an unapproved product and, therefore, the transport across state lines has to 
be under IND.  In addition, there has to be a streamlined approach to collection of AEs. 
Day 1:  Public Comment 
Dr. Stanley Plotkin
Vaccine Consultant
Once again I apologize for keeping the committee, but I just don’t have any choice in the matter
so to speak.  What I am now urging on the committee is to form a Lyme Disease Vaccine WG.  
That a Lyme disease vaccine is sorely needed I think is without question.  The CDC itself 
estimates 300,000 annual cases, and there are another 20,000 estimated in Europe.  Carditis, 
neurological complications, and rare deaths occur.  I have spoken to this committee before and 
mentioned that one of my own sons had a life-threatening case of Lyme carditis.  At any rate, 
the original vaccine that was licensed in the late 90s worked quite well in terms of its efficacy, 
although boosters were needed because of the mechanism of the OspA (outer surface protein 
A) antigen that was in the vaccine.  Unfortunately, and I say this carefully but clearly, that CDC 
did not support the original Lyme disease vaccine. That was one of the reasons why it was
taken off of the market.  Another reason was that the manufacturer did not do a pediatric study
until it was too late. Then there was a questionable safety signal, which was never supported 
by VAERS analysis, was never supported by laboratory analysis, but was enough to decrease 
sales and the manufacturer took it off.  I should mentions as far as the pediatrics is concerned,
the study that was done late in the game shows that if anything, children responded about 10
times better to the vaccine than did adults.  So, the question now is can we have a new
vaccine?  I’ve been working with potential Lyme vaccine manufacturers, and I should say clearly
that I have no financial interests in this whatsoever.  But, they do not know if ACIP is interested 
and will make a positive recommendation.  Clearly, ACIP cannot make a recommendation 
without having an actual vaccine.  But, it could indicate interest in having one.  I think a Lyme 
Disease WG to consider the target product profile and to meet with potential new vaccine 
manufacturers, and there are candidate vaccines, would be very desirable.  The situation I think
is similar to the rotavirus situation.  If you recall, the original rotavirus vaccine was taken off of 
the market because of intussusception.  Then the issue for the manufacturers, and I was
personally involved in this, was will a new vaccine be recommended?  It was clear at the time 
that ACIP wanted to prevent rotavirus disease and, therefore, two manufacturers undertook to 
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make new vaccines, which ultimately were licensed.  Again, and lastly, I hope that the ACIP will
consider forming a Lyme Disease Vaccine WG to indicate that they have an interest in an 
eventual vaccine.  In 2000, the IOM did an analysis of what vaccines—that is, what diseases for
which we need vaccines, what are the first priorities for developing vaccines?  That was a very
important document.  That had a major effect on the manufacturers in terms of choosing targets.  
That sort of analysis is really needed.  NVAC should do it, but they won’t.  The ACIP could do it 
by various mechanisms, but again, has not undertaken to do that.  Thank you.
Dr. Bennett responded that Dr. Plotkin posed an interesting problem, but that it probably was
beyond the purview of the ACIP to develop a WG to advocate for the development of a vaccine. 
However, it is not beyond the purview of the CDC or the SMEs at the CDC.  This is an 
overarching problem in the US.  How do we decide which vaccines we advocate for the 
development of?  There is not a very good systematic approach to this.
In response to whether this would fall under NVAC’s purview, Dr. Birkhead (NVPO) said he
thought that the NVPO addresses the development of new vaccines.  However, he was not 
aware of a formal mechanism by which recommendations are made for vaccines that are of 
interest for further development.
Dr. Thompson (NVAC) indicated that NVAC has been very interested in recent meetings in the 
area of vaccine innovation.  She thought this would fall into that category as it would be a new
vaccine.  NVAC certainly is assessing all of the incentives that the whole system faces with 
respect to innovation in the vaccine area, so she thought this was something NVAC could take 
up as a question, but in the context of the broader theme.  One issue that Dr. Plotkin raised that 
has been raised by others to NVAC is the fact that manufacturers or developers in general
would like some assurance that there would be a market for a product. That is very hard for any
advisory committee to give.  The concept of target profiles is interesting and is worthy of 
exploration, and certainly is something that NVAC could consider.  Perhaps ACIP could in some 
way consider that as well at some point.
Christina Hildebrand 
A Voice For Choice Advocacy
To finish off the evening, I wanted to come back to a few comments that I made earlier and just 
expand on them.  The first one is, you know, looking at all of the data that was presented today, 
it was either really small base sizes or it was by the pharmaceutical companies, which is not 
independent research by any means.  I really urge the CDC to do independent research that is
not the CDC or the pharmaceutical companies doing research, because both of you get money
out of this, and so we need an independent research body doing research.  We’ve got 12 CDC
researchers who came out today questioning the ethics of the CDC, and the infiltration of money
into the CDC and into our government.  We know that pharmaceutical companies are the 
largest lobbying force out there.  We also have one CDC whistleblower, Dr. William Thompson, 
who has shown that there’s been fraud at the CDC.  He’s shown that there has been fraud on 
the MMR studies.  There’s also, you know, efficacy research on the MMR.  There’s a lawsuit 
right now questioning the efficacy of the MMR.  I just, you know, I look at this data and I look at 
what you’re doing here at the ACIP and at the CDC and I just ask that independent research is
done or that you use the independent research that is out there, because using paid for
research or your own research just isn’t good enough.  Thank you.
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Zika Virus Update
Ms. Stacey Martin
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention
Ms. Martin explained that Zika virus is an ribonucleic acid (RNA) flavivirus related to dengue, 
YF, Japanese Encephalitis (JE), and West Nile Virus (WNV).  Transmission to humans is
primarily by Aedes (Stegomyia) species mosquitoes. Infection is typically asymptomatic or
causes mild dengue-like illness.  However, recent outbreaks have identified new modes of 
transmission and clinical manifestations.
Zika virus was first isolated from a sentinel rhesus macaque monkey in Uganda in 1947. Before 
2007, only sporadic human disease cases were reported from Africa and Southeast Asia.  In 
2007, the first Zika outbreak was reported on Yap Island, Federated States of Micronesia.  In 
2013–2015, more than 30,000 suspected cases were reported from French Polynesia and other
Pacific islands.  Local transmission was first identified in the Americas in May 2015 and 
subsequently spread across the region.
As of October 13, there are 47 countries and territories in the Americas that have confirmed 
mosquito-borne transmission of Zika virus.  The map below provides a timeline of the first 
reports of local transmission with Brazil confirming its first case prior to October 2015 and the 
US confirming its first case this summer.  The table on the right reflects the number of locally
transmitted Zika virus disease cases reported to the Pan American Health Organization (PAHO) 
by country in the Americas, now in excess of 660,000:
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Approximately 60% of the total cases were reported from two countries, Brazil and Colombia.  
Of note, most of the reported cases are suspect cases and only 23% of cases are laboratory-
confirmed.  Most suspected and confirmed locally transmitted cases reported to PAHO, as of 
October 2016, were reported from South America (73%), followed by the Caribbean (18%), and 
then Central America (8%).
Zika virus disease was made a notifiable condition in Brazil in February 2016.  For this reason, 
temporal trends of cases are only available in 2016.  There was an increasing trend starting in 
January that peaked in February.  Since then, there has been a steady decline in both 
confirmed and suspected reported cases. Zika became a reportable condition in Columbia in 
October 2015.  Reported cases began to increase in August 2015 and continued until early
February 2016. Reported cases have declined since the peak.  In Mexico, the first confirmed 
case was reported in late 2015.  In 2016, Mexico reported an increase in cases that peaked in 
August.  As of epidemiology week 42, and given the expected lag in reporting, it was too soon to 
say whether they are experiencing a decline in cases. CDC also has recently learned about 
cases being identified in communities along the border with Texas.
In the US, a total of 3892 travel-associated cases have been reported to ArboNET as of October 
12th. Of these travel-associated cases, 98% were reported from the States.  For locally 
acquired cases, a total of 25,999 cases have been reported, and 98% of these were reported 
from Puerto Rico.  In the States, 128 locally-acquired cases have been reported to ArboNET, all 
from Florida. 
The following map shows laboratory-confirmed Zika virus disease case reported to ArboNET by
state or territory, with 49 states having reported cases.  The highest reporting states are New 
York and Florida, each reporting over 20% of the cases, followed by California and Texas.  All 
other states have reported less than 5% of the total cases:
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Between January and October 2016, there have been a total of 3775 travel-associated cases
and 137 locally acquired cases in the US reported to ArboNET. The epi curve suggests the 
number of reported cases peaked in July, but there is a lag in reporting.  Also, the US reported 
its first locally transmitted case in June from Florida.  Florida continues to report locally
transmitted cases. The majority of cases occur in adults, with the highest number of cases in 30
through 39 year olds. Travelers returning from the Caribbean represent the highest proportion 
of travel-associated cases, followed by travelers from Central America, South America, and 
North America.
Puerto Rico reported its first case at the end of 2015.  The number of reported confirmed cases
increased from January through August of 2016.  Following the peak, the weekly number of 
reported cases has declined. The Puerto Rico Department of Health has reported over 28,000 
cases.  As shown in the following map, the cases are distributed throughout the island.  This is
likely a significant underestimate of the true number of infections, since the clinical presentation 
of Zika virus infection is typically mild or asymptomatic:
As previously mentioned, Florida has reported over 100 locally acquired Zika cases.  The first 
area to be identified was the Wynwood neighborhood of Miami-Dade County, followed by Miami 
Beach, and then most recently, Little River, also in Miami-Dade County. To summarize, Florida 
has experienced sporadic locally acquired cases in multiple counties in Florida. Many of these 
are believed to be single transmission events without further spread.  The three areas
highlighted on the following maps were found to have multi-person transmission, which 
prompted Florida and CDC to recommend that pregnant women avoid travel to those areas: 
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In Wynwood, state and local officials appear to have successfully ended local transmission after 
aerial spraying and other mosquito control efforts.  As of October 17th, Florida has reported 160 
cases of locally transmitted infections.  Concerns about low levels of transmission outside of the 
three designated areas zones prompted Florida and CDC to state that pregnant women and 
their sex partners may consider postponing nonessential travel to all parts of Miami-Dade 
County.  As of October 19th, CDC began recommending laboratory testing for all pregnant 
women who have had exposure to all areas of Miami-Dade County after August 1st. 
 
Before ending, Ms. Martin provided a high-level overview of Zika virus vaccine development 
activities.  She indicated that a US government interagency working group that includes
members from the Assistant Secretary for Preparedness and Response (ASPR), National
Institutes of Health (NIH), Biomedical Advanced Research and Development Authority
(BARDA), FDA, CDC, and Walter Reed Army Institute of Research (WRAIR) was established 
to: 1) evaluate promising candidate vaccines for safety, immunogenicity, and efficacy; 2) ensure 
availability of one or more candidate vaccines in 2018 for emergency use in US population at
high risk of exposure or disease; and 3) work with partners to commercialize vaccines for broad
distribution by 2020.  Currently, there are many vaccine candidates in preclinical development 
which will be presented to ACIP at a later date.  There are expected to be four vaccines in 
phase 1 clinical trials by the end of 2016, and phase 2 studies are scheduled to begin in 2017.
Discussion Points
Given that about 80% of Zika cases are asymptomatic, Ms. Pellegrini asked whether CDC
thinks it is possible or likely that the 25,000 plus in Puerto Rico could be 20% or possibly even 
less for people not seeking care at all in terms of the actual number of infections in Puerto Rico.
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Ms. Martin stated that it is possible.  The only data CDC has that provides a ratio of 
symptomatic to asymptomatic cases is from Yap Island.  It is believed to be about 1:4.  The 
number of reported cases is likely a dramatic underestimate of the true burden of disease on the 
island.
Once the epidemic curve has run its course in a population, Dr. Hunter asked what the role of 
vaccination would be in a country that is going to be endemic versus a country that has different 
areas that are going to be endemic and others that are not.
Ms. Martin replied that there always are likely to be susceptible populations in new cohorts, but 
the use of vaccines may differ between a country that has had large epidemics versus countries
that have endemic disease.
Noting that there is endemic dengue in Puerto Rico, Dr. Sun (FDA) asked whether in the 
epidemic curve for Zika the dengue cases could be superimposed with Zika cases in order to 
get a sense of whether Zika is declining is because the rainy season is over and there is less
transmission of all types of mosquitos, or if it is just a case of Zika going away.
Ms. Martin responded that it is probably a combination of multiple factors.  They have had a 
large epidemic, and it is likely that the true burden has been underestimated.  In addition, most 
of the island has now been affected, so the number of susceptibles has also probably dropped.  
She said she did not want to make any comments about the vector side because she is not an 
arboviral expert, but it is likely multi-factorial.
Dr. Fryhofer (AMA/ACP) requested guidance on what to tell patients when they are traveling to 
areas like French Polynesia that do not have high levels of active infection right now, but 
certainly have had peaks in the past.
Ms. Martin replied that CDC is currently considering its guidance for endemic areas.  Obviously,
pregnant women who are traveling to any areas that may have transmission of Zika should take 
precautions.
Dr. Bennett reminded everyone that in February 2017, there will be a session on Zika vaccine to 
update ACIP on the state of the science.
Agency Updates 
Centers for Disease Control and Prevention (CDC)
Dr. Messonnier emphasized that CDC remains very occupied with the Zika response.  Dr. 
Frieden always characterizes it as the most complicated response CDC has ever managed.  
This is partly due to the fact that so many parts of the agency are engaged, because it is so 
multifactorial and because the science continues to evolve.  Regarding the use of vaccines, as
always, CDC will call upon the ACIP for assistance in thinking about US vaccination policy.
On September 29th, CDC and the National Foundation for Infectious Diseases (NFID) held a 
joint press conference to kick off the 2016-2017 Influenza Vaccination Campaign.  For the 2016­
2017 season, vaccine manufacturers have estimated that up to 168 million doses of injectable 
influenza vaccine will be available.  More than 93 million doses of influenza vaccine already 
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have been delivered.  This season’s vaccines have been updated.  Most of the research 
suggests that they will cover the strains that are more common during 2016-2017.  As of this
week, overall influenza activity was low in the continental US (CONUS).  Adult influenza 
coverage was low last year, but CDC is working to try to understand that and figure out what to 
do to improve influenza coverage this year.
The National Immunization Conference (NIC) was held in September in Atlanta, with thousands
of immunization enthusiasts in attendance.  It was actually the largest number of attendees NIC
has ever had.  She expressed gratitude for the many individuals and groups in the room for their
strong support.  The next National Adult and Influenza Immunization Summit (NAIIS) will be
held in Atlanta in May 2017.
In terms of the election, CDC is working with HHS and the Office of Management and Budget
(OMB) to plan and prepare for any administrative changes to come.  The processes will
accelerate following the election.
Globally, CDC is consistently reminded of the challenges to building global capacity for public
health.  Earlier this year, colleagues in CDC’s Global Immunization Division (GID) released 
CDC’s Strategic Framework for Global Immunization 2016-2020. The framework is built around 
five interconnected goals: an overarching goal to improve global health impacts; three goals to 
increase the amount of people reached by strengthening country-owned immunization 
programs; and CDC’s foundational goal of providing evidence for effective policy and program
implementation. That framework is available on the CDC website.
International collaboration will continue to be important as CDC looks to enhance new
technologies, including for example learning about other countries that are continuing to use the 
nasal influenza vaccine this year.  There is also much that can be learned about vaccine policy
from CDC’s international partners.  CDC is pleased to be able to welcome its partners from
China who are here to discuss priority scientific activities, and is glad to have the opportunity to 
learn from each other.
Centers for Medicare and Medicaid Services (CMS)
CMS recently issued a Medicare Provider notice regarding Medicare payment for the 
quadrivalent influenza vaccine.  This notice instructs Medicare Administrative Contractors to pay
for this vaccine using code 90674 with no coinsurance and deductibles.  Coverage of the 
quadrivalent influenza vaccine was effective August 1, 2016.  Because claims processing 
changes will be implemented on January 1, 2017, contractors and providers have been told to 
hold the claims until after that date.
Department of Defense (DoD)
Dr. Deussing expressed DoD’s appreciation for the valuable work of ACIP and the opportunity 
to participate in this work, which helps protect this country’s service members, their families, and 
all 9.4 million DoD beneficiaries worldwide.  He briefly highlighted two current vaccine issues for 
the DoD.  First, the DoD is working with the manufacturer of IMVAMUNE®, the non-replicating 
smallpox vaccine, to fulfill the final Phase 3 study requirement for licensure.  Complete 
enrollment is expected by December 2016.  IMVAMUNE®  is projected to meet the US 
government’s preparedness requirement for development of an attenuated smallpox vaccine in 
sufficient quantity to protect 66 million people, comprising those for whom replicating smallpox 
vaccine is contraindicated and their household contacts.  Second, he reminded everyone that 
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the previous day they heard an excellent presentation on the current YF vaccine supply 
challenges.  The DoD has worked very hard to mitigate the effects of the YF vaccine shortage 
through close collaboration with the Defense Logistics Agency (DLA), the military departments, 
other federal partners, and Sanofi Pasteur.  As a result of this concerted effort, the DoD reduced 
utilization of YF vaccine by 80%, but still vaccinated all service members and beneficiaries 
deploying to or traveling to a YF endemic area.  The DoD looks forward to the availability of the 
Expanded Access IND for STAMARIL®, and will continue to work with its partners on solutions 
to this shortage. 
Department of Veterans Affairs (DVA)
Dr. Pittman reported that the VA is nearing completion for national release of its latest software
patches as part of the Veterans Immunization Enhancement 2.0 Project.  These patches
improve support for upcoming user-facing enhancements in its EMR and the Enterprise Health 
Management Platform (eHMP).  They also provide multidivisional support for the VA’s larger
integrated facilities to track immunization inventory more closely.  VA has partnered with 
Walgreen’s for the 2016-2017 influenza season and will receive data for veterans who obtain 
their immunizations at Walgreen’s during the influenza season.  This information with then be 
available in the VA’s Veterans Information Systems and Technology Architecture (VistA) EHR in
any facility where that veteran is registered.
Food and Drug Administration (FDA)
Dr. Sun reported that since the June 2016 ACIP meeting, FDA approved two additional 
seasonal influenza quadrivalent vaccines, Afluria®  and Flublok®. In addition, FDA approved the 
use of Prevnar13®  for ages 18 through 49 and the 9vHPV 2-dose regimen.  In addition, 
recognizing the importance of LAIV for both seasonal and pandemic influenza, FDA has been 
working very closely with the manufacturer, representatives from the ACIP Influenza WG, and 
CDC on further evaluation of the root cause of the observation of lower effectiveness in the 
observational studies.  This includes work on many fronts, including manufacturing issues, 
further analysis of observational data, and virologic studies.  FDA will continue to work closely to 
address these problems. 
Health Resources and Services Administration (HRSA)
Dr. Nair reported that the National Vaccine Injury Compensation Program (VICP) has had a very
busy year processing claims for Fiscal Year 2016, for which 1116 claims were received.  At the 
end of the Fiscal Year, the VICP awarded approximately $250 million that were paid to 
petitioners and attorneys for their fees for compensated and dismissed claims, as well as interim
fees and costs. More information and data about this program can be found on HRSA’s
website.  HRSA is in the process of updating the Vaccine Injury Table.  Comments on the 
Notice for Proposed Rulemaking proposing changes to the Vaccine Injury Table have been 
reviewed, and a draft Final Rule is being developed.  It is currently going through the clearance 
process, and HRSA hopes to have that finalized and published in the Federal Registry before 
the end of this calendar year.  As of August 2016, HRSA’s Countermeasures Injury 
Compensation Program (CICP) has compensated 39 claims totaling $4.9 million.
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Indian Health Services (IHS)
Dr. Groom reminded everyone that IHS developed a policy to require influenza vaccine for its
HCP last season, but had not successfully bargained for it with the unions, so they were able to 
only partially implement it in IHS facilities.  Even with only partial implementation, they achieved 
about a 10% increase and had coverage of approximately 85% for IHS HCP.  She said she was
very pleased to report that they completed bargaining with two of the largest unions, so 97% of 
IHS union employees are now covered by this policy, which they expect to implement fully
across the IHS.  They are hopeful that they might achieve the Healthy People 2020 goal this
season.  IHS is pleased to join a number of private and public institutions on the IAC’s honor roll
and have their federal mandate there along with the DoD colleagues.  Regarding maternal
immunizations, IHS is partnering with Johns Hopkins to develop a performance measure for the 
IHS to assess influenza and Tdap vaccination among pregnant women, and a reminder in the 
IHS EHR for its providers. 
National Institutes of Health (NIH)
Dr. Gorman reported that with regard to revision of the Common Rule, the comment period is
now closed.  Approximately 1500 public comments were received during the comment period.
Some comments contained over 150 signatures.  The agencies involved are now reviewing 
these comments and making decisions on how to respond.  The multiple agencies involved are 
presently driving toward consensus. They have heard that there may be an announcement 
soon.
NIH is now requiring a single IRB for all clinical trials that include multiple sites.  Policy
Announcement NOT-OD-16-094: Final NIH Policy on the Use of a Single Institutional IRB for
Multiple Site Studies was published on June 21, 2016.  This policy describes the rational for this
policy and exemption criteria during the transition period.
In terms of personnel, NIH has two new institute Directors.  The National Institute of Mental
Health (NIMH) has appointed Dr. Joshua Gordon as its new Director: https://www.nih.gov/news­
events/news-releases/nih-names-dr-joshua-gordon-director-national-institute-mental-health
The National Institute of Child Health and Development (NICHD) has appointed Dr. Diana 
Bianchi as its new Director: https://www.nih.gov/news-events/news-releases/nih-names-dr­
diana-bianchi-director-national-institute-child-health-human-development.
In terms of the National Institute of Allergy and Infectious Diseases (NIAID), NIAID researchers
in influenza have advanced the understanding of how influenza protection can facilitate the 
development of a universal or broadly protective influenza vaccine.  A nanoparticle vaccine 
based on an H1N1 stem, rather than the HA head, offered protection against a lethal dose of 
H5N1 challenge.  This protection was antibody based, but did not develop neutralizing titers, 
which will present an issue in terms of attempting to license the new vaccines: 
http://www.niaid.nih.gov/diseases-conditions/niaid-researchers-advance-development-universal­
flu-vaccine.
In terms of personnel at NIAID, Dr. Stephen Holland was named the Director of the Division of 
Intramural Research (DIR): https://www.niaid.nih.gov/news-events/niaid-selects-director­
division-intramural-research.  NIH continues to search for a new Division Director for Division of 
Microbiology and Infectious Diseases (DMID). Dr. Fred Cassels, Branch Chief of the Enteric
and Hepatic Diseases Branch (EHDB) retired from government service on September 30, 2016.  
He will be continuing his career with a new position at PATH.
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NIAID is working on a new YF vaccine.  A phase 1 trial is underway for safety and 
immunogenicity:  https://www.nih.gov/news-events/nih-launches-early-stage-yellow-fever­
vaccine-trial.  While it will not answer Dr. Plotkin’s question about Lyme Disease vaccine, NIAID
is in the early planning phases for a clinical trial to evaluate the effectiveness of prophylaxis of 
tick bites to prevent Lyme Disease. In terms of the Zika virus, NIAID is actively pursuing 
multiple vaccine candidates to prevent Zika virus infections, including the following strategies:
 A DNA-based vaccine that uses a strategy similar to an investigational flavivirus vaccine for
West Nile virus infection, which entered an early-stage trial in August 2016 and the dosing of 
those individuals is now complete
 A live-attenuated investigational Zika vaccine building on a similar vaccine approach for the 
closely-related dengue virus
 An investigational Zika vaccine that uses a genetically engineered version of vesicular
stomatitis virus (VSV), with plans underway to evaluate this candidate in tissue culture and 
animal models
 A whole-particle inactivated Zika vaccine based on a similar vaccine approach used by the 
Walter Reed Army Institute of Research (WRAIR) to develop vaccines against the related 
Japanese Encephalitis (JE) and dengue viruses; information regarding NIAID-supported 
Zika research may be found here: https://www.niaid.nih.gov/diseases-conditions/zika-virus
NIH and Fundacao Oswaldo Cruz-Fiocruz (Fiocruz), a national scientific research organization 
linked to the Brazilian Ministry of Health, have begun a multi-country study to evaluate the 
magnitude of health risks that Zika virus infection poses to pregnant women and their
developing fetuses and infants. The study is also opening in Puerto Rico and will expand to 
several locations in Brazil, Colombia, and other areas that are experiencing active local
transmission of the virus. The Zika in Infants and Pregnancy (ZIP) study plans to enroll as
many as 10,000 pregnant women ages 15 years and older at up to 15 sites. The participants
will be in their first trimester of pregnancy and will be followed throughout their pregnancies to 
determine if they become infected with Zika virus and if so, what outcomes result for both 
mother and child. The participants’ infants will be carefully followed for at least one year after
birth.  Here is a link to the NIH press release from June 21, 2016: https://www.nih.gov/news­
events/news-releases/nih-launches-large-study-pregnant-women-areas-affected-zika-virus.
Some suggested publications include:
 Gonorrhea Vaccine: LM Wetzleret al. Summary and recommendations from the National
Institute of Allergy and Infectious Diseases (NIAID) workshop "Gonorrhea Vaccines: the 
Way Forward."ClinVaccine Immunol(2016 Aug 5)
 Zika Vaccines: Nature: Vaccine protection against Zika virus from Brazil, 
http://www.nature.com/nature/journal/v536/n7617/full/nature18952.html
 Zika Vaccines: Science: Protective efficacy of multiple vaccine platforms against Zika virus
challenge in rhesus monkeys,  
http://science.sciencemag.org/content/early/2016/08/03/science.aah6157
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National Vaccine Program Office (NVPO) / NVAC
Dr. Birkhead reported for both NVPO and NVAC.  First, as a companion to the National Adult 
Immunization Plan (NAIP) released last February, NVPO plans to release a Pathway to
Implementation of Adult Immunization Report in the near future to facilitate action on the goals
of the original plan.  The report suggests 8 priorities and potential activities to focus on, down 
from the 78 strategies in the original plan, and include:
 Addressing technical and legal and administrative and practical barriers to greater use of 
EHRs and immunization registries to track adult immunization data
 Evaluating the impact of current healthcare quality measures for adult vaccination and the 
feasibility of developing composite measures
 Assessing the impact of financial barriers such as co-pays on adult vaccination uptake
 Identifying legal, practical, and policy barriers impeding expansion of adult immunization
 Encouraging all providers to implement the NVAC Standards for Adult Immunization 
Practice
 Engaging community leaders in promoting the importance of adult vaccination to the public
 Examining the total costs of adult vaccination to adult vaccine providers for providing 
vaccine services such as vaccine ordering, handling, storage, administration, patient recall
and reminders, counseling, et cetera
NVPO recently awarded two contracts that may be of interest.  The first contract addresses the 
last point about the cost to providers of adult immunization by looking in detail at the business
case for providers of adult immunizations, taking into account both the costs and the
reimbursement by provider type and geographic region.  The second contract is for the 
development and testing of a composite healthcare quality measure for maternal immunizations
with the National Committee for Quality Assurance (NCQA), incorporating both Tdap and 
influenza vaccinations.  This was referenced the previous day by Dr. Carol Hayes in the context 
of the Adult Vaccine Summit Quality Performance Measure WG led by LCDR Angela Shen at 
NVPO.
NVPO and CDC are collaborating to put on a webinar entitled Vaccines During Pregnancy:  A 
Strong Record of Safety to help providers address patient concerns around maternal 
immunization.  The webinar will be on November 9th  from 12:00 PM to 1:30 PM Eastern Time 
and will cover the effectiveness of influenza and Tdap vaccines in pregnant women, their safety 
profile and common mild AEs, a review of the vaccine safety surveillance efforts and research 
activities specific to maternal immunizations, and strategies and resources to address patient 
concerns around maternal immunizations.  To view the webinar, register at the NVPO home 
page at hhs.gov/nvpo. 
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The last NVAC meeting was on September 20th  and included presentations / discussions on 
CDC’s Strategic Framework for Global Immunization 2016-2020, the mid-course review of the 
2010 NVP, NVPO’s Pathway to Implementation of Adult Immunization Report, and a review of 
the process of developing healthcare quality measures.  That discussion kicked off the process 
to develop consolidated quality measures, both for adult and maternal immunizations.  During 
the meeting, NVAC also voted on and unanimously adopted a Maternal Immunization WG 
(MIWG) report called Overcoming Barriers and Identifying Opportunities for Developing 
Maternal Immunizations. That report is available on the NVPO website and will be published in 
Public Health Reports (PHR).  The next NVAC meeting is February 7-8, 2017 at the Humphrey 
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Child and Adolescent Immunization Schedule 
Introduction
Dr. José R Romero
Chair, Child and Adolescent Immunization Work Group
Dr. Romero introduced this session on behalf of Child and Adolescent Immunization Schedule 
WG.  He reminded everyone that the schedule is presented for a vote every fall, given that the 
ACIP’s approval is necessary prior to publication of the schedule in the MMWR January or
February of the following year.  ACIP’s approval is also necessary before its partners the 
American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), and 
American Congress of Obstetricians and Gynecologists (ACOG) review and approve the 
schedule. He emphasized that no new policy is established by the schedule; rather, it reflects a 
summary of published ACIP recommendations. These edits are intended to improve readability
and utility of the schedule, and hence translate the respective ACIP recommendations into 
language that is easy to use and interpret by busy practitioners.
Dr. Romero indicated that for the remainder of this presentation, Dr. Robinson would discuss 
proposed edits to some specific vaccine footnotes as well as Figure 1, and would introduce a 
proposed child/adolescent high-risk figure which, if adopted, would become figure 3.  This year,
a few vaccines’ schedules required attention. ACIP members were provided with these slides in 
their binders, as well as on the meeting background materials’ website.  The slides presented 
during this session were updated to include footnote and figure edits that incorporate the results
of the previous day’s votes.  The changes to the footnotes include edits to the HepB, Hib, 
pneumococcal, influenza, meningococcal, and HPV footnotes.
Child and Adolescent Immunization Schedule 2015
Candice L. Robinson, MD, MPH
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Robinson indicated that on the title page, the title was changed to “Recommended
Immunization for Children Aged 18 Years or Younger.”  This new title harmonizes with the new
adult immunization title to be presented later in the morning.  The year was updated to 2017.
There are no proposed changes for Figure 2, the catch-up schedule.
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In the 2016 version of the schedule, the text beneath Figure 1 was largely a repeat of the text 
that already appeared on the title page of the schedule.  In the proposed 2017 version, this text 
has been removed.  There are a number of proposed additions to Figure 1 for the 2017 
schedule.  The age 16 years has been separated from the ages 17 through 18 years, and the 
16-year column has been shaded. The WG felt that this change would highlight the need for the
meningococcal conjugate vaccine booster dose at this age.  This also may provide an 
opportunity for catch-up vaccination if other adolescent vaccinations have not yet been 
administered or the series has not yet been completed.
Within the influenza row, live attenuated influenza vaccine (LAIV) has been removed as a 
recommended vaccine given the ACIP recommendation to not use LAIV during the 2016-2017 
influenza season. Last year, a purple bar was added within the HPV row at age 9 through 10 
years to represent the recommendation to begin the HPV series at age 9 years in children with 
a history of sexual abuse or assault.  Feedback was received from providers who indicated that 
this bar did not reflect the recommendation that HPV may be started at 9 years of age for those 
without a history of sexual abuse or assault. A blue bar was added at age 9 to 10 years to 
indicate that vaccination may begin at 9 years of age, even if there is no history of sexual abuse 
or assault.  Here is the revised schedule:
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The proposed high-risk figure pictured below demonstrates that most children with medical
conditions can, and should, be vaccinated according to the routine child/adolescent 
immunization schedule.  It indicates when a medical condition is a precaution or contraindication 
to vaccination. It also indicates when additional doses of vaccines may be necessary
secondary to the child’s/adolescent’s medical condition:
On the high-risk figure, the yellow color indicates “Vaccination according to the routine schedule
recommended.” The purple color indicates “Recommended for persons with an additional risk
factor for which the vaccine would be indicated.” The black and yellow stippled pattern indicates
“Vaccination is recommended and additional doses may be necessary based on medical
conditions.  See footnotes.” The white color indicates “No recommendation.” The red indicates
vaccination is “Contraindicated.” The orange color indicates “Precaution for vaccination.” 
Within the Additional Information section of the footnotes, providers are referred to the ACIP
general recommendations on immunization and the relevant vaccine specific ACIP statement 
for additional contraindications and precautions information. The following additional changes
were made to the footnotes:
 A bullet was added on the National VICP.  This addition was made to harmonize with the 
adult schedule, which already contains information regarding the program and the vaccines
covered.
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 The HepB footnote was updated to reflect the recommendation for HepB administration 
within 24 hours of birth.  For infants born to HBsAg-positive mothers, the post-vaccination 
testing window was updated to reflect the new recommendation of testing at age 9 through 
12 months.
 Within the Haemophilus influenzae type B (Hib) footnotes, HIBERIX® was added to the list of 
vaccines that may be administered for the primary Hib series.  Additionally, COMVAX™ was
removed from the list of available vaccines, as this vaccine is no longer produced and all
doses of the vaccine have now expired.  Language regarding the restricted use of HIBERIX® 
has been removed. The Catch-Up Vaccination section has been clarified to reflect that 
unvaccinated children 15 through 59 months of age should receive 1 dose of Hib vaccine.
 Throughout the pneumococcal footnotes, mention of PCV7 vaccine has been removed as
the last doses of PCV7 vaccine expired in 2010.  Thus, children who received PCV7 as part 
of a primary pneumococcal series have since aged out of the routine pneumococcal
recommendation.
 Within the influenza footnotes, information regarding LAIV has been removed and the 
following statement has been added, “For the 2016-17 season, use of live attenuated
influenza vaccine (LAIV) is not recommended.”  The MMWR reference has been updated to 
reflect the 2016-2017 influenza recommendations publication.
 In the meningococcal footnotes, the Clinical Discretion section outlines the MenB category B
recommendations.  This section has been updated to read, “Young adults aged 16 through 
23 years (preferred age range is 16 through 18 years) may be vaccinated with a 2-dose 
series of either Bexsero® (0, ≥1 month) or Trumenba® (0, 6 months) vaccine to provide short-
term protection against most strains of serogroup B meningococcal disease.” This reflects
the recommendations made during the previous day’s vote. Within the Meningococcal
Conjugate Vaccine section, children with HIV infection have been added to the section 
regarding vaccination of persons with high-risk conditions. The footnote regarding use of 
MenB among persons with high-risk conditions will remain unchanged, recommending a 2­
dose series of Bexsero® at least 1 month apart, or a 3-dose series of Trumenba® with the 
second dose at least 1-2 months after the first and the third dose at least 6 months after the 
first dose.  The reference and website for the meningococcal and HIV-infected persons
MMWR will be added once the citation is available.
 Within the Tdap footnote, language was added regarding vaccination among pregnant 
women.  The footnote states, “Administer 1 dose of Tdap vaccine to pregnant adolescents
during each pregnancy, preferably early during gestational weeks 27 through 36 weeks
gestation, regardless of the time since prior Td or Tdap vaccination.”  Additionally, the 
Catch-Up Vaccination section has been updated to indicate that persons who receive a 
dose of Tdap at age 7 through 10 years as part of a catch-up series, may receive a Tdap at 
11 through 12 years of age.
 The HPV footnote was re-written to reflect the recommendations approved during the 
previous day’s vote.  Routine vaccination now reads, “Administer a 2-dose series of HPV
vaccine on a schedule of 0, 6-12 months to all adolescents aged 11 or 12 years.  The 
vaccination series can start at age 9 years.  Administer HPV vaccine to all adolescents
through age 18 years who were not previously adequately vaccinated.  The number of 
recommended doses is based on age at administration of the first dose.  For persons
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initiating vaccination before age 15, the recommended immunization schedule is 2 doses of 
HPV vaccine at 0, 6-12 months.  For persons initiating vaccination at age 15 years or older, 
the recommended immunization schedule is 3 doses of HPV vaccine at 0, 1–2, 6 months.  A
vaccine dose administered at a shorter interval should be re-administered at the 
recommended interval.”  For special populations the language reads, “For children with a 
history of sexual abuse or assault, administer HPV vaccine beginning at age 9 years.  
Immunocompromised persons* including those with human immunodeficiency virus (HIV)
infection, should receive a 3-dose series at 0, 1–2, and 6 months regardless of age at 
vaccine initiation. Note: HPV vaccination is not recommended during pregnancy, although 
there is no evidence that the vaccine poses harm. If a woman is found to be pregnant after
initiating the vaccination series, no intervention is needed; the remaining vaccine doses
should be delayed until after the pregnancy. Pregnancy testing is not needed before HPV
vaccination.”
In conclusion, Dr. Robinson posed the following questions for discussion:
 Does ACIP approve of the edits to the pre-existing portions of the child/adolescent 
schedule?
 Does ACIP approve of the proposed high-risk figure for inclusion in the 2017 schedule?
Discussion Points
Dr. Bennett requested that the discussion be limited to conceptual issues, and that any edits to 
the wording be submitted to Dr. Robinson to be taken into consideration.
As a primary care pediatrician, Dr. Szilagyi said he thought the high risk figure could be 
incredibly helpful.  The next burden will be on partner organizations, AAP and AAFP, for how to 
translate that into very practical methods such as prompts or alerts in the EMR or codes so that 
high risk patients can be flagged.
Dr. Moore agreed that the high risk figure would be very helpful for those caring for children.  
Focusing on the two vaccines being used now that have a 2-dose or 3-dose schedule, MenB-
FHbp and HPV vaccine, she requested that someone look carefully at the math on 
recommended intervals.  For example, if someone is using a 2-dose schedule and gives the 
dose too early at less than 6 months, the recommendation for MenB-FHbp is if it is 0 and less
than 6 months, repeat the dose 6 months later.  That actually is much longer than the interval
that could be used for an ordinary 3-dose schedule of that vaccine, which is 0, 1-2, and 6 
months.  This issue is also true for the HPV vaccine.  She emphasized that a minimum schedule 
for administration of 3 doses should not vary based on one’s intention to try a 2-dose schedule 
versus a 3-dose schedule.  There should just be one minimum schedule regardless of what is
intended for those 3 doses.  Operationally, that is really important.  She said she would feel silly
telling someone they would have to wait longer than they would if they were using a 3-dose 
schedule.
Dr. Robinson replied that the Policy Note for HPV vaccine has some draft language about what 
to do if a dose is administered early in a 2-dose schedule versus administering a dose early in a
3-dose schedule.  Portions of that Policy Note draft can be added to make it clear to providers
what to do based on what schedule they were attempting initially.
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Dr. Cohn added that they could speak with the SMEs for those two vaccines as well to ensure 
that the Policy Notes math is right as well.
Dr. Middleman (SAHM) expressed gratitude for the great schedules.  She pointed out that the 
title still uses the word “children” instead of “persons.”  All of the figures state “persons.”  From a 
developmental perspective in terms of what constitutes a child, adolescent, or adult, those are 
developmental terms.  The preference would be to use ages, because they do not talk about a 
toddler schedule.  It is a developmental stage.  SAHM appreciates the highlighting of places in
the schedule with 4-6, 11-12, and 16 where there is a new place to have a vaccine.
Dr. Robinsons said they could change it to “persons” or “children and adolescents.” She 
thought they did this because the other schedule uses “adults.”
Dr. Belongia expressed gratitude for a really great figure for practitioners.  He asked about any
plans for translating this for clinical decision support systems, which will become increasingly
important going forward, and development of rules to translate these categories into analytical
quantitative measures.
Dr. Wharton responded that the challenges of translating the ACIP recommendations into 
clinical decision support is something CDC recognizes as well and is continuing to think about 
how to incorporate this into WG work.  This cannot be undertaken within the schedule process.
It needs to be addressed with individual recommendations.  CDC is open to suggestions for how
to proceed with that.  This is an ongoing challenge that they are trying to take on.
Dr. Kempe said she knew of a number of different systems that already have done this.  She 
suggested beginning with people who have already done this to avoid duplication.
Dr. Lee said that she loved the figures.  She recalled that the previous day, there was
discussion about standardizing terminology or perhaps providing examples of what constitutes
CLD.  Similarly, this should be done for all of the categories.  Some of them are very binary and 
others are more challenging.  For example, “level of immunocompromise” is difficult to assess. 
It might be helpful to offer categories of guidance, depending on the level of 
immunocompromise.
Dr. Cohn indicated that there are plans to address this issue over the next year more completely
throughout all of the language and recommendations.  Making sure these schedules are clear
can be included in that process.
Vote:  Child and Adolescent Immunization Schedule
Dr. Belongia made a motion to approve the Child and Adolescent Immunization Schedule and 
the High-Risk Figure.  Dr. Kempe seconded the motion.  The motion carried with 14 affirmative 
votes, 0 negative votes, and 0 abstentions.  The disposition of the vote was as follows:
14 Favored: Atmar, Belongia, Bennett, Ezeanolue, Hunter, Kempe, Lee, Moore, Pellegrini, 
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Adult Immunization Schedule 
Introduction
Laura E. Riley, MD
Chair, Adult Immunization Work Group
Advisory Committee on Immunization Practices
Dr. Riley began by thanking Dr. Kathleen Harriman for her leadership as Chair of the Adult 
Immunization WG for many years, recognizing her remarkable ability to cut through the forest of 
footnotes and succinctly get them to where they needed to be.  She will remain on the WG as a 
consultant.  She also welcomed new member Dr. Paul Hunter, who brings his public health and 
clinical perspective to the WG.
She reminded everyone that ACIP updates the adult immunization schedule each year.  The 
schedule represents current ACIP policy and also updates approved policy changes from ACIP
meetings.  The Adult Immunization WG meets monthly and engages in ongoing consultation 
with vaccine SMEs to recognize changes over time.  Updates in the adult immunization 
schedule are approved by the following:
 American College of Physicians (ACP) 
 American Academy of Family Physicians (AAFP)  
 American Congress of Obstetricians and Gynecologists (ACOG) 
 American College of Nurse Midwives (ACNM)
The adult immunization schedule is published in the MMWR and the Annals of Internal
Medicine.
There will be several updates to the schedule, which are derived from the ACIP
recommendations and include the following:
 Influenza vaccination (June 2016)
 Do not use LAIV in 2016–2017, modified language on egg allergy
 Tdap vaccination (October 2016)
 Guidance for use during pregnancy
 HPV vaccination (October 2016)
 Updated dosing schedule
 Hepatitis B vaccination (October 2016)
 Updated at risk populations
 Meningococcal vaccination (June and October 2016)
 Use MenACWY vaccine for adults with HIV, updated schedule for MenB-FHbp
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 Format changes
Recommended Immunization Schedule for Adults Aged 19 Years or Older, United 
States, 2017
Unified cover page, figures, footnotes, table – 6 panels
Considered human factors and ergonomics for figures
Modified footnotes for simplicity and consistency
Adult Immunization Schedule
Dr. David Kim
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
In this presentation, Dr. Kim described the proposed changes to the 2017 Adult Immunization 
Schedule.  The 2017 schedule is now a 6-panel document with a cover page of introduction and 
general information, two figures with accompanying footnotes, and a table of contraindications
and precautions.
On the updated cover page, the title has been changed to “Recommended Immunization 
Schedule for Adults Aged 19 Years or Older, United States, 2017.”  It is now consistent with the 
Child and Adolescent Schedule.  The text that was in the periphery of Figures 1 and 2 in the 
2016 schedule has been moved to the cover page.  The revised cover page introduces a list of 
acronyms used for vaccines routinely recommended for adults.  When these changes are 
incorporated, the cover page for the proposed 2017 schedule contains more information and 
looks like this:
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The changes proposed for Figure 1 for 2017 include the following:
 Revise the title and instruction to the reader
 Combine age groups 27 through 49 and 50 through 59 to create the new age group 27 
through 59
 Use the acronyms introduced in the cover page in the vaccine column
 Lump the live vaccines (MMR, varicella, zoster) together to consolidate information and to 
simplify graphics
 Use colored blocks instead of colored bars for indication
 Move the footnote on the VICP to the cover page
 Remove the clause “zoster vaccine is recommended regardless of past episode of zoster” in 
the legend, because the information is contained in the footnote for zoster vaccination
 Move the text to the cover page.
After incorporating the proposed changes, this is what the proposed Figure 1 would look like:
The changes proposed for Figure 2 for 2017 include the following:
 Make the changes already described for Figure 1
 Move the column for MSM to the right of healthcare personnel to lump at-risk populations
 Update the footnotes to link them with the information specified by medical conditions and 
other indications
 To reflect the recommendation made by ACIP in June to routinely vaccinate adults with HIV
infection with serogroups A, C, W, and Y meningococcal vaccine, change the color of this
indication bar for this group from purple to yellow
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After incorporating the proposed changes, this is what the proposed Figure 2 would look like:
Proposed changes to the Table of Contraindications and Precautions include the following:
 Add general information to explain the significance of contraindications and precautions for
vaccination
 As in Figures 1 and 2, use acronyms for the vaccine column and list the acronyms at the 
bottom of the new page
 Consolidate contraindications and precautions that are applicable to all routinely
recommended vaccines
 List additional contraindications and precautions for applicable vaccines
 Revise precaution for IIV in egg allergy per June 2016 update
 State that LAIV should not be used during the 2016-2017 influenza season 
Currently, this table is available through the ACIP website and is a standalone document that is
not integrated into the schedule.  However, it will become a part of the schedule in 2017.  Here 
is what the Table of Contraindications and Precautions will look like based on these changes:
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The footnotes went through a substantial makeover.  The proposed footnote revisions for
Figures 1 and 2 include the following:
 The footnotes are limited to information about vaccines:
 The footnote on General information was moved to the cover page
 The footnote on Immunocompromising conditions was removed, with applicable 
information added to specific vaccination sections
 To standardize the structure, each footnote has been formatted to include the following:
 A general information section that describes routine recommendations
 A special populations section that describes recommendations for groups identified 
in Figure 2
 To standardize the content, each footnote has been reviewed and revised to ensure the 
following:
 Consistent sentence structure, flow of information, use of mathematical symbols and 
acronyms
 Trade names are included for identification purposes only (hepatitis B and 
meningococcal vaccines)
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Changes to the content of specific footnotes follow, with the changes shown as strikethroughs
(deletions) and / or underlines (additions): 
Footnote 1. Influenza Vaccination
 General information
All persons aged 6 months or older…
Adults aged 65 years or older may receive high-dose IIV or adjuvanted IIV
Healthcare personnel who care for severely immunocompromised persons… should 
receive IIV or RIV; [those] who receive LAIV should avoid providing care for severely
immunocompromised…
 LAIV should not be used during the 2016–2017 influenza season
 Special populations
Adults with a history of egg allergy who have only hives after exposure to egg should 
receive age-appropriate IIV or RIV
Adults with history of egg allergy other than hives may receive age-appropriate IIV or
RIV. IIV should be administered in… medical setting and supervised by a healthcare 
provider…
Pregnant women and women who might become pregnant in the upcoming influenza 
season should receive IIV
Footnote 2. Td/Tdap Vaccination
 General information
Adults who have not received Tdap or for whom pertussis vaccination status is
unknown should receive 1 dose of Tdap followed by a Td booster dose every 10 
years
 Special populations
Pregnant women should receive 1 dose of Tdap during each pregnancy, preferably
early during gestational weeks 27–36, regardless of her prior history of receiving 
Tdap
Footnote 4. Varicella Vaccination
 General information
Adults without evidence of immunity to varicella should receive…
 Special populations
Pregnant women should be assessed for evidence of varicella immunity… Birth 
before 1980 is not considered evidence of immunity
Healthcare institutions should assess and ensure that all healthcare personnel have 
evidence of immunity to varicella. Birth before 1980 is not considered evidence of 
immunity…
Adults with a malignant condition, including those affecting the bone marrow or
lymphatic system, or systemic immunosuppressive therapy should not receive 
varicella vaccine
Adults with HIV infection and CD4+ count ≥200 may be considered for a 2-dose 
series of varicella vaccine… CD4+ count <200 should not receive varicella vaccine
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Footnote 5. Zoster Vaccination
 General information
Adults aged 60 years or older should receive 1 dose of zoster vaccine, regardless of 
whether they had a prior episode of herpes zoster
Although… licensed by the U.S. Food and Drug Administration for… persons aged 
≥50 years… ACIP recommends… begin at age 60 years
 Special populations
Adults aged 60 years or older with chronic medical conditions may be vaccinated 
unless they have a medical contraindication…
Adults with a malignant condition affecting the bone marrow or lymphatic system or
who receive systemic immunosuppressive therapy should not receive zoster vaccine
Adults with HIV infection and CD4+ count ≥200 have no zoster vaccine 
recommendation because there is a lack of evidence available for or against zoster
vaccination… CD4+ count <200 should not receive zoster vaccine
Footnote 6. HPV Vaccination
 General information
Adult females through age 26 years and adult males through age 21 years who have 
not received any HPV should receive a 3-dose series of HPV at 0, 1-2 and 6 months. 
Males aged 22 through 26 years may be vaccinated
Adult females through age 26 years and adult males through age 21 years (and 
males aged 22 through 26 years) who initiated HPV series before age 15 years and 
received 2 doses at least 5 months apart are considered adequately vaccinated and 
do not need an additional dose of HPV
Adult females and males… who initiated HPV series before age 15 years and 
received 1 dose or 2 doses at least 5 months apart are not… adequately
vaccinated… and should receive 1 additional dose of HPV
Note: HPV is routinely recommended… at age 11 or 12 years. For adults who 
initiated but did not complete HPV series, consider their age at first HPV vaccination 
and other factors to determine… adequately vaccinated
 Special populations
MSM through age 26 years, if not previously vaccinated, should…
Adults through age 26 years with immunocompromising conditions (described 
below), including HIV, should receive…
Pregnant women are not recommended to receive HPV…
Footnote 9. Hepatitis B Vaccination
 General information
Adults who seek protection from HBV infection may receive a 3-dose series of…
hepatitis B vaccine at 0, 1, and 6 months
 Special populations
Adults with chronic liver disease, hepatitis C virus infection, HIV infection, age <60 
years with diabetes… should receive…
Adult patients receiving hemodialysis or with other immunocompromosing conditions
should receive a 3-dose series of 40 mcg/mL Recombivax HB at 0, 1, and 6 months
or a 4-dose series of 40 mcg/mL Engerix-B at 0, 1, 2, and 6 months
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Footnote 10. Meningococcal Vaccination
As a reminder, the ACIP recommendations made October 19, 2016 were:
• 	 For persons at increased risk and for use during outbreaks, 3 doses of MenB-FHbp 
should be administered at 0, 1–2, and 6 months
• 	 For healthy adolescents who are not at increased risk for meningococcal disease, 2 
doses of MenB-FHbp should be administered at 0 and 6 months
• 	 If second dose is given at an interval less than 6 months, a third dose should be given 
at least 6 months after the first dose
This footnote reflects these recommendations and the recommendation made during the 
June 2016 meeting that persons with HIV should receive MenACWY as shown below.
 Special populations
Adults with… asplenia or… complement component deficiencies should receive…
MenACWY… and either a 2-dose series of MenB-4C at least 1 month apart or a 3­
dose series of MenB-FHbp administered at 0, 1–2, and 6 months
Adults with HIV infection… should receive a 2-dose primary series of MenACWY at 
least 2 months apart... Revaccinate with MenACWY every 5 years… MenB for 
adults with HIV infection is not routinely indicated…
Microbiologists… should receive… MenACWY… and either a 2-dose series of 
MenB-4C… or a 3-dose series of MenB-FHbp…
Adults at risk because of… outbreak… should receive… either a 2-dose series of 
MenB-4C… or a 3-dose series of MenB-FHbp… if the outbreak is attributable to 
serogroup B
Young adults aged 16 through 23 years may be vaccinated with either a 2-dose 
series of MenB-4C at least 1 month apart or 2-dose series MenB-FHbp at 0 and 6 
months… 
When incorporated, the footnotes in the 2017 schedule would look like this:
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Based on ACIP comments and suggestions during this session, the draft 2017 adult 
immunization schedule will be revised and reviewed again by the WG and SMEs.  Concurrence 
will then be obtained by the ACP, AAFP, ACOG, and ACNM.  The revised adult immunization 
schedule, including figures and footnotes, will be submitted to CDC for clearance by January
2017. The cleared adult immunization schedule will be submitted to the MMWR as a Notice to 
the Reader referring the reader to the CDC website to access the updated schedule, and the
Annals of Internal Medicine for publication in February 2017.  With help from its partners, CDC
will work to disseminate the schedule widely to help promote adult immunization.
The 2017 Adult Immunization Schedule has gone through a lot of changes.  The graphics were
evaluated for usability and simplicity, the text in footnotes and elsewhere were overhauled for
readability, completeness, and consistency.  However, there is more work to do to improve the 
schedule as a useful tool for healthcare providers.  Toward that end, CDC will kick off the Adult 
Immunization Schedule Evaluation Project in November 2016.  Over the next year, CDC will
conduct in-depth interviews of healthcare providers who use the adult immunization schedule to 
learn what their needs are, continue the efforts to improve the graphics and content of the 
schedule, and continue to work on improving the implementation of ACIP recommendations for
immunizing adults.
Discussion Points
Dr. Messonnier explained that typically the schedule has been presented on the first day of the 
ACIP meeting.  However, there would then be votes that impacted the schedule.  This seemed 
out of order, so the decision was made to purposely change the schedule presentation to the 
second day of this meeting.  She thanked Dr. Kim for incorporating all of the changes from the 
first day, and apologized for the copies provided to the members with incredibly small font.  She 
assured everyone that they would keep working to give the members better access to ensure 
that they have adequate time to think about substantive changes.
Dr. Bennett requested that everyone focus on the content versus the wording, given that there 
will be additional time to submit comments to Dr. Kim and his team to have some impact on the 
wording.
Dr. Kempe said she thought they had done an incredibly good job of simplifying the schedule 
and that it was a great improvement.  While the footnotes are still voluminous, she found them
to be very well-organized.
Dr. Lee said she liked having the presentation on the second day and thought the schedule was
great.  In many ways, it reinforced the intent of the recommendations, which came across in the 
wording of the schedule.  Regarding the zoster vaccine, she wondered whether it should be 
distinguished that it was referring to the live attenuated vaccine because that will need to be 
clarified now or later as things change over time.  Regarding immunocompromised individuals, 
the 3 doses of Hib post-stem cell transplant stood out to her, in part because stem cell
transplants also are done in young children.  That one recommendation seemed out of place to 
her, in part because she was trying to make it concordant with persons 18 years of age and 
younger, and she was trying to figure out why not the other vaccines that also would be 
administered.  She suggested that additional thought be given to that detail.
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Dr. Kim said that as a general reference, the Adult Immunization Schedule and the Child / 
Adolescent Immunization Schedule reflect decisions already made by ACIP and approved for
publication.  The inclusion of select vaccines, such as Hib, is because there are indications for
that vaccine for adults.  However, there are exceptions to routine recommendations.  It is these 
exceptions that drive the volume up on in the footnotes.  Where possible, the work group tried to 
minimize outlining all details but it’s a balancing act to have enough detail but not drive up the 
volume of the footnotes.  The goal is to be as comprehensive as possible based on the 
recommendations already made by ACIP.
Dr. Cohn added that as part of what they are talking about in terms of making some of these 
definitions consistent throughout the different vaccines over the next year, they also intend to 
find inconsistencies in the recommendations, but it may just be a different WG proposing 
different things.  The goal is to harmonize in places where it seems reasonable.
Dr. Fryhofer (AMA/ACP) did not think that the blocks instead of bars were practical.  If looking at 
Figure 2 when trying to pick one of the special conditions and follow it down, it is not clear what 
goes with what.  It would be a lot more practical for the busy practicing physician to be able to 
follow the headings down and figure out what immunizations that particular patient needs.  
Regarding Footnote 9: Hepatitis B Vaccination, she could not tell from what was shown on the 
screen if fatty liver disease was included specifically because this is being seen so much in 
practices and might not be a condition that many clinicians realize is an indication for hepatitis B
vaccine.
Referring to Figure 2, the high-risk figure in the pediatric schedule, with lines behind it, Dr.
Messonnier asked whether that would solve the issue.
Dr. Fryhofer (AMA/ACP) said that she had specifically compared the two and it would be very
helpful.
While she appreciated Figure 2 and the effort to address high-risk, Dr. Groom (IHS) expressed 
concern about how it will be interpreted.  For example, looking down the list for MSM, it appears
that MSM should receive PCV13 and PPSV23.  For those who do not know that this is just for a 
certain medical indication, but not that medical indication, clinicians will look at it and think
PCV13 must be given to all of their diabetic patients.  Perhaps the footnote could be changed to 
state “may be recommended for patients with the appropriate medical condition,” but this is a 
high risk table and when people see that condition, she is afraid they will assume if it is purple, it 
means that a high-risk person should get it because they are in that special risk group.
Dr. Thompson (NVAC) applauded the efforts to further develop this table and thought it was a 
big step forward.  She noted that the tables for the younger individuals under 18 years of age 
did not include an MSM column.  There also are some differences between the two tables in the 
pregnancy columns, which appear in both.  Tdap is recommended for each pregnancy, so it is
probably unusual that there are many individuals who have pregnancies under the age of 18.  
But, she wondered what the recommendation would be in that case in terms of the clinician 
reconciling these two things.  Adolescents are “falling through the cracks” still, so reconciling 
these might be useful.  Also, it was not clear to her why the vaccines were listed in the order
that they were.  It seemed to her that they could be listed alphabetically or at least in the same 
order on both charts.
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Regarding the footnote under influenza pertaining to pregnant women and women who are 
planning to become pregnant during the upcoming influenza season, Dr. Wayne Hachey 
(Protein Science) suggested adding recombinant influenza vaccine (RIV) as it does have a 
Class B category for pregnancy and does not contain extras in the vaccine that many pregnant 
women avoid.  He also suggested adding RIV for adults 65 years of age or greater.  Protein 
Science submitted data to the WG and ACIP showing that Flublok®  had increased effectiveness 
in the over 50 population to include the over 65 population during the influenza season.  Even 
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Regarding the exclusion of MSM on the child / adolescent schedule, Dr. Robinson pointed out 
that though vaccines for adults differ by MSM status, they do not differ for children.  For
instance, adult males 22 through 26 years of age receive HPV if they are MSM.  However, all
adolescents through 18 years of age are recommended to receive HPV vaccine.
Regarding the order of vaccines presented for Figures 1 and 2, Dr. Kim indicated that these 
were done with graphics in mind.  In years past, an effort was made to use alphabetical order
but that simply did not work because of the complexity that it imposed on the eyes to follow.  
Other attempts were made with different colors, different shades, and hatching of the bars.  
However, through trial and error, the current listing was made.  He invited recommendations to 
improve on that.
Dr. Romero indicated that the ordering for the childhood / adolescent vaccines was an attempt 
to reflect how these vaccines are used and the timing in which they are used.  There was
discussion about putting them in alphabetical order, but it made more sense to the WG to leave 
them in the order in which they are introduced in children.
Dr. Kempe wondered whether one of the concerns might be addressed by using the same 
wording for the purple color on the childhood schedule that basically states that one has to have 
an additional risk factor for which the vaccine would be recommended, or using the hatch 
marks.  Those two wordings were created because of the concern raised that it was difficult to 
tell whether something was indicated or additional doses were needed.
Dr. Messonnier expressed appreciation for all of the comments.  One issue is that it is unknown 
how the schedule is used, especially by adult providers.  It is clear that Pediatricians are using it 
routinely as part of their normal practice, and that the schedule has been vetted a lot.  The issue 
of the adult schedule and extensive footnotes is that this is the first step toward moving the adult 
schedule.  The questions everyone was asking were the same as the ones CDC is asking and 
hopes to get at through the testing of the schedule with adults, and asking how many clinicians
use the schedule versus clinical support tools or online aids versus a hard, flat copy of the 
schedule on the wall.  More information will be provided about this over the next year.  They do 
not want to make dramatic changes until more information is acquired.
Dr. Bennett replied that the goal was to ensure that the recommendations on the schedule 
match the influenza recommendations.
Regarding the issue of how schedules are used in clinical practice, Dr. Hunter said that as a 
clinician and a public health practitioner, he did not think they were talking about the audience 
who administers vaccination, which is medical assistants and nurses.  He suggested including 
their impressions of how the schedules are being used.  Forecasts are printed out from
registries or the EHR for a particular patient, but his impression is that clinicians look at the 
133





































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
schedule to double-check it to determine whether it really makes sense and then look at 
standing orders to determine whether to give the vaccination.
Dr. Hayes (ACNM) registered her objection to using the word “lifestyle” as she does not think it 
is clinically appropriate.  She agreed with Dr. Kempe about using the language for the purple 
bar from the child / adolescent schedule.
Dr. Kim said he was hesitant to comment on that because it was not a decision made by him.  It 
was a reflection of the content of previous publications on ACIP policy.  ACIP could address
that, as could the community that deals with these issues in general.
Dr. Moore echoed the encouragement that if it is feasible at all, to use exactly the same wording 
on the purple bar for both adults and children in order to clean up the question about lifestyle.  If 
using the same color, people who treat children and adults will anticipate that when they see the 
same color, it means exactly the same thing.
Dr. Messonnier replied that they would review this to determine whether there is a way to make 
the language more harmonious with the childhood schedule and avoid pitfalls wherever
possible.
Dr. Fryhofer (AMA/ACP) said she thought internists are having to grapple with the increased 
complexity of adult immunization.  They must learn from their pediatric colleagues and become 
more disciplined in looking at the adult schedule.  It is totally different from the training many
clinicians received in training during residency.  It is a wonderful fact of life that there are now
wonderful ways to keep people healthy, so the ACP has many efforts underway to help increase 
internists’ knowledge and use of the schedule.  It is a very valuable tool.  She expressed great 
appreciation for all of the work that the WG has put into making the schedule a “go to” source.  
She also expressed support for changing Figure 2 back to bars.
Dr. Moore suggested that a nice way to deal with 2-dose versus 3-dose based on feedback from
her colleagues who work in registry programming is simply for vaccines that may be given on a 
2- or 3-dose schedule to state “if the minimum interval for a 2-dose schedule is not met, please 
complete using the 3-dose schedule.”  This avoids dealing with all of the convoluted language 
about invalid doses.
Dr. Savoy (AAFP) emphasized that the schedules were simply summarizing what had already
been decided and voted upon in the actual recommendations, so they could not just make 
changes as they pleased.  For example, the term “lifestyle” must have been used in a 
recommendation so they could not just edit it in the schedule.  She thought they probably would 
have to find the source recommendation and bring it before the committee for review.  While 
family physicians have been relatively easy to train on the schedule because they see all ages, 
she is finding that a number of people are using electronic ways of managing the schedule.  
Although most everyone’s office has the schedule posted on the wall, the vast majority of 
people are getting their information from some type of electronic version.  For example, the 
schedule has been translated into a variety of apps that people are using.  Others are using it 
directly out of their EMR or their registry for their state pulls and sends them that information.  
Even though they spend a lot of time on how to make the schedule look pretty or how to make it 
work, she honestly did not think the vast majority of clinicians are spending as much time 
looking directly at the child or adult schedule as they are the content of what is behind it.  She 
would be more interested in ACIP being crystal clear about the definitions of what they want and
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the start and end points so that the registries are as accurate as possible, than worrying as
much about the lines.
Dr. Pittman (DVA) said that DVA eagerly awaits the release of the adult schedule every year, 
and asks Dr. Kroger to hold a webinar for the people in the field to discuss the changes, and it is
very well-received.  They do use the schedule to translate into an electronic record, because it 
is growing increasingly complex.
Regarding the comment about influenza vaccine, Dr. Belongia thought it was a valid point that 
since ACIP does not make any preferential recommendations for any particular product, the 
language should state “use any licensed influenza vaccine” or it should list all of them.
Ms. Stinchfield (NAPNAP) underscored the earlier comment about the end users of the 
schedules, the MAs and RNs.  Their schedule WG takes that into consideration and talks about 
it quite a bit.  CDC sent a team to Children’s Minnesota clinics to conduct focus groups, 
speaking to most of their MAs.  The agency has done this across the country, and it is a really
important point to keep focused on.
Dr. Fryhofer (AMA/ACP) added the importance of eventually establishing a national
immunization registry.  Because the adult schedule has become so complicated, it is sometimes
very difficult for a practicing clinician to know which vaccines to give because they do not know
which vaccines patients have received.  Some EMRs will report vaccines to the state registry, 
but people do not always live in one state.  Currently, the registries do not speak back to the 
EMRs.  She has patients who are over-vaccinated and others who are under-vaccinated due to 
this.  Children and young adults cannot go to school or college unless they have immunizations.  
But there is not a similar check-up for adults who go to a new job unless they are in healthcare.  
A national immunization registry would help with this and improving the interface between 
registries and EMRs.
Dr. Kempe said she very much supported the prospect of a national registry; however, they
recently conducted a national survey of internists, family physicians, and pediatricians across
the country.  The unfortunate fact is that a very small minority of internal medicine physicians
are using their state registries.  A national registry is not going to work unless there is much 
more consistent use of registries by adult providers.  She thought that was where they needed 
to go first.
Vote:  Adult Immunization Schedule
Dr. Riley made a motion to approve the Adult Immunization Schedule.  Dr. Romero seconded 
the motion.  The motion carried with 14 affirmative votes, 0 negative votes, and 0 abstentions.  



























   
    
    









ACIP recommended that there should be monitoring of the impact of the new recommendation 
in the target population of adults >65 years old, as well as continued monitoring of disease 
trends among PCV13-naïve adults 19 through 64 years of age without PCV13 indications, to 
evaluate the impact of herd effects and the long-term utility of routine PCV13 use among adults.  
In addition, ACIP is to be updated routinely on the changes in the vaccine-preventable disease 
burden among adults due to PCV13 direct and indirect effects during the next 3 years, and 














Pneumococcal Vaccines Work (Arthur Reingold, Chair, unable to be present)
Advisory Committee on Immunization Practices
Dr. Kempe
She reminded everyone that the Pneumococcal Vaccines WG’s terms of reference are to:
 Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of 
pneumococcal vaccines;
 Review current recommendations considering up-to-date evidence, including 
epidemiological studies conducted post-licensure, and assess strength of the evidence; and
 Revise or update recommendations for pneumococcal vaccine use, as needed.
As a reminder, ACIP recommended PCV13 for adults ≥65 years of age in August 2014.  The 
WG conclusions at that time were that in the short-term, such a recommendation for universal
PCV13 use in this age group was warranted for the opportunity to prevent disease for the 2014­
2015 respiratory seasons and for a number of additional years.  However, the WG did realize 
that in the long-term, continued herd effects could limit the utility of such a universal
recommendation.  The magnitude of indirect effects were unknown, and there was uncertainty
around the burden of vaccine preventable non-bacteremic pneumonia.
Because of the recognition of this being a time-limited recommendation, the following statement 
was included in the ACIP vote:
The recommendations for routine PCV13 use among adults >65 years old should be re­
evaluated in 2018 and revised as needed.
During this session, updates were provided on the direct and indirect impact of PCV13 use on 
invasive disease among adults and children in the US; PCV13 impact among adults with chronic
medical conditions with and without indications for PCV13 use; and the proposed research 
agenda to inform potential policy reconsideration in 2018 for PCV13 use among adults.
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Direct and Indirect Impact of PCV13 on Invasive 
Disease Among Adults and Children in the US
Tamara Pilishvili, MPH
Respiratory Diseases Branch
National Center for Immunization & Respiratory Diseases
Centers for Disease Control and Prevention
Ms. Pilishvili reminded everyone that in 2010, PCV13 replaced PCV7 in the US infant 
immunization schedule.  In 2014, PCV13 was recommended for use in series with PPSV23 for 
all adults >65 years.  The impact of PCV13 on invasive pneumococcal disease (IPD) among 
adults and children was evaluated.  Data were used from the ABCs system to compare 
incidence as cases/100,000 population before PCV13 was introduced using the time period 
2007-2008 to post-PCV13 using the time period 2014-2015. 
With regard to trends in IPD incidence by serotype group in children under 5 years of age from
2007–2015, dramatic reductions were observed in invasive infections shortly after 2010.  These 
reductions continued through 2012.  All of the reductions observed were driven by PCV13 
serotypes.  From 2012 through 2015, the rates plateaued at around 2/100,000.
Regarding the changes observed in individual serotypes, the most dramatic reductions in 
PCV13-type disease were driven by reductions primarily in serotypes 19A and 7F.  These also 
were the only statistically significant reductions observed.  Reductions were observed in 
serotype 3 disease, but they were not statistically significant.  Also being monitored is whether
any replacement disease is being observed due to non-vaccine serotypes.  Thus far, no 
increases have been observed in non-vaccine serotypes.  To put everything in perspective, Ms. 
Pilishvili showed the following graph of the overall impact of conjugate vaccines, PCV7 
introduced in 2000 and PCV13 introduced in 2010:
In children under 5 years of age, overall invasive pneumococcal infections have been reduced 
from approximately 100/100,000 to about 9/100,000.  Vaccine-type infections have been 
reduced to 2/100,000.  This is a great success story.
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In terms of annual trends in IPD incidence among adults ≥65 years of age from 2007 through 
2015, when the pediatric vaccine was introduced, reductions also were observed in adult 
disease.  The incidence among adults decreased from approximately 40/100,000 to about 25/ 
100,000 for overall infections.  PCV13 types drove these changes with the introduction of the 
pediatric vaccine.  Infections caused by PCV13 types in this age group are down to 
approximately 5/100,000.  Looking at other serotypes that are included only in the 
polysaccharide vaccine, PPSV23 (11 serotypes not included in PCV13), or serotypes that are 
not included in any vaccine formulation, no significant changes have been observed at the 
population level.
Regarding rate differences by serotype among adults ≥65 years from 2007 through 2008 versus
2014 through 2015, PCV13 serotypes 19A and 7F essentially drove the reductions observed.  
These were statistically significant, but among adults, statistically significant decreases also 
were observed in serotype 3 infections.  In 2014 and 2015, vaccine type IPD has plateaued and 
a slight increase in serotype 3 disease was observed.  So far, the 2014 / 2015 increases
observed in serotype 3 infection have not been statistically significant and it is unclear how to 
interpret this, but monitoring will continue.  Very small magnitude increases have been observed 
in non-vaccine serotypes, with statistically significant increases only for type 23B IPD.  With 
respect to trends in invasive pneumococcal disease among adults aged ≥65 years old from
1998 through 2015, again, there were very dramatic reductions in invasive pneumococcal
infections that were driven with the introductions of PCV7 and PCV13 serotypes.
The following pie charts demonstrate how the serotype distribution has changed since
introduction of PCV13 in adults:
In 2007-2008, PCV7 serotypes accounted for 43% of invasive infections.  In 2014-2015, that 
decreased to 22% of all invasive infections.  In 2014-2015, serotypes that are unique to 
polysaccharide vaccine accounted for 36% of invasive disease and non-vaccine serotypes
account for 42% of invasive disease.
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 5-18  PCV13  -84.78 (-91.04, -74.13)*
 
  ALL IPD  -55.28 (-66.11, -41.00)*
 19-64  PCV13  -68.66 (-72.17, -64.72)*
 
 NVT  -10.9 (-21.47, 1.08)
 
 >65  PCV13  -69.29 (-73.73, -64.10)*
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This table shows the picture being observed across the age groups in terms of the impact of 
PCV13: 
* statistically significant decrease 
In summary, significant reductions were observed in PCV13-type IPD following the 5 years of 
PCV13 use.  Reductions were driven by types 19A and 7F.  There were significant decreases in
overall IPD among children and adults.  No significant changes were observed in non-PCV13
types among children and adults.  There were increases of a small magnitude of <0.5/100,000
in select non-PCV13 serotypes.  In 2010-2015, PCV13 use in children has prevented an 
estimated 280,000 IPD cases and 20,000 deaths among all ages.
In conclusion, in the 5 years post-PCV13 introduction, significant reductions were observed in 
IPD caused by the PCV13 serotypes in children and adults, indicating continued direct and 
indirect effects.  There has been no evidence of serotype replacement in children or general
population of adults.
Discussion Points
Dr. Schmader (AGS) emphasized that 66 year olds are generally different from 88 years in their
vulnerability to problems, and asked whether the data could be categorized in different age 
groups above 65 such as 70 through 79 and above 80.
Ms. Pilishvili replied that they have stratified it across different age groups.  The impact is
similar.  Obviously, 85 year olds have higher overall incidence of disease.  In terms of 
decreases in PCV13 types and lack of strong replacement observed, it is similar across age 
groups.
Dr. Bennett requested further information about why plateauing was occurring.
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 Age  (years)  Serotype group   % change (95%CI)
 Non-PCV13  -5.77 (-34.63, 35.83)
 PPSV11  6.19 (-4.85, 18.52)
 PPSV11  -10.11 (-22.59, 4.39)
 ALL IPD  -35.11 (-39.23, -30.72)*




-86.82 (-90.59, -81.53)* 
-10.88 (-28.09, 10.44) 
-58.24 (-64.67, -50.65)* 
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Ms. Pilishvili responded that through 2014, reductions were observed in all PCV13 serotypes.  
From 2014 through 2015, there were plateaus or slight increases that were driven by serotype 
3. At this point, it is not statistically significant and the meaning of it is difficult to interpret.  They 
will continue to monitor this. 
Dr. Romero asked how granular Ms. Pilishvili could get with regard to invasive disease.  For
example, could it be broken out by pneumococcal meningitis?  In a consortium of 8 children’s
hospitals, since the introduction of PCV13, there was not a decrease in the number of cases of
pneumococcal pneumonia.  There was a decrease in the number of vaccine strains, and there 
was a slight trend of increasing non-vaccine types. 
Ms. Pilishvili indicated that they can look at individual clinical syndromes.  Some of those 
analyses are still ongoing.  They did assess pneumococcal meningitis, and the trends they are 
seeing are similar.  Although there seems to be more replacement observed with meningitis in 
the elderly.
Dr. Gemmill (NACI) asked whether there was any information on coverage rates for children 
versus those over 65 years of age since the recommendation in 2014, to determine what type of 
impact that is having.
Ms. Pilishvili indicated that the last presentation would address adult coverage.  Pediatric
coverage has been pretty stable.  After the transition from PCV7 to PCV13, uptake was similar
in the pediatric population.
Dr. Whitley-Williams (NMA) asked whether there has been any reduction in the disparity gap 
between blacks and whites, particularly as it relates to IPD.
Ms. Pilishvili responded that they have not analyzed this with the most recent data, but they
have assessed the disparities and how those have changed post-PCV7 and shortly after PCV13 
was introduced.  The disparities have been eliminated in terms of the PCV13 vaccine-type 
infections.  However, the disparities still exist in terms of overall IPD caused by other serotypes.
Dr. Whitley-Williams (NMA) asked whether that was due to the fact that other serotypes are not 
contained in the vaccine that are more prevalent in the black population.
Ms. Pilishvili indicated that the distribution is similar overall.  In later years, non-vaccine 
serotypes account for a higher proportion of infections.  While the vaccine did prevent cases
among various groups and reduced or eliminated those disparities, overall infections are caused 
by non-vaccine serotypes in every group.  However, the disparities still exist in terms of the 
rates of disease cause by non-vaccine types.
Dr. Sun (FDA) said his understanding was that the recommendation was subject to reevaluation 
because it depends on the challenges of sorting out the direct and indirect effects of the impact 
of PCV13 on the elderly. He asked how direct and indirect effects would be sorted out with 
these observed trends.
Ms. Pilishvili requested that Dr. Sun hold this question until after her next presentation, during 
which she planned to discuss how direct and indirect effects would be sorted out.
Dr. Stephens asked whether there are specific data on Alaska Natives and / or other susceptible
populations among whom pneumococcal disease has been significant.
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Ms. Pilishvili responded that ABCs does not have data on the Alaska Natives or other highly
susceptible populations.  Disparities are typically addressed in terms of racial disparities.  There 
are studies ongoing in Alaska similar to the ABCs surveillance that monitors the trends and 
impacts of PCV13.  She believes they see a similar impact of PCV13 introduction, with
somewhat more replacement in the Alaska population than observed in the general US
population. She deferred to Dr. Whitney for additional information.
Dr. Whitney (SME) added that Alaska had very good impact quickly with PCV13 serotypes
disappearing.  They may have experienced a little bump up in the non-vaccine types.  It is a 
population that needs to be observed more closely because they are susceptible to other
serotypes, but it also is a population for which the numbers are small so it is hard to draw too 
much of a conclusion from the early figures.  They will check this again and will provide 
additional information to ACIP.
Ms. Groom (IHS) indicated that Johns Hopkins is continuing to monitor in the Southwest.  In 
some American Indian populations, there is an ongoing disparity similar to what is observed in 
the African American population that continues to perplex them.  They are contemplating ways
to continue to tease that out.  Great gains have been made with PCV13, but at the same time, 
they are still observing a disparity of IPD in the American Indian population.
Changes in Invasive Disease Burden Among 
Adults With and Without Indications for PCV13 Use
Sana Shireen Ahmed, MD
National Center for Immunization & Respiratory Diseases
Centers for Disease Control and Prevention
The focus of Dr. Ahmed’s presentation was to discuss the impact of PCV13 on invasive disease 
among various groups of adults, with and without indications for PCV13 use.  ACIP has
recommended the 13-valent pneumococcal conjugate vaccine (PCV13) in series with 23-valent 
polysaccharide vaccine (PPSV23) for all adults 65 years and older and for adults 19 through 64 
years old with immunocompromising conditions.  For immunocompetent adults <65 years of age 
with chronic conditions, such as heart disease or diabetes, only PPSV23 is recommended
currently. Thus, this subgroup of adults with no PCV13 indications is experiencing only indirect 
PCV13 effects through PCV13 use in children.
The objectives of this study were to: 1) evaluate PCV13 impact in terms of direct and indirect 
effects on IPD burden among adults 19 through 64 years of age, with and without current 
indications for PCV13 use; 2) estimate remaining vaccine preventable IPD burden among adults
19 through 64 years old with select medical conditions in 2013–2014, following 4 years of 
PCV13 use in children.
For the numerators, IPD cases were identified through the ABCs system, a laboratory and 
population-based surveillance system ongoing at 10 sites.  An IPD case was defined as
isolation of pneumococcus from a normally sterile site.  For the denominators, the National
Health Interview Survey (NHIS) was used to estimate the US population of adults.  NHIS is a 
data collection program of the CDC’s National Center of Health Statistics (NCHS). It is a cross-
sectional survey with interviews administered to households and non-institutional groups
throughout the year. The analysis included ABCs IPD cases among adults 19 through 64 years
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of age with and without select chronic conditions, and corresponding NHIS population
denominators.
Adults with the following conditions were identified within ABCs and NHIS and were placed into 
three groups:
Conditions and risk factors for which there are current indications for PPSV23 vaccination alone 
will be referred to as “PPSV23-only indications group” shown on the left.  Adults with 
immunocompromising conditions for which PCV13 and PPSV23 are recommended will be 
referred to as “adults with PCV13 indications.”  Please note that HIV and renal failure, both 
current indications for PCV13 use, were not included in this analysis due to NHIS data 
limitations. Healthy adults in the same age group who did not have any of the medical
conditions listed above will be referred to as the “healthy group.” 
In order to compare the effects of PCV13 use on IPD burden among adults 19 through 64 years
of age with select conditions, two distinct periods were assessed during the 2007-2014 period.  
PCV13 replaced PCV7 in 2010 for use among children, so anything prior to 2010 was
considered pre-PCV13, the baseline. From 2010-2014, adults were experiencing PCV13 
indirect effects.  This is considered to be the post-PCV13 era.  In 2012, PCV13 was
recommended for use among adults with immunocompromising conditions. Since 2012, healthy
19 through 64 year old adults and adults with conditions for which only PPSV23 is
recommended continued to experience indirect PCV13 effects. Since 2012, adults with PCV13 
indications have been experiencing both direct and indirect vaccine effects. Therefore, in order
to evaluate PCV13 effects on burden, a pre-PCV13 baseline for the period 2007-2008 was
compared to the post-PCV13 period 2013–2014.
To address the first objective, estimates were calculated for IPD incidence, percent changes in 
overall and PCV13-type IPD incidence between the 2 periods, and the contribution from direct 
and indirect effects on overall impact among adults with PCV13 indications.  Overall, IPD rates
declined among healthy adults from 8/100,000 to 4/100,000 with a 47% decline in overall IPD
rates. Among adults with PPSV23-only indications, IPD incidence declined from 15/100,000 to 
12/100,000 with a 19% decline.  Among the group with PCV13 indications, IPD rates declined
from 36/100,000 to 27/100,000 persons with a 24% decline. To further understand the primary
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drivers of these declines in IPD rates, the burden was broken down by serotype groups. This
table shows IPD incidence pre- and post-PCV13 and percent changes in the last 3 columns by
serotype group and presence of vaccine indication:
The serotypes were grouped as PCV13-types, the 11 serotypes unique to PPSV23 labeled as
“PPSV23 unique,” and non-vaccine types, which includes serotypes not covered by any
vaccine. Looking at the rate changes across serotype groups, the reductions in overall IPD
rates are driven by declines in PCV13 IPD rates.  PCV13 IPD rates declined by 73% in the 
healthy group and by 57% among adults with and without indications for PCV13 use.  Similar
absolute changes in rates among healthy adults and adults with PPSV23 indications
demonstrate that both groups experience similar indirect effects from child vaccination.  Similar
percent declines in IPD incidence were seen in adults with and without PCV13 indications,
suggesting that the adults with vaccine indications largely experienced indirect effects. In 2013­
2014, PCV13-type IPD rates were low across all groups. No reductions or increases were seen 
in IPD caused by PPSV23 unique serotypes across all condition groups, and no evidence of 
replacement disease was seen in non-vaccine type IPD across condition groups.
This bar graph demonstrates the disease incidence and underlying conditions among adults 19
through 64 years old by serotype groups 3 to 4 years after PCV13 introduction:
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To estimate the contribution from direct effects alone, additional assumptions were made. 
Vaccine coverage was assumed to be about 5% to 7% based on a recent study estimating 
cumulative PCV13 uptake through 2014 for adults 19 through 64 years with current PCV13 
indications.  Also assumed was that vaccine efficacy was 74% against vaccine type IPD based 
on the results of an efficacy trial in HIV+ adults and similar to IPD efficacy in adults >65 years 
old from the CAP Immunization Trial in Adults (CAPiTA).  The number of cases prevented from 
direct PCV13 effects is the factors of baseline PCV13 type IPD burden, vaccine coverage and 
vaccine efficacy.  Given these assumptions, it was estimated that approximately 33 to 46 cases 
would be expected to be prevented from direct protection afforded by PCV13 use in adults.  The 
remaining 584 to 597 cases would have been prevented through indirect PCV13 effects.  These 
estimates demonstrate that in a setting of 5% to 7% coverage with PCV13, 93% to 95% of the 
observed impacts in 2013-2014 is expected to be due to indirect or herd effects from childhood 
vaccination.  If higher PCV13 coverage of 20% is assumed, similar to the current PPSV23 
coverage in adults <65 years old with vaccine indications, the number of cases estimated to be 
prevented directly by PCV13 increases, decreasing the proportion prevented through indirect 
effects to 79% of observed total PCV13 impact.  In a setting of remaining vaccine-preventable 
disease burden, the relative contribution of direct PCV13 impact increases with increase in 
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Looking across the different conditions, overall incidence rates were higher among adults with 
select medical conditions compared to the incidence of 4/100,000 in healthy adults.  The rates
among those adults with chronic medical conditions ranged from 10/100,000 for adults with 
heart disease to 136 / 100,000 for adults with hematologic malignancy. In addition, the largest 
burden of disease for all groups was caused by serotypes not covered by PCV13 as shown in 
the yellow bars.  The incidence of PCV13 type IPD ranged from 2/100,000 to 12/100,000 in 
adults with PPSV23-only indications to 4/100,000 to 21/100,000 adults with PCV13 indications
and accounted for 16% to 28% of all IPD. PPSV23 unique serotypes and non-vaccine type IPD
accounted for 71% to 84% of overall IPD burden.
In order to estimate the contribution from direct and indirect effects on observed reductions in
IPD among adults with PCV13 indications, adults with hematologic malignancy were chosen as
a demonstration example since it is a group for which PCV13 has been recommended since 
2012. In this group, a contribution is expected through both the direct and indirect effects of
PCV13. An estimated 890 cases of PCV13-type IPD would be expected to be observed among 
adults with hematologic malignancy in the US with pre-vaccine IPD rates applied to the 2013­
2014 population of adults with hematologic malignancy.  There were an estimated 260 cases of 
PCV13-type IPD observed in adults with hematologic malignancy in 2013-2014. For simplicity, 
it was assumed that the observed burden in the post-PCV13 era was influenced only by PCV13. 
It was also assumed that there were no PPSV23 effects, and that PCV13 direct and indirect 
effects had an additive impact on disease burden.  With those assumptions, it was inferred that 
the difference in the number of estimated cases between the time periods is the number of 
cases prevented by direct plus indirect effects.  There were 630 cases prevented by PCV13 
effects.
There were several limitations to the study.  NHIS population estimates and ABCs IPD
estimates were obtained using different methodologies.  Groups from ABCs and NHIS are 
subject to misclassification bias.  Because of the limitations in the data sources, vaccine impact 
among adults with HIV and dialysis could not be evaluated and, due to the same data 
limitations, these groups could not be excluded from the healthy group, so the incidence 
estimate for this group may be an overestimate. Medical conditions were not mutually exclusive 
and interactions may exist.  However, similar trends in disease burden were seen when certain 
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groups were restricted to adults with only one condition. The analysis was focused on IPD and 
did not include community-acquired pneumonia (CAP), which contributes to the largest burden 
in adults.  The burden of vaccine-preventable pneumonia should be considered for estimating 
overall impact on pneumococcal disease burden.
In summary, the investigators found that that PCV13 introduction among children reduced 
incidence among healthy 19 through 64 years old adults and those with underlying conditions. 
Reductions of a similar magnitude were observed in those with and without PCV13 indications
in the context of low PCV13 coverage, suggesting that observed benefits to date are largely due 
to indirect PCV13 effects. Adults with underlying conditions still continue to experience higher
IPD rates compared to healthy adults in the post-PCV13 period, but most of the remaining 
burden of IPD in adults is from non-PCV13 serotypes with little remaining PCV13 disease. 
There is no evidence of serotype replacement disease among these groups of adults.
Discussion Points
Regarding the risk groups, Dr. Maldonado (AAP) pointed out that for diabetes or smoking, the 
risk is lower but the population base may be higher.  She asked whether Dr. Ahmed thought the 
indirect impacts may be larger and if she looked at any others besides the immunologic
malignancy group for the rough estimation.
Dr. Ahmed responded that for the rough estimation, they looked at that group because PCV13 
already was indicated for them.  They were able to distinguish between direct and indirect 
effects.
Dr. Bennett pointed out that so far, PCV13 is not recommended for risk groups other than those 
who are immunocompromised, in that age group.
Dr. Maldonado (AAP) suggested that they still could look at a larger burden of disease for
indirect effects.
Dr. Atmar asked whether instead of subtracting the direct effects from the total cases, they
considered coming at it from the other direction and looked at the impact of the indirect effects, 
assuming they were similar for what was observed in groups for whom PCV13 is not indicated.  
It looked like the magnitude of decrease was similar, so they might be able to better estimate 
about the direct effects by taking that approach to get the range.
Dr. Ahmed responded that they did not take that approach in the calculations, but agreed that it 
was another way they could consider looking at it.
It seemed to Dr. Zahn (NACCHO) that in the past when they assessed indirect effects when 
PCV7 was introduced, the indirect effects for high risk populations was not as impressive.  That 
is, indirect protection of non-high risk individuals was better than high risk individuals.  This
seemed somewhat different from that in a better way.  He wondered whether it actually was
different or if the data they have now is just more robust in terms of teasing out the answer to 
that question.
Dr. Ahmed said she thought historically looking at PCV7, there were similar effects even for high 
risk groups at that time.
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Dr. Moore observed that this study did not include any assessment of CAP.  She asked whether
studies were underway or were being planned to assess any impact on CAP.
Dr. Ahmed indicated that Ms. Pilishvili would address this in the next presentation.
Dr. Lee noted that Dr. Ahmed’s presentation was very elegant, pointing that it was a lot of 
complicated data and Dr. Ahmed did a really nice job presenting it visually.  Similar to Dr. 
Atmar’s question, she wondered whether Dr. Ahmed could do a sensitivity analysis by flipping it 
to take an indirect effects perspective since she came up with estimates for the herd protected 
only groups.  She said part of her rationale for thinking about this was because it was easy for
her to believe that for the general population, the vaccination rates are 5% to 7%, but it was
harder for her to believe that the vaccinations rates are that low for the immunocompromised 
population.  She wondered whether Dr. Ahmed could back into it that way to come up with 
guesstimates of vaccine delivery in that population to see if that actually quantitatively makes
sense.  It would at least offer two different bounds.
Dr. Ahmed indicated that in terms of vaccine coverage, what she listed as 5% to 7% was for
those 19 through 64 years of age with current PCV13 indications.  She agreed that the 
coverage rates for each condition group might vary, with some higher and lower, so depending 
on coverage they may be afforded a higher level of protection if they are higher coverage.
Dr. Lee suggested that it might also be helpful to capture mean and median age of the 
population of those with chronic conditions, in part from the pediatric perspective because she 
feels like they see a lot of families.  If the median age is among families and young children, it 
might make sense that their exposure is just inherently different than another population that is
either much older or much younger.
Dr. Bennett asked whether a sensitivity analysis was performed looking at the immunization 
rates.  That does seem to drive the analysis to a large extent.  It was surprising to her even that 
among people with a hematologic malignancy, the vaccination rates would be only 20%.  It 
seems that they would be higher.
Dr. Hunter said he was not surprised from an implementation point of view based on his
experience in the City of Milwaukee.  The health department was asked to come to a tertiary
care center to provide vaccination services, because they were not able to provide it within the 
subspecialty clinics.  Based on some manuscripts he has seen related to a hematologic
malignancy, the vaccination rates for that particular condition were quite low.  He was really
surprised about that.  He wondered why they thought specialists would do any better job than 
primary care physicians.
Dr. Cohn requested clarification about whether the coverage estimates Dr. Ahmed used were 
for any pneumococcal vaccine or just for PCV13, and how the question was asked in the survey
from which the 5% to 7% was obtained.
Dr. Ahmed replied that that analysis was done by Pfizer which assessed uptake and did 
modeling, which showed that among those 19 through 64 years of age in high risk groups that 
included immunocompromised individuals, PCV13 coverage was about 5% to 7%.
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Dr. McLaughlin (Pfizer) said the first thing to note about uptake is that it is a very difficult 
question.  The way they addressed it was through a multifactorial approach.  The easiest way to 
do it is to look at IMS Health claims uptake, which are claims for the vaccine.  The difficulty is by 
just looking at the claims, some claims are missed that might have occurred in the pharmacy or
a specialty office that are not typically captured by an entity like IMS Health.  They also looked 
at Pfizer’s internal sales data.  Even though sales data are not split by pediatric and adult, they
tried to parse it out by which practices the claims came from.  Essentially, they looked at the 
IMS claims data and then factored that to what they were seeing in the sales data to try to get 
an overall picture of not just claims from health insurance, but also missed claims that were 
showing up in their sales.  For risk groups, the numbers are probably a slight underestimate 
because not only is it more difficult to get data from these specialty clinics, but also it is more 
difficult to know what the underlying health status is of people with these claims.  That has to be 
based on claims rather than a medical record.  It is more likely that coverage will be 
underestimated in the risk groups than in the general population.
Outline of Research Agenda to Inform Potential 
Policy Change in 2018 for PCV13 Use Among Adults
Tamara Pilishvili, MPH
Respiratory Diseases Branch
National Center for Immunization & Respiratory Diseases
Ms. Pilishvili indicated that lastly during this session, the WG wanted to share with the 
committee a roadmap of how the WG plans to approach the potential policy consideration in 
2018 for PCV13 use among adults.  She highlighted some of the key ongoing studies that will
help contribute to this evidence that the WG will share with the committee in 2018.  The WG
thought that in order to address the potential policy reconsideration in 2018, the following basic
but key questions need to be answered before the 2018 review:
 Is PCV13 use preventing disease among adults >65 years old?
 To what extent are the observed benefits driven by adults PCV13 use (direct effects) versus
pediatric PCV13 use (indirect effects)?
 What benefits would be expected from continued PCV13 use among adults versus
reconsidering this policy?
For each of these questions, Ms. Pilishvili presented on the types of studies the WG believes
will be helpful in answering the questions and highlighted some of the methodologies and 
objectives for some of the key ongoing studies.
In terms of the first question regarding whether PCV13 use is preventing disease among adults
>65 years old, the obvious study and action is to continue monitoring the impact of new
recommendations in the vaccine target age group.  In order to understand how much of the 
impact being observed can be attributed to the direct PCV13 effects in adults, it is important to 
understand changes in the IPD burden before and after PCV13 recommendation; changes in 
pneumococcal pneumonia burden before and after PCV13 introduction; uptake of vaccine 
among adults >65 years old; and the effectiveness of PCV13 and PPSV23 against IPD among 
adults >65 years old.  CDC is conducting a PCV13 case-control effectiveness study among 
adults >65 years of age.  The idea is to determine how the new recommendations work in the 
US population.
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With respect to the second question regarding the extent to which the observed benefits are 
driven by adults PCV13 use versus pediatric PCV13 use, the data shared thus far demonstrate 
the indirect effects that have been observed to date.  That is important for IPD, but it also is 
important to assess the same data for pneumonia.  It is important to continue to monitor the 
impact of PCV13 use in children on adult disease burden to assess changes in IPD and 
pneumonia among adults >65 years old before and after PCV13 introduction for children and 
before PCV13 recommendations for adults; and changes in IPD and pneumonia among adults 
<65 years old without current PCV13 indications.  This will allow for assessment of the indirect 
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Colonization studies are important among adults and children to understand the residual
circulation and transmission of PCV13 types in a setting of herd effects in the community.  
Disease trends will continue to be monitored through 2018 to estimate the contribution of direct 
versus indirect effects to observed reductions in IPD and pneumonia.  What is being observed 
are direct and indirect effects combined, so it will be challenging to tease those effects apart.  
Therefore, several approaches are being taken that involve mathematical modeling to 
understand the contribution of direct versus indirect effects.  This will rely on understanding of 
vaccine uptake and how much of the observed reduction can be attributed to direct effects.  
There also is the PCV7 experience on indirect effects, as well as indirect effects post-PCV13
that are still being observed in certain adult age groups that will allow for projection of what the 
expected continued indirect effects should be.  These studies will be important for IPD as well
as pneumonia.
In terms of the impact on PCV13-type IPD burden among adults >65 years of age, PCV13-type 
IPD rates declined through 2014 due to indirect PCV13 effects.  No additional declines were 
observed in 2015 and appear to have plateaued.  PCV13-types accounted for 22% of IPD in 
2015 compared to 43% pre-PCV13.  Continued monitoring of disease trends among adults <65 
years old is needed to evaluate the impact of herd effects.  PCV13-type IPD burden continues 
to decline among adults without current indications for PCV13 use.  PCV13-types accounted for 
24% of IPD in 2014 compared to 48% pre-PCV13 among adults without indications for PCV13. 
PCV13 case-control effectiveness study among adults ≥65 years of age mentioned earlier is 
ongoing, with the objectives were to: 1) evaluate the effectiveness of PCV13 against PCV13­
serotype invasive pneumococcal disease; and the effectiveness of PCV13 and PPSV23 when 
given in series; and 2) evaluate risk factors for IPD among adults >65 years of age in a setting 
of PCV13 and PPSV23 use when given in series because this is the recommendation for adults 
>65 years of age.  Cases of IPD among adults >65 years old are identified through ABCs.  
Pneumococcal isolates are serotyped, so they will be looking at the very specific endpoint of 
vaccine-type disease.  Controls are being identified using a commercial database, with a goal to 
enroll 4 controls per case matched on age group and zip code of residence.  For both cases and 
controls, vaccination histories are being obtained by identifying all medical care encounters and 
providers in the last 6 years, and then attempting to contact each of these providers who may 
have provided vaccines to the participant. 
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To date, 200 cases and 520 controls have been enrolled.  Pneumococcal serotyping is ongoing
to determine the number of vaccine-type (VT) cases that have been enrolled so far.  In terms of 
the projection of the sample size estimates, at approximately 30% PCV13 coverage, the sample 
size estimation suggests that approximately 46 VT cases will be needed to demonstrate a VE of 
75%.  Enrollment began in about November 2015 and it is estimated that the end of enrollment
will be in winter 2017-2018, based on the VT cases occurring and increases in coverage.
CAP is also a very important endpoint.  The policy decision in 2014 was largely driven by the 
estimated vaccine-preventable burden of community-acquired pneumonia.  Therefore, studies
to monitor PCV13 impact on pneumococcal pneumonia are ongoing and are very important in 
contributing to review in 2018.  Ms. Pilishvili highlighted three ongoing studies assessing various
endpoints:
 A CDC study assessing the impact of PCV13 on all-cause pneumonia hospitalizations
 CDC population-based surveillance for non-invasive pneumococcal pneumonia
 Population-based surveillance for PCV13-type pneumococcal pneumonia being conducted 
at the University of Louisville, funded by Pfizer
The objectives of the CDC study assessing the impact of PCV13 on all-cause pneumonia 
hospitalizations are to:  1) measure the impact of PCV13 introduction in children on pneumonia 
hospitalizations across all age groups in terms of PCV13 indirect effects only; and 2) estimate
the additional impact of the 2014 adult PCV13 recommendation on pneumonia hospitalizations
among adults ≥ 65 years of age in terms of PCV13 direct effects.  This is to tease apart the 
direct and indirect effects.  For the first objective, the data source is statewide inpatient data 
from 2004-2014.  The study methodology is a time-series analysis using “synthetic controls” to 
adjust for unmeasured confounding (e.g., changes in coding practices, change in healthcare 
seeking behavior).  For the second objective pertaining to adults ≥ 65 years of age, the data 
source is statewide inpatient data from 2004-2014 and the CDC is collaborating with CMS to 
use Medicare Part B beneficiary data from 2008-2016 to assess hospitalizations and 
vaccination status.  The study methodology is a time-series analysis using “synthetic controls” to 
adjust for unmeasured confounding with two intervention points, 2010 and 2014.  Because 
these are administrative data using ICD-9 codes, a control measure is needed, so the new
method of using synthetic controls has been proposed in order to adjust for unmeasured 
confounding.  In terms of the outcomes, CDC is using the classification algorithm based on 
discharge codes to assess all-cause CAP and pneumococcal pneumonia hospitalizations.
The objectives of CDC’s population-based surveillance for non-invasive pneumococcal
pneumonia are to: 1) conduct population-based surveillance for noninvasive pneumococcal
pneumonia for 2013 and onward; 2) measure the burden of non-invasive pneumococcal
pneumonia in adults; and 3) measure the potential impact of adult PCV13 recommendations.  
This expands and builds on CDC’s ABCs that conducts surveillance for invasive disease.  
Through the same sites, they are expanding to include non-invasive pneumonia in the 
surveillance.  The case definition for this surveillance is positive pneumococcal urine antigen 
test (UAT) from January 2013 onward, hospitalized adult ≥18 years of age who are residents of
the surveillance area, clinically or radiographically-confirmed pneumonia documented in the 
medical record, and no evidence of invasive disease.  The catchment area includes 15.6 million 
persons.  Hospitals are included that offer the UAT.  In order to obtain incidence estimates, 
adjustments will be made to account for the fact that not all at-risk patients are tested by UAT at 
hospitals offering it, and not all hospitals in the catchment area offer UAT.
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The objective of the population-based surveillance for PCV13-type pneumococcal pneumonia 
being conducted at the University of Louisville is to estimate the incidence and outcomes of 
hospitalized CAP among adults >18 years old in 9 adult hospitals.  This is an active prospective 
population-based cohort.  They are able to estimate the denominators of the catchment area 
and, therefore, estimate the incidence of CAP among adults.  They have a very stringent 
inclusion criterion, which is pulmonary infiltrate on chest x-ray + >1 of the following: 
cough/sputum, or fever/hypothermia, or leukocytosis/leukopenia and no alternative diagnosis. 
Perhaps the only study that will look at more specific outcome of VT pneumococcal pneumonia, 
the serotype-specific urine antigen detection (SSUAD) study, is also funded by Pfizer and is 
ongoing at 20 hospitals.  The objective of the SSUAD study is to estimate the proportion of adult 
CAP caused by PCV13 serotypes among adults >18 years of age.  This is active prospective 
hospital surveillance that includes subjects who presented with suspected pneumonia and 
positive chest x-ray for CAP and had a discharge diagnosis of CAP. 
 
  





   
 







    
     
  
   
 
Measuring vaccine uptake of PCV13 and PPSV23 in the target population of adults >65 years 
old is crucial in order to understand the contribution of the direct effects and attribute the 
observed impact of vaccine use among adults.  PPSV23 coverage has been assessed through 
the NHIS annually.  PPSV23 coverage has been relatively stable through 2014 at 59.7% to 
62.3%.  A limitation of the survey is that the current survey question does not distinguish 
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Each of these studies has its own set of challenges in terms of monitoring the impact on 
pneumonia.  The endpoint for the first study is all-cause CAP, which is a non-specific endpoint 
that may limit the ability to detect reductions of small magnitude.  In addition, any replacement 
with non-vaccine types may wash out the effects that might be detected looking at all-cause 
CAP as an endpoint.  To further complicate and add to the challenge, changes from ICD-9 to 
ICD-10 overlap with the vaccine introduction period for adult immunization with PCV13.  
Therefore, it will be important to eliminate bias that is related to the coding using ICD-10 codes.  
To address this, cross-validation studies are being conducted mapping ICD-9 algorithms to ICD­
10 code algorithms.
For the study using the UAT to assess pneumococcal CAP, UAT does not distinguish 
pneumococcal serotypes.  Again, replacement with non-vaccine types may wash out the effects. 
UAT sensitivity is 50% to 80% among non-bacteremic patients, so it may underestimate the 
burden.  PPSV23 receipt prior to UAT or carriage may influence test results.  For the PCV13­
type CAP study, SSUAD is not commercially available so the results will be limited to this one 
study.  SSUAD does not detect non-PCV13 serotypes, and PPSV23 receipt prior to UAT or
carriage may influence test results.
As mentioned earlier, adult pneumococcal colonization studies are important to understand 
what strains are circulating in the community and what the residual circulation and transmission 
are of the VT strains in a setting with pediatric use of the vaccine, as well as the adult use of 
PCV13.  To that end, CDC is conducting an adult pneumococcal colonization study.  The 
objectives of this study are to: 1) define the prevalence and serotype distribution of S. 
pneumoniae carriage in seniors; 2) assess risk factors for colonization; and 3) provide baseline 
data to assess the impact of the new ACIP recommendation on carriage rates through later
carriage studies.  The study population is adults 65 years of age or older enrolled at outpatient 
clinics and senior centers who are not severely immunocompromised.  Both nasopharyngeal
(NP) and oropharyngeal (OP) swabs are being obtained, and vaccination history is being
collected.  To date, 2773 participants have been enrolled across 4 US states.  The target is to 
enroll 3353 participants.  Enrollment will continue through December 2016.
150
                                                                                                 
 
 
   
   
































Advisory Committee on Immunization Practices (ACIP)	 Summary Report October 19-20, 2016
2014 recommendations, CMS data have been used for PCV13 and PPSV23 claims to estimate 
coverage among Medicare Part B beneficiaries.  It is important to note that the Medicare 
Advantage Plus population is excluded from the CMS data analysis because CDC does not 
have access to those data. Based on the results of the CMS claims data analysis through 
October 2015, PCV13 uptake was 15.86% and PPSV23 uptake was approximately 45%.
PPSV23 coverage is likely an underestimate based on other sources of information CDC has on
PPSV23 coverage, so not including the Medicare Advantage Plus population might lead to 
some underestimate of the PCV13 coverage related to the data being limited to Part B
population only.
In the study that was referred to in Dr. Ahmed’s presentation, analysis of vaccine sales and 
Insurance Management Services (IMS) claims were used to estimate PCV13 coverage1,2. 
Modeling was done to attribute the vaccine doses given to adults versus children in various 
populations.  Through July 2016, uptake of PCV13 by adults ≥65 was approximately 40%.  At 
the end of 2015, uptake was estimated to be approximately 31% using the IPD data.  In high-
risk individuals 19 through 49 years of age, coverage was estimated to be 11%.  Among high-
risk individuals 50 through 64 years of age, coverage was estimated to be 10% [1QuintilesIMS, 
Anonymized Patient-Level Data (APLD), Oct 2016 (includes diagnostic and prescription 
utilization claims for PCV13); 2 Pfizer, Inc. internal sales data for PCV13, Oct 2016]. 
In terms of the third question regarding what benefits would be expected from continued PCV13 
use among adults and how direct and indirect effects could be teased apart, CDC is developing 
a mathematical model to evaluate the impact potential changes in the adult recommendations
would have on the adult disease burden, given observed and expected herd effects ofthe 
pediatric PCV13 program.  Again, the key from all of the parameters and data inputs presented 
is to estimate the relative contribution of the direct versus indirect effects on the adult disease 
burden.  CDC will evaluate various policy options, including removal of the PCV13
recommendation versus continued use.  The outcomes for each policy option will include the 
potential public health impact of changing the policy, including the cost-effectiveness.
The next steps are to continue to update ACIP on the changes in vaccine-preventable disease 
burden among adults due to PCV13 direct and indirect effects during the next 2 years, and 
update ACIP on the results of the ongoing studies.  These data should inform revisions as
needed to the proposed adult PCV13 recommendations in 2018.  The declining burden of 
PCV13-type disease among adults over 65 years of age due to indirect effect of vaccinating 
children may signal that PCV13 is no longer needed.  A revised cost-effectiveness evaluation 
incorporating changes in disease burden, uptake, and the cost of the vaccines will help align 
this recommendation with other adult vaccines in use.
In conclusion, Ms. Pilishvili posed the following questions for ACIP’s consideration and 
discussion regarding a potential policy change in 2018:
 Is the proposed research agenda appropriate to help determine if a policy change is needed 
in 2018?
 What additional information will the committee need to help determine in 2018 whether
continued PCV13 use in adults is warranted?
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Discussion Points
Regarding the National Health Interview Survey on slide 14, Ms. Pellegrini asked whether that 
survey requests permission to correlate answers against patients’ medical records.
Ms. Pilishvili replied that there is no cross-check with any medical or vaccination records for this
survey.
Ms. Pellegrini said she was not sure she would be confident of the quality of responses from
that survey.  It is one thing to ask people if they have received one pneumococcal vaccine, but 
to expect them to know that they received both and if so, which one first and which one second 
may not be terribly useful.
Ms. Pilishvili said this was exactly the discussion that had been ongoing in terms of trying to 
determine whether they can use this survey to understand which vaccines have been given.  
For self-report, it is not expected that people would remember.
Dr. Belongia said he had one note of caution on the studies related to all-cause CAP based on 
his own research.  In the influenza vaccine world, they learned about a decade ago that they
could get wildly inaccurate estimates if they based their endpoint on a non-specific
administrative data source.  Fortunately, NCIRD has other studies planned that will assess very
specific pneumococcal and serotype specific outcomes, so he thought that was good.  He asked 
what a “synthetic control” is.
Ms. Pilishvili replied that this new methodology has been proposed by Dr. Dan Weinberger at 
Yale for the analysis of administrative data on CAP hospitalizations, which has been presented 
as an improved methodology to use administrative data to evaluate impact of vaccines.  The 
idea behind his methodology is that in previous studies where administrative data were used to 
document the impact of PCV7 or PCV13, as a control measure/condition, specific ICD-9 codes
unrelated to pneumonia diagnosis have been used such as fractures.  Whereas, the 
methodology of synthetic control, rather than using a single ICD-9 code or single condition as a 
control, creates a composite control that adjusts for potential changes that may be occurring 
with each individual condition.  It optimizes the control of potential bias due to changes to coding
practices, or some inherent trends in any particular condition.
Dr. Stephens was struck by the fact that there was not a lot of emphasis on molecular typing or
whole genome analyses.  He knew they were doing whole genome analyses on most of the 
invasive isolates now.  A lot was learned about 19A emergence in the replacement era with 
PCV7 through that methodology, and he wanted to get Ms. Pilishvili’s comments about the role 
of molecular typing as it relates to these studies.
Ms. Pilishvili responded that in the ABCs surveillance, they are moving toward whole genome 
sequencing (WGS).  This is still new and she does not think they have solidified how it will
contribute to this particular question.  Certainly, in terms of monitoring the trends and the 
emergence of new strains, they plan to use the WGS data.
Dr. Moore asked whether they are using immunization information systems (IISs) as a source 
for data for adult immunizations.  It is hard for people to remember what they have had.  Almost 
all states have lifelong registries, some of which are outstanding and would have good 
information on exactly what kind of vaccines people have had.  It would be a great resource 
rather than recollection and other less direct methods.
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Dr. Bennett pointed out that this is somewhat problematic because the adult registries are fairly
new in most states, so the data for adults is not as good as it is for children.
Dr. Mel Kohn (Merck) raised the issue of series completion.  The recommendation from ACIP
includes both vaccines.  He expressed his hope that series completion would be taken into 
account when the WG reevaluates the recommendations.  Merck has reviewed some of the IMS
data to determine how many of the people who received PCV13 went on to receive a second 
vaccine of PPSV23.  The early indication with about 20 months of follow-up for the first month’s
cohort after the recommendation was passed suggests very low rates of about 12%.  As they
move into influenza season, he expects that number will increase.  He said this also was an 
exhortation to anyone listening to go ahead and complete that series.  He believes that yet 
another factor that will be important for the WG to consider is how well the series is being fully
implemented.
Dr. Bennett agreed that many complexities to implementation are being observed in different 
settings that are not ideal, and they will want to try to figure that out.
Dr. Gemmill (NACI) indicated that Canada has not made a recommendation for use of PCV13
for healthy people over 65 years of age.  They are very interested in all of these results, and 
may even look upon it as an opportunity to collaborate.
Dr. Paradiso (Paradiso Biologics Consulting) noted that it appeared that the indirect effect in the 
19 through 64 year old healthy population was in the 70% range; whereas, in the high risk
populations, the indirect effect was about 57% for the indications for polysaccharide or
conjugate.  There was an earlier discussion about a distinction or differences in those 
populations.  He thought those would be interesting to look at, because when trying to estimate 
based on the coverage, what portion was direct and indirect, those differences will be important.  
In the case-control studies, they distinguished populations of people who got the conjugate 
based on whether they got it before or after polysaccharide.  Many of the over 65 year olds
would have had previous polysaccharide.  It would be interesting to see the difference between 
those who had polysaccharide previously, and then subsequently got a conjugate vaccine.
Ms. Pilishvili replied that in their case-control study, they are identifying indication period or look-
back period for both cases and controls.  They are contacting providers and obtaining history of 
PCV13, PPSV23, and any other vaccines they have received.  If they have sufficient power to
look at various schedules, they certainly will be interested in looking at the sequence in which 
the vaccines were received as well.  She agreed that the impact in terms of the ratio measure 
they have seen in healthy adults versus those with underlying conditions is higher; however, 
looking at the percent reductions alone is not quite sufficient.  That is why they look at the 
absolute change as well.  Looking at the absolute changes in rates, they actually were quite 
similar among healthy and those with underlying conditions.  Taking both pieces of evidence 
into account, as well as looking at the remaining vaccine-preventable disease burden in both 
healthy and those with indications, and understanding what it means at the population level is
important.
Dr. Hunter expressed concern about the cost of missed opportunities to vaccinate, and errors in 
vaccination that can occur when there are complicated recommendations for high risk
individuals who have a higher rate of vaccine-preventable diseases.  There are large numbers
of lower risk healthy people who have lower risks of vaccine-preventable diseases.  But if there 
are very complicated recommendations to implement the vaccine administration, people who 
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actually administrate the vaccines will be confused.  He wondered if there was any way to 
capture in the research whether increasing the complexity of the vaccine recommendation for a 
small group of people affects the uptake amongst a large group of people.
Ms. Pilishvili thought this was a very good point that they would have to think about.
Dr. Sun (FDA) said he was struggling to understand how to tease out the indirect effect from an 
increase in the coverage rate of PCV vaccination for the elderly.  One might imagine that there 
would be some indirect effect from having other elderly people around you vaccinated and, 
therefore, less pneumococcal disease, and the additional indirect effect on not being exposed to 
young children who do not carry pneumococcus as a result of vaccination.  That is, the indirect 
effect from adults versus the indirect effects from children.
Ms. Pilishvili responded that this would not be simple, which was why they were proposing 
several approaches.  It will not be simply subtracting one from the other, although there was a 
nice demonstration in Dr. Ahmed’s presentation.  Going forward, especially in the population 
that is receiving the vaccine and also experiencing the indirect effects, they will have to learn 
from the past data what the observed indirect effects have been and what is expected projecting 
those indirect effects, of course, making certain assumptions, and also understanding what the 
contribution of direct effects is by measuring the coverage and estimating what the contribution 
of the direct effects to indirect effects would be going forward.  Though the answer is not simple, 
they have certain models that they are developing that will take into account various scenarios
based on the observed data they have, and the data they will continue to observe in terms of 
indirect effects among adults who are not currently receiving the vaccine.  This will be done 
using the modeling approach and performing various sensitivity analyses, because certain 




Chair, Influenza Work Group
Dr. Walter reported that since the June 2016 ACIP meeting, the 2016-2017 ACIP Influenza 
Statement was published in the MMWR August 26, 2016. In addition, there were two new
licensures:
 AFLURIA® Quadrivalent manufactured by Seqirus™, which is a quadrivalent inactivated 
influenza vaccine (IIV) on August 26, 2016
 FLUBLOK® Quadrivalent manufactured by Protein Sciences Corporation, which is a 
quadrivalent recombinant influenza vaccine, on October 7, 2016
He indicated that the topics for this session would focus on an influenza surveillance update and 
AFLURIA®  Quadrivalent vaccine.  As a reminder, there was a discussion during the February 
2016 ACIP meeting on FLUBLOK®  Quadrivalent. 
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Epidemiology / Surveillance Update
Lynette Brammer, MPH
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
During this session, Ms. Brammer provided updates on international influenza activity, recent 
US influenza activity, and the Southern Hemisphere vaccine recommendations recently made.
Regarding influenza activity for the last year in the Northern Hemisphere, influenza 
A(H1N1)pdm09 predominated along with some influenza B viruses and some H3N2 activity
toward the end of the season.  Currently, Northern Hemisphere activities are very low.  The 
Southern Hemisphere’s season started out predominated by H1N1 viruses, with an increase in 
H3N2 viruses toward the end of the season.  Looking at the Southern Hemisphere and a few
representative countries, Australia contributed a large proportion of the late season H3N2 
viruses.  That actually was their predominant virus for that season.  South Africa had an 
interesting season.  They started out as influenza-B predominant, went into an H3 predominant 
period, and then had a third wave of influenza activity during which H1N1 viruses predominated.  
Argentina and Chile are representative of what occurred in South America, with both having 
H1N1 predominant seasons with some influenza B activity.
In terms of recent activity in the US, 1.7% of specimens tested for influenza were positive for
influenza at week 40 compared to the 24% seen at peak last season. Based on results from
public health laboratories, recent influenza activity was low relative to what would be seen at 
peak.  Influenza B viruses predominated going into the summer, but influenza A(H3N2) viruses
became more frequently detected and predominated at about 90% by October.  The public
health laboratories submitted a subset of their influenza positives to CDC for genetic and 
antigenic characterization.  Over the summer, 52% of the viruses reported by public health 
laboratories were H3N2 viruses.  Among those that CDC was able to characterize genetically, 
there are three genetic groups among the H3s currently:  1) 3C.3a, which last year’s
A/Switzerland vaccine component represented; 2) 3C.2a, which is this year’s H3N2 component 
A/Hong Kong/4801; and 3) 3C.2a1.  From May 22, 2015 through October 8, 2016, 27% of the 
H3N2 viruses have been 3C.2a viruses, 34% have been 3c.2a1 viruses, and 39% have been 
3C.3a viruses.  Although there are multiple genetic groups among the H1 viruses, all of the ones
detected in the US have been 6B.1 viruses.  There is not a lot of diversity among either lineage 
of the influenza B viruses.
Looking at the genetic data on an international level just to put things into context, 3C.2a and 
3C.2a1 predominated in most areas of the world.  In North America, there were 3C.3a viruses at 
the end of the season last year.  Those viruses seemed to be decreasing in prevalence, and 
North America was really the only one to see that level of 3C.3a viruses circulating.  Of the 
A(H1N1)pdm09 viruses, there are 6B, 6B.1, and 6B.2 genetic groups.  Almost all viruses
worldwide are 6B.1 at this point, although 6B.2 viruses were being seen in Asia and Oceania.
Antigenically, all 8 of the A(H1N1)pdm09 viruses characterized from the US over the summer
are similar to the A/California/7/2009-like vaccine component. Among the 53 A(H3N2 viruses, 
44 (83%) are antigenically similar to the A/Hong Kong/4801/2014-like, the 3C.2a genetic group 
in this year’s vaccine for the US.  Some of those are low reactors.  Among the viruses that 
reacted poorly with ferret antisera raised against A/Hong Kong/4801/2014-like viruses, 8 of 9 
(90%) are more closely related to A/Switzerland/9715293/2013 (genetic group 3C.3a).  Among 
the influenza B viruses, all 26 B/Victoria-lineage viruses were antigenically characterized as
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B/Brisbane/60/2008-like, which is the influenza B component of the 2016-2017 Northern 
Hemisphere trivalent and quadrivalent influenza vaccines. All 33 B/Yamagata-lineage viruses
were antigenically characterized using ferret post-infection antisera as B/Phuket/3073/2013-like, 
the influenza B component of the 2016-2017 Northern Hemisphere quadrivalent influenza 
vaccines.
In terms of geographic spread as of Week 40 in the US, 36 states and the Virgin Islands had 
sporadic activity.  One state, New Hampshire, experienced local activity.  Regarding outpatient 
visits for influenza-like illness (ILI) during the same week, 1.1% of outpatient visits were for ILI.  
This is what would be expected at this time of year compared to other recent seasons.  There is
no difference by state in that no states are experiencing more activity, with all states currently at 
minimal influenza activity.  The percent of death certificates that have any mention of 
pneumonia or influenza is low at 5.4% for deaths that occurred for the week ending September
24, 2016 compared to the baseline of 6.3%.  That is probably somewhat lower than what the 
final percentage will be, but there is no reason to believe that any influenza-associated mortality
is being observed at this point.
The recommendation for 2017 Southern Hemisphere trivalent influenza vaccine components is
as follows:
 A/Michigan/45/2015 (H1N1)pdm09-like virus
 A/Hong Kong/4801/2014 (H3N2)-like virus; and
 B/Brisbane/60/2008-like virus.
The recommendation for 2017 Southern Hemisphere quadrivalent influenza vaccine
components are as follows:
 A/Michigan/45/2015 (H1N1)pdm09-like virus
 A/Hong Kong/4801/2014 (H3N2)-like virus
 B/Brisbane/60/2008-like virus
 A B/Phuket/3073/2013-like virus
In summary, influenza A(H1N1)pdm09, A(H3N2), and both lineages of influenza B viruses
continue to circulate worldwide.  Activity in the US and other Northern Hemisphere countries
remains low at this time.  The recommended components for the 2017 Southern Hemisphere 
vaccine includes an updated H1N1 virus, which is the first change in the H1 component since 
the 2009 pandemic.  Global laboratory data continue to indicate that most currently circulating 
viruses are antigenically similar to the vaccine viruses included in the 2016-2017 US vaccines. 
This suggests that vaccination with Northern Hemisphere influenza vaccine should offer
protection against the majority of circulating viruses analyzed to date.
Discussion Points
Dr. Belongia asked whether there had been any antigenic characterization of the 3C.2a1 
viruses.
Ms. Brammer replied that from what she understood, the 3C.2a1 viruses are antigenically very
similar to the 2As.
Ms. Stinchfield (NAPNAP) inquired as to whether there was any indication of severity of the 
different genetic subgroups that would allow for predictive work.
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The FDA approved AFLURIA®  trivalent influenza vaccine (TIV) for use in individuals ≥ 18 years 
of age in November 2007.  AFLURIA®  TIV was approved for use in individuals ≥ 5 to 18 years of 
age in December 2011.  In August 2016, AFLURIA®  quadrivalent influenza vaccine (QIV) was 
approved for use in individuals ≥ 18 years of age. The current ACIP recommendation for 
AFLURIA®  is for use in individuals ≥ 9 years of age. 
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Ms. Brammer responded that at this time, there were no data to indicate that the severity of any
of these viruses would be different from what is typically observed with influenza viruses.
AFLURIA® Quadrivalent Influenza Vaccine
Gregg C. Sylvester, MD, MPH
Head of Medical Affairs
Seqirus™ A CSL Company
During this session, Dr. Sylvester presented the pivotal Phase 3 trial that led to the US approval 
of the AFLURIA®  Quadrivalent Influenza Vaccine in adults 18 years of age and older.  As a 
reminder, influenza is a highly infectious respiratory infection1. Seasonal epidemics occur 
predominantly during winter, with an annual incidence of 5% to 10% in adults2. Infection is 
associated with significant morbidity and mortality, with an estimated 250,000 to 500,000 deaths 
directly attributed to influenza annually worldwide2. Conventionally, influenza vaccines are 
trivalent, consisting of two influenza A subtypes and one influenza B lineage.  However, two 
antigenically distinct B lineages co-circulate from year-to-year3. Predicting which B will 
predominate during the season can be problematic.  Thus, the quadrivalent vaccines have been 
developed comprised of the 3 strains contained in the trivalent plus the additional B strain 
[1Bouvier NM, Palese P. Vaccine. 2008;26 Suppl 4:D49-53; 2World Health Organisation. 
Influenza. factsheets/fs211/en/. 13 July, 2016; 3Beran J, Wertzova V, Honegr K, Kaliskova E, 
Havlickova M, Havlik J, et al. BMC Infect Dis. 2009;9:2]. 
AFLURIA®  is licensed in the US as a trivalent and quadrivalent vaccine.  It is an egg-derived, 
purified, inactivated, split virion influenza vaccine.  It is manufactured in Parkville, Australia.  
There are two vaccine formulations:  
 0.5mL pre-filled syringe, thimerosal-free 
 5mL multi-dose vial, thimerosal-containing
In terms of the Phase 3 adult QIV study, Seqirus™ is taking a stepwise approach to its
quadrivalent clinical development program.  The study for children ≥5 to <18 years of age is
completed and will soon be submitted to the FDA.  The QIV pediatric study among children 6 
months to <5 years of age is underway, and the last Dr. Sylvester heard, about 300 participants
were enrolled in that study.
Here is the clinical trial algorithm for the adult study, which was conducted in the US in 31 
centers during the 2014-2015 Northern Hemisphere influenza season:
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A total of 3484 participants were randomized into 3 groups in a 2:1:1 ratio.  The vaccine group 
included 1741 participants, the AFLURIA®  TIV B/Yamagata group had 871 participants, and the 
AFLURIA®  TIV B/Victoria group had 872 participants.  The demographics of the participants 
were well-balanced between groups.  The mean age was 58 years, with a +/- of 18 years.  The 
age groups were stratified, with half of them below 65 years of age and the other half 65 years 
of age and above.  There were slightly more females than males, and the majority of the study 
participants were white.  Nearly two-thirds of the study participants received an influenza 
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Healthy men and women ≥18 years of age who resided in the US were enrolled in the study.  
The exclusion criteria were:
 Allergic to egg proteins or any study vaccine component
 Acutely ill
 Immunocompromised
 Influenza vaccine within the preceding 6 months or any licensed vaccine within 14 days for
inactivated vaccines or 28 days for live vaccines
 Immunoglobulins or blood products within the last 3 months
 Investigational product within the last 28 days
 Anticoagulant therapy, except antiplatelet agents
 History of Guillain-Barre Syndrome (DBS) or demyelinating disease
 History of drug or alcohol abuse 
 Clinically significant disease in the investigator’s opinion 
The primary objective of the study was to compare the QIV to a US licensed seasonal vaccine, 
AFLURIA®  TIV.  A non-inferiority immunogenicity design was used with eight co-primary 
endpoints (2 endpoints, 4 viral strains).  GMTs and seroconversion rates (SCRs) were analyzed 
for the 4 viral strains.  These endpoints were defined in accordance with the FDA criteria for 
non-inferiority studies.  For GMTs, the upper bound of the 95% confidence interval of the GMT 
ratios was not to exceed 1.5.  For SCRs, the upper bound of the 95% confidence interval of the 
difference for the SCRs was to be ≤ 10%. If all 8 co-primary endpoints meet the pre-specified 
FDA criteria, then non-inferiority for the QIV compared to the TIV can be concluded. 
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For secondary endpoints, the same non-inferiority criteria were applied in each age group 18 to 
64 years and ≥65 years. Superiority was assessed for the unmatched B strain included in the 
QIV, but not in the respective TIVs overall and in each age group (18 to 64 years and ≥ 65 
years).  This allowed them to use the FDA superior criteria which states that for the GMTs, the 
lower bound of the 95% confidence interval of the GMT ratio should be greater than 1 and the 
lower bound of the 95% confidence interval of the SCR differences should be greater than 0%.  
If these two criteria are met, superiority can be concluded for the alternative lineage B strain.
Regarding the results, the ratios for GMTs were similar between vaccines in the entire age 
group.  The pre-specified non-inferior criterion for the ratio of GMT was met for all 4 strains.  
The ratio for GMTs were similar for each of the age groups.  SCR also were similar between 
QIV and each TIV comparator for the matched strains.  The pre-specified non-inferiority criterion 
for the SCR difference was met for all 4 strains, as well as for each age cohort.  The 
immunological superiority of the unmatched B strain was demonstrated for both B strains in the 
QIV when comparing the ratio of GMTs to each TIV in which the strain was absent.  The 
superiority criterion also was met for the B strains contained in the QIV when analyzing the 
difference in SCRs for all participants 18 years of age and above, and for each age cohort.
All three vaccines were well-tolerated.  The safety profile for the QIV was similar to that of the 
TIV comparators.  Over half of the participants reported an AE during the study.  The majority of 
those AEs were classified as Grade 1, meaning symptoms that are easily tolerated and do not 
interfere with normal everyday activity.  No participants left the study due to an AE.  The most 
common solicited local AE in all three groups was pain at the site of injection at 36.5% overall.  
The percentage of vaccine-related unsolicited AEs was slightly higher in the QIV group.  There 
were 4 SAEs in 3 patients, which were assessed by the investigators as being related to QIV.  
One was asthma 2.5 weeks after the vaccine, one was acute pancreatitis 1 week later, one was
hypoxia 10 days later, and one was pneumonia 4 days after receipt of the vaccine.  Similar
frequency and intensity were seen in all three vaccine groups, with the vast majority in the 
Grade 1 category.  As mentioned earlier, pain at the site of injection was the most common local
reaction.  Myalgia and headaches were most commonly reported as systemic.
In terms of the strengths of the study, the trial design was prospective, double-blinded, and
randomized.  It was a Phase 3 with active-control, and it was a multicenter study in 31 centers in 
the US.  The study was sufficiently powered to meet the primary endpoints.  However, there are 
potential limitations.  The use of immunogenicity as a surrogate for protection may not be a true 
representation of clinical efficacy.  In addition, participants with moderate to severe acute 
illnesses were excluded from the trial.
In summary, AFLURIA® Quadrivalent Influenza Vaccine met non-inferior immunogenicity for all
strains to both comparator TIVs in adults ≥18 years of age and in each age group 18 to 64 years
and ≥ 65 years. Immunologic superiority of the alternate B strain (B/Yamagata and B/Victoria 
strain) was also met for both of the age cohorts by the GMT ratios and SCR for each virus
strain.  The vaccine safety profile was found to be acceptable.  FDA approval was granted on 
August 24, 2016.
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Discussion Points
Ms. Pellegrini noted that the study population had a very low percentage of minority participants
despite the fact that it was conducted in 31 centers.
Dr. Sylvester replied that the study population was 82% white.  As they heard the previous day, 
all industry is trying to do a better job of increasing the diversity within clinical trials.  As they
assess the population of under 6 to 59 months of age, they certainly will take that into
consideration.
Dr. Messonnier requested that Dr. Sylvester discuss vaccine supply for this and next year.
Dr. Sylvester responded that both the QIV and TIV formulations are available in the US this
year, and plan to do the same next year.  He called on one of his colleagues to provide further
details.
Aaron Rak (Seqirus™) added that because the QIV formulation was just licensed in August, the 
vast majority of the doses coming in are trivalent, although there has been a lot release of QIV.  
Next year, the plan is to have a mix of both QIV and TIV in addition to Seqirus’s™ other
licensed vaccines.
Dr. Belongia requested information on the relative price increase from the TIV to the QIV.
Aaron Rak (Seqirus™) replied that the list price for the TIV prefilled syringe is $14.92, and the 
list price for the QIV prefilled syringe is $16.61.  That is a $1.70 increase for the prefilled 
syringe.  They will bring in both formulations next year (prefilled and multi-dose vials), currently
only the prefilled syringe is available.
Respiratory Syncytial Virus Vaccine  
Introduction
Robert Atmar, MD
Baylor College of Medicine
Chair, ACIP RSV Vaccines Working Group
Dr. Atmar reminded everyone that the ACIP Respiratory Syncytial Virus (RSV) Vaccines WG
was convened to evaluate vaccine use in adults ≥60 years of age and in adults with underlying 
medical conditions.  This was in anticipation of results of a vaccine product that is in Phase 3 
clinical trials.  The RSV session during the June 2016 ACIP meeting focused on providing an 
overview of RSV and RSV vaccine development, including targeted vaccine populations.  On
September 15, 2016, top-line results from the NOVAVAX RSV F Vaccine Phase 3 clinical trial
were released.  This is a snapshot of RSV vaccine development:
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This session included an update on the burden of RSV disease in older adults, as well as an 
update on NOVAVAX RSV vaccine development programs. 
The next steps for the RSV Vaccines WG are to: 1) continue to review RSV vaccine product 
clinical trial data in targeted populations as they become available for older adults, pregnant 
women, and infants and young children; and 2) present to ACIP when new updates in RSV
epidemiology and clinical trial data occur.
Burden of Disease in Older Adults
Ann R. Falsey, M.D.
University of Rochester
Dr. Falsey pointed out that people stop thinking about RSV when they leave medical school if 
they do not go into pediatrics.  With that in mind, she gave an overview of the studies that 
suggest that RSV has a significant burden of disease in adults.  First, she shared some history
and basics.
In 1956, Morris described an outbreak of respiratory illness in a chimpanzee colony at Walter
Reed.  The cytopathic agent isolated from a chimp named Sue was called CCA, for chimpanzee 
coryza agent.  The following winter, Dr. Robert Chanock recovered a similar virus from infants
hospitalized with lower respiratory tract symptoms, and the virus was very sensibly renamed 
Respiratory Syncytial Virus (RSV) to reflect the giant syncytia seen in culture. For the past 40 
years, the epidemiology of RSV has been exhaustively studied in infants and young children, in
whom it is the single most important respiratory pathogen in the first year of life.  It has been 
linked to 90,000 to 100,000 annual hospital admissions in the US and approximately 300 to 500 
deaths.  In 1966, there was a formalin inactivated vaccine trial that was a disaster.  It resulted in 
enhanced disease, such that infants who got the vaccine had higher rates of hospitalization and 
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even some deaths.  Needless to say, vaccine development has been very slow and cautious
ever since and there still is not a vaccine for either children or adults.
It was not until the 1980s that RSV was appreciated as a potential pathogen in adults.  Before 
launching into the clinical descriptions, Dr. Falsey quickly reviewed a few relevant points about 
the virus structure.  There are 10 genes that encode for 11 proteins.  It is a single-stranded RNA
virus with 8 structural proteins.  There are two major surface glycoproteins, the F or fusion 
protein and the G which serves as the attachment protein, both of which induce neutralizing 
antibodies. The G protein has a fair amount of antigenic diversity and defines group A and B
viruses.  In contrast, the F protein is relatively well-conserved among RSV isolates and 
therefore has been identified as an important component of candidate vaccines.  RSV is not like 
influenza in that it does not undergo major antigenic shift and drift, but it is likely that antigenic
diversity plays some role in adult reinfection, but it is really not clear how much.
There is a variety of evidence that looks at RSV disease.  Initially, most of the reports were just 
case reports or outbreaks, which were primarily in nursing homes.  There is a body of indirect 
evidence that uses modeling studies.  There are some illness-based studies that look at people 
presenting for medical care either to their general practitioner, the emergency department (ED), 
or the hospital.  There are prospective studies following groups of people for respiratory illness, 
which are the most difficult and expensive to conduct.
As mentioned, RSV came to the medical community’s attention when outbreaks started to be 
described in nursing homes.  In these situations with closed populations, the attack rates can be 
quite high, up to 89%.  Looking at prospective studies in nursing homes, the incidence of RSV
can vary from 1% to 15%.  Generally, it is considered a nosocomial infection that either the staff 
or family members are bringing into the facility.  The reported severity in nursing home patients
is highly variable, with reports of pneumonia ranging from 0% to 55% and reports of deaths 
ranging from 0% to 53%.  Part of that probably is the population in a specific nursing facility.  
Some facilities have healthy older people who are only somewhat dependent, while others have 
very frail residents.
Only about 5% of older people reside in institutions, with 95% of older people living in the 
community.  One of the first studies that examined community-dwelling elderly was conducted 
by Scott Dowell in which he looked at lower respiratory tract infections in hospitalized adults.  
Using serology, he found that RSV was third right after pneumococcus and influenza A and B as
a cause of respiratory illness, in this study conducted over 2 winters with almost 1200 
participants.
As a lead in to the modeling studies, Dr. Falsey shared the following formula emphasizing that 
modeling is an important way to predict disease burden:
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Modelers basically correlate culture data and viral activity with events in other populations.  The 
first and one of the best studies looking at RSV in all ages correlated viral activity with national
death data for the time period 1976-1997, looking at deaths due to pneumonia, influenza, 
circulatory, and respiratory illness.  They found that while flu dominated over RSV, what took
everybody by surprise was that in the adult age groups, there were nearly 11,000 RSV deaths
amongst older adults.  This was not previously well-appreciated.  Compared to influenza, it is
about two-thirds to about half of influenza.  This was one of the first assessments that 
suggested that maybe RSV is not like influenza in an older adult, but it is not insignificant either
[Thompson et al JAMA 2003].  This approach was then used again to assess the next 20 years
from 1997-2009.  Using a very similar analysis to Thompson’s, this group from GSK got very
similar results looking at adult deaths in the US.  These two studies looked at 40 years of data 
[Matias et al IORV 2014].
Douglas Fleming is from the UK and he has been looking at RSV in older adults for the last 20 
years using modeling studies as well.  In a very recent publication, he showed that influenza 
burden tends to go up and down over time.  That may be because when there are major H3N2
years, a lot of excess deaths are observed among older people.  However, RSV is more 
monotonous.  Fleming then looked further and broke it down by age groups of 18 through 49, 50 
through 64, 65 through 74, and over 75.  This revealed that the greatest increase occurred in 
people over 75 years of age, and there was some increase in people 65 through 74 years of 
age. It is important to note that the population of people over 80, which geriatricians refer to as
the old old, is growing significantly in most developed nations [Fleming DM et al BMC 2015].
Dr. Falsey pointed out that before moving into a discussion of studies looking at disease burden, 
it is important to understand diagnosis because the way RSV is diagnosed will alter the results
of studies assessing disease burden.  Children produce a lot of mucous.  An infant with a 
primary infection has a great deal of virus in their respiratory secretions, and this produces a 
characteristic clinical symptom of bronchiolitis.  So, it is not so hard to make the diagnosis in
young children.  When she began studying the virus, the tools available were viral culture and 
serology.  Viral culture is very insensitive for making the diagnosis.  RSV is more labile than 
influenza.  It does not survive transit.  There is not that much in secretions, and it would take a 
while for the virus to grow.  While serology is good, it is necessary to have convalescent 
serology.  The patient has to survive to be able to get that, and it also has to be well-timed.  
When the advent of PCR came along, it was anticipated to be able to solve all of the problems.  
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PCR has revolutionized the understanding of many viruses, because it allows them to be 
detected in many ways that could not be done before.
There are a number of diagnostic challenges in older adults.  Unlike children, they lack
distinctive syndromes (croup, bronchiolitis).  Older people have a diminished febrile response.  
A lot of the studies looking at RSV are tag-on studies to influenza studies in which the case 
definition is ILI, which includes fever.  The presence of a respiratory infection sometimes may be 
completely overshadowed by exacerbations of comorbid diseases when these individuals
present to the hospital.  They may be having a chronic obstructive pulmonary disease (COPD) 
or heart failure exacerbation, and so no one thinks about the fact that it all started with a virus.  
One of the most important things is that most people just do not even consider the diagnosis of
RSV when an adult is admitted to the hospital.  In addition, adults shed lower titers of virus for a 
shorter period of time in the nose than infants.
Based on some data from an epidemiologic study that the University of Rochester conducted 
using viral culture, PCR, and serology to define infection, it was not very surprising that in the 
study population, culture was not very sensitive, as it only detected 4.1%.  PCR was a 
significant jump at 9%.  Serology yielded the highest number of people with infection at 12.4%.  
Everybody had a PCR in that study, but not everybody had serology because they did not return 
or they died.  Of the participants, 1,114 people had all of the tests available.  A substantial
proportion, 37, were positive by all three tests and an equal number were positive by PCR and 
serology, which is no surprise.  Nobody was culture positive and PCR negative.  It is worth 
pointing out that out of the 117 people with RSV, 30 people were serologically positive only and 
had negative PCR and culture.  If just using PCR, those people would have been missed.  That
is not to say that serology is perfect, because 13 people were either PCR or culture positive and 
serologically negative.
If there is very well-timed serology in a prospective study; that is, there is a baseline antibody
level and then good tight acute and convalescent serology, almost all older people do have a 4­
fold serological response.  The reason that serology sometimes is not so great is because if 
people are being evaluated at the time they present for medical attention, they usually are 5 to 6 
days into their illness.  In all adults, RSV is a reinfection so everybody has baseline immunity
and they have a fairly rapid amnestic response.  Antibody starts to rise around day 3 and by the 
time the patient presents at day 5 or 6, they have already had a 2-fold rise in antibody.  So the 
rise in antibody might be missed in people presenting to the hospital because nobody goes in 
with a runny nose.  In the typical RSV illness, the patient gets a cold.  They have a runny nose 
for a few days.  They then begin to get wheezy.  Then they get more short of breath.  It really
takes 5 or 6 days for them to decide that they need to see a doctor.
In terms of the location of the sample, as the illness progresses, it may be that the virus is no 
longer in the upper airway and has moved down to the lower airways.  When thinking about viral
testing, people always think about the swab up the nose and really do not think about testing 
sputum.  Angela Branch at the University of Rochester conducted a study in which she 
assessed the improved diagnostic yield by combining sputum and nasal swab testing.  It was
not specific to RSV, but 63 people were RSV positive and 22% were positive only in their
sputum.  Nasal swab positive only was mostly because they did not have a sputum. They could 
not cough it up.  One of the issues with sputum is that not everyone can raise a sample.  
However, if it can be collected, it can add to the diagnosis, particularly if someone has been sick
for a while [Branche et al JMC 2014].
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To summarize the sensitivity of RT-PCR and serology, the timing of samples is important for
both PCR and serology.  Early in illness, in the first couple of days, a nasal swab for PCR is
very sensitive.  Later in illness PCR may be negative, but sputum may be of value.  Well-timed 
serology is very sensitive in older adults.  However, the rapid amnestic response may obscure 
antibody rises in people presenting for medical attention 5 to 6 days into illness.  The sensitivity
of diagnostic methods in the elderly varies widely.  Standard culture is 5% to 40% sensitive, but
only in a research institution where someone runs right to the laboratory with the cultures. It is
still not a great way to make the diagnosis.  The rapid antigen tests with 0% to 24% sensitivity
are next to worthless and they are not recommended.  PCR (75% to 82% sensitive) and 
serology (85% to 90% sensitive) are the best ways to make the diagnosis.  Obviously, in a 
clinical scenario, only PCR is needed.  But when thinking about vaccine and epidemiologic
studies, these two tests are complementary and each have an advantage.
One of the major problems with RSV is that it has an identity crisis.  Looking at the discharge 
medical record of a women who was diagnosed with RSV, she presented with congestion, 
difficulty breathing, poor appetite, and dehydration.  She eventually went into respiratory failure, 
was intubated, required dialysis, had a gastrointestinal (GI) bleed, and then died.  She had a 
PCR that was positive for RSV and an illness that was fairly characteristic at the onset.  But her
ICD-10 discharge diagnoses were hypotension, hyperkalemia, dehydration, diabetes mellitus, 
and chronic kidney disease (CKD).  Nowhere in there was RSV.  Dr. Falsey said she would 
propose that none of these other things would have happened had she not had RSV and it 
began a cascade of bad outcomes.
Dr. Falsey presented some data from a study that she and Dr. Edward Walsh conducted a 
number of years ago.  This was a prospective diagnosis-based study conducted for 4 winter
seasons between 1999 and 2003.  They conducted prospective surveillance of healthy older
people living in the community and adults with underlying cardiorespiratory disease in the 
community.  At the same time the prospective evaluations were being done, they evaluated 
adults who were hospitalized at their institution with acute cardiopulmonary conditions, with the 
exception of an acute myocardial infarction (MI).  To diagnose RSV, they used culture, one tube 
nested RT-PCR, and serology. At this point, it was new that thought was being given to 
developing vaccines and drugs for RSV.  Everybody would agree that influenza is a major
problem in the elderly, so they used influenza as a yardstick.  They enrolled over 600 healthy
elderly and over 500 high-risk and evaluated nearly 1500 illnesses in the hospital over the 4 
years.
Regarding the incidence data in the prospective group, RSV ranged from 3.2 in a low year to 
7.6 in a high year, with an average of 5.5 infections per 100 per season.  That was about twice 
as common as influenza A, which was 2.1.  It is important to point out that this is a heavily 
vaccinated population.  These numbers would likely look very different if there was not influenza 
vaccination.  It is also important to point out that this is infection, not only symptomatic 
infections.  Among both the influenza and RSV patients, 10% had asymptomatic serological 
rises from baseline to the end of season.  It is not clear whether these people had illnesses they 
did not report because they were mild illnesses, or if they were truly asymptomatic.  Most of 
these individuals, 90%, had symptomatic illnesses that were evaluated. 
Also important to address in older adults is functional impact.  To assess this, they looked at 
whether the patients were housebound, bedbound, or unable to do their activities of daily living 
at any point during their illness.  Influenza had a greater effect on the healthy elderly, but it is
important to point out that 39% of the healthy elderly could not do their activities of daily living
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when they were sick.  In the high-risk patients, the influenza and RSV differences were less
dramatic and there was a more functional impact.
In terms of utilization of healthcare resources, in the high-risk group, there were 54 infections, 
16% were hospitalized, and 5% died.  While the healthy older persons might have felt terrible 
and might have gone to see their doctors, nobody was hospitalized and nobody died.  The 
medically attended rates of illness in the healthy group varied between 0.50 - 1.20 / 100
depending on the year.  For the high-risk group, it was about double at 1.8 - 4.4 / 100.  Using 
the population of Rochester, the investigators estimated a hospitalization rate of about 1 / 1000. 
With regard to admissions due to RSV and influenza, there was a dramatic seesawing for
influenza because year 1 and year 3 were big H3N2 years.  RSV was somewhat steadier.  Over
the 4 years, RSV accounted for 9.0% of the wintertime hospitalizations due to cardiopulmonary
diseases and influenza A accounted for 9.5%.  The characteristics of those presenting with RSV
and influenza were very much the same.  The mean age was 76 and there were very high rates
of underlying heart and lung disease.  The people who are hospitalized are not the healthy older
adults, with the exception of the old old.
With big groups of people with RSV and influenza, it is possible to get nice p-values and find 
that there is more nasal congestion, dyspnea, and wheezing among those with RSV; whereas, 
influenza patients have higher rates of fever.  However, it is not possible to tell the difference on 
an individual basis.  A case-based definition cannot be developed that provides any kind of 
discriminatory ability.  It is necessary to perform a test, and studies require a laboratory
component.  In terms of outcomes in the hospitalized subjects, rates of pneumonia, intensive 
care use, ventilator support, and death rates were nearly identical.  Once someone is frail
enough to end up in the hospital with either one of these viruses, the outcomes are very similar. 
Falsey et al estimated that about 177,000 people would be hospitalized and there would be 
about 14,000 deaths in the US.  Thompson estimated 11,000 using modeling.  So, they felt very
good that these were pretty close using very different methodologies.  Therefore, she does
believe that is roughly the attributable mortality each year [Falsey et al NEJM 2005;352:1749].
There is nothing unique about the extremely long, cold, dreary, snowy Rochester weather.  In 
2012, Dr. Keipp Talbot and her group at Vanderbilt used only PCR and estimated that 6.1% of 
their wintertime hospitalizations were due to RSV.  If the serological results were added, this
would be very similar to the Rochester data.  They did some estimates using the population of 
Davidson County and calculated a hospitalization rate of 1.5 / 1000.  So again, in a different 
geographic location, this team came up with similar data [Widmer et al JID 2012].
Dr. Edward Belongia and colleagues at Marshfield Clinic conducted some studies in conjunction 
with influenza vaccine efficacy studies to assess influenza vaccine efficacy using a test-negative 
case design.  They had periods of surveillance when influenza was very active.  RSV activity is
usually just a broader base, so they were missing some of the times that RSV was active and 
needed to fill in with some modeling in addition to specific viral testing.  They used PCR to do 
testing. Their estimate of medically attended respiratory illness in adults ≥50 was 1.54 / 100 
[McClure et al Plos One July 2014 ;9:e1025].
One of the questions sometimes pertains to how variable RSV is in a season in adults in terms
of mild versus bad years, so Dr. Falsey put together some of the Rochester data from the 
prospective cohort studies to illustrate the variability because they have been conducting these 
studies for a long time.  The low one year was 2.5 and the high year that was a banner year
among their COPD patients was 10.7.  It is variable, so investigators may have the misfortune to 
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conduct a vaccine study in a low year.  Looking at illness-based data, there was a low of 4% of 
the respiratory illnesses being RSV and a high in another study of 13%.
A number of studies are being conducted throughout the world.  It is important when evaluating 
other studies to look at the way they diagnosed the infection.  Van de Hoogen in the 
Netherlands, who is a superb virologist, found 0 RSV infection.  The diagnostic methodology
used was serology and culture.  Culture is insensitive, but it would seem that some serological
infections would have been picked up.  A German study found 25% RSV infection rates using 
purely PCR.  That is so high that it may suggest something about the specificity of the PCR or
whether there was contamination of results.  There are a lot of studies being conducted in many
countries around the world that typically use a multiplex PCR that generally has 15 targets.  It is
important to remember that when a test is optimized for 15 different targets, it is going to lose 
some sensitivity for a specific target.  But these data coming from around the world report a low
of <1% RSV to a high of 7%.  It is always important to remember with these studies to 
determine whether they were conducted over an entire year, in which the incidence would be 
lower, or if they focused on the winter season.
Turning to some data from China, Dr. Falsey noted that Nelson Lee has been conducting some 
very good influenza work.  He works in Hong Kong and has more recently turned his attention to 
RSV and has some interesting data coming from Hong Kong.  In a 3-year study, he and his
team identified 607 adults hospitalized with RSV at the same time that there were 547 with 
influenza A.  The mean age was almost identical to the other side of the world in Rochester
where it was 76.  They also found that those who were hospitalized had a lot of chronic medical
conditions.  One thing that differed was the fact the people in Hong Kong seemed to go to the 
hospital quicker than people in the US.  Influenza patients present earlier than RSV patients.  A
high fever in an older adult is likely to drive them to medical attention more quickly than the 
runny nose that evolves into shortness of breath [Nelson Lee et al CID 2013;57 1069].
One thing that is not known is the complication rate—the downstream problems that result from
RSV.  Dr. Falsey believes there are plenty, but it is just not well-understood at this point.  This
would include functional decline, bacterial complications, and cardiovascular events.  This is
clear with influenza.  In large influenza epidemics, there is a clear spike in heart attacks and 
strokes, but this is not clear with RSV.  Dr. Falsey and her colleagues conducted a study
recently to assess the issue of bacterial complications with viral infections.  It is much talked 
about, and clearly there is a relationship between viral infection and bacterial superinfection.  
However, it is very hard to diagnose a bacterial infection with any specificity and sensitivity.  In 
this 3-year study, they evaluated people presenting with respiratory illness.  In addition to 
comprehensive viral and bacterial testing, they did a serum biomarker of procalcitonin.  
Procalcitonin is high in people with bacterial infections and normal in viral infections.  By
combining traditional bacteriology with high procalcitonin, they found that 31% of RSV patients
admitted to the hospital had some evidence of a bacterial infection.  There did not seem to be 
any major differences between the common respiratory viruses [Falsey et al JID 2013].
While Dr. Falsey said she could find almost nothing on cardiovascular complications in RSV, 
she did find a study from Volling in Toronto.  This was an observational study in which 22% of 
their RSV patients who were admitted had some type of cardiovascular complication [Volling 
BMC 2104].
To summarize the rates that the evidence provides, infection ranges from 2 to 6 per 100 per
season, medically attended disease from 0.5 to 4 per 100, hospitalization from 1 to 1.5 per
1000, and death rates from 0.4 to 7 per 10,000.  Secondary complications are unknown.
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Discussion Points
Dr. Atmar said he was interested in Dr. Falsey’s thoughts on the use of serology in vaccine 
studies.  For example, they found with influenza that vaccinees are less likely to have serologic
responses than are non-vaccinees, which can bias in favor of vaccine efficacy.  He asked 
whether she anticipated that this could be a problem using that diagnostic method in the 
evaluation of vaccine efficacy or effectiveness.
Dr. Falsey replied that she did not think an antigen could be used that is in the vaccine.  Most of 
the RSV vaccines in development are based on the fusion protein, so another purified antigen 
could be used, the attachment protein could be used, the nuclear protein could be used—it 
would just be important to eliminate whatever antigen happens to be in the vaccine.
Dr. Hahn (CSTE) asked whether anything was known on the source of infection in elderly.  For
example, are caregivers of young children at higher risk of becoming hospitalized with RSV?
Dr. Falsey replied that it is certainly sensible to think that young children are the origin.  RSV
exposure during the winter is probably fairly prevalent, even if not exposed to young children.  
They have assessed exposure to children as a risk factor for infection, and have found that it is
a factor.  However, it is not an overwhelming factor.  They recently conducted a study with 
MedImmune to examine whether there was any group who could be at really high-risk.  They
enrolled people who had regular exposure to school-aged children and underlying heart and 
lung disease, and found that the rate of infection in that group was almost 14%.
Evan Anderson (Emory) noted that several groups have now described cross-reactive
antibodies between RSV and human metapneumovirus (hMPV).  He asked whether she had 
seen any evidence in her data of RSV serologic conversion due to a recent hMPV infection.
Dr. Falsey indicated that in the large epidemiologic study, they did do serology for
metapneumovirus and did not find that it was an issue.  They were very distinct.
Update on NOVAVAX RSV Vaccine Development Programs
Dr. Jeffrey Stoddard
Vice President Medical Affairs
Novavax, Inc.
Dr. Stoddard shared a high-level company overview indicating that they have a proprietary
vaccine technology platform that involves baculovirus (BV) transfection of and Spodoptera 
frugiperda (Sf9) insect cell line for the production of recombinant immunogenic nanoparticles.  
They have 5 facilities, including Gaithersburg and Rockville, Maryland and Uppsala, Sweden.  
There is a high degree of experience across their management team, and the development and 
commercialization infrastructure necessary to bring products to market.  They have commercial
grade GMP manufacturing capacity, a strong balance sheet, and substantial funding support 
from the Bill & Melinda Gates Foundation for maternal programs.
In terms of Novavax’s history of leadership in RSV vaccine development, they have achieved 
several milestones.  Their Vice President of Preclinical Vaccine Research, Gale Smith, was the 
original discoverer in the early 1980s of the Sf9 insect cell line that could grow and produce 
recombinant protein nanoparticles based on transfection with the BV.  The company’s work in 
RSV vaccine development dates back to about 2009, for which they have reached a number of 
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To summarize the Phase 2 trial, it was well-tolerated and had an acceptable safety profile.  It 
was the largest ever prospective study of the RSV attack rate in community dwelling older 
adults.  Of the older adults in the placebo group, 4.9% had symptomatic RSV and 88% of these 
illnesses were associated with LRTI.  In terms of immunogenicity and efficacy, there were 
robust and specific anti-F IgG and PCA responses.  There was a 41% to 44% reduction in 
symptomatic RSV in vaccinees, and a 64% to 75% reduction in RSV LRTD with ≥3 or ≥4 LRTI 
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milestones.  Their development experience focused primarily on viral pathogens.  They use the 
technology platform alluded to in that effort.  They divide the RSV at-risk population into three 
groups:
 Older Adults ≥60 years of age
 Infants, particularly in the first few months of life
 Children 6 months to 5 years of age
They have work ongoing that is either in preclinical or early clinical state in pandemic and 
seasonal influenza, combination respiratory (RSV + influenza), and some emerging virus work
(Ebola and Zika).
The RSV F vaccine is a BV-Sf9 insect cell-derived recombinant nanoparticle vaccine.  It is
known to produce broadly neutralizing antibodies to three separate epitopes, so it is a purified 
recombinant protein nanoparticle that has at least three epitopes that produce neutralizing 
antibodies.  Those are Sites I, II and IV.  This vaccine is known to protect animals from
challenge with wildtype RSV challenge.  That has been shown in cotton rat and baboons.  
Multiple Phase 2 trials have been conducted in various populations.
Beginning with the Phase 2 study in 1600 older adults ≥60 years, this study was conducted 
during the 2014-2015 season.  It is a notable trial because it was the first late-stage human trial
to show vaccine efficacy for any RSV vaccine in any population.  It was a randomized 1:1, 
observer blind, placebo controlled trial that utilized 135µg of the RSV F vaccine with no 
adjuvant.  The subjects were followed for 1 year for safety, immunogenicity, and efficacy
endpoints.  The study demonstrated a high degree of tolerability and a safety profile that was
notable for no imbalances between the placebo group and the vaccine group.  There were 5­
fold increases in both Palivizumab-competing antibodies (PCA) and Anti-F antibodies measured 
at Day 28 post-vaccination.  Importantly, there was a 4.9% placebo attack rate for RSV-acute 
respiratory disease (RSV-ARD) confirmed by RT-PCR.  That is comparable to the 5.5% average 
attack rate that Dr. Falsey just presented from the 4-season study in Rochester.  Vaccine 
efficacy of 41% was demonstrated against RSV-ARD, which was the primary pre-specified 
endpoint.  A post-hoc analysis assessing a more severe endpoint defined as moderate to 
severe lower respiratory tract disease (msLRTD) showed a 64% efficacy against RSV-msLRTD.  
While that was a post-hoc analysis, that was compelling enough in the end of Phase 2 
discussions with the FDA that they decided to make that a primary endpoint for the Phase 3 
trial.  They embarked on that Phase 3 trial at the end of November 2015.
The Phase 3 was called RSV-E-301.  This was a large randomized, observer-blind, placebo-
controlled trial in 60 US sites with almost 12,000 subjects ≥60 years of age randomized 1:1.  
There were 5921 active arm subjects and 5935 placebo arm subjects.  The placebo was
formulation buffer and the test agent was 135µg RSV F nanoparticle vaccine without adjuvant.  
The primary endpoint for this trial was defined as PCR-confirmed PCR positive msLRTD.  For
mild LRTD, there had to be at least 3 signs or symptoms of LRTD.  For severe LRTD, there had 
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to be at least 4 or more signs or symptoms of LRTD.  Enrollment was conducted from
November 9, 2015 through December 12, 2015.  Immunogenicity was assessed at 5 time points
after enrollment.  The last patient’s last visit was in June 2016.
Efficacy was not demonstrated in the Phase 3 trial.  There were 28 cases of RSV msLRTD in 
the vaccine arm and 26 cases in the placebo arm, yielding a point estimate of -7.9% with 
confidence intervals ranging from -84 to 37, which is essentially zero efficacy.  Comparing that 
to Phase 2 results, there were 5 cases in the RSV-msLRTD arm and 14 in the placebo arm, with 
confidence intervals of 1 to 87.  There is about a 4-fold difference in the attack rate in Phase 3 
for this primary end point case definition of 0.44% in the placebo arm versus 1.7% in the Phase 
2 trial.  It can be very difficult in Phase 3 trials to demonstrate efficacy when the attack rates are 
this low.  The secondary endpoint for efficacy was not met either.  There was arguably a modest 
trend toward efficacy with a 12.6% point estimate with confidence intervals of -14 to 33.  For
comparison, there was a sizeable difference in the attack rates in the Phase 2 study.  The attack
rate was under 2% in the Phase 3 trial and almost 5% in the Phase 2 trial, so about a 2.5-fold 
lower attack rate in Phase 3.
In summary, the safety profile for the Phase 3 trial was consistent with Phase 2 results.  There 
were no safety signals, and there were no imbalances between the placebo and vaccine arms.  
The tolerability and reactogenicity profiles were virtually identical with placebo.  The RSV-ARD 
and RSV-msLRTD attack rates were markedly lower than expected based on the Phase 2 trial
and the work that Dr. Falsey conducted in Rochester.  The Phase 3 trial failed to show efficacy
against RSV msLRTD and RSV ARD.  There were trends that suggested some positive impact 
on the RSV ARD endpoint and associated healthcare utilization outcomes, but none of these 
was statistically significant.  The immunogenicity results observed in the Phase 3 trial are 
broadly consistent with Phase 2 results.  This work is still ongoing and has demonstrated robust 
PCA and Anti-F responses and modest increases in microneutralizing antibodies.  Analyses in 
search of correlates are ongoing.
In conclusion, unlike E-201, E-301 failed to show efficacy against RSV ARD or msLRTD,
although non-significant trends suggest a reduction in RSV ARD and healthcare utilization 
outcomes.  However, a few points deserve call-out.  The trial was operationally well-conducted 
and randomization was executed correctly.  The immunogenicity was exactly what would have 
been expected, demonstrating exactly what was observed in Phase 2 across 3 different assays. 
Investigations to date suggest that there were no product integrity issues.  The safety profile of 
the RSV F vaccine remained similar to the placebo and is consistent with E-201.  There was no 
clear decrement in the immunogenicity of the vaccine, although work is still being done with 
respect to the immunogenicity data.  The RSV attack rate was 2.5- to 4-fold lower than seen in 
E-201 for both msLRTD and ARD, and may have had an impact on the detection of vaccine 
efficacy.  This has been an issue with other vaccines.  Work that has been done in influenza 
when there was a very low attack rate, made it very difficult to demonstrate vaccine efficacy.
In terms of moving forward, Novavax is committed to further development of the RSV F vaccine 
construct in older adults.  They understand that there are still questions that need to be 
answered with respect to immunogenicity, which is notably more robust in younger adult 
subjects.  There are several avenues available for enhanced immunogenicity and / or efficacy
and Novavax is actively exploring those.  The current suite of immunologic endpoints may not 
adequately capture protective responses in the elderly, and additional assay development is
needed. There also is a need for additional epidemiologic understanding and a more 
sophisticated epidemiologic level of understanding is important, so Novavax appreciates the 
CDC’s work in that respect.  The differences observed in the attack rates is one example of 
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where the epidemiology is still something of a conundrum.  RSV is only the second annually
recurring respiratory virus for which late-stage vaccine development has been attempted, and 
RSV appears to evade or modify population immunity in a manner that is different from that of 
influenza.  Influenza does this through antigenic drift.  It is not exactly clear how RSV does what 
it does, but it seems to modify population immunity in ways that are less than 100% clear. 
Novavax is currently considering dosing or formulation approaches that may overcome 
heterogeneity in background immunity and / or seasonal attack rate differences.
Novavax’s infant-maternal program is in Phase 3.  As far as Dr. Stoddard is aware, this is the 
only RSV vaccine in Phase 3 currently.  Three separate Phase 2 trials have been conducted of 
Novavax’s maternal vaccine—2 in women of childbearing age and 1 in pregnant women.  
Multiple animal studies have been conducted, including vaccine challenge studies and 
transplacental antibody transfer studies and a host of other types of studies.  An enormous
amount of work has gone into getting into Phase 3 in the maternal program.
With respect to the formulation, it is a different vaccine than what is used in older adults.  It is
the same antigenic construct, but with a slightly lower dosage of 120 µg and it is aluminum­
adjuvanted.  It is known from the Phase 2 trials that there is no advantage to giving more than 
one dose.  A single dose results in the same response as 2 doses, which is good from a 
pragmatic and programmatic point of view.  It is also known that a single aluminum-adjuvanted 
dose provides enhanced neutralizing antibody responses, particularly in young women with the 
lowest pre-immunization titers.  That is, those women who have the highest risk of having their
infants develop RSV bronchiolitis get the most robust response to a single dose of the
aluminum-adjuvanted vaccine.
The Phase 2 trial in pregnant women was initiated in September 2014.  It involved 50 pregnant 
women at 8 sites in the US during the 2014-2015 RSV season.  As mentioned, a 120 µg dose of 
RSV F vaccine + 0.4 mg of aluminum.  In the Phase 2 trial, all of the women received the 
vaccine between 33 and 35 weeks of gestation.  That window was opened up for the Phase 3 
trials.
In terms of the safety summary from the Phase 2 trial, the only imbalance of AEs were solicited 
and local.  They were predominantly mild to moderate transient injection site pain, which is
consistent with prior trial in women of child-bearing age.  This is expected with any aluminum­
adjuvanted vaccine in a younger population.  There were no SAEs attributed by the 
investigators as causally related.  Regarding infant safety, there were no imbalances of AEs
noted between the placebo and active groups.  There were no SAEs attributed as causally
related to the vaccine.  With respect to labor and delivery events, the events monitored were
determined by Brighton Collaboration guidance.  Only a single imbalance was noted, which was
that the C-section rate was higher in the active group.  This was attributed to past obstetrical
history and not vaccine-related.
In summary of the Phase 2 RSV F vaccine trial in pregnant women, the vaccine was well-
tolerated with an acceptable safety profile.  The response to the RSV F vaccine in pregnant 
women replicated the immune responses in non-pregnant women from the other two Phase 2 
trials.  Maternal antibody seems to peak 14 days post-vaccination.  Anti-F, PCA, and
neutralizing transplacental antibody transfer were all confirmed.  There was also noted to be a 
balance of vigorous early antibody response and 100% or higher transplacental transfer in 
women immunized >30 days prior to delivery, which offers flexible timing for antenatal
immunization.  The observed half-life of 41 days for the PCA through the first 60 days post-
delivery was also an important finding.  This suggests protection of infants for a minimum of 90 
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To determine the efficacy of maternal immunization with the RSV F vaccine against RSV 
lower respiratory tract infection (LRTI) with hypoxemia (SpO2  <95% at sea level or <92% at 
altitudes >1800 meters) through the first 90 days of life in infants of maternal RSV F 



















Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
days based on simple first-order decay kinetics, meaning that protective levels might persist 
longer if late elimination kinetics are slower.  This will be important in terms of the Phase 3 data.
The Phase 3 infant-maternal study is now a very large global initiative underway in multiple 
countries throughout the world.  A major effort has been made to include many RSV experts
from around the world, as well as many of the top vaccine clinical trial sites throughout the 
world.  This is a randomized, observer-Blind, placebo-controlled, group sequential trial design 
that will be conducted over at least 3 seasons.  The trial is currently in season 2.  The trial may
enroll up to 8616 subjects in total globally.  In the first year, there were sites in the USA, South 
Africa, Australia, New Zealand, and Chile.  Second year additions included Argentina, the UK,
Spain, Italy, Mexico, and the Philippines.  The length of study participation is 9 months for the 
mothers and 1 year for their infants.  The window of injection has been extended down to 28 
weeks gestational, making the window of vaccination 28 to 36 weeks.
A lot of thought and effort were put into defining the primary endpoint for efficacy.  Novavax had 
conversations with many top RSV experts from the pediatric community and the pediatric
infectious disease community and WHO.
The primary efficacy endpoint is:
In the event that efficacy is shown through the first 90 days of life, sequential hypothesis 
tests will be carried out to examine efficacy at 120, 150, and 180 days of life. 
The secondary efficacy endpoint is:
To determine the efficacy of maternal immunization with the RSV F vaccine in reducing the 
incidence of RSV LRTI with severe hypoxemia (SpO2  <92% at sea level or <87% at altitudes 
>1800 meters) or the need for high flow nasal cannula or mechanical ventilatory support; 
RSV LRTI leading to hospitalization; RSV LRTI resulting in death; and all RSV LRTI. 
There is a DSMB that is actively engaged.  It is comprised of both pediatric and obstetrical
experts.  They review the study on a regular basis.  To date, the formal recommendations made 
by the DSMB have been to continue with this trial with no alternations.  There have been no 
apparent safety concerns and no advisements to modify or halt the study to date.
To summarize, Novavax is committed to pursuing clinical development programs to fully assess
the safety and efficacy of the RSV F vaccine in populations at highest risk of RSV LRTI.  That 
includes RSV LRTI in older adults, as well as RSV LRTI in infants and young children, with 
maternal immunization as the central approach to protecting the youngest infants from
bronchiolitis and pneumonia.  Novavax has a distinguished history of RSV vaccine 
development, with multiple noteworthy contributions to the field and an unwavering commitment 
to addressing a major unmet medical need and a public health priority.
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Discussion Points
Given the window of vaccination of pregnant women, Dr. Riley asked whether Novavax is also 
assessing the impact of concomitant immunization with influenza and Tdap vaccines.
Dr. Stoddard replied that they were not doing this in the Phase 3 trial.  It is an important 
question programmatically, and there is some reason to think that based on the older adult trial
that there may be some immunologic interference between the RSV F vaccine and the influenza
vaccine.  Partly on the basis of that and partly on the basis of needing to run a really clean, 
straightforward, and scientifically pure study, Novavax is not permitting concurrent 
immunization.  As important as those vaccines are, in the Phase 3 protocol, they cannot be 
given concurrently with the RSV vaccine because of the confusion it could cause.  To be very
clear, they are not precluding the pregnant women in the Phase 3 trial from getting those 
vaccines, but they are making sure in the protocol that there is some separation in time.
Dr. Lee said it was great to see this much progress.  She requested further information 
regarding the effect modification in the older adult Phase 3 trial in terms of the differences in the 
responsiveness based on whether they had co-administration of influenza vaccine on the same 
day.
Dr. Stoddard responded that they did observe differences according to concomitant influenza 
and RSV vaccine immunization.  For those subjects who received the vaccinations
concomitantly, there was about a 10% reduction in efficacy observed in the Phase 2 trial.  There 
was roughly a 10% reduction in immunogenicity as well.  The impact is unidirectional.  The 
influenza vaccine negatively impacts the immunogenicity and efficacy of the RSV vaccine, not 
the other way around.
Given the uncertainty in the attack rates, which seems to be a year-to-year fluctuation, it 
seemed to Dr. Thompson (NVAC) that it would be a good idea to inflate the power calculations
assuming that the attack rates might be low.  It seemed like the sample size was significantly
too low given the attack rates.
Dr. Stoddard replied that increasing the sample size in a low attack rate year probably would not 
have made a difference.  It is very difficult to demonstrate VE in an exceptionally low attack rate 
year.  The point is a good one in terms of better understanding the variation that might occur in 
terms of attack rates with RSV.  They may have been naïve in retrospect thinking that 5% was
about what could be expected year in and year out.  Thinking about the data from Fleming in the 
UK that Dr. Falsey discussed, that consistent pattern year in and year out was something that 
investigators had come to believe based on relatively few data points.  There needs to be a 
better understanding of what the attack rate is and how much it varies year-to-year.  The data 
Dr. Falsey presented are very good in that they captured the fact that there could be broader
ranges than Novavax anticipated going into its Phase 3 older adult trial.  For the maternal trial, 
they do not think this is an issue because they are working in multiple geographies over several
seasons.
Dr. Bennett asked if they have hypothesized why the attack rate was so low last year.  There 
was variability but also some stability in Dr. Falsey’s data.
Dr. Stoddard said they wish they knew the answer.  It is a great question, but they just do not 
have an answer.  There is a lot about RSV epidemiology that is enigmatic and humbles them, 
but they are not giving up.
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Dr. Messonnier thanked Dr. Stoddard and Novavax for coming before ACIP during this meeting 
to present these data.  Everybody likes to present great data, so CDC offered its appreciation 
for Novavax’s willingness to present disappointing data and for the transparency and 
engagement that they have had with ACIP and CDC’s SMEs.
Dr. Gorman (NIH) commented that understanding that the multiple year study delays approval
might mitigate Novavax’s risks going forward in the elderly.  Regarding the adult study, he 
asked whether Dr. Stoddard was free to discuss which direction they were leaning toward in 
terms of dose or adjuvanting the product.
Dr. Stoddard replied that they are probably leaning toward both.  They are looking at all
potential options to optimize the immunogenicity of the vaccine in the older adult population.  
Dose and adjuvantation are the two considerations.  They will have more to say specifically on 
that in the ensuing weeks.  They are still working on exactly what the next study design should
look like.
With the wide geographic range and 8000 births, Dr. Gorman (NIH) asked how they will
operationalize the reality that some of them will be premature and some of them will have lung 
disease.
Dr. Stoddard responded that this is a complex trial. The premature births will be very difficult to 
analyze.  This is going to be a trial that is directed toward analyzing the efficacy in the full-term
population.
Paul Offit (Children’s Hospital of Philadelphia) indicated that in the Southern Hemisphere, RSV 
alternates with peaks and troughs.  He asked whether Novavax had the capacity in its adult trial
to follow up those recruits these season, which may be quite a different season than last.
Dr. Stoddard replied that they are exploring all possibilities, including conducting a Phase 2 
clinically.  They are no longer in Phase 3 in the older adults, but are interested in going back to 
Phase 2 for dose ranging and formulation assessments potentially in the Southern Hemisphere.  
That is certainly in the realm of possibilities for them in the coming season.
Evidence -Based Recommendations Work Group Update 
Wendy Carr, PhD
ACIP Evidence-Based Recommendations Work Group Lead 
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Dr. Carr reminded everyone that the purpose of the Evidence-Based Recommendations WG 
(EBRWG) is to provide a forum for discussion of best practices for the evidence-based 
recommendation process for ACIP, including development and use of GRADE evidence tables
and an evidence to recommendation framework to ensure consistency and enhance 
transparency in the development of ACIP recommendations, with the goal of developing a 
uniform approach to evaluation and use of the evidence base for ACIP recommendations.
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In support of this purpose, the aims of the WG defined in the Terms of Reference propose
additional guidance for the ACIP evidence-based recommendation process, including GRADE
and subsequent use of an evidence to recommendation framework, specifically for three areas:
 Improving and harmonizing the development and use of GRADE evidence tables by the 
ACIP WGs
 Developing criteria to guide the determination of when GRADE evidence tables should be 
prepared in support of a given recommendation
 Further defining the process of going from the certainty of the evidence base as presented 
by the GRADE tables to recommendations, in particular ensuring that the additional factors
that contribute to decision-making are considered and communicated.
Regarding the first aim to harmonize development and use of GRADE tables, several CDC WG
leads presented their experience using GRADE methodology for past recommendations to the 
WG.  Several areas were identified for which additional guidance would be useful.  These 
included: 1) applying GRADE methodology to the evaluation of immunogenicity data, including 
further clarifying when evidence should be rated down for indirectness when used as a 
surrogate outcome for efficacy; 2) the acceptability of rating up a body of evidence after
previously rating it down; 3) the assessment of observational data using GRADE, in particular
ensuring that the confidence generated by strong observational data is reflected in the ultimate 
evidence rating; and 4) evaluating burden of disease.
The next steps for moving forward with this goal of harmonizing the development of GRADE
Tables are to develop draft Frequently Asked Questions (FAQ) documents that provide more 
explicit guidance on how to consistently approach topics that often generate questions during 
the use of GRADE by ACIP WGs.  The hope is to draft and gather feedback on these materials
with a goal of presentation to the ACIP during the June 2017 meeting.
With respect to the second aim of the WG which centers around providing reference materials, 
to clarify when GRADE should be used to evaluate the evidence for recommendations, the 
intent is to develop a checklist or flowchart to enable WGs to more efficiently determine whether
GRADE tables should be prepared for a given topic.  The intent is to develop draft materials, 
incorporate feedback, and present to ACIP during the June 2017 meeting.
For the third aim of the WG, to provide additional structure and clarity for the process during 
which factors in addition to the evidence base are considered when formulating 
recommendations, the GRADE WG, a collaboration of methodologists, clinicians, and others
working to develop, refine, and provide guidance regarding the GRADE evidence-based 
recommendation approach have outlined a process to support movement from evidence to 
decisions.  This has been termed Evidence to Decision (EtD) or Evidence to Recommendation 
(EtR) framework.  The framework is presented as a table that includes key background 
information, criteria that should be considered, and conclusions.  Of note, the certainty of the 
evidence as depicted in GRADE tables is only one consideration in this process and as such is
only one of the elements of the framework.  One advisory group that has adopted the EtR
framework is the WHO Strategic Advisory Group of Experts on Immunization (SAGE). Members
of the SAGE Secretariat presented the EtR methodology currently used by SAGE to the 
EBRWG in addition to the discussion of the successes and challenges that have been so far
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encountered.  A recent example of a completed SAGE EtR table can be found at the WHO
website at this link:  http://www.who.int/immunization/policy/position_papers/dengue/en/ 
When queried about potential development of a similar EtR framework for ACIP, feedback from
members of the EBRWG was positive.  Each element of the framework would be customized to 
the needs of ACIP to provide additional structure and clarity in the communication of the 
spectrum of elements considered during recommendation development.  The next step is to 
develop a draft ACIP-specific EtR framework, which would be first used to solicit feedback from
the EBRWG and CDC WG leads for refinement, with a goal of presenting draft materials to 
ACIP during the February 2017 meeting.
The following is a summation of the proposed timeline for development of additional guidance 
materials:
 During November / December 2016 and January 2017, the EBRWG meetings will focus on 
specific elements of the EtR framework
 The draft EtR framework will be presented during the February 2017 ACIP meeting 
 During March, April, and May 2017, the EBRWG will revise the framework and further define 
the elements and will develop and review proposals to address harmonization of GRADE
usage and when to GRADE evidence
 The proposals to address key questions will be presented during the June 2017 ACIP
meeting
 During the October 2017 ACIP meeting, the final proposals will be presented for an ACIP
vote on the proposed modifications
Discussion Points
Dr. Schaffner (NFID) thought it was wonderful that the EBRWG was addressing the GRADE
process and adapting it to public health needs.  One issue that has frequently arisen in 
discussions as GRADE has been applied is that the indirect effect of vaccines was not 
represented in GRADE, but is often thought to be a huge advantage.  He asked whether she 
could address this.
Dr. Carr acknowledged that indirect effects are not specifically addressed, but pointed out that 
one of the advantages of developing an EtR framework is that it would allow that sort of 
evidence to be incorporated and those considerations to be more clearly presented.
Dr. Bennett noted that the committee had an opportunity to discuss this at some length the 
previous day and to offer comments at that time.
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Vaccine Supply 
Dr. Jeanne M. Santoli
Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
In December 2015, Sanofi Pasteur announced a manufacturing delay with Pentacel®  (DTaP-
IPV-Hib) vaccine.  As a result, Sanofi Pasteur is only able to meet approximately 70% of 
historical Pentacel®  vaccine demand.  At this time, sufficient supplies of the relevant individually 
administered vaccine antigens are available to address the anticipated gap in the Pentacel®  
supply.  Sanofi Pasteur anticipates resolution of this Pentacel®  delay sometime during the fourth 
quarter of 2016. 
 
 
GSK is currently on back order for both presentations of BEXSERO®  (1-pack and 10-pack).  
They anticipate beginning to clear back orders in October.  CDC received communication from 
GSK on October 19th  that they would be able to resume shipping in the next couple of days.  
However, they anticipate that there will be some shipping delays throughout the fourth quarter of 
2016.  GSK does maintain a medical reserve that can be used to fill public or private orders in 
the event of an immediate need, such as an outbreak.  The reserve is still available, and GSK is 
currently using this to fill orders as appropriate. 
In terms of adult vaccines, two vial presentations of Merck’s adult vaccines are currently 
unavailable for shipping, the single dose PNEUMOVAX®  vial and the 10-pack of single dose 
adult VAQTA®  vials.  Availability of both of these products is expected to resume the week of 
November 17th. Until that time, Merck has a sufficient supply of the syringe presentation of both 
of these two adult vaccines available to meet the historical demand for both the vial and syringe 
presentations. 
CDC’s Vaccine Supply/Shortage Webpage can be found
at: www.cdc.gov/vaccines/vac-gen/shortages/default.htm 
Day 2:  Public Comment 
No public comments were offered during this session.
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Certification 
Upon reviewing the foregoing version of the October 19-20, 2016 ACIP meeting minutes, Dr. 
Nancy Bennett, ACIP Chair, certified that to the best of her knowledge, they are accurate and 
complete.  Her original, signed certification is on file with the Management Analysis and 
Services Office (MASO) of CDC.
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ACIP Membership Roster 
September 26, 2016
 
Department of Health and Human Services 

Centers for Disease Control and Prevention
 
Advisory Committee on Immunization Practices
 
July 1, 2016 through June 30, 2017
 
CHAIR
BENNETT, Nancy, MD, MS
Professor of Medicine and Public Health Sciences
Director, Center for Community Health
Co-director, Clinical and Translational Science Institute





Senior Advisor for Vaccines
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Atlanta, GA
MEMBERS
ATMAR, Robert L., MD
John S. Dunn Clinical Research Professor in Infectious Diseases
Interim Chief, Section of Infectious Diseases
Departments of Medicine and Molecular Virology & Microbiology
Baylor College of Medicine
Chief, Infectious Diseases Service
Ben Taub General Hospital, Harris Health System
Houston, TX
Term: 7/1/2016 – 6/30/2020
BELONGIA, Edward, MD
Director
Center for Clinical Epidemiology & Population Health 
Marshfield Clinic Research Foundation
Marshfield, WI
Term: 07/01/2014-06/30/2018
EZEANOLUE, Echezona, MD, MPH
Professor of Pediatrics and Public Health
Department of Epidemiology and Biostatistics
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HUNTER, Paul, MD 
Associate Professor of Family Medicine and Community Health 
University of Wisconsin School of Medicine and Public Health 
Associate Medical Director
City of Milwaukee Health Department
Milwaukee, WI
Term: 7/1/2016 – 6/30/2020
KEMPE, Allison, MD, MPH
Professor of Pediatrics
Director of Primary Care Fellowship
University of Colorado School of Medicine
Director of Research
Division of General Academic Pediatrics
Director of Children’s Outcomes Research Program
The Children’s Hospital of Denver
Denver, CO
Term: 07/01/2013 - 06/30/2017
LEE, Grace M., MD, MPH
Associate Professor of Population Medicine & Pediatrics
Director, Center for Healthcare Research in Pediatrics (CHeRP)
Harvard Pilgrim Health Care Institute & Harvard Medical School
Associate Medical Director of Infection Control, Boston Children's Hospital
Boston, MA
Term: 7/1/2016 – 6/30/2020
MOORE, Kelly, MD, MPH,
Director, Tennessee Immunization Program
Tennessee Department of Health 
Assistant Clinical Professor, Department of Health Policy









REINGOLD, Arthur L., MD 
Professor of Epidemiology 
Edward Penhoet Distinguished for Global Health and Infectious Disease 
Associate Dean for Research 
School of Public Health 
University of California 
Berkeley, CA 
Term: 07/01/2013-06/30/2017 
RILEY, Laura E., MD 
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ROMERO, José R., MD, FAAP
Professor of Pediatrics
Horace C. Cabe Endowed Chair in Infectious Diseases
Director, Pediatric Infectious Diseases Section
University of Arkansas for Medical Sciences and Arkansas Children's Hospital
Director, Clinical Trials Research




Professor of Medicine, Division of Infectious Diseases
Chair, Department of Medicine 




SZILAGYI, Peter MD, MPH
Professor of Pediatrics 
Executive Vice-Chair and Vice-Chair for Research
Department of Pediatrics 
University of California, Los Angeles (UCLA) Los 
Angeles, California
Term: 7/1/2016 – 6/30-2020
WALTER, Emmanuel (Chip), Jr., MD, MPH
Professor of Pediatrics




Centers for Medicare and Medicaid Services (CMS) 
HANCE, Mary Beth 
Senior Policy Advisor 
Division of Quality, Evaluations and Health Outcomes 
Children and Adults Health Programs Group 
Center for Medicaid, CHIP and Survey & Certification 








         
       
     
       















































Advisory Committee on Immunization Practices (ACIP) Summary Report October 19-20, 2016
Department of Defense (DoD)
Department of Defense (DoD) DEUSSING, ERIC, MD, MPH
Commander, Medical Corps, United States Navy
Department of Defense Liaison
Centers for Disease Control and Prevention
Atlanta, GA
Department of Veterans Affairs (DVA)
KIM, Jane A., MD, MPH
Deputy Chief Consultant for Preventive Medicine
Office of Patient Care Services
National Center for Health Promotion and Disease Prevention
Durham, North Carolina
Food and Drug Administration (FDA)
SUN, Wellington, MD
Director, Division of Vaccines and Related Product Applications
Office of Vaccines Research and Review
Food and Drug Administration
Rockville, MD
Health Resources and Services Administration (HRSA)
NAIR, Narayan, MD
CAPT, USPHS
Acting Division Director/Chief Medical Officer
Division of Injury Compensation Programs
Healthcare Systems Bureau
Rockville, MD





National Vaccine Program Office (NVPO)
GELLIN, Bruce, MD, MPH
Director
National Vaccine Program Office
Department of HHS, Public Health and Science
Washington, DC
National Institutes of Health (NIH)
GORMAN, Richard L., MD
Associate Director for Clinical Research
Division of Microbiology and Infectious Diseases/NIAID
National Institute of Health
Bethesda, MD
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LIAISON REPRESENTATIVES
American Academy of Family Physicians (AAFP) 
SAVOY, Margot, MD, MPH  
Medical Director, Department of Family & Community Medicine 
Christiana Care Health System 
Wilmington, DE 
American Academy of Pediatrics (AAP)
BYINGTON, Carrie L., MD 
Chair, AAP Committee on Infectious Diseases 
H.A. and Edna Benning Presidential Professor of Pediatrics 
Associate Vice President for Faculty and Academic Affairs 
University of Utah Health Sciences Center 
Salt Lake City, UT 




Division of Pediatric Infectious Diseases
The University of Alabama at Birmingham School of Medicine
Birmingham, AL
American Academy of Physician Assistants (AAPA)
LÉGER, Marie-Michèle, MPH, PA-C
Senior Director, Clinical and Health Affairs
American Academy of Physician Assistants
Alexandria, VA






American College of Nurse Midwives (ACNM)
HAYES, Carol E., CNM, MN, MPH
Atlanta Perinatal Associates
Atlanta, GA
MEHARRY, Pamela M., PHD, CNM
Midwifery Educator, Human Resources for Health
In partnership with University of Rwanda and University of Illinois, Chicago
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American College of Obstetricians and Gynecologists (ACOG)
AULT, Kevin A., MD, FACOG
Professor and Division Director
Department of Obstetrics and Gynecology
University of Kansas Medical Center
Kansas City, KS
American College of Physicians (ACP)
FRYHOFER, Sandra Adamson., MD, MACP
Adjunct Associate Professor of Medicine
Emory University School of Medicine
Atlanta, GA
POLAND, Gregory A., MD
Mary Lowell Professor of Medicine and Infectious Diseases
Mayo Clinic
Rochester, MN




Duke University and Durham VA Medical Centers
Durham, NC
America’s Health Insurance Plans (AHIP)
NETOSKIE, Mark J., MD, MBA
Market Medical Executive, CIGNA
Houston, TX 
American Medical Association (AMA)
FRYHOFER, Sandra Adamson., MD
Adjunct Associate Professor of Medicine
Emory University School of Medicine
Atlanta, GA
American Nurses Association (ANA)
RITTLE, Charles (Chad), DNP, MPH, RN
Assistant Professor, Nursing Faculty
Chatham University, School of Health Sciences
Pittsburgh, PA
American Osteopathic Association (AOA)
GROGG, Stanley E., DO
Associate Dean/Professor of Pediatrics
Oklahoma State University-Center for Health Sciences
Tulsa, OK
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American Pharmacists Association (APhA)
FOSTER, Stephan L., PharmD
Professor and Vice Chair, Department of Clinical Pharmacy
University of Tennessee Health Sciences Center, College of Pharmacy
Memphis, TN
Association of Immunization Managers (AIM)
FINLEY, Christine, RN, MPH
Immunization Program Manager
Vermont Department of Health
Burlington, VT
Association for Prevention Teaching and Research (APTR)
McKINNEY, W. Paul, MD
Professor and Associate Dean
University of Louisville School of Public Health and Information Sciences
Louisville, KY
Association of State and Territorial Health Officials (ASTHO)
DWELLE, Terry L, MD, MPHTM
State Health Officer
North Dakota Department of Health
Bismarck, ND
Biotechnology Industry Organization (BIO)
ARTHUR, Phyllis A., MBA
Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy
Washington, DC
Council of State and Territorial Epidemiologists (CSTE)
HAHN, Christine, MD
State Epidemiologist
Office of Epidemiology, Food Protection and Immunization
Idaho Department of Health and Welfare
Boise, ID
Canadian National Advisory Committee on Immunization (NACI)
GEMMILL, Ian MacDonald, MD
Medical Officer of Health 
Kingston, Frontenac and Lennox & Addington Public Health 
Kingston, Ontario, Canada
Infectious Diseases Society of America (IDSA)
NEUZIL, Kathleen M., MD, MPH
Professor of Medicine
Director, Center for Vaccine Development
University of Maryland School of Medicine
Baltimore, MD
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BAKER, Carol J., MD
Professor of Pediatrics
Molecular Virology and Microbiology
Baylor College of Medicine
Houston, TX
National Association of County and City Health Officials (NACCHO)
ZAHN, Matthew, MD
Medical Director, Epidemiology
Orange County Health Care Agency
Santa Ana, CA
DUCHIN, Jeffrey, MD
Health Officer and Chief, Communicable Disease Epidemiology and Immunization Section 
Public Health - Seattle and King County
Professor in Medicine 
Division of Allergy and Infectious Diseases
University of Washington School of Medicine and School of Public Health
Seattle, WA
National Association of Pediatric Nurse Practitioners (NAPNAP)
STINCHFIELD, Patricia A., RN, MS, CPNP
Director
Infectious Disease/Immunology/Infection Control
Children's Hospitals and Clinics of Minnesota
St. Paul, MN
National Foundation for Infectious Diseases (NFID)
SCHAFFNER, William, MD
Chairman, Department of Preventive Medicine
Vanderbilt University School of Medicine
Nashville, TN
National Immunization Council and Child Health Program, Mexico
VILLASEÑOR RUIZ, Ignacio, MD
Directora del Programa de Atencion da la Salud de la Infancia y la Adolescencia / Director
General, Child and Adolescent Health
Centro Nacional Para la Salud de la Infancia Y La Adolescencia / National Center for Child and 
Adolescent Health
Ministry of Health / Secretaría de Salud
Mexico
National Medical Association (NMA)
WHITLEY-WILLIAMS, Patricia, MD
Professor and Chair
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
New Brunswick, NJ
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National Vaccine Advisory Committee (NVAC)
THOMPSON, Kimberly, ScD
Chair, NVAC
Professor of Preventive Medicine and Global Health 
University of Central Florida, College of Medicine Orlando, FL
O’LEARY, Sean, MD, MPH




University of Colorado School of Medicine
SAWYER, Mark H, MD
Professor of Clinical Pediatrics
University of California, San Diego School of Medicine
San Diego, CA
Pharmaceutical Research and Manufacturers of America (PhRMA)
JOHNSON, David R, MD, MPH 
Associate Vice President, Global Medical Affairs, Sanofi Pasteur
Swiftwater, PA
Society for Adolescent Health and Medicine (SAHM)
MIDDLEMAN, Amy B., MD, MSEd, MPH
Professor of Pediatrics
Chief, Section of Adolescent Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, OK
Society for Healthcare Epidemiology of America (SHEA)
WEBER, David, MD, MPH
Professor of Medicine, Pediatrics, and Epidemiology
University of North Carolina Schools of Medicine and Public Health
Medical Director, Hospital Epidemiology and Occupational Health, UNC Health Care
University of North Carolina
Chapel Hill, NC
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